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Abstract 
 
The field of ME/CFS research is challenged by many often confusing and conflicting reports 
of immune, neuroendocrine, autonomic, neurological dysfunction. During the prodromal 
phase of this condition patients often report flu-like symptoms, persistent chronic fatigue 
and gastro-intestinal symptoms including abdominal pain and discomfort. 
Its study is complicated by the lack of specific biomarkers and criteria to accurately define 
the illness, relying on the exclusion of other fatiguing illnesses. Recent publications suggest 
an altered intestinal microbiota and increased intestinal permeability are associated with 
ME/CFS.  Further evidence is accumulating for dysfunctional energy, lipid and amino acid 
metabolism that may indicate oxidative stress and/or immune-mediated damage to 
mitochondria, disrupting the efficiency of aerobic respiration, explaining the effect of post-
external malaise (PEM), a unique characteristic for the diagnosis of ME.  
 
In this study, Next Generation Sequencing (NGS) and Nuclear Magnetic Resonance (NMR) 
spectroscopy probed the composition of the intestinal microbiota and faecal and serum 
microbiomes in 17 severe, house-bound patients and house-hold healthy controls (HHC). 
Severe, house-bound patients account for 0.5% of all ME/CFS research, yet it is estimated 
they represent 25% of the patient population. We found Faecalibacterium prausnitzii was 
significantly reduced in severe patients (p = 0.018) but did not replicate individual 
differences in faecal and serum metabolites that others have previously reported. We 
further enhanced a flow cytometry technique for detecting IgA coated bacteria in faecal 
suspensions and analysed the proportional differences between patients and HHCs. This 
demonstrated a trend for increased IgA-coated bacteria in most patients; however, this 
trend was reversed when repeated with a second sample produced a year on.  
 
Since the initial concept for this study, several advances have been made in sequencing 
methods and quality control standards for metagenomic and metabolomic studies. Based 
on these, we conclude further investigations are warranted using whole genome 
sequencing and targeted metabolomics to address the emerging hypotheses in ME/CFS 
research, with an emphasis on the study of severe, house-bound ME patients. 
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RR Relapsing-Remitting 
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SCFA Short Chain Fatty Acids 
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SEID Systemic Exertional Intolerance Disorder  
SF-36 Short-form 36 item questionnaire 
SFB Segmented Filamentous Bacteria 
SLE Systemic Lupus Erythematosus 
SPF Specific-pathogen free 
TDA Topological Data Analysis 
TFT Thyroid Function Test 
TGR5 Takeda G-protein receptor 5 
Th1/Th2 T-helper 1/T-helper 2 
TJ Tight Junction 
TLR Toll-like Receptor 
TNFa Tumour Necrosis Factor Alpha 
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1.0 Background to ME 
 
Myalgic Encephalomyelitis (ME) has been classified by the World Health Organisation 
(WHO) since 1969 as a disease of nervous system (ICD-10; G93.3) and until recently 
included Chronic Fatigue Syndrome (CFS) under the same classification code. This 
enigmatic and ill-defined condition primarily affects young to middle aged adults, more 
often women, and is usually of sudden onset in apparently healthy and otherwise active 
individuals. Typically, ME/CFS is preceded by a ‘flu-like’ illness or viral infection associated 
with immunological abnormalities culminating in highly disabling physical and mental 
fatigue.  The name ME implies a recognised (neuro-)pathology consisting of muscle pain 
(myalgia) and inflammation in the brain (encephalomyelitis), that so far the has not be 
established consistently within all patients (Blomberg et al., 2018). The use of ME is 
preferred by many patients who argue CFS reduces the seriousness and presents the illness 
in the context of a psychosomatic disorder (Dickson et al., 2007; Looper & Kirmayer, 2004). 
However, clinical examination and routine blood tests provide no obvious explanation for 
this pathological fatigue and variety of other symptoms including: cognitive dysfunction, 
muscle pain, exhaustion after minimal physical or mental exertion, orthostatic intolerance 
(Bansal, 2016; Haney et al., 2015). This list is not extensive, and symptoms vary in 
frequency and severity from patient to patient. Many illnesses can be represented by some 
or all of these symptoms and therefore must be ruled out before ME/CFS can be 
diagnosed. 
 
Evidence is gathering to support a hypothesis of an infectious trigger causing long-lasting 
fatigue and immunological and gastrointestinal symptoms that could give rise to wider 
multi-systemic dysfunction involving signalling between intestinal microbes and the 
central, autonomic and enteric nervous systems, in addition to signalling between the 
(neuro-)immune and neuroendocrine systems and the brain. Other syndromes closely 
associated with ME include fibromyalgia (FM) and irritable bowel syndrome (IBS) which 
may represent a discrete subsets of ME patients.  
 
- Prevalence 
It is unclear how many people suffer with ME/CFS worldwide. A recent indication from the 
Institute of Medicine (IOM) suggests between 836,000 and 2.5 million Americans have 
ME/CFS (Reynolds et al., 2004). In the UK between 0.23-1.29% of the population are 
affected (Science Media Factsheet, 2018). The only prescribed treatment to these patients 
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consists of psychological-led interventions such as Cognitive Behaviour Therapy (CBT) for 
management of anxiety and depressive-like symptoms that manifest as a result of being 
chronically ill.  
 
- Early reports 
An illness that appears synonymous with characteristics of ME/CFS first described in 1869 
became known as neurasthenia (Van Deusen, 1869). Symptoms included fatigue, 
headaches, dizziness, weakness, and emotional disturbances (Beard, 1869). It was originally 
associated as a result of physical isolation of farmer’s wives who were socially inactive, but 
was also attributed to stress and a busy lifestyle (Beard, 1869; Van Deusen, 1869). To that 
end it was viewed as a psychogenic, rather than organic illness which altered the behaviour 
of the individual. From 1938 up until 1955 several apparent outbreaks of an illness with 
similar symptoms to poliomyelitis were described. These followed patterns of discrete 
clusters firstly, in Los Angeles in 1938 where the disease was called “atypical poliomyelitis” 
with symptoms of muscle weakness and severe pain aggravated by exercise (Gilliam, 1938). 
In Switzerland, in 1939, 73 soldiers developed low grade fever, with autonomic 
disturbances, fatigability and loss of concentration that was labelled epidemic 
neuromyasthenia. What appeared to a case of poliomyelitis in 1948 developed into 
another outbreak, involving 488 cases in rural areas around Akureyri, Iceland leaving 
patients severely paralysed particularly within the 15-19 age group, and occurred in 49% of 
pupils resident at a high school within Akureyri. Seventy percent of these patients had 
characteristic low grade fever, muscle tenderness, whilst 30% had muscle weakness with 
pyrexia (Parish, 1978). Other areas of outbreaks of a “polio-like” illness include Denmark, 
South Africa and Australia (Patarca-Montero, 2004). 
 
1.1 Controversy of ME 
 
ME/CFS controversy is driven by the lack of a defined pathophysiology with routine clinical 
and physical examination, including blood biochemistry revealing no obvious medical 
abnormalities as a specific cause. Over the decades separate definitions have been 
generated for ME and CFS with patients who do not meet either criteria diagnosed with 
idiopathic chronic fatigue which is classified as mental and behavioural disorders (ICD 
F48.0). An apparent outbreak of this disease was reported in 1955 describing patients 
suffering from malaise, tender lymph node, sore throat, pain and appeared to be infectious 
with signs of encephalomyelitis from limb spasms (Staff, 1957). Despite the appearance of 
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an epidemic of viral encephalomyelitis, the cause was never established and a lack of 
physical symptoms in these patients convinced many doctors that they were not physically 
ill, labelling it as ‘benign myalgic encephalomyelitis’ since no one died as a result the illness 
(IOM, 2015). This along with other reported outbreaks were explained by psychiatrists as a 
“psychosocial phenomena caused by one of two mechanisms; either mass hysteria on the 
part of the patients or altered medical perception of the community” and the fact most 
patients were female fitted with the hypothesis of epidemic hysteria considered 
characteristic among females (McEvedy & Beard, 1970; IOM, 2015).  
 
Over 200 cases of this chronic illness were documented by Dr Melvin Ramsay, a physician 
at the Royal Free hospital, who later published the first criteria for ME to refute its 
proposed psychological aetiology based on apparent involvement of the central nervous 
system (Staff, 1957). Interestingly some sporadic cases were reported at the time have 
following a viral infection and had been diagnosed as post viral fatigue syndrome (PVFS) 
(Lewis Price, 1961; Speight, 2013). Similar epidemics had previously occurred in 1934 and 
1947 in Los Angeles and Nevada, respectively (Speight, 2013). These outbreaks have been 
documented in the literature as poliomyelitis and were indistinguishable from Ramsay’s 
patients, with a similar neuromuscular condition. 
 
- Psychiatry and ME 
 
Psychiatry has dominated the media and public interpretation of ME/CFS and has had 
unfortunate consequences for the treatment of patients. Patients can easily be accused of 
malingering or being ill in the mind.  Many doctors and nurses formulate their own opinion 
based on various psychiatric explanations labelling the condition as a disease of the mind 
and is largely down to the fact very little or no training is given on how to manage these 
patients. Therefore, patients are easily stereotyped as neurotic or attention seeking. Other 
suggested causes include the stress of modern day living and ‘middle class’ disease 
(Speight, 2013). In the past it is fair to say the media has marginalised campaigns for 
biomedical research and excluded their voices in favour of the psychosomatic argument 
(Blease & Geraghty, 2018).  This has created a significant amount of frustration for patients 
who are desperate for answers to this debilitating and life-threatening illness. This is not 
unusual throughout medical history which tends to favour a psychological explanation 
when there is no convincing somatic origin. Asthma was once considered one of the ‘holy 
seven’ psychosomatic illness during the 1930-50s with talking therapy as an alleged cure 
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(Opolski & Wilson, 2005). Indeed, psychiatric conditions such as depression do have a 
negative effect on symptoms in somatic illnesses, like asthma, with a reduction in quality of 
life, that are not aetiologically relevant to its pathogenesis (Opolski & Wilson, 2005).  
 
1.2 The challenge for ME/CFS Research 
 
The foundations of ME/CFS research rely on the description of self-reported symptoms and 
clinical expertise when assessing the patient before making a diagnosis of ME/CFS. The 
application of reliable and highly specific criteria would be a significant breakthrough for 
research and in primary care.  Indeed, the psychological concept for this condition is still a 
problem in front line care with 20% of staff believing CFS is all in the patient’s head.  
International agreement on how we study the ME/CFS population is not forthcoming and is 
still frequently discussed until the medical and research communities agree on how this 
heterogenous group of patients be further stratified according to specific symptoms and 
severity other than subjective categories of: mild, moderate, severe and very severe. How 
these categories are defined is still a matter of clinical opinion and varies significantly from 
country to country. Further confusion is generated by the various names that have been 
introduced to describe unexplained and persistent fatigue. ME and CFS remain the most 
frequently used, however others including post-viral fatigue or post-infectious fatigue 
syndrome are named so after the apparent infectious event triggering long-term 
symptoms. There is symptom overlap with these illnesses makes it unclear if these are 
separate conditions or all the same (Twisk, 2014). 
 
1.3 Diagnosing ME/CFS  
 
The diagnosis of ME/CFS relies entirely on the exclusion of medical or psychiatric conditions 
associated with fatigue or any other symptoms presenting in the patient (Bansal, 2016). As 
a minimum criteria, fatigue must persist beyond four months according to current NICE 
guidelines. Fatigue is a universal symptom making it difficult to distinguish patients who 
each present their own set of unique symptoms. An added complication for accurate 
diagnosis is that many of the symptoms are not disease specific and encompass marked 
variability in severity and a daily and even hourly basis (Bansal et al., 2011). It is perhaps 
more helpful to view ME/CFS as an umbrella term for a number of conditions defined by 
chronic persistent fatigue that cannot currently unexplained, that may have discrete 
pathogenic aetiologies.  
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-  Assessing fatigue 
 
Fatigue effects an individual’s ability to function physically and mentally. However, the 
concept that fatigue can manifest as illness without a pathological explanation called 
idiopathic fatigue, suggests a psychogenic cause since very little is known about the 
physiological mechanisms for the sensation of fatigue. Indeed, this makes fatigue difficult 
to assess with no objective physiological marker. Ultimately, it relies upon highly subjective 
measures and assessments including patient interviews and completing questionnaires 
regarding their perception of fatigue and how it impacts their daily functioning. Self-
reported scales of fatigue such as the Chalder Fatigue Scale (Chalder et al., 1993) and 
measures of the impact fatigue has on a patients’ function such as the Short-Form 36 item 
questionnaire (SF-36) have been used extensively in ME/CFS research (Jason et al., 2009).  
 
The “envelope theory” proposed in 1999 suggests patients pace themselves according to 
the perceived amount of total energy they have available (Jason et al., 2012). To this end, 
crashes or worsening of symptoms can be avoided my limiting energy expenditure within 
this ‘envelope’. Patients kept an activity record to provide a self-assessment report on 
feelings of fatigue, pain, type and intensity of activity and enjoyment every 30 min to build 
a comprehensive picture how CFS impacted their daily functioning. Using this method, CFS 
patients were found to experience fatigue more of the time and to spend 2.5 times more 
resting than those with major depressive disorder and 4 times longer than the healthy 
control group after low intensity activity (Hawk et al., 2007; Jason et al., 2012). 
 
However, a review of 39 measures of fatigue has highlighted that no single method 
encompasses the full nature of fatigue in ME/CFS (Whitehead, 2009). Researchers are 
challenged as to how to use this subjective information to identify potential underlying 
physiological aetiologies. However, there are some aspects of the type and severity of 
fatigue experienced in the ME/CFS population that would not be perceived as normal part 
of experiencing fatigue that appear to separate these patients from other fatigue-related 
illnesses (Bansal, 2016). This is the most significant and characteristic symptom of ME, 
described as a delayed reaction to minimal physical or mental exertion, referred to as post-
exertional malaise (PEM).  
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- alternative sickness behaviour 
  
The similarities between ME/CFS and sickness behaviour have been extensively reviewed 
(Morris et al., 2013). The behaviour responses to infection have been modelled in mice 
challenged with Lipopolysaccharide (LPS) derived from Gram-negative bacteria, which have 
shown systemic inflammation can lead to neuroinflammation and sickness behaviour 
(Biesmans et al., 2013). Behavioural disturbances seen in LPS-treated animals cause 
depressive-like symptoms and withdrawal from social interaction and the environment. 
Many ME/CFS patients present with symptoms of “infection” that may drive 
proinflammatory cytokines IL-1b, IL-6, and TNFa able to trigger vagal nerve stimulation (the 
nerve from the  gut to the brain) or activate brain microglial cell to produce 
proinflammatory cytokines locally (Hoogland et al., 2015). In humans, an extreme example 
of sickness behaviour may manifest as delirium, a common and severe neuropsychiatric 
syndrome, delirium causes confusion, agitation and attentional deficits (MacLullich et al., 
2009; Pandharipande et al., 2013). Delirium is associated with aging, a period defined by a 
declining in the microbiota and therefore insults on the intestinal microbiota may alter 
brain function causing neuroinflammation and alter a person’s behaviour or response to 
physical, mental stress or infection (Di Sabatino et al.,  2018; Vaiserman et al., 2017). 
 
The overriding issue with ME/CFS research is that patient selection still remains highly 
ambiguous with interchangeable use of ME and CFS and case definitions. In a systematic 
review evaluating the application of case definitions, the authors highlighted the existence 
of over 20 sets of case definitions with significant overlap (Brurberg et al., 2014). As a result 
healthcare providers do not feel confident in about  ME/CFS (Bowen et al., 2005; Brimmer 
et al., 2010). The lack of specificity and accuracy in the diagnosis of ME/CFS is evident in the 
fact that CFS-like fatigue has been reported in 30.5% of 9050 randomly selected adults in 
the Netherlands using the Center for Disease Control (CDC) criteria by questionnaire, 
commonly referred to as Fukuda criteria (Fukuda et al., 1994; Van’T Leven et al., 2010). 
Moreover, this application of broader case definitions has led to a lack of reproducibility in 
ME/CFS research further fuelling the perception that this illness is psychogenic. A recent 
critical review has argued that there is ‘no convincing pathogenesis model for CFS’ (Mm & 
Ssung, 2017).  
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- Case definitions 
 
In the absence of a definitive diagnostic clinical test, guidance is set out in a series of case 
definitions used to described symptoms of ME/CFS to the detriment of having a 
homogenous patient population with varying degrees of overlapping symptoms, figure 
1.1.1. This has many limitations such as selection criteria biases and methodologies to 
assess patients and will be influenced by researchers’ own preconceptions of disease 
aetiology (Morris & Maes, 2013b). Application of case definitions in an apparently 
multisystem disorder such as ME/CFS can require multiple medical specialities to assess 
each symptom meets any threshold requirements, e.g. frequency and duration. This can 
generate difficultly comparing studies using different definitions and criteria to score 
fatigue and severity. Moreover, many symptoms included in the following case definitions 
risk including groups of patients that do not suffer from the same disease, with more 
general criteria including a group of patients in some cases with very little symptom 
overlap (IOM, 2015). 
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ÜFigure 1.1.1 Overlapping case definitions can result in patients being diagnosed with ME/CFS 
with very little symptoms shared between cases. Fukuda criteria sets out symptoms required for 
diagnosing CFS and it the most widely used case definition. The larger the area within circle of each 
case definition reflects the more encompassing rather than specific it is for defining patients with 
broad number of symptoms, in addition to mandatory chronic persistent fatigue. Figure from 
(Twisk, 2017). 
 
- Ramsay (1986) 
 
The acceptance of ME as a neurological condition by the WHO was attributed to the work 
of Dr Melvin Ramsay, a clinician at the Royal Free at the time of the 1955 outbreak, who 
proposed ME was a polio-like, neuromuscular disease and refuted any argument for it 
being psychogenic based on opinion of psychiatrists reviewing patients notes. The original 
criteria proposed by Ramsay generally considered most accurate and specific to the nature 
of ME symptoms including muscle weakness/tenderness, and pain after only minor 
exertion lasting for days, concentration and memory impairment, sleep disturbance, cold 
extremities, hypersensitivity and orthostatic tachycardia. Ramsay also documented the 
fluctuating nature of many of the symptoms and the dramatic effect of exercise upon 
muscle function which are not observed in IM or ‘glandular fever’ cases (Ramsay, 1986). 
Here, ME was described as distinctive from poliomyelitis as it did not cause paralysis or 
resulted in death and was termed ‘benign Myalgic encephalomyelitis’. 
 
- Holmes (1988) 
 
In 1988 the Centres for Disease Control (CDC) introduced the name CFS and provided the 
first definition. Holmes et al. (1988) produced this criteria to standardise the population 
and distinguish CFS from potentially viral infection aetiologies that had be associated with 
outbreaks of EBV infection (Holmes et al., 1988)(Holmes et al., 1987). CFS was described as 
persistent or relapsing fatigue for at least 6 months severe enough to impair the persons 
daily activities below 50% of previous capacity before becoming ill. It also stated that 8 or 
more other symptoms from a list of 11, including ‘neuropsychologic complaints’ had to be 
present. This led to the inclusion of patients with psychiatric problems such as depression 
base on generalised overlapping symptoms (Friedberg & Jason, 1998).  
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- Oxford (Chronic Fatigue) 
 
This criteria was established in the 1990s that has been criticised since it only requires 
severe and disabling fatigue and no longer used for its lack of specificity for diagnosis of 
CFS, or any neuro-muscular symptoms of ME described by Ramsay in 1987.  
 
- Fukuda (1994) (Chronic Fatigue Syndrome) 
 
In 1994 the CDC introduced a new definition commonly referred as the Fukuda criteria 
after its primary author. Similar to the Holmes criteria, the criteria Fukuda criteria does not 
provide guidance on interpreting these symptoms and has been criticised for being too 
broad and encompassing of all cases (Reeves et al., 2003). This sets out the requirement for 
moderate or severe fatigue lasting at least 6 months in addition to four or more of eight 
symptoms: post-exertional malaise, unrefreshing sleep, impairment in memory or 
concentration, headaches, muscle pain, joint pain, sore throat, or tender lymph nodes 
(Fukuda et al., 1994). None of these symptoms are characteristics of ME are mandatory in 
the Fukuda definition of CFS; but also, are rather unspecific and potential inclusive of other 
medical and psychiatric disorders. 
 
It is still the most widely used case definition that has largely been adopted in clinical 
practice (Brurberg et al., 2014). However, this criteria is frequently judged too vague and 
polythetic, essentially highlighting a group of patients with chronic fatigue as the 
predominant factor in their illness. Not all CFS patients will have post-exertional malaise 
and memory/concentration impairment as these are not strictly required to satisfy Fukuda 
criteria. The review of the original ME criteria established by Ramsay (1987) suggest a 
distinct disease that is more than persistent chronic fatigue, with particular emphasis on 
neuro-immunological exhaustion (Dowsett et al., 1990).  In the patients from the Royal 
Free outbreak, muscular pain, autonomic symptoms and malaise following any form of 
physical or mental exertion where triggered after a flu-like illness are the hallmarks of ME 
which Fukuda does not require but help differentiate true cases of ME from ones with 
general chronic fatigue.  
 
Patients with major depression may also be misdiagnosed with CFS (Jason et al., 1999). It is 
also possible for patients which very little symptom overlap to be diagnosed with CFS, with 
the only primary feature of unexplained fatigue being shared with Ramsay’s criteria for ME. 
Further heterogeneity is introduced when some CFS patient fit the criteria for ME and vice 
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versa. ME and CFS are used interchangeable or combined as ME/CFS, given many patients 
satisfy various diagnostic criteria for both. However, there is little understanding about the 
pathophysiology of ME and how it is separate from CFS, although the delayed exhaustion 
to minimal physical or mental exertion is considered unique to ME.  
 
- Canadian Consensus Criteria (2003) for ME/CFS 
 
The 1955 definition of ME involves post-exertional malaise and impairment of memory and 
concentration as distinguishing features that are not absolutely required by Fukuda 
(Dowsett et al., 1990). Thus, the shortcomings of the Fukuda criteria lacking overall 
specificity for ME, led to the introduction of the Canadian Consensus criteria which had 
more emphasis on ME-like symptoms requiring two or more neurological/cognitive 
symptoms and at least one symptom of autonomic, neuroendocrine and immunological 
dysfunction, as well as post-exertional malaise (PEM) which often causes a delayed 
exacerbation of all symptoms. The inclusion of more core symptoms identifies patients 
overlapping with the Ramsay criteria, but also because of the increased number of possible 
symptoms, like the Holmes criteria, introduces higher rates of psychiatric co-morbidity 
(Katon & Russo, 1992; Williams, 2014).   
 
The early 2003 criteria required several other symptoms (see figure 1.1.3) in addition to 
two core symptoms referred in the previous paragraph (Jason et al., 2010). Up to 75% of 
CFS cases identified with Fukuda also satisfy the Canadian (2003) criteria for ME/CFS (Jason 
et al., 2013a; Nacul et al., 2011; Jason et al., 2012a.)  To address this problem, the updated 
Canadian Consensus Criteria (2010) introduced structured questionnaires (DePaul 
Symptoms Questionnaire; SF-36) to gather standardised information in addition to 
operational definitions for assessing symptoms that must be present within 6 categories 
(see figure 1.1.3) and must be of moderate severity for at 50% of the time as well as scoring 
sufficiently low on the SF-36 for substantial reduction in functioning  Jason et al., 2014; 
Jason et al., 2010; IOM, 2015). This is viewed as a stricter definition than Fukuda with a 
focus on more severe patients since it does require PEM and memory/concentration 
impairment and indication of minimum frequencies and severity of symptoms. Fewer 
patients met this revised definition compared with using the 2003 version and with Fukuda. 
To this end, the revised Canadian Consensus Criteria perhaps represents severe group of 
CFS patients with significantly more frequent psychiatric co-morbidity. By contrast
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original 2003 Canadian Consensus highlighted patients with less psychiatric co-morbidity 
than Fukuda (Services et al., 2015).  
 
- ME International Consensus Criteria (ICC) 
  
The International Consensus Criteria (ICC) for the diagnosis of ME essentially evolved from 
the Canadian Census Criteria for ME/CFS. Introduced by Carruthers et al. in 2011 it 
recommended a distinction of ME based on recent research of “widespread inflammation 
and multisystem neuropathology” (Carruthers et al., 2011). Delayed exhaustion following 
minimal physical or mental exertion (PEM), termed post-exertional neuroimmune 
exhaustion by the authors, is an absolute requirement. In addition, neurocognitive 
impairments, pain, sleep disturbance, neurosensory, perceptual or motor disturbances 
must be present. Importantly, at least one symptom has to be present from 3 of 5 immune, 
gastro-intestinal and genitourinary categories – including flu-like symptoms, recurrent 
viral/bacterial infections, GI discomfort and sensitivities to food, medicines, odours, 
chemical sensitivities had to be present. Finally, at least one symptom associated with 
energy production/transportation impairments including cardiovascular/respiratory 
symptoms, intolerance to extremes of temperature also needs to be present (Twisk, 2017; 
IOM, 2015). 
 
- Systemic Exertional Intolerance Disorder (SEIDS) 
 
An extensive review was conducted by the Institute of Medicine, USA in 2015 of the 
published studies of ME/CFS and the implementation of case definitions and subsequent 
diagnosis made from these (IOM, 2015). As a result, the report introduced SEIDS to replace 
ME/CFS. To qualify for diagnosis of SEIDS, fatigue, PEM and non-refreshing sleep, cognitive 
deficits and orthostatic intolerance are absolute requirements. Although the application of 
this criteria is straightforward and simpler (see diagnostic algorithm, figure 1.1.2) than 
other case definitions, it can still miss symptoms attributed to neuro-immune, 
neuromuscular and neuroendocrine dysfunction that are the hallmarks of Ramsay’s original 
ME criteria meaning this definition could essentially still include cases with little symptom 
overlap. 
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Figure 1.1.2 Pathway to the diagnosis of Systemic Exertional Intolerance Disorder (SEID) produced 
by the Institute of Medicine, USA in 2015. 
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Figure 1.1.3 Common symptoms of ME/CFS shared across various case definitions Figure adapted 
from (Online, 2018) assessed 29th September 2018, with additional information included from (Jason 
et al., 2010). 
 
- Symptoms 
  
The case definitions for ME/CFS (CCC), and ME (ICC), and the IOM replacement of ME/CFS 
with SEID are not entirely satisfactory criteria since they still include patients with other 
medical and psychological illness that are not defined by neuro-muscular features, delayed 
muscle fatigability with an apparent prodromal phase that precedes a very serious chronic 
illness. The list of symptoms and references below are taken from the 2015 IOM report, 
and provide an overview of all the different symptoms that stand out across multiple 
studies implementing CFS, ME/CFS and ME criteria, these include: persistent fatigue and 
unrefreshing sleep, orthostatic intolerance, widespread pain (myalgia), cognitive 
dysfunction, and immune dysregulation, along with secondary anxiety and depression, 
contribute to the burden imposed by fatigue in this illness:  
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- Neurocognitive symptoms defined as slowness of thought; mental fog; and 
problems with concentrating, memory, or understanding (Arroll and Senior, 
2009; Hickie et al., 2009; Jason and Taylor, 2002; Ray et al., 1992).  
 
- Musculoskeletal factors: muscle or joint aches and pains and weakness 
(Brimacombe et al., 2002; Hickie et al., 2009; Nisenbaum et al., 2004; Tseng and 
Natelson, 2004); 
 
- Infectious symptoms: a “viral flu-like” factor that includes such complaints as fever, 
sore throat, and tender lymph nodes (Brimacombe et al., 2002; Nisenbaum et al., 
1998, 2004; Tseng and Natelson, 2004);  
 
- Psychological emotional distress or mood or anxiety disturbance factor (Arroll and 
Senior, 2009; Fostel et al., 2006; Hickie et al., 2009; Ray et al., 1992);  
 
Other common symptoms of the autonomic nervous system include GI disturbances, such as 
constipation, diarrhoea, nausea, increased bowel sounds, mild bloating and abdominal 
tenderness are reported by majority (92%) of patients. It is typical for symptoms of IBS to 
precede onset of ME/CFS that become closely associated with worsening of fatigue, mood, 
malaise, and severity of muscular and joint pain. 
 
 
- Post-exertional malaise (PEM) 
 
The CCC and ICC emphasise post-exertional malaise (PEM) to help clinicians rule out cases 
of idiopathic fatigue. It however can still be viewed as a symptom of ME/CFS rather than 
exclusively belonging to ME, based on its requirement in the Canadian criteria. PEM 
generally causes a global worsening of all ME/CFS symptoms for which the trigger can be 
patient specific and can take different periods for recovery.  PEM can be described as a 
“crash”, “relapse” or “collapse” of varying degrees of duration, severity, impairment, and 
symptoms that are exacerbated by minimal physical or mental activity (IOM, 
2015). Objectively testing the extent of a patients’ PEM by inducing a stressor or forcing the 
patient exercise is considered unethical given the disabling effects and pain that can last up 
to days. Therefore, self-reported experiences of PEM and associated triggers are frequently 
recorded in questionnaires of the patient’s previous experience. How these questions are 
asked and their wording can influence how the patient responds (Leonard et al., 2015). 
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PEM is considered a unique symptom of ME/CFS that distinguishes it from cases of 
idiopathic chronic fatigue, anxiety, depression and other psychiatric and/or fatiguing 
disorders fatigue-related illness, yet it is still largely an ill-defined and vague. It has been 
suggested, PEM be further described by the period of delay in its onset, and how long the 
period of the exacerbation of all ME/CFS symptoms last. For instance, PEM may be more 
immediate in some patients, as little as 3 hrs, or delayed up to 12-24 hrs after completion 
of a specific activity, and can endure longer than 24 hrs in severe cases (Bansal, 2016).  
Interestingly there is a subtle difference between PEM which entails a full-body sensation 
of malaise and post-exertional muscle weakness observed in Ramsay’s ME patients. Indeed 
it has now been proposed the PEM be categorised according to its nature either as a 
general factor of exacerbating illness, or extreme muscle pain and weakness, both 
following from minimal physical or mental exertion (McManimen et al., 2016). 
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Figure. 1.1.4 The IOM definition of SEID sits between the Fukuda cases definition for CFS and 
Ramsay’s proposed criteria for ME in 1988. SEID does not have require muscle pain (myalgia) with 
optional orthostatic intolerance. Figure from (F. Twisk, 2018) 
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- Summary 
 
There is currently no clear agreed distinction between CFS and ME. The Fukuda criteria 
upon which the majority of clinical research has implemented to date, has perhaps 
hindered consistent findings because the patients it diagnoses includes various disease 
entities which share persistent fatigue; including Chronic Fatigue, Chronic Fatigue 
Syndrome and ME – see figure 1.1.1. The 2010 Canadian definition attempts to separate 
CFS by defining more symptoms of a neurological nature but is still has considerable 
overlap with the earlier CFS definition and therefore attracts a heterogeneous ME/CFS 
patient population with varying degrees of symptom overlap. The IOM criteria for SEID has 
been suggested to replace ‘ME/CFS’ and uses simpler criteria than CCC and ICC definitions 
which should be relatively straightforward to translate into the clinic. 
 
The CDC introduction of the term CFS on the back of the Holmes criteria has led to the 
confusion of CFS and ME being the same disease (Twisk, 2018).  All it has served is to 
identify a group of patients who share persistent fatigue and does not give insight to the 
seriousness and severity of the original cases highlighted by Dr Ramsay (Dowsett et al., 
1990; FNM, 2017). The more recent Canadian and International ME criteria hybridise 
CFS/ME with emphasis on PEM and reduce the frequency of depressive disorders with this 
criteria more successfully selecting against those individuals in whom depression may be a 
significant factor in their chronic fatigue symptoms (Jason et al., 2012).  
 
The most recent SEID definition attempts to bridge together Fukuda and Ramsay criteria 
but completely lack requirement for muscle-specific symptoms and will therefore likely 
continue to represent a heterogenous patient population that remain very distinct the 
condition of ME described by Ramsay and colleagues (Dowsett et al., 1990). Many 
symptoms used by Ramsay relating to neuro-muscular pathology, including: muscle 
weakness particularly after exertion, spasms, extreme tenderness, as well as neurological 
symptoms such as light and sound sensitivities are unique to ME, yet not defined specified 
or used as absolute requirement by other case definitions.  
 
In 1990, the year of the death of Ramsay and therefore his last publication before his 
death, the criteria for ME is re-iterated: “a syndrome commonly initiated by respiratory 
and/or gastrointestinal infection, but an insidious or more dramatic onset following 
neurological, cardiac or endocrine disability occurs…features are general or local muscle 
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fatigue following minimal exertion with prolonged recover”(Dowsett et al., 1990). A table 
for this paper (reproduced as table 1.1.1) lists the symptoms and signs in 420 patients 
monitored during the Royal Free outbreak. Ramsay discusses the epidemiological evidence 
for ME being caused by “non-immune individuals of widespread subclinical non-polio 
enteroviruses (NPEV)” based on the neurological manifestations for which many NPEVs had 
been associated with. Out of the 420 cases, 205 (33%) of these had coxsakie B virus 
neutralisation tests that revealed an ongoing infection (Dowsett et al., 1990) . Of course, it 
cannot be said for certain these cases were a result of an enterovirus, but enteroviruses are 
well-known causes of acute respiratory and/or gastrointestinal infections and non-specific 
flu-like illness. Interestingly more recently enteroviruses have been suggested a common 
trigger, along with EBV, for causing ME/CFS in a subgroup of patients (Zhang et al., 2010). 
Indeed, many patients show ongoing signs of bacterial/viral infection that could explain 
their long-term sickness behaviour. These observations have led an infectious-neuro-
immune hypothesis model which will now be introduced in the next section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1.1. Symptom repertoire of patients diagnosed with ME used Ramsay criteria in 1988. This 
list is presented as a summary of symptoms found in 420 patients at the Royal Free Outbreak in 
1955, highlights muscle fatigue is the defining characteristic of ME with 49% of patients experiencing 
gastro-intestinal disturbances. Table reproduced from (Dowsett et al., 1990). 
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1.4 A proposed infection-neuro-immune disease mechanism in ME/CFS 
 
ME/CFS is a complex multifaceted disease involving disruptions to the neurological, 
neuroendocrine and immune systems. An infectious aetiology can be appreciated from the 
early documented cases of a fatiguing neuro-muscular condition, that became known as 
ME.  The polio-like nature and symptom onset suggest a systemic infection, possibly 
originating from the gut which influences immune-inflammatory events responsible for 
causing sickness behaviour and other symptoms prevalent among neuro-psychiatric 
conditions where the behaviour may be a result of persistent immune activation and 
chronic stress and anxiety surrounding not getting better. Persistent infections are known 
to increase intestinal permeability. This may then explain the self-perpetuating nature of 
ME, since increased exposure of intestinal immune cells to commensal bacterial antigens 
such as LPS across the intestinal bacteria can activate the immune system and 
proinflammatory cytokines that have been documented to cause sickness behaviours but 
also trigger autoimmunity. Moreover, increased permeability is already known to occur 
during periods of stress and is significantly influenced during early colonization of microbes 
along the GI tract. In an attempt to bring order to the sequences of events, this model 
proposes a step by step process leading to intestinal barrier leakiness as a result of 
persistent immune activation and disruption to centres of the brain regulating the 
physiological response to systemic infections. 
 
The following sections of this chapter, present various aspects of this model and explore it 
in the context of the current observations in ME/CFS, but also wider studies mainly 
performed in animals attempting to unravel crossover interactions with the immune 
system, neuroendocrine system and signalling with the brain via the hypothalamus-
pituitary-adrenal (HPA) axis.  This pathway has been most studied in animal models of 
infection where in becomes activated leading to distinct physiological changes. Moreover, 
evidence is emerging of the gut microbiome providing physiological input to the regulation 
of the immune system and HPA axis during stress test situations. 
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Figure 1.1.5 Current psycho-biology model for the pathophysiology of ME/CFS. Several symptoms 
of ME/CFS, chiefly among which post-exertional malaise (PEM), are suggestive of a dysfunctional 
Hypothalamus-Pituitary-Adrenal axis during times of stress. Stressors can originate from 
psychological processing of emotions and negative thoughts. Chronic stress can also weaken 
immunity and cause susceptibility towards infection. Long term exposure stress hormones can also 
impair intestinal barrier function, causing a “leaky gut” and exposure to intestinal microbes 
(Lambert, 2009). The immune system reacts with commensal bacteria previously hidden from 
immune cells, as a result this causes inflammation and further tissue damage and low-grade 
inflammation resulting from increased exposure to endotoxin (bacterial LPS). Serum antibodies IgM 
and IgA antibodies have been detected in ME/CFS are raised against intestinal microbes and may 
potentially cross-react with the CNS engender neuroinflammation and altered behaviour (Maes, 
Kubera, Leunis, & Berk, 2012; Morris, Berk, Galecki, & Maes, 2014). Finally, health anxiety and the 
damaging social impact resulting from this illness can causing further stress and GI-disturbances 
which appear to perpetuate this cycle. 
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1.5 The Hypothalamus-Pituitary-Adrenal (HPA) axis 
 
The HPA axis is a major gut-brain pathway that protects the body from the dangers of 
stress. Components of this axis include the immune, neuroendocrine and central, 
autonomic, and enteric nervous systems, with various positive and negative feedback 
mechanisms designed to coordinate physiological and behavioural adaptations collectively 
called the stress response.  This response is governed by several pathways (figure 1.1.6) 
and by the balance of immune (cytokines), endocrine (cortisol) and neural inputs from the 
intestines (vagus pathway and enteric nervous system) (Rea, Dinan, & Cryan, 2016). Activity 
of the HPA axis is determined by the release of corticosterone-releasing factor (CRF) from 
neuro-endocrine neurons from the paraventricular nucleus (PVN) of the hypothalamus 
during stress (Watts, 2005). Neuro-anatomical tracing studies reveal the suprachiasmatic 
nucleus (SCN) found in the anterior hypothalamus contains vasopressin-releasing neurons 
in close proximity to neurons in the PVN which can strongly inhibit corticosterone release 
during daytime (Kalsbeek et al., 1992). In response to actual or perceived (psychological) 
stress, CRF stimulates release of adrenocorticotrophic hormone (ACTH) from the anterior 
pituitary triggering successive release of glucocorticoids (cortisol in humans, corticosterone 
in animals), catecholamine (adrenaline and noradrenaline), mineralocorticoids 
(aldosterone) from the adrenal cortex into the systemic circulation causing mobilisation of 
gluconeogenesis (energy production), increased awareness (hypersensitivity), increased 
heart rate and blood pressure, and altered behaviour commonly referred to as the “fight or 
flight” response (Dallman et al., 1993; Rea et al., 2016; Taub, 2008). 
 
Control of the PVN integrates signalling from catecholaminergic, glutamatergic and 
serotonergic neurotransmitters and is inhibited by the GABA-ergic neurons (Bellavance & 
Rivest, 2014). Glucocorticoid receptors (GR) expressed in the hippocampus and prefrontal 
cortex provide autoregulatory feedback to prevent HPA hyperactivity (Herman et al., 2012). 
The SCN has master control over the release of corticosteroids from the HPA axis, defined 
by the CLOCK system relying light and dark signals on photosensitive retina ganglion cells to 
coordinate circadian rhythm of peripheral CLOCKS throughout the body via humoral and 
neural connections (fig 1.1.6) (Tsigos et al., 2016). The release of CRF follows a circadian 
and ultradian rhythms measured by glucocorticoids in plasma revealing a day/night cycle 
and clustering of 6 to 9 surges in plasma cortisol in the very early hours of the morning and 
before getting up to facilitate awakening and arousal to start the day (Kalsbeek et al., 
2012). 
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Figure 1.1.6 Daylight activates the central CLOCK in the suprachiasmatic nucleus (SCN) which 
coordinates the daily circadian rhythm for releasing glucocorticoids via neural inputs to CRH/AVP-
containing neuron in the PVN of the HPA axis. Secreted glucocorticoids also synchronise 
peripheral CLOCKs by causing expression of CLOCK-related genes in local tissues. CRH: 
corticotropin-releasing hormone; AVP: arginine vasopressin; PVN: paraventricular nucleus. 
Figure from (Tsigos et al., 2016). 
- HPA disruption in ME/CFS 
 
Sleep disturbances are common in ME/CFS patients and is acknowledged this can have an 
impact on the daily rhythm of cortisol secretion (Jackson & Bruck, 2012). Circadian rhythm 
may also be perturbed in some patients who cannot withstand light and therefore disrupt 
daylight signals to the SCN via the retino-hypothalamic tract giving inadequate 
environmental cues when transitioning between day and night (Balbo et al., 2010). Low 
cortisol in CFS compared with healthy controls were reported to be related to the “low 
arousal state” in CFS patients (Demitrack et al., 1991). Generally, reduction in cortisol levels 
are more apparent in women and are associated with worse symptoms (Papadopoulos & 
Cleare, 2012; IOM, 2015). One report has found patients with more severe symptoms had 
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lower awakening cortisol and a flatter diurnal curve suggesting dysfunction within HPA 
signalling (IOM, 2015)  However, not all studies have generated consistent data to support 
blunted HPA activation in all cases of ME/CFS. Interestingly, hyperactivity of CRF-releasing 
neurons have been associated to early life exposure to stress and is a risk factor in primates 
for developing major psychiatric disorders in adulthood (Coplan et al., 1996). Early life 
stress can also be conferred by viral infections such as Epstein-Barr Virus commonly 
associated with risk for developing ME, as well as enteroviruses which may precipitate a 
pre-programmed altered HPA response. As a result of a blunted HPA axis, immune-
mediated inflammation may persist even with minor physical or psychologic stressors. 
- Intestinal microbiota programmes the HPA response 
 
There is evidence to support that stressful insults (antibiotic exposure, bacterial/viral 
infections) which impact the early intestinal microbiota composition can increase the risk 
neurodevelopmental behaviour disorders (Borre et al., 2014; O’Mahony et al., 2017).  
Excessive corticosteroid exposure during postnatal development influences the developing 
brain and neuronal complexity within areas such as the amygdala, hippocampus, and pre-
frontal cortex in addition to GR expression (Borre et al., 2014). The hippocampus has 
inhibitory effects on HPA activation, however, stress causes reduced synaptic plasticity and 
decreased expression of NR1 and NR3B subunits of the N-methyl-D-aspartate (NMDA) 
receptor contributing towards HPA hyperactivity (Farzi et al., 2018).  
Later in life stress can increase intestinal permeability and activate proinflammatory 
cytokines and prostaglandins with stimulate the HPA axis (De Punder & Pruimboom, 2015). 
Hyperactivation of HPA axis decreases GR expression and negative feedback to immune 
cells resistance to anti-inflammatory properties of cortisol which further weaken the 
intestinal barrier (Farzi et al., 2018; Kelly et al., 2015). Systemic inflammation and increased 
circulating cortisol is associated in stress-related neuropsychiatric disorders, particularly 
Major Depressive Disorder (MDD) (Doolin et al., 2017; Jacobson, 2014). Stress and negative 
emotions are also a major factor in the development of Irritable Bowel Syndrome (IBS) 
where peripheral neuro-immune interactions can contribute to abdominal hyperalgesia 
(Elsenbruch, 2011). As with ME/CFS case definition criteria is applied to the diagnosis of 
IBS, with 50-90% of patients having an associated psychiatric co-morbidity (Singh et al., 
2012). IBS has been found to increase the risk of depressive, anxiety, sleep, and bipolar 
disorders. Furthermore, gastroenteritis, prior to anxiety and depression are risk factors for 
the subsequent development of post-infectious IBS (Lee et al., 2015). 
       
 
 44 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.7 Critical windows between the development of neurons, diversity of the intestinal 
microbiota and the age of onset of neuropsychological disorders. The stability of the intestinal 
microbiota can affect development of the neural complexity of the CNS in early life. Early life 
physical and mental stressors (antibiotic treatment, psychological abuse) can impact the 
composition of the intestinal microbiota and increase the risk of developing psychiatric illnesses in 
adult life. Animal studies have shown bidirectional communication between intestinal microbes and 
the central nervous system that is essential for neurodevelopment and programming of stress-
responsivity responses governed by the HPA axis. Figure from (Borre et al., 2014). 
 
The intestinal microbiota colonisation occurs during a critical window of neurogenesis 
during which time neuronal structures within the CNS are undergoing axonal and dendritic 
growth and forming synaptic connections (fig 1.1.7). The networks of neuronal connections 
are complex and highly plastic during this development. Early insults on the intestinal 
microbiota during this process can cause life-long changes in behaviour and physiological 
response to stressors later in life. The majority of this work is pre-clinical and 
predominantly conducted on animal models with targeted manipulation to the intestinal 
microbiota to observe how these animals respond behaviourally and physiologically to a 
variety of physical and immune stressors.  
Gnotobiotic mice continue to be the most accessible tool for neurobiologists to explore the 
capacity of the intestinal microbiota to influence the HPA axis and behaviour via immune 
and neuro-endocrine systems as well as central, autonomic and enteric nervous systems, 
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(figure 1.1.8) (Cryan & Dinan, 2015; Farzi et al., 2018). High levels of ACTH and 
corticosterone concentrations are found in germ-free (GF) mice in response to restraint 
stress and are consistent with HPA hyperresponsiveness  (Sudo et al., 2004). GF mice have 
less brain-derived neurotrophic factor (BDNF) important in neuronal growth, 
differentiation and survival (Sudo et al., 2004). Some of the differences in GF mice are 
dependent on sex; for example serotonin concentration is higher in the hippocampus of GF 
mice with decreased 5-HT1A receptor expression only in female mice (Clarke et al., 2013). 
GF status appears to disrupt the programming of the HPA axis response via permeant 
reduction of GR and mineralocorticoid receptor (MR) gene expression in the hippocampus 
and increasing hippocampal volume (Luczynski et al., 2016). 
 
 
 
 
 
 
 
 
 
Fig. 1.1.8 Neural and humoral signalling pathways between the intestine and the brain. These 
pathways together represent the microbiota-immune-gut-brain axis. The architecture and formation 
of the CNS and brain occur during early life, when intestinal microbes provide external 
environmental cues at specific windows of time. Additional factors later in life, such as diet, stress, 
infections, antibiotic exposure, can also influence the microbiota and its function via the production 
of microbial specific metabolites, that mimic neurotransmitters, can impact on signalling via the gut-
brain axis. The immune system also interacted with the microbiota and can become activated in 
response to dysbiosis, causing changes in intestinal permeability and production of pro-
inflammatory cytokine that can trigger sickness behaviour and activated microglial cells in the brain 
that increase the risk of neurodegenerative disorders affecting cognition and memory. Figure from 
(Cenit et, 2017). 
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Probiotic administration of a single strain, Bifidobacterium infantis, restored normal HPA 
response to stress in GF mice, whilst reduced anxiety behaviour and increased locomotor 
activity could only be reverted in young mice, not adult mice, with adoptive transfer of SPF 
microbiota (Sudo et al., 2004). Early life disruptions to the colonisation of the intestinal 
microbiota occurs simultaneously during neurodevelopment of the brain and CNS and it 
emerges there are temporal critical windows for colonisation to ameliorate HPA 
dysfunction later in life (figure 1.1.9). 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.9 Germ free mice raised without exposure to microbes display reduced anxiety-like 
behaviour which cannot be reversed by recolonization following adolescence. GF mice spend more 
time in the light and more time spent in the open arm of the elevated plus maze, suggesting they are 
less anxious. Adolescence is a critical period when the intestinal microbiota influences anxiety-like 
behaviour, that can have life-long effects. From (Foster et al., 2013). 
Altered hippocampal gene expression and increased serotonin production may explain why 
GF mice display reduced anxiety-like behaviour and increased locomotor activity compared 
with specific-pathogen free (SPF) mice with a normal microbiota (Neufeld et al., 2011). 
Antimicrobial treatment in SPF mice alters the composition of the microbiota and increased 
exploratory behaviour and BDNF expression; and transfer of stress-prone BALB/c mice 
microbiota into GF NIH Swiss mice transferred anxiety-related behaviour, while transfer of 
SW microbiota to GF Balb/C mice had an anxiolytic effect, suggesting a direct causal link 
between the intestinal microbiota and behaviour (Bercik et al., 2011).  
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Post-natal development can be influenced by antibiotic exposure during the microbial 
“colonisation window”  causing visceral hypersensitivity in adult male rats, without 
perturbing anxiety, cognition and immune-related stress responses (O’Mahony et al., 
2014). Conversely, antibiotic depletion later in life of the microbiota in rats causes 
depressive behaviour, cognitive deficits, and reduces visceral pain sensitivity (Hoban et al., 
2016). Reduction in the number of bacterial species (richness) is associated with depression 
with evidence for beneficial treatment using lactobacillus and bifidobacterial species to 
modulate depressive symptoms (Bravo et al., 2011). A stable and diverse microbiota is 
attributed to colonisation resistance to effectively limit colonisation and overgrowth of 
pathogens as well as supporting a balance of anti- and pro-inflammatory responses (Lawley 
& Walker, 2013). Transferring the intestinal microbiota from depressed patients to rats 
induced anxiety-like behaviour and anhedonia characteristic of depression which suggests 
a causal role for intestinal microbes in the pathogenesis of depression (Kelly et al., 2016). 
It seems paradoxical that GF exhibit both exaggerated HPA activity in response to stress 
and yet have reduced-anxiety and increase locomotor activity highlighting the complexity 
of microbiota-gut-brain signalling. Both the amygdala and hippocampus are enlarged in 
these animals, along with differential gene expression pattern involved in neuronal 
plasticity, neurotransmission and morphology, and evidence of  defects in a subpopulation 
of immune cells, resident in the brain, called microglial cells (Farzi et al., 2018; Stilling et al., 
2015). There is evidence that Blood-Brain-Barrier (BBB) permeability in increased in GF 
mice with a similar effect in antibiotic-induced disruption to the intestinal microbiota 
causing tight-junction defects in specific brain regions, predominantly the hippocampus 
and amygdala (Braniste et al., 2014). Antibiotic treatment has the capacity to effect brain 
neurochemistry evidenced in the depletion of the SFP mice microbiota during the human 
equivalent of adolescence causing reduced anxiety, memory impairment, altered 
tryptophan metabolism, and reduced BDNF, oxytocin, and vasopressin expression in the 
hypothalamus (Desbonnet et al., 2015).  
- Maternal Immune Activation 
 
Maternal Immune Activation (MIA) offspring display an altered composition of intestinal 
microbiota compared to control offspring (Hsiao et al., 2013). These offspring result from 
pregnant dams injected with viral mimic poly(I:C) to simulate maternal infection link to an 
increased risk of autism probably caused by elevated level of inflammatory molecules in 
the maternal blood (Hsiao et al., 2013). Altered intestinal permeability was measured in 
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MIA offspring was attributed excess leakage of gut-derived metabolites into systemic 
circulation and consequently is demonstrated to alter the serum metabolome.  
Administration of B fragilis to MIA offspring every other day for 6 days at weaning was able 
to ameliorate GI barrier defects associated with an improvement in intestinal permeability. 
The impact B fragilis has on gut barrier integrity and is shown to be through a mechanism 
involving changes in expression of claudins 8 and 15 in the colon, but not in the small 
intestine, consistent with the fact that the majority of the microbiota including B 
fragilis resides in the colon and therefore may be an effective treatment for restoring gut 
permeability defect, at least in MIA offspring. Serum metabolites significantly altered by 
MIA treatment (around 8% of all 322 serum metabolites detected in adult sera by GC/LC-
MS based metabolomics profiling) were restored by B fragilis treatment revealed the most 
dramatically affected metabolite, 4-ethylphenylsulfate (4EPS) (Hsiao et al., 2013). 4EPS 
exhibited a 46-fold increase in serum levels of MIA offspring. This is interesting because 
conventional germ-free mice do not have detectable levels of 4EPS indicating it originates 
from intestinal microbes. This work remains preclinical so its relevance to humans with 
autism and similar neurodevelopmental disorders is uncertain. 
 
- Maternal separation and stress 
 
Depressive-like behaviours are noted during maternal separation of new born mice causing 
HPA activation, immune activation and visceral hypersensitivity akin to IBS-like symptoms 
in humans (O’Mahony et al., 2011). The integrity of the intestinal microbiota is susceptible 
during maternal separation in infant monkeys; in addition to stress-related behavioural 
changes caused by elevated cortisol, these infants had significant decreases in faecal 
Lactobailli, and were more susceptible to bacterial infection and associated emotional 
behaviour, and stress to disruption to the immune system (Bailey & Coe, 1999). Maternal 
prenatal stress measured by consistent elevated salivary cortisol during pregnancy induced 
a higher relative abundance of Proteobacteria and lower Lactobacilli and Bifidobacterium 
that are hallmarks of inflammatory diseases and GI symptoms and did cause infant GI 
symptoms related to changes (Zijlmans et al., 2015). 
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- Intestinal microbiota and neural communications  
 
The autonomic nervous system (ANS) integrates the communication between the CNS and 
the gut viscera, with resident microbiota signalling interacting with enteric nervous system 
influencing the brain and the perception of abdominal pain. Primary functions of the 
enteric nervous system (ENS) include control of movement and transmucosal fluid in 
maintaining mucosal barrier function and absorption of nutrients – as well as modulation 
of the immune system through the neuroendocrine system. Several classes of 
neurotransmitters can be synthesised by specific bacterial species including g-aminobutyric 
acid (GABA), serotonin, catecholamines and acetylcholine (Cenit et al., 2017). Strains of 
Lactobacillus spp. and Bifidobacterium spp. are known to contribute to the synthesis of 
GABA; Escherichia spp. Bacillus spp., and Saccharomyces spp. produce noradrenaline; 
Candida spp., Streptococcus spp., Escherichia spp. and Enterococcus spp. produce 
serotonin; Bacillus spp. produce dopamine, while Lactobacillus have been shown to make 
acetylcholine (Barrett et al., 2012; Cenit et al., 2017; Dinan et al., 2013). Neuronal 
communication between intestinal microbes and the brain is evidenced by benefits of 
probiotic treatment of social and emotional behaviour. Administering Lactobacillus 
rhamnosus to mice had a reduction on stress-induced level of corticosterone and on GABA 
receptor regional expression in the brain. GABA-nergic neuron projecting from the 
hypothalamus to PVN inhibiting CRF neurons, serving as a gate keeper for PVN activation 
and receive projections of glutamatergic neurons from the hippocampus and prefrontal 
cortex – indeed lesions in these brain areas exacerbate responses to psychogenic stress 
(Figueiredo et al., 2003; Herman et al., 2016).  Alteration to GABA receptor expression is 
known to be implicated in anxiety and depressive states and is also the main CNS inhibitory 
neurotransmitter. Alterations in the GABAergic system have pathological implications for 
stress-related psychiatric conditions, as such; these receptors are also main targets for anti-
anxiety agents such as benzodiazepines (Bravo et al., 2011). 
 
- Immune system and HPA axis 
 
Systemic infection via pro-inflammatory cytokines can activate the HPA-axis and trigger 
release of corticosterone in animals (Dunn, 2000; Turnbull & Rivier, 1999). However, the 
HPA axis is normally tightly regulated during infection providing negative feedback to the 
immune system via immune cells  glucocorticoid receptors to downregulate CRF and limit 
pro-inflammatory cytokine production enabling host adaption to the ongoing stress and to 
effect certain behavioural changes (Silverman et al., 2005). Stress effects on the immune 
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system include reduced NK cell activity, changes in peripheral lymphocyte subsets and 
proliferation, diminished antibody production and reactivation of latent viral infection 
(Taub, 2008). Early life exposure to LPS in mice causes life-long HPA hyperresponsiveness 
measured by elevated ACTH and corticosterone reduced GR-mediated negative feedback 
(Shanks et al., 1995).  
The composition of the intestinal microbiota influences the host’s susceptibility and 
response to infection; mouse enteropathogenic Citrobacter rodentium infection is mild in 
NIH Swiss mice (resistant) compared to lethal in C3H/HeJ mice, however antibiotic 
depletion of the microbiota in resistant mice and transfer the microbiota from C3H/HeJ to 
the resistant mice made them more susceptible to infection; although not lethal, this 
highlights additional factors including genetic background, but also demonstrated the 
microbiota can influence host resistance seen by transfer of NIH Swiss microbiota into HeJ 
mice which delayed pathogen colonisation and mortality (Willing et al., 2011). C. rodentium 
can drive anxiety like behaviour in CF-1 male mice, challenged at nine weeks old their 
immune cytokine levels were unchanged, but displayed elevated c-Fos (marker of neuronal 
activity) within vagal afferent neurons suggesting vagal stimulation confers this type of 
behaviour rather than immune mediated inflammatory cytokines (Bullitt, 1990; Lyte et al., 
2006). 
E. coli a gut pathogen which elicits activation of the HPA axis and the secretion of pro-
inflammatory cytokines causing changes in the hypothalamus regulation of body 
temperature, e.g. fever. The adrenal cortex is sensitive to ongoing pro-inflammatory 
molecules, such as Prostaglandin E2 (PGE2) and correlated with rising corticosterone 
(Zimomra et al., 2011). The rise in circulating corticosterone is a product of COX-induced 
prostanoid synthesis which correlates with PGE2 production (Dinan & Cryan, 2012). 
Psychopathologies with evidence of HPA hyperactivation may therefore be associated 
immune responses to ongoing infections. Activation of the HPA may be triggered by 
increased intestinal permeability caused by stress, coupled with short term exposure to 
stress causing disruption to the microbiota (Bailey et al., 2011; Galley et al., 2014) (De 
Punder & Pruimboom, 2015).  
Neonatal immune challenge with LPS during neurodevelopment increases activity of 
tyrosine hydroxylase needed to catecholamine synthesis (Shanks et al., 1995). Stress-
induced increases in neuroendocrine hormones noradrenaline and dopamine can support 
growth of intestinal Gram negative bacteria and are a source LPS (Lyte & Ernst, 1992). 
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Infection elicits HPA activation with challenges using E.coli and LPS in rats causing IL-1 and 
neuroinflammation leading to memory impairment after a second inflammatory challenge 
in adulthood (Bilbo, 2005). Interestingly, maternal high fat diet (MHFD) increases 
circulating pro-inflammatory cytokines and negatively affects the neurodevelopment and 
microbiota of the foetus (Sullivan et al., 2014). Moreover, HFD is associated with an altered 
intestinal microbiota and increased vulnerability of anxiety-like behaviour.  
- Stress and neuroinflammation 
 
Neuroinflammation is synonymous with microglial cell activation; these are innate immune 
cells resident through the CNS and brain and undergo extreme morphological changes 
during ageing consistent with them being in an activated, pro-inflammatory state (figure 
1.1.10). Innate immune cells display pattern recognition receptors (PPRs) which recognise 
common microbial and virus structures known as pathogen associated molecular patterns 
(PAMPS) for example, bacterial cell wall components such as peptidoglycan (PGN) and 
lipopolysaccharide (LPS) recognised as non-self by Toll-like Receptors (TLR) leading to 
activation and downstream intracellular signalling associated with myeloid differentiation 
primary response gene MyoD88 and NF-kB activation of pro-inflammatory cytokines 
(Mogensen, 2009). In the absence of bacterial or viral infection, the primary function of 
microglial cells during resting state (M0) is to carry out immune surveillance within the 
brain and CNS (Kettenmann et al., 2011). The sensing of these bacterial products may 
regulate the neurodevelopment of the CNS in health as well as triggering 
neuroinflammation in pathological states.  A recent study suggests PPR interactions with 
the intestinal microbiota are needed for brain development; PGN-recognition proteins and 
NOD-like receptors are highly expressed during the postnatal window of colonisation, 
occurring simultaneously with the developing brain (fig. 1.1.7), are sensitive to changes in 
the intestinal microbiota (Arentsen et al., 2017). Fragments of PGN have been reported to 
cross the BBB in postnatal development of healthy mice (Arentsen et al., 2017). Using PGN-
recognition protein 2 knockout mice lead to the development of changes in social 
behaviour similar to GF or antibiotic treated mice (Arentsen et al., 2017). Thus 
translocation of PGN across the BBB and activation of PRRs during neurodevelopment 
appears to a mechanism for mediating early programming of neuronal circuits associated 
with emotions, cognitive and motor activity (Arentsen et al., 2017).  
GCs are also expressed on microglial cells and thus their immune status, morphology, and 
number are influenced by peripheral immune events and stress-induced HPA activity 
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(Sierra et al., 2008). Cytokine and other inflammatory markers such as PGE2 caused due to 
peripheral events, such as infection, can traverse the chorus plexus and BBB as well as 
promote prostaglandin release from endothelial cells within the vascular of the PVN and 
activate microglial cells and the stress response (Rivest, 2001). Moreover, vagal nerve 
stimulation can transmit information of peripheral inflammation in the gut to the brain to 
influence the HPA stress response and feedback to the peripheral immune system (Rea et 
al., 2016).   
- Microglia activation and polarisation 
 
Under steady state conditions (M0) microglial labelled with CX3CR1-GFP in mice, time-lapse 
two-photon microscopy shows they have multiple processes which continue to survey their 
environment (Nimmerjahn et al., 2005). Recognition of bacterial or viral PAMPS by PPRs 
will stimulate an innate immune response.  Bacterial LPS (endotoxin) binds to TLR4 which 
activates microglia (M1 polarisation) to adopt an amoeboid morphology, show increased 
motility and production of pro-inflammatory cytokines and reactive species (oxygen or 
nitrous derived) designed to engulf pathogens and mobilise CD4+ IFNg-producing Th1 cells 
and trafficking of immune cells to the brain (Nakagawa & Chiba, 2014). Microglial cells are 
a prime target for glucocorticoids to control this pro-inflammatory phenotype (Sierra et al., 
2008).  Figure 1.1.10 shows M1 activated microglial cells produce pro-inflammatory 
cytokines and chemokines such as IL-1b, IL-6, TNFa, CCL2, ROS, NO that are associated with 
sickness behaviour (Parnet et al., 2002). Depending on the cytokine milieu, Th2-derived 
cytokines, IL-4 and IL-13 can promote activation and polarisation of M2 microglia which 
express anti-inflammatory cytokine IL-10 (Nakagawa & Chiba, 2014). The lowered threshold 
for microglial activation, known as “microglial priming” is associated with ageing and 
neuroinflammation, consequently animal studies of neurodegenerative diseases find 
microglial cells are primed or activated (M1) and are more sensitive to peripheral immune 
activation (Perry & Holmes, 2014; Perry & Teeling, 2013). Thevaranjan and colleagues 
recently reported ageing in mice is also associated with decline of the intestinal microbiota 
(dysbiosis) and increased permeability of the intestinal barrier as well as the BBB triggers 
chronic systemic inflammation whilst GF mice are protected from these effects 
(Thevaranjan et al., 2017).  
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Figure 1.1.10 Polarisation and differentiation of microglial cells resident in the brain and CNS. 
Microglial cells are frequently referred to as the tissue-resident macrophages of the CNS and have 
an immunoregulatory function.  M1/M2 polarisation occurs when resting microglia are stimulated 
by pattern and/or danger associated molecular patterns, e.g. LPS, via TLR receptors. M1 microglia 
are associated with pro-inflammatory cytokine responses and release of PICs into the CNS. 
Conversely, M2 activation is stimulated by Th2-assocated cytokine IL-4 and IL-13 which causes 
microglia to secrete anti-inflammatory IL-10. Reproduced from (Nakagawa & Chiba, 2014). 
As a consequence of damage to the intestinal microbiota, caused by stress or infections, 
increased intestinal permeability may facilitate increases in plasma endotoxin which 
activate innate immune responses. Initial (primary) exposure to LPS did not increase IL-1b 
in the brain, however, long-term repeated dosages of LPS (secondary infection) in mice 
resulted in increased brain IL-1b, TNFa and IL-12 and an activated (M1) microglial 
phenotype and exaggerated response to infection with S. typhimurium (Püntener et al., 
2012). The characteristics of microglia during stress are similar to ageing, and are likely 
explained fact both lead to microglial priming, neuroinflammation and heightened 
reactivity to peripheral immune stimuli caused by low grade inflammation (Jurgens & 
Johnson, 2012). To this end, prolonged stress could be facilitating the acceleration 
microglial age-associated M1 polarisation and driving neuroinflammation. The effect of 
stress is paradoxical since under normal circumstances stress hormones releasing GCs are 
considered anti-inflammatory causing inactivation of immune cells via GRs. However, stress 
prior to immune activation in rats enhanced NF-kB activation and proinflammatory 
cytokine production in the frontal cortex and hippocampus, but was blocked by pre-
treatment of an GC receptor antagonist (Munhoz, 2006). 
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As discussed, early intestinal microbiota colonisation is necessary for postnatal 
development of the CNS and microbial-gut-brain signalling pathways in coordinating stress 
and immune responses. Defects in microglial cells are emerging as an important mediator 
of neuropsychiatric and neuroinflammatory disorders and may also be vulnerable to 
disruption in the intestinal microbiota. The importance of acquisition of the microbiota in 
early life for microglial homeostasis is apparent in GF mice which display immature neurons 
and BDNF. During early life, microglia support neuronal survival, modelling and pruning 
synaptic pruning as well as producing various neurotrophic factors to promote neuronal 
circuit development and synaptic formation (Erny et al., 2015). However, a number of 
downregulated genes required for microglial activation were discovered in GF mice 
microglial, including type 1 interferon receptors, Janus kinase 3 (Jak3) and signal transducer 
and activator of transcription 1 (Stat1) are evident compromised immune function and 
immaturity of microglia cells (Erny et al., 2015). Disruption of synaptic pruning by microglial 
cells during development is evident in mice lacking Cx3CR1 chemokine receptors, these 
mice had significant reduced number of microglial cells, and lacked functional neuronal 
connectivity, and display autism-related behaviour (Zhan et al., 2014). 
 
In addition to the variety of neurotransmitters produced by the intestinal microbiota, Short 
Chain Fatty Acid (SCFA) production can effect changes in brain neurophysiology being 
readily absorbed across the BBB and contribute to microglial homeostasis (Rea et al., 
2016). GF free mice re-introduced to a normal microbiota reversed deficits in microglial cell 
numbers, morphology and maturity, however SCFA alone were sufficient in reproducing 
this outcome (Erny et al., 2015). Moreover, mice deficient for SCFA receptor, FFAR2, also 
produce the same microglial phenotypic defects seen in GF mice with increased BBB 
permeability, yet under normal conditions FFAR2 is not expressed in any cell type in the 
brain and CNS (Braniste et al., 2014; Erny et al., 2015). Psychological stress causes 
prolonged HPA activation, and alteration in the microglial phenotype may involve 
trafficking of peripheral monocytes from the spleen (Wohleb et al., 2015). Thus, the 
intestinal microbiota may regulate microglial activation and neuroinflammation through 
trafficking of immune cells dependent on the production of SCFA (Rea et al., 2016). 
Interestingly faecal SCFAs have been reported significantly higher in children with autism 
spectrum disorder compared with control, suggesting increased fermentation process 
within the microbiota (Wang et al., 2012). 
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Studies in GF mice show their microglial cells are less efficient at mounting pro-
inflammatory responses to pathogens.  It is also revealed the intestinal microbiota can 
influence BBB permeability since butyrate-producing bacteria can increase expression of 
tight junction (TJ) protein occludin in the hippocampus and frontal cortex; in addition, 
transfer of SPF microbiota to GF decreased their BBB permeability (Braniste et al., 2014). 
Antibiotic-induced intestinal dysbiosis reduces bacterial metabolites in plasma, enhances 
HPA activity, with similar altered expression to TJ proteins seen in GF mice (Fröhlich et al., 
2016). To this end, hyperactivation of HPA and BBB permeability defects may facilitate 
circulating pro-inflammatory cytokine directly interacting with microglial cells during 
systemic infections.  
Indeed, neuropsychiatric disorder bi-polar and schizophrenia show involvement of the 
immune system as both TNFa and CRP are elevated in both conditions. Increasingly 
psychiatric disorders including these, and anxiety and depression are being characterised 
by neuroinflammation. Ageing is also associated to this immune profile and is termed 
“inflammageing” with profound effects on mood and emotion (Frasca & Blomberg, 2016) 
Recently a study collecting cerebral spinal fluid (CSF) in relation to psychiatric symptoms 
and cognitive dysfunction found CSF-resident microglia patients with schizophrenia and bi-
polar disorder have activation markers including CD14, a co-receptor for TLR4 (Johansson 
et al., 2017). Detection of soluble CD14 in CSP was associated with psychotic symptoms in 
twins with psychotic disorders compared with their un-unaffected twin (Johansson et al., 
2017). It is unclear what may be driving these differences, however, it is tempting to 
speculate increased exposure to bacterial components may drive neuroinflammation as a 
consequence of increased intestinal permeability (Kelly et al., 2015).  
- Stress impacts the intestinal barrier function 
 
Stress-induced increases in intestinal permeability are well documented in animal models 
for behaviour and in colitis where it is discussed  as causing exposure of the body to huge 
quantities of antigenic material derived from the microbiota which interacts with innate 
immune cells to drive low grade chronic inflammation (De Punder & Pruimboom, 2015; 
Fasano, 2012; Kelly et al., 2015; Visser et al., 2009). Stress-response and systemic 
inflammation in mice is dependent of PPR recognition of bacteria via TLR4 and do not 
respond to Gram negative bacteria when this receptor is knocked out (Gosselin & Rivest, 
2008). Negative emotions and stress-related hormones and neurotransmitters exert 
influence on the intestinal microbiota and alter physiological of the immune and neuro-
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endocrine pathways in complex humoral pathway and neuronal circuits (Rea et al., 2016). 
Maternal separation in rats, causes increased expression of choline acetyltransferase 
(ChAT) and hyperactivation of cholinergic neurons belonging to the ENS and is linked to 
stress-induced CFR activation of CRF-receptor 2 (CRFR2), a G-protein coupled receptor 
(GPCR) expressed on enteric neurons to induce barrier dysfunction (Gareau et al., 2007).  
The mechanism was further uncovered by the work of Overman et al., who revealed CRF 
mediated its permeability effects in this cholinergic neural pathway via activation and 
release of TNFa and proteases from mast cells, including histamines that impact tight 
junction proteins (Overman et al., 2012). The expression of PRRs (e.g. TLRs) present on 
enteric neurons suggests that microbes may interact directly with afferent nerve terminals 
belonging to the ENS and provide further feedback to the ENS and HPA axis via vagal 
stimulation (Dinan & Cryan, 2012; Rhee et al., 2009).  
 
Stress is known to induce endotoxin and low-grade inflammation by increasing intestinal 
permeability and may also cause neuroinflammation by altering permeability of the blood 
brain barrier through disruption to vascular endothelial tight junctions (De Punder & 
Pruimboom, 2015; Verma et al., 2006). The genus Lactobacillus is significantly reduced in 
mice exposed to social stress and in early life stress (Galley et al., 2014; O’Mahony et al., 
2011). In rats, probiotic treatment may offer solution to prevent increased permeability 
following oral administration of Lactobacillus farminis for 2 weeks resulted in decreased 
circulating LPS and attenuated HPA responses to acute psychological stress (Ait-Belgnaoui 
et al., 2012).  
 
Further to the work published on germ-free models and maternal separation of animals, GI 
barrier defects and alterations in the microbiota have been explored in a disease mouse 
model for autism, as well as in children (Hsiao et al., 2013; Luna et al., 2017).  Increased 
intestinal permeability appears to be an influencing factor in pathogenesis of autism; 
increased permeability was found in 36.7% of  adults patients with ASD, and in 21.2% of 
their relatives, compared to just 4.8% in healthy children (De Magistris et al., 2010). Similar 
changes in intestinal permeability have been reported to precede onset of type 1 diabetes 
in a study of 81 preclinical/new-onset/long-term patients versus 40 healthy controls using 
the lactulose/mannitol urinary excretion test (Bosi et al., 2006).  
 
       
 
 57 
An alternative stress signalling  pathway may be via enterochromaffin cells which may act 
as signal transducers between the luminal microbiota and underlying enteric neuronal 
network by secreting various signalling peptides and hormones including serotonin, CRF, 
cholecystokinin and somatostatin (Rhee et al., 2009). Low-grade chronic inflammation is 
associated with an altered intestinal microbiota in depression, with low abundance of 
butyrate-producing Faecalibacterium and high levels of Enterobacteriaceae (Jiang et al., 
2015).  Targeting these changes in the microbiota may influence intestinal immunity and 
consequently the level of inflammation that is detriment to causing increased permeability 
(De Punder & Pruimboom, 2015). Potential future therapies for stress-related and 
behavioural defects may redress the microbiota’s input using probiotics in neuropsychiatric 
disorders appears promising (Dinan et al., 2013). 
 
- Summary 
 
The microbiota is essential to the development and training of neuroendocrine and 
neuroimmune pathways in neurodevelopment and the HPA axis. Early life stress 
(antibiotics, infections) can impact the intestinal microbiota and disrupt temporal 
environmental cues to this process which have life-long consequences for stress handling 
and response to infection and can lead to priming of microglia in the brain. Many of the 
symptoms of ME/CFS, such as cognitive impairment, memory deficits, sleep disturbance, 
malaise, fatigue, are synonymous with ageing, a period where a decline in the diversity of 
the intestinal microbiota is paralleled with weakened immunity, and GI functions of 
digestion and motility is often compromised. Low-grade inflammation associated with 
ageing is apparent from increased levels of TNFa, IL-6 and CRP, and are known to affect 
cognitive functions and mood (Frasca & Blomberg, 2016). Just as the intestinal microbiota 
is necessary for post-natal neurogenesis and maturation of macrophage-related microglial 
cells, perturbations of the intestinal microbiota in later years influences the state of 
neuroinflammation and risk for neurodegenerative conditions with similar symptoms of 
cognitive defects and sickness behaviours influenced by peripheral inflammatory events 
caused by progressive priming and activation of microglial cells via vagal, HPA signalling and 
inflammatory immune mediators, altering their morphology and function in the brain to 
the effect of behavioural changes and social deficits similar to anxiety and depression. 
Finally, intestinal dysbiosis and increased intestinal permeability are plausible mechanisms 
for exposing the body to non-self antigenic material, predominantly, LPS and PGN from the 
microbiota which activate innate immune responses and activate microglial cells in the  
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brain and promote the pathogenesis of neuroinflammatory disorders. Animal models are 
leading the way in deciphering the relative impact GI function has in neuropsychiatric 
disorders; GF mice for example show exaggerated stress response and depletion of BDNF 
that can be rescued with B. infantis (Bercik et al., 2011; Sudo et al., 2004); reveal SCFAs are 
required for maturity and function of microglial cells (Erny et al., 2015). 
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1.6 Immune Abnormalities in ME/CFS  
 
Immunological studies attempting to characterise immune dysfunction in ME/CFS, are 
further complicated when stress and disruption to sleep is a known impact on the immune 
system and is prevalent among the patient population. The main immunological factors 
that vary between ME/CFS and healthy individuals are serum/plasma levels of chemical of 
cytokines, which facilitate crosstalk between the innate and the adaptive immune system. 
The available literature provides a conflicting view on the status of the immune system in 
ME/CFS (Theorell et al., 2017). Despite this, imbalances in the regulation of the immune 
system of ME/CFS patients have been documented in multiple studies, ranging from 
individual case studies to moderately sized patient cohorts (Broderick et al., 2010; Fletcher 
et al., 2009)Lorusso et al., 2009). The cytokine profiles reported are more indicative of an 
ongoing immune response to an underlying infection rather than being specific to ME/CFS. 
However, more recently a specific cytokine immune profile has emerged during early onset 
of ME/CFS which may help early diagnosis. In these immunological surveys there is 
potential evidence in some patients of a persistent stimulus triggering the immune system, 
which results in activation of immune-inflammatory pathways and is highly likely to 
account for many of the symptoms of ME/CFS including sickness behaviour (Morris & 
Maes, 2013). However, individual patient cytokine profiles may also depend on patient 
subgroup and staging of the disease, acute flares versus partial remission, and render it 
difficult to study the precise nature of the immune dysfunction seen in ME/CFS. Without 
effective grouping with ME/CFS patient there is a limit the value of determining cytokine 
levels in patients’ serum due to intraindividual differences and varying methodologies to 
detect them.  
 
- Inflammation 
 
Early reports suggested ME/CFS presented with activation of a chronic low-grade 
inflammatory responses by the presence of pro-inflammatory cytokines such as TNFα, IL-
1β, IL-6 which positively correlates with symptoms of fatigue and the feeling of 
experiencing an infection, or flu-like illness (Maes et al., 2012) (Morris & Maes, 2013). It is 
known these cytokines can impact tight-junction protein causing leakiness in the gut and in 
the blood brain barrier and correlate strongly with sickness behaviour of fatigue and 
malaise commonly experienced during viral infections. (Morris et al., 2013).  
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- Cytokine network analysis 
 
In an analysis of the cytokine networks of CFS, Broderick and colleagues studied the co-
expression of interleukins: 1a, 1β, 2, 4, 5, 6, 8, 10, 12, 13, 15, 17, 23, IFNg, lymphotoxin-α 
and TNFα and found distinct modules signalling a shift in the paradigm of Th1, Th2, and 
Th17 responses of CFS patients versus healthy controls (Broderick et al., 2010). Th1 
responses promote inflammatory cytokines secreted by innate immune cells and the 
activation of cytotoxic T cells as well as natural killer cells (Segerstrom & Miller, 2004), 
Conversely, Th2 responses produce anti-inflammatory cytokines, which promote humoral 
immunity by differentiation of B cells into antibody-secreting B cells and antibody class 
switching to IgE (allergy response). Associated cytokines belong to Th1 and Th2 and 
typically inhibitory of one another and high anti-inflammatory response reduce the risk of 
inflammation but can allow existing intracellular infections to persist if there are not 
adequately cleared. 
 
The association network pattern demonstrated significant attenuation of cytokines IL-1b, 
IL-4, IFNg and TNFα promoting Th1 and Th17 responses with higher expression of Th2-
inducing cytokines to be responsible for driving the inflammatory milieu in CFS (Broderick 
et al., 2010). IL-4 concentration was observed three-fold in CFS while IL-2, IFNg and TNFα 
remained unchanged. Anti-inflammatory cytokine IL-10 also increased substantially in CFS 
in contrast to IL-13, 17 as well as IL-5 and 6 which were diminished in the CFS network 
(Broderick et al., 2010) . 
 
Interestingly this supports the bias towards a Th2 response as IL-4 demonstrates an 
antagonistic effect on Th1-inducing cytokines such as IFNg and IL-2 (Brenu et al., 2011; 
Hornig et al., 2015). Ordinarily, IL-2 is associated with Th1 response but can also act as a 
growth factor for NK-cells which is are consistency found to be diminished in CFS patients 
(Brenu et al., 2011; Broderick et al., 2010) . Moreover, the direct antagonistic role of IL-2 on 
IL-17 production maintained in healthy controls was removed in CFS and in concert with IL-
1β emerges as another network within CFS permissive of an IL-23/Th17/IL-17 inflammatory 
response (Broderick et al., 2010). A question that is remaining is what causes this 
disruption within cytokine networks? It may partially be answered by a decreased 
sensitivity to IL-12 released by macrophages and dendritic cells during viral infection. 
Normally IL-12 production stimulates Th1 differentiation driven by IL-2 and their 
subsequent release of IFNg and TNFα would consequently enhance NK activation and 
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proliferation during viral clearance. By contrast, in CFS recurrent viral infection may be as a 
result of reduced NK cell cytotoxicity and elimination of virus-infected cell as shown by the 
lower expression of activation marker CD69 associated with a reduction in IL-2 and IFNg in 
an IL-4 dominant milieu (Mihaylova et al., 2007). An earlier study in 2004 by Skowera et al. 
demonstrated increases in IL-4 producing CD4 and CD8 T cells; which together with the loss 
of Th1 antiviral responses may be a factor in decreased NK activity, a bias towards Th2 
responses, consistent with a latent viral infection (Skowera et al., 2004). 
 
- Cytokine profiles in early versus long-term ME/CFS diagnosis 
 
Pro- and anti-inflammatory cytokines have been evaluated in early cases (< 3years) of 
ME/CFS and compared with long-term patients (> 3 years) demonstrating a significance of 
disease progression in cytokine analysis (Hornig et al., 2015). An immune response was 
noted by IFNg associated with CD4+ and CD8+ T-cell, and NK cell activity in the early phase, 
with decreased CD40L expression. CD40L is necessary for B cell class switching; and its 
deficiency causes susceptibility to infection triggering  progressive neurologic and cognitive 
decline (Bishu et al., 2009).  In long-term cases many cytokines were reduced below levels 
found in healthy control (Hornig et al., 2015). Elevated TGFb has emerged as the most 
consistent finding based on a meta-analysis (Blundell et al., 2015). Montoya and colleagues 
have studied the association of 51 cytokines with disease severity and found that 13 pro-
inflammatory cytokines may contribute to long term immunological changes. None of 
these were statistically higher in ME/CFS, but measurement for severe patients were found 
to be in the higher range for controls, whereas mild/moderate cases were in the lower 
range (Montoya et al., 2017). This may explain why past studies using heterogenous CFS 
criteria have yielded confusing and conflicting analyses of the immune system.  
 
Finally, increases in TGFb in ME/CFS may have a negative effect on persistent infections, 
during an of the immune system to downregulate persistent inflammation. Despite its anti-
inflammatory properties via the induction of T(regs), TGFb has been found in the gut 
mucosa of IBD patients with active disease (Shen et al., 2015) and thus ongoing pro-
inflammatory milieu observed in ME/CFS may alters its role (Morikawa et al.2016). 
Interestingly mice with T-cell targeted inactivation of TGFb  signally develop systemic 
autoimmunity with spontaneous colitis highlights the importance of the TGFb signalling 
pathway in immunity (Gorelik & Flavell, 2000). Also the higher prevalence of Non-Hodgkin’s 
Lymphoma in older ME patients may result from immunosuppression by TGFb and 
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upregulation of CD70 expression which is found to inhibit T cell memory effector function 
referred to as T cell exhaustion (Yang et al., 2014). These defective CD8+ T cells do not 
produce cytokines such as IL-2 and lose their ability to proliferate during chronic viral 
infection (Wherry, 2011). Severity of CD8+ T cell exhaustion also depends on the viral load 
(Wherry, 2011).  Decreased CD8+ responses to the lytic phase of EBV reaction in virus-
infected B cells have been found during all stages of Multiple Sclerosis (MS) and in CFS 
patients highlighting impaired viral immunity (Loebel et al., 2014; Pender et al., 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1.11 Formal analysis of plasma cytokine networks in 40 female Chronic Fatigue Syndrome 
patients and 59 female Healthy Controls.  HC and CFS display significantly different network 
topologies than expected by chance; CFS cluster II- being more “hub-like” design integrating a 
distinct subnetwork in CFS consisting of cytokines:  Il-1b, 2, 4, IFNg, and TNFa. Note cytokine nodes 
in CFS cluster I+ are more sparsely connected compared to HC. Figure obtained from (Broderick et 
al., 2010). 
 
Macrophages stimulated by IFNg during an ongoing pro-inflammatory response produce 
neopterin, a marker of cell-mediated immunity and indicator to ongoing oxidative stress 
(Murr et al., 2002). Interestingly some evidence has been found for increased IFNg 
production and elevated neopterin in ME/CFS, as well as IL-12 associated with Th1 immune 
response and positively correlated with fatigue and flu-like symptoms (Morris & Maes, 
2013a). One study that has separated ME from CFS using PEM lasting longer than 24 hr as 
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the hallmark symptom of ME showed that ME patients had higher levels of IL-1, TNFα and 
compared to the CFS (Maes et al.,2012). 
 
 
- Natural Killer (NK) cell deficiency 
 
In addition to cytokine profiles, immunophenotyping of peripheral blood mononuclear cells 
(PBMCs) has shown various of immunological abnormalities in ME/CFS patients with 
significant increases in IL-10, IFNg, TNFα, and reduction in cytotoxic activity of NK and 
CD8+T cells (Brenu et al., 2011). Reduced cytotoxicity in NK cells has been found in ME/CFS 
and has been attributed to an ongoing virus infection, although this has not been 
consistently found across all studies (Rivas et al. 2018). This may be down to technical 
factors some as using fresh whole blood versus frozen PBMCs as well as the time taken to 
analyse the sample in which small molecule such as cytokines may diminish in 
concentration (Rivas et al., 2018). CD69 expression is lower in ME/CFS and normally 
functions to stimulate T cell and NK cytotoxicity (Mihaylova et al., 2007) . Indeed, perforin 
expression has been found lower in patient compared with healthy controls, and is intrinsic 
to NK cytotoxic effects since it enables membrane disruption to cells targeted by NK cell to 
allow granzymes to enter and cause apoptosis (Baran et al., 2009; Mihaylova et al., 2007). 
Finally, a recent article has failed to reproduce previous findings regarding altered NK 
function which brings it to question any potential use of NK activity and other 
immunological abnormalities as a diagnostic marker in ME/CFS (Theorell et al., 2017). 
 
- Virus Infection 
 
Infectious mononucleosis, IM (Glandular Fever) bears resemblance to CFS but is usually 
self-limited to recovery within 12 weeks after onset. Typically, around 25% of teenagers 
and young adults infected with the Epstein Barr Virus (EBV) will go on to develop infectious 
mononucleosis and a further subset of these cases will also develop CFS after recovery 
from initial infection, suggesting that CFS may be a prolonged mononucleosis syndrome.  
EBV infection is common across the population, but the infection usually passes silently in 
most people without any obvious clinical symptoms. The virus initially targets mucosal 
epithelium before gaining entry to memory B cells, after which life-long latency usually 
ensues and is controlled by NK and CD8+ T cell responses. However, the virus may be 
reactivated and emerge in immune suppressed individuals. The frequency of EBV detection 
in those with no history of infectious mononucleosis shows that most individuals acquire 
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adaptive immunity, with the frequency of detection in CFS being no different to the rest of 
the general population. The idea that EBV is responsible for causing CFS remains 
controversial. Moreover, viral load and serological responses detected in CFS are 
inconsistent and are not helped by the use of different viral antigens in different serological 
assays (Bansal et al., 2011). CFS patients have demonstrated a mixture of enhanced and 
diminished specific antibody titres towards EBV suggesting possible latent reactivation 
caused by immune dysfunction in these patients. Diminished NK cytotoxicity and reduced 
NK-derived perforin production remain concurrently reported and specific to CFS (Brenu et 
al., 2013), suggesting chronic immune activation by viral infection may be responsible for 
clonal exhaustion and subsequent depletion of memory T cells (Maher et al., 2005). 
Regulatory T cells are seen to be increased in ME/CFS and may hinder antigen presentation 
by dendritic cells through interaction with CD80 and CD86 markers on the surface of DCs. 
Furthermore, this may contribute to the altered pattern of cytokine secretion by Th cells, 
favouring a type 2 immune response (Brenu et al., 2014) (Corthay, 2009; Serra et al., 2003).  
 
Despite scepticism surrounding EBV infection as a cause of ME/CFS, some evidence 
suggests underlying immune abnormalities and stress can promote reactivation of the virus 
and would likely contribute to the relapsing nature of ME/CFS. Circumstantially, the onset 
of symptoms with viral infections, apparent outbreaks of the illness, persistence of 
infections in ME/CFS individuals and beneficial treatment of EBV and human herpesvirus 6 
infection is consistent with an immune response to infection. Abnormalities within the HPA 
axis occur in CFS and can be affected by physical and psychological stressors e.g. anxiety 
and depression. This could play a role in ME/CFS pathogenesis as glucocorticoids secreted 
as part of the signalling axis are known to drive Th2 polarity and furthermore could support 
the latent reactivation of EBV leading to chronic recurrent viral infection (Webster et al., 
2002). Relentless exposure to virus infection is likely to drive CD8+ T cells to exhaustion and 
may be further exacerbated by high levels of IL-10 (Angelosanto & Wherry, 2010).  An 
example is HIV infection where IL-10, IFNg, and TNFα correlate with chronic infection and 
viral load (Couper et al., 2008).  
 
A recent publication exposed deficient EBV-specific B- and T-cell responses in CFS patients 
[Loebel et al, 2014]. Serum IgG derived from long-lived plasma cells can persist years after 
primary infection. Therefore, the authors looked at the memory B cell function, in vitro, 
toward specific EBV antigens and found low to undetectable antibody responses against 
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EBNA-1 and VCA antigens in 76% of CFS patients despite normal titres of IgG antibodies to 
VCA found in serum. This could represent an inability to generate significant numbers of 
EBV-specific memory B-cells during primary infection or loss of memory B cells in ME/CFS. 
EBV-specific T cell responses were analysed after stimulation with fragments consisting of 
overlapping 15-mer peptide derived from EBNA-1 protein normally expressed during early 
latency phase. Frequency of EBV-specific CD4 and CD8 triple producing TNFα+, IFNg+, IL-2+ 
memory T cells were significantly lower in 58% of cases (n=23) than the non-fatigued 
control group (n=17). 
 
Vast numbers of studies have assayed for sero-prevalence of viral DNA using RT-PCR and 
conducted sero-analysis of antibodies to different viral antigens leading to mixed results 
(Bansal et al., 2011). However, no evidence linking a single pathogen, viral or bacterial, to 
causing ME/CFS pathology has been found. Instead, CFS may be caused by an aberrant 
response to infection (Hickie et al., 2006) therefore, multiple viral infections may 
perpetuate a chronic persistent immune activation by exploiting the Th2 bias and 
disruption to NK cytotoxic function.  
 
- Summary 
 
There is no consistent cytokine profile in ME/CFS. Nevertheless, there is a tendency for IL-1, 
IL-2, IL4, IL-10, IL-17A, IFNg and TNFα to be elevated in ME/CFS patients particularly with 
respect to illness (Hornig et al., 2015) . Given the high prevalence of GI symptoms in 
ME/CFS it is interesting to note proinflammatory cytokines, IL-1, TNFα are also found at 
high levels in patients with inflammatory bowel disease (Strober & Fuss, 2011). Reduced 
natural killer (NK) cell activity is a common observation in ME/CFS, with multiple studies 
reporting elevations in FoxP3+ Tregs which may further limit NK cell activity (Brenu et al., 
2013b).  The cause for this elevation Tregs and heightened IL-10 production is unknown but 
could represent a counter mechanism to attenuate pro-inflammatory responses during 
chronic persistent infection in ME/CFS. 
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1.7 Autoimmunity in ME/CFS 
 
No consistent autoantibodies have been identified in all ME/CFS patients, with those that 
have been identified overlapping with other autoimmune disorders. Mild to moderate 
improvement in 67% CFS patients (10/15) was seen treated with Rituximab®, an anti-CD20 
B cell depletion therapy (Fluge et al., 2011). This drug works but causing targeted 
depletions of the CD20 B cell population with a delayed response of 2-7 months before 
both self-reported and physician-assessed fatigue scores were significantly improved. The 
trial authors speculate delay in clinical response is due to the gradual elimination of serum 
autoantibodies (Fluge et al., 2011). Prior to this finding, increases in the naïve/transitional B 
cell population had been reported in a study by Bradley and colleagues, as well as marked 
depletion in the plasmablasts.  
 
Blood taken from 56 ME/CFS patients and 37 healthy controls, show ME/CFS may be 
characterised by increased levels of plasma peroxides and serum oxidised LDL (oxLDL) 
antibodies which demonstrate ongoing oxidative stress caused by chronic immune 
activation (Maes et al.,, 2011). Evidence is emerging that many ME/CFS patients have 
increased levels of oxidative stress following exercise (Jammes et al., 2005). Interestingly 
there have been reports of autoimmune responses in some ME/CFS patients against self-
epitopes as a result of damage caused by intermediate reactive oxygen species (ROS) from 
immune processes. These include components of lipid membrane, palmitic, myristic and 
oleic acid, and anchorage molecules, S-farnesyl-L-cysteine which undergo conformational 
changes, presenting to the immune system as neoepitopes (Maes et al., 2006; Morris & 
Maes, 2014). ROS are essential for killing of bacterial pathogens, however overproduction 
or inadequate removal of these intermediates by redox pathways may cause significant 
tissue damage and disruption to the intestinal epithelial barrier (Aviello & Knaus, 2017).  
These observations in ME/CFS posit the theory that chronic immune activation and ROS 
cause self-epitopes to be damaged and become a target for the immune system (Morris et 
al., 2014; Morris & Maes, 2013a). Microbial infection may drive chronic inflammation and 
cause autoimmune cross-reactivity by a process of molecular mimicry explained by sharing 
of amino acid sequence homology between bacterial antigens and host self-antigens 
leading to autoantibodies targeting both (Morris & Maes, 2013a). Increased bacterial 
translocation is increasingly evident as a result of increased intestinal permeability now 
demonstrated several human diseases including Crohn’s disease and in liver cirrhosis 
(Pastor-Rojo et al., 2007; Pijls et al., 2013).    
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Autoimmune reactions lead to inflammation, increased permeability of blood vessels and 
migration of lymphocytes to sites of injury that contribute towards patient fatigue and 
malaise (Maes et al., 2013). The nature of the stimuli and antigen(s) responsible for 
generating any auto-antibodies in ME/CFS remains to be determined. Several autoantibodies 
have been documented in ME/CFS patients however, the profiles vary between patients. The 
most interesting are anti-5-HTA receptor antibodies since the majority of serotonin is 
produced in the gut (Maes et al., 2013). Additional evidence supports a subset of ME/CFS 
(29.5%) patients have antibodies against one or more M acetylcholine and b adrenergic 
receptors (Loebel et al., 2016). Remarkedly those patients with elevated antibody levels pre-
treatment of Rituximab were the majority of clinical responders; their total IgG, IgA and IgM 
levels post-treatment were lower, but not significantly different compared to non-
responding patients (Loebel et al., 2016). The presence of these antibodies is not disease 
specific but have been found in autoimmune diseases that share common features with 
ME/CFS including fatigue and autonomic dysfunction. An example is postural orthostatic 
tachycardia syndrome (POTS) is estimated to affect 10-20% of CFS patients, where b1 and 
b2 adrenergic receptor antibodies have also been reported, as well as in orthostatic 
hypotension cases (Thieben et al., 2007; X. Yu et al., 2012).  
  
- Infection elicited autoimmunity 
  
It is known that microbial-derived stimuli can influence the nature and function of immune 
cells in the intestinal mucosa, and when dysregulated can lead to systemic inflammation 
(Strober, 2013; Maloy & Powrie 2011; Tanoue et al., 2010). For example, Guillain-Barre 
(GB) syndrome has been associated with certain bacterial infections including 
Campylobacter jejuni, Haemophilus influenza and Mycoplasma pneumonia (Heikema et al., 
2010). LPS exhibit structural homology to human gangliosides, found chiefly on neuronal 
ganglia that are major constituents of neuronal cell membranes, and are possible target for 
cross-reactive antibodies found in the serum of GB patients in response to bacterial 
infection (Nishimura, 1996).  Reactive arthritis (ReA) has been strongly associated with the 
HLA-B27 allotype and is triggered by diverse bacteria (Alvarez-Navarro 2013). HLA-B27-
restricted epitopes of bacterial and self-antigens cross-react to activate cytotoxic 
lymphocytes and therefore play a role in ReA. The role of HLA-B27 in inflammatory 
rheumatic diseases also highlights the importance of HLA allotypes being factors in 
autoimmune disease. 
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Both viral and bacterial infections have long been associated with pathogenesis in 
autoimmunity, notably mycoplasma infection in Rheumatoid Arthritis (RA). Mycoplasma-
derived antigens are capable of generating cytotoxic cross-reactive effector lymphocytes, 
which upon isolation from the synovial tissue of RA patients bear the same receptor-
targeted specificity to Mycoplasma arthritidis antigen (MAM) (Oldstone, 1998; Cole et al., 
2000; Sherbet, 2009). The occurrence of viral infection preceding onset of autoimmunity 
has been recognised in ME/CFS patients (Morris et al., 2013), and in type 1 diabetes (van 
der Werf et al., (2007). However, it is difficult to dissect and validate the mechanisms, e.g. 
molecular mimicry, by which viruses generate autoimmunity.  
 
Reduced cytotoxic T-cell responses to EBV can also increase activating autoreactive B cells 
as a result of exposure to gut-derived microbial antigens that induce chronic inflammation 
and T cell exhaustion (Loebel et al., 2014). Blomberg and colleagues have reviewed various 
aspects of the ME/CFS and suggest a mechanism of microbial infection driving autoimmune 
processes which impacts on the severity of ME/CFS symptoms (Blomberg et al., 2018).  
Emerging data supports disruption to intestinal microbiome in ME/CFS and changes in 
intestinal permeability that are likely to have negative consequences for mucosal tolerance 
to commensal bacteria as well as wider implications for the immune system that have not 
yet been explored in ME/CFS. 
 
1.8 The Human Intestinal Microbiota 
 
Intestinal microbes represent the greatest concentration of microbes than any other area 
on or in the human body whose genetic repertoire (the microbiome) is estimated between 
2-20 million genes which vastly exceeds the genetic information of the ~20,000 genes 
representing the human genome (Kurokawa et al., 2007). Most are bacteria, consisting of 
more than 1000 different species whose inhabitancy affording functional benefits have 
become fully integrated with biological pathways controlling our metabolism, immune 
system, neuro-endocrine system, and development of the brain and central nervous 
system (Heijtz et al., 2011; Kawamoto et al., 2014; Qin et al., 2010; Round & Mazmanian, 
2009; Sudo et al., 2004). Initial colonisation of the intestinal tract occurs immediately after 
birth and is dominated by Bifidobacterium species belonging to the phyla Bacteroides and 
runs in parallel with the developing mucosal immune system (Rodríguez et al., 2015). Data 
from the Human Microbiome Project classifies intestinal bacteria into 5 distinct phyla, 
listed here from highest to lowest proportional abundance: Firmicutes, Bacteriodetes, 
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Actinobacteria, Proteobacteria and Verrucomicrobia, the only representative of this last 
phyla in humans  being an intestinal species called Akkermansia muciniphila (Li et al., 
2014). Members belonging to Firmicutes (F)and Bacteroides (B) contribute approximately 
92% of the microbiota (Eckburg et al., 2005). The ratio of F:B in infants begins at 0.4 (3 
weeks to 10 months) , evolving to 10.9 in adulthood (25-45 years old) and declining 
towards 0.6 in the elderly (70-90 years old) (Mariat et al., 2009). The average person’s 
faecal samples contains approximately 160 different species and regardless of the variation 
in diversity and composition of the intestinal microbiota between different people, there is 
similarity in their metabolic statuses, which may be more important in defining aspects of 
health (Huttenhower et al., 2012; Moya & Ferrer, 2016; Rodríguez et al., 2015). For 
example, a core microbiota of 57 species has been reported to exist in more than 90% of 
individuals which suggests these species have critical metabolic functions (Qin et al., 2010). 
However, defining the composition of a ‘healthy’ microbiota is complex due to variations in 
host genetics, diet, lifestyle, age, fitness, stress, geographical location, antibiotic exposure 
and history of infections, between individual persons (Huttenhower et al., 2012). This 
variability in the composition of the microbiota from person to person and in disease 
versus healthy will influences it the metabolic and immunological functions and has driven 
interest in defining the role of individual species involved in these processes (Rowland et 
al., 2018). Specific members of microbiota stimulate an equilibrium between pro- and anti-
inflammatory immune responses to control diversity and growth of bacterial populations. 
Altering the composition of the microbiota, through diet, stress, mediations, antibiotics 
exposes it to possible pathogenic bacteria which promote inflammation and outgrowth 
over members of the community (Baümler & Sperandio, 2016).  
 
Compositional differences within the profile of gut bacteria have been observed in several 
human diseases, including ME/CFS, when compared to healthy subjects ( Bajaj et al., 2014; 
Carding et al., 2015; Clemente et al., 2018; Giloteaux et al., 2016; Joossens et al., 2011; 
Norman et al., 2015; Quigley, 2018). Most strikingly, these observations are not limited to 
GI disorders such as IBD and IBS (Carding et al., 2015). There is increasing evidence to 
suggest intestinal bacteria contribute towards systemic chronic inflammatory-based 
disorders such as obesity, metabolic disorders have now been linked to changes in gut 
permeability, immunity and the composition of this microbiota referred to as gut dysbiosis 
(Carding et al., 2015; Fasano, 2012).  
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The function of the intestinal microbiota is largely mediated through diet. The composition 
of the diet can substantially alter growth of specific members microbiota as well as its 
metabolic activity which influences availability of bacterial-derived metabolites to the host. 
For example, SCFAs are the products of fermentation of dietary fibres which can reduce the 
pH affecting the growth of pH-sensitive species (Escherichia coli and Salmonella spp.) 
within the intestine (Cherrington et al., 1991). SCFA production is reduced by the 
consumption of high levels of animal saturated fats from meat, and low complexity 
(refined) carbohydrates (David et al., 2014). Moreover, refined sugars increases the risk of 
opportunistic pathogen colonisation, e.g. Clostridium difficile and Clostridium perfringens 
(Brown et al., 2012). High sugar consumption has been shown to elevate 
Enterobacteriaceae associated with brain and intestinal inflammation and deficits in 
cognitive capabilities in hepatic encephalomyelitis which is seen as a complication of liver 
cirrhosis associated with endotoxin exposure and increasing intestinal barrier dysfunction ( 
Bajaj et al., 2012). SCFAs are relevant to inflammatory disorders since the can support 
immune tolerance by promoting anti-inflammatory responses towards commensals of the 
intestinal microbiota and have been shown to reduce inflammation in the dextran sulfate 
sodium (DSS)-induced colitis mouse model (Atarashi et al., 2011). As we age the 
composition of the microbiota changes towards an increased abundance of Bacteroidetes 
and Clostridium cluster IV, however, the capacity to produce SCFAs appears to be reduced 
and is understood to contribute to the increasing pro-inflammatory tone as we age (Biagi 
et al., 2010; Claesson et al., 2011; Frasca & Blomberg, 2016). SCFAs also act as signalling 
molecules via activation of GPCRs, GPR41 and GPR43 also called FFAR2 which have been 
associated with in reducing pro-inflammatory cytokines; and affecting pathway involved in 
epithelial integrity, fatty acid oxidation via the activation HDAC (Kimura et al., 2014; 
Vanhoutvin et al., 2009; Waldecker et al., 2008). 
 
- Intestinal microbiota and mucosal immunity 
 
The gut-associated lymphoid tissue (GALT) is home to the majority of immune cells in the 
body, containing over 70% of the immune system (Vighi et al., 2008). A key function of the 
immune system is to discriminate between the threat of pathogens and commensal (non-
pathogenic) members of the microbiota. To that end, there are several mechanisms the 
immune system employs which help shape the intestinal microbiota and limit pathogen 
colonisation.  
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GF mice has proven valuable in understanding how the intestinal microbiota influences the 
developing immune system and sets the inflammatory tone through mediating the balance 
of pro and inflammatory mechanisms. GF mice are more susceptible to pathogen infections 
compared to conventional mice and have fewer intestinal antigen-presenting cells (APCs) 
and defects in gut-associated lymphoid tissues (GALT) compared with SPF mice (Kim et al., 
2017). Lymphocytes structures for presentation of antigen, for example Peyer’s Patches 
(PP) and mesenteric lymph nodes (MLN) are sites for , are missing in GF mice but can be 
restored with intestinal bacteria, or PGN derived from Gram-negative bacteria (Bouskra et 
al., 2008; Falk et al., 1998). 
  
The microbiota regulates the differentiation of T helper (Th) cells and therefore the balance 
of T(reg) and Th1/Th2/Th17 subsets which respond accordingly to the presentation of 
bacterial protein antigens via MHC complexes on dendritic cells (DCs) and macrophages 
(Mf) patrolling the lamina propria (Kim et al., 2017). Figure 1.1.12 summaries the functions 
of each T cell subset and its associated cytokine profile and transcription factors. TLRs are 
also present on the apical surface of intestinal epithelial cells exposed to bacterial antigens 
and are themselves significant producers of cytokines contributing to the cytokine milieu 
(Akira & Hemmi, 2003). The cytokine environment is important as it will influence the 
activation of a particular T cell subset upon antigen presentation. For example, under 
normal circumstances, antigen presenting cells (APCs) reside within PPs and produce 
significant amounts of anti-inflammatory IL-10 to promote T(reg) differentiation and 
immune tolerance (Iwasaki & Kelsall, 1999). Moreover, Mf cells do not produce pro-
inflammatory cytokines upon activation of TLRs by common bacterial antigens such as LPS 
(Smythies et al., 2010).  
 
In addition to the defects in secondary lymphoid structures, GF mice have significantly 
fewer CD4+ T cells in the lamina propria which an imbalance towards a Th2 immune 
response (H. J. Wu & Wu, 2012). In addition to SCFA production, specific members of the 
microbiota are known to induce T(reg) cells which include those belonging Clostridia 
clusters IV and XIVa (Atarashi et al., 2011), polysaccharide A of Bacteroides fragilis 
(Telesford et al., 2015), and Faecalibacterium praunitzii (Qiu et al., 2013). However, there 
are also certain groups of bacteria such as segmented filamentous bacteria (SFB) are 
capable of elicit higher numbers of Th1 and Th17 cells critical in the induction of 
autoimmune pathogenesis and the acceleration of experimental autoimmune 
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encephalomyelitis (EAE) (Forbes et al. , 2016; Lee et al., 2011). Further close protection of 
the epithelial barrier is afforded by a specialised class of immune cells, called innate 
lymphoid cells (ILCs) whose role includes the release of IL-22 during infection and in 
addition to its association with Th17-mediated inflammation, is it protective and counter-
active in IBD of mice (Zenewicz et al., 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.12 Commensal bacteria induce T cell differentiation. Each T cell subset is defined by its own 
transcription factor associated cytokine production. Th1 responses are critical in responding to 
intracellular infections, whereas Th2 is associated in allergy responses. Th17-mediated inflammation 
controls infection but also has been attributed to the pathophysiology of several chronic auto-
inflammatory disorder, including IBD. T(reg) cells induce tolerance and inhibit T cel differentiation 
into the other subtypes. Several beneficial intestinal bacteria are known to stimulate T(reg) 
responses which control inflammation. Figure reproduced from (Wu & Wu, 2012). 
 
In addition to stimulating T(regs), secretory IgA (sIgA) enables the immune system to 
coordinate a response without causing inflammation and protect the epithelial barrier from 
invasion. Further evidence that single strains of bacteria can alter the balance of pro- and 
anti-inflammatory responses was demonstrated in probiotic treatment with Lactobacillus 
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kefiri CIDCA 8348 in Swiss mice for 21 days increased the production of faecal IgA and 
moreover stimulated IL-10 (Carasi et al., 2015). The production sIgA can occur through T 
cell-dependent and T cell-independent pathways. DCs and Mf present antigen to naïve B 
cells at Germinal Centres (GCs) for interaction with Th cells in order to effect differentiation 
and class switching to become IgA secreting plasmablasts before homing to the intestinal 
lamina propria as resident IgA producing plasma cells, figure 1.1.13 (MacPherson et al., 
2008; Macpherson & Uhr, 2004). IgA production is another feature compromised in GF 
mice as a result of poor maturation of naïve B cells and underpins the requirement for 
exposure to intestinal microbes to coordinate commensal-specific IgA production and may 
also contribute to intestinal barrier defects (Kim et al., 2017). IgA responses are induced 
following the introduction of commensal bacteria to a reversible colonisation of GF mice 
however, following repeated dosage of commensal bacteria, IgA responses were in 
recognition of the exposure of microbes at that time and therefore IgA induction lacks 
immunological memory or prime boost effect as is the case with systemic vaccination 
(Hapfelmeier et al., 2010). 
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Ü Figure 1.1.13 Induction of Immunoglobulin A at Peyer’s Patches (PP). Specialised epithelial cells, 
called M cells, capture luminal antigens at PPs for uptake by CD103+ dendritic cells which migrate 
within the PP to establish contact with CD4+ T(regs) cells which remain tolerant to the commensal 
microbiota and support IgA-production. This response requires DC-derived retinoic acid, TGFb, IL-10 
for T(regs) to differentiate into T-follicular (Tfh) helper cells which interact with antigen-specific 
naïve B cells to become activated. Once activated B cells then migrate towards the follicle (blue 
area) where they interact with follicular dendritic cells which retain antigen, enabling rapid 
expansion of B cells and induction of SHM, IgA CSR and affinity maturation in response to CD40L, IL-
21 and TGF-b secreted by Tfh cells. IL-10, retinoic acid further enhances this process and IgA 
production within the germinal centre by inducing gut-homing markers on B cell, such as a4b7 and 
CCR9. B cells eventually differentiate into plasmablasts and long-lived plasma cells within the lamina 
propria that secrete IgA which following pIgR-mediated transcytosis across the epithelial barrier 
comes into contact with luminal microbes. Figure and description adapted from (Gutzeit, Magri, & 
Cerutti, 2014). 
 
- Microbial-neuro-immune interaction 
 
Afferent vagal neurons are in close contact with the mucosal and display receptors for 
common signalling molecules such as cytokines that are released from activated immune 
cells such as macrophages. The explanation therefore for sickness behaviour during 
infection is best explained as cytokine-mediated activation of the vagus nerve in response 
to inflammatory changes. In these instances, peripheral cytokines influence the CNS are 
coupled with mucosal production of other inflammatory mediators many effective upon 
receptors expressed on enteric neurons such as TNFα receptors, overall facilitating 
sensitization and perception of abdominal pain via afferent neurons which innervate the 
gut wall (Mayer, 2011). The basic mechanisms of sensing the microbiota, primary neurons 
of the ENS, immune cells and enteroendocrine cells are at the forefront of signalling in the 
gut-brain axis linking functionality of the HPA axis, the neuroendocrine system and the 
immune system together in gastrointestinal function.  
 
Neuronal signalling is a vital component for modulating immune responses at the intestinal 
epithelial barrier - particularly controlling mucosal inflammation. Enteric neurons express 
TNFα receptors (TNFR1 and R2), but neuropeptide Y (NPY) KO mice produce less 
endogenous TNFα compared with wild-type mice; which has been shown to activate 
expression of NYP in the ENS leading to changes in intestinal permeability 
(Chandrasekharan et al., 2008). NPY has a role for pro-inflammatory effects in the GI tract 
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and is shown to induce changes in permeability via tight-junction protein, claudin-2 
(Chandrasekharan et al., 2008). Enteric neurons also express PPR immune signalling 
receptors, including Toll-like receptors 2, 3, 4 and 7. Mice lacking expression of TLR2 and 
TLR4 exhibit defects within the architecture of their ENS, abnormal mucosal secretion and 
reduced motility, where similar to mice with a depleted microbiota; however Tlr2(-/-) mice 
developed more severe form of colitis than wild-type mice following SSD treatment (Brun 
et al., 2013) As a consequence of an underdeveloped ENS, TLR2 KO mice exhibited severe 
colitis supporting the notion that intestinal microbes are necessary for enteric 
development and maturation of the mucosal immune system later in life (Sharkey & 
Savidge, 2014). 
 
1.9 Stress and neuroendocrine manifestations in ME  
 
Psychological stress is a critical factor in the pathological development and maintenance of 
ME/CFS symptoms. As well as reports of flu-like illness preceding ME, significant life events 
hyper-activate the stress response through cortisol production as well as from the pressure 
to perform well at work or school and to succeed. Individuals of this kind are highly 
ambitious and competitive and have a desire to feel in control with a direction in their lives. 
However, many ME/CFS patients appear to reach a state of burnout and are unable to fully 
recover and become increasingly distressed and anxious as well as physically exhausted in 
pursuit of great expectations. Emotions and negative thoughts lead to further stress, 
underpinning a psycho-biological mechanism (figure 1.1.5, page 40), this is likely to become 
self-perpetuating as the stress of not being able to recover and return to normal life will 
have negative effects on the immune system and consequently the gut microbiota and gut 
barrier. Thus, the characteristics of inability to rest and unwind, may represent dysfunction 
within the negative feedback pathways integrated with HPA axis, immune system and the 
central nervous system.   
 
Further symptom-based evidence for altered stress-responsivity manifests within post-
exertional malaise, the main symptom of ME/CFS which highlights the effect physical and 
psychological stressors endure on patients. Patient’s undertaking any form of physical or 
mental challenge can expect severe worsening of their symptoms after an initial delay of 12 
hours or more in severe ME/CFS. Interestingly, the delay in the effect of PEM is an unusual 
phenomenon as it is not symptom that has been associated with any other disease, other 
than ME. Speculatively, PEM may represent a variation of stress response regulated by the 
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HPA axis. Dysfunctional HPA-axis is also substantiated further by symptoms of cold hands 
and feet since the hypothalamus regulates the body temperature. Usually body 
temperature is elevated in response to peripheral infection, but is not in ME/CFS, 
potentially a weakness in developing infections or allowing reactivation of latent infections 
such as EBV (Bansal, 2016). Finally, HPA dysfunction is also implicated in the 
pathophysiology of anxiety and depression and ongoing low-grade chronic inflammation in 
these conditions.  
 
1.10 Intestinal microbiota impacts neuropathology 
  
Neurological and neuropsychiatric illnesses are strongly linked to intestinal dysbiosis and 
physical and emotional stressors (Cryan & Dinan, 2015). In addition to immunomodulation, 
intestinal microbiota can influence the ENS and communicate with the CNS to alter animal 
behaviour and social stress. This has been demonstrated by faecal microbiota 
transplantation (FMT) from depressed patients into GF rats inducing alterations in 
tryptophan metabolism and characteristics of depression, such as increasing anxiety and 
anhedonia (Kelly et al., 2016). For instance, lactic acid producing bacteria (LAB) are known 
produces of GABA. Moreover, Lactobacillus rhamnosus (JB-1) induces GABA receptor 
expression throughout the brain, but is dependent of neuronal transmission between the 
intestine and brain via the vagus nerve, just as the effect of Bifidobacterium longum since 
its anxiolytic action was blocked in vagotomised mice (Bercik et al., 2011; Bravo et al., 
2011). Stress is implicated in hyperactivity and hyperresponsivity of the amygdala (the 
brain centre for emotions and emotional behaviour) and upregulation of CRF expression 
and is concomitant with a lack of inhibitory control by GABA neurotransmitter signalling. 
Such dysfunctional GABAergic signalling is associated with anxiety, depression and 
schizophrenia and abnormal HPA dysfunction (Wang et al., 2016). Glucocorticoid 
production by the HPA regulates GABA receptor expression and induces atrophy in 
GABAergic neurons in early life development, thus chronic activation of the HPA 
contributes to stress and mood disorders by blocking inhibitory GABA feedback in the 
amygdala (Wang et al., 2016).  
There are other factors that may compound dysbiosis such as leakiness of the gut epithelial 
barrier which is known to be impacted by chronic stress. The enteric nervous system 
responds to CRF to change gastrointestinal functions during stress events which include 
during response to pathogen infection. This can heighten visceral pain perception, and to 
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stimulate inflammatory responses within the gut and CNS. In addition to vagal nerve 
stimulation, sensory neurons within the ENS can sense specific molecular patterns of 
molecules expressed on commensal bacteria via TLRs, providing feedback to the brain and 
immune system.  Given the high frequency of GI disease in neurological and 
neuropsychological disorders these microbiota-derived physiological inputs are emerging 
critical to the formation of pro-inflammatory conditions as a requisite to developing (and 
progressing) autoimmune disorders affecting the brain and CNS.  
 
MS is a chronic autoimmune inflammatory disease driven by autoreactive T cells causing 
demyelination of the CNS.  It manifests with similar neurological impairment and gradual 
degeneration presented in ME/CFS with symptoms including muscle weakness, 
paresthesia, fatigue, cognitive impairment, numbness and relapsing (flares) and remitting 
nature affecting the CNS. In addition to genetic susceptibly, the state of the composition 
intestinal microbiota is emerging as a contributor towards risk of developing autoimmune 
disease. Clinical studies on patients with relapsing-remitting (RR) onset Multiple Sclerosis 
(MS) exhibit differences in the composition of intestinal microbes at the taxonomic level 
compared with healthy controls (Chen et al., 2016; Jangi et al., 2016; Miyake et al., 2015). 
In a cohort of Japanese patients, these taxa comprise of significant changes to 21 species, 
of which a depletion of 19 was in RR MS samples; 14 belonging to Clostridia clusters XIVa 
and IV. 
In terms of the richness, the number of species the MS patients (a-diversity) did not differ 
from healthy controls, unlike in IBD which is characterised by significantly lower species 
richness (Gong et al., 2016). Therefore, intestinal dysbiosis in MS appears distinct from 
other inflammatory disorders which have lower a-diversity.  In a separate study, species 
richness also did not separate RR MS from healthy controls, rather active disease patients 
compared to RR MS showed decreased species richness and warrants further longitudinal 
studies to determine if and how compositional changes within the intestinal microbiota 
relate to progression of MS or enhance its severity, or frequency of relapses (Chen et al., 
2016).  
Interestingly there is very little overlap between the Clostridia species found reduced in RR 
MS and those that have been documented in IBD (Atarashi et al., 2013). Clostridia are 
known producers of Short Chain Fatty Acids (SCFAs), particularly butyrate which is a used 
as an energy source and stimulates anti-inflammatory responses and induction of colonic 
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T(regs) in the support of immune tolerance towards commensal bacteria (Zhang et al., 
2016). In experimental colitis models, SCFAs effect epigenetic changes via inhibition of 
histone deacetylase 1 (HDAC-1). In particular, Faecalibacterium prausnitzii, one of the most 
abundant bacteria in the intestinal microbiota found less abundant in RR MS, has been 
identified to regulate Th17/T(reg) differentiation by inhibition of HDAC-1 which blocks IL-
6/signal transducer and activation of transcription 3 (STAT3)/IL-17 pathway,  causing Foxp3 
induction of T(regs) and differentiation (Zhou et al., 2018). T(regs) can produce TGFb an 
anti-inflammatory cytokine in order to suppress pro-inflammatory Th1/Th17 cell responses.  
Peripheral events leading up to, or during the onset, and progression/exacerbation of 
neurological diseases are being studied. In a recent pilot study comparing the intestinal 
permeability of RR MS patients with 18 age and sex-matched healthy controls, the ratio of 
lactulose/mannitol measured in urine was significantly higher in 16/22 patients (p=0.0284) 
(Buscarinu et al., 2017). Increased intestinal permeability is a proposed mechanism for 
developing autoimmune disease that develops over time and in response to intestinal 
dysbiosis (Fasano, 2012).  The interactions between intestinal microbes and the immune 
system in MS remain unclear and challenging to study in humans. Experimental 
Autoimmune Encephalomyelitis (EAE) is generated in rodents through peripheral 
immunisation with CNS antigens including; myelin basic protein (MBP) and myelin 
oligodendrocyte glycoprotein (MOG). As a result, pro-inflammatory infiltration of 
autoreactive T cells into the brain and CNS of mice, causing chronic inflammatory 
demyelination that resembles clinical aspects of MS in humans (Stromnes & Goverman, 
2006).  
In addition to exposure to MOG peptide, T-cell mediated neuroinflammation in EAE 
requires IFNg producing Th1 cells and IL-17 and expression of a4b1 integrin for 
extravasation across the BBB. There is some evidence to suggest systemic infections 
increased the chances of relapse in MS patients (Correale et al., 2006). Systemic challenge 
with lipopolysaccharide (LPS) is used to model systemic inflammation. The induction of 
proinflammatory cytokines including IL-1b, IL-6 and TNFa can influence sickness behaviour 
and delirium commonly associated with CNS disorders. Pro-inflammatory stimuli and 
ongoing CNS neuroinflammation induce cyclooxygenase-2 (COX-2) which causes astrocytes 
supporting the BBB to secrete prostaglandin E2 (Font-Nieves et al., 2012). The induction of 
fever during infection is described by the IL-6-COX2-PGE2 axis which culminates in the 
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activation of EP3 receptors expressed in thermoregulatory neurons within the 
hypothalamus to induce fever and malaise (Eskilsson et al., 2017; Evans et al.,, 2015). 
B cell mediated autoimmunity may also influence RR MS since the intestinal microbiota has 
been shown necessary to drive autoantibody-producing B cells and for stimulating myelin-
specific CD4+ T cells in the process of spontaneous RR EAE (Pöllinger et al., 2009). RR mice 
are transgenic SJL/J mice predisposed to spontaneously developing EAE due to increased 
TCR expression specific for MOG peptide 92-106 (Pöllinger et al., 2009). In contrast to 
induced EAE, RR mice develop the characteristic remission and relapsing nature of RR MS in 
humans which leads to neuroinflammation causing demyelination throughout the CNS. B 
cell autoantibodies  enhance demyelination and severity since mice deficient in MOG 
antigen or with depleted B cells do not develop spontaneous RR EAE (Pöllinger et al., 2009). 
Latent EBV reaction have been documented to cause serious neurological complication in 
paediatric patients, with long term consequences including cognitive impairment and 
epileptic seizure and symptoms of Alice in Wonderland Syndrome affecting sense of vision, 
sensation, touch, hearing and perception of one’s own body (Fine, 2013). The lytic phase of 
EBV infection is reactivated when memory B cells undergo differentiation into plasma cells. 
Normally EBV-specific CD8+ T cells target EBV-infected B cells. However, defective control 
of EBV reactivation may facilitate generating autoreactive B cells in MS who display 
defective T cell control of EBV infection with a reported decrease of CD8+ T cells against 
lytic phase EBV (Pender et al., 2017).  
B-cell targeted therapies have been trialled in CNS autoimmune disorders MS and 
neuromyelitis optica (NMO) despite being considered T-cell mediated (Fillatreau, 2018). 
Anti-CD20 therapy called Rituximab® has been successful in reducing inflammatory brain 
lesions and clinical relapses in RR MS during a 48-week trial in 104 patients (Hauser et al., 
2008). B cell are potent cytokine produces and also antigen presenting cells, thus 
engagement with T cells through CD40 and produce IL-6 that enhances Th17 differentiation 
(Barr et al., 2012). Depletion of B cells may reduce ongoing proinflammation cytokine 
production as well as removing auto-reactive B cells that may contributing towards 
pathogenesis. For example, NMO, also called Devic’s disease, is a variant of MS that 
represents demyelination restricted to the optic nerve and spinal cord. However, IgG1 
autoantibodies produced by B cells target AQP4, an aquaporin, expressed in astrocytes to 
attack myelin. These autoantibodies belong to the class IgG1 and require direction of T-
follicular helper cells for class switching and maturation of plasma cells of this antibody 
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isotype. Rituximab® clinical trials in NMO deplete B cells decreased rate and severity of 
relapses (Etemadifar et al., 2017). 
Analysis of the intestinal microbiota in NMO patients identified enrichment at the species 
level of Clostridium perfringens, compared with healthy controls (Cree et al., 2016). AQP4-
reactive T cells are elevated in NMO patient and specificity mapped to amino-acid residues 
63-76. This immunodominant region revealed 90% sequence homology (207-216) to an 
adenosine-triphosphate binding cassette transporter permease (ABC-TP) expressed by C. 
perfringens (Zamvil et al., 2018). To put this finding into perspective, myelin-specific T cell 
responses in MS, reveal less sequence homology between immunodominant T-cell targeted 
epitopes in myelin and microbiota-derived antigens (Zamvil et al., 2018).  
 
Figure 1.1.14 Pathogenesis of NMO arises from Clostridium perfringens molecular mimicry driving 
autoantibodies against AQP4 channels in the central nervous system. Bacteria become internalised 
by M cells at the PPs and delivered to dendritic cells which in a healthy microbiota promote anti-
inflammatory cytokines and naïve T cells to different into regulatory T cells and T follicular cells 
which support the induction of IgA secretion. Specific IgA responses to members of the intestinal 
microbiota can protect against disease and inflammation (Kawamoto et al., 2014; Kubinak & Round, 
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2016). Overgrowth of C. perfringens is thought to contribute to the development of NMO, which 
becomes internalised by M cells for presentation to immune cells. ABC-TP(p204-217) shares 
sequence homology with Aquaporin 4, AQP4 (p63-76) and leads to the activation and expansion T 
cells which recognise both antigens (Oldstone, 1998). Dysbiosis may alter the balance between pro 
and anti-inflammatory T cell responses in the immune system, causing Th17-polarisation and 
expansion of auto-reactive ABC-TP/AQP4-specific Th17 cells which promote B cells to differentiate 
into antibody secreting plasma cells. These pathogenic antibodies further mediate destruction of 
AQP4 within the CNS causing inflammation of the optic nerves and spinal cord. Figure from (Zamvil 
et al., 2018). 
Clostridia strains from clusters IV, XIVa and XVIII are considered as producers of SCFA and 
promote TGFb (Atarashi et al., 2013). C. perfringens is not included within these clusters 
and may well contribute to long-chain fatty acids, similar to Segmented Filamentous 
Bacteria (SFB) which promote Th17 differentiation (Ivanov et al., 2009). Indeed, CD4+ T 
cells isolated from NMO patients are characterised by IL-17 production as well as IFNg and 
IL-6, inducing Th17 differentiation (Ochoa-Repáraz & Kasper, 2018; Varrin-Doyer et al., 
2012).  
 
The intestinal microbiota strongly influences the balance between proinflammatory and 
anti-inflammatory immune reactions, leading to either protection or induction/progression 
of disease. Mice SFB induce fewer Th17 cell in the small intestine (Ivanov et al., 2009).  
Commensal members of the microbiota influence the balance of T(regs)/Th17 in the 
intestine and so it can be seen the dysbiosis would potential altered this balance. GF mice 
are in fact protected against EAE producing lower IFNg and IL-17 as well as having more 
FoxP3+ T(regs). Re-colonisation with B. fragilis producing capsular polysaccharide Ag 
maintains protection against EAE , as well as some Clostridia species through enhanced 
stimulation of IL-10 producing FoxP3+  T(regs) (Atarashi et al., 2013; Ochoa-Reparaz et al., 
2010). B. fragilis has also been shown to be effective at correcting IP in MIA offspring, and 
alters microbial composition to the benefit of ameliorating ASD-like behaviour and GI 
complications in these mice (Hsiao et al., 2013).  
 
Intestinal permeability determined by histological sectioning of duodenum, jejunum and 
ileum of EAE mice show they develop increased intestinal barrier permeability preceding 
the onset of neurological symptoms (Nouri et al., 2014). Indeed there have been 
observations of increased intestinal permeability preceding clinical onset and relapses in 
Crohn’s Disease and type 1 diabetes (Bosi et al., 2006; Fasano, 2011; Irvine & Marshall, 
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2000). Th1 associated proinflammatory cytokines, TNFa and IFNg in combination with IL-17 
may trigger overexpression of zonulin and disorganisation of TJs to increase intestinal 
paracellular transit (Nouri et al., 2014). Metabolic disorders have been well studied with an 
association between low-grade chronic inflammation sustained by systemic endotoxin 
measured in obese and diabetic mice with evidence of dysbiosis characterised by increased 
Proteobacteria abundance which are Gram negative bacteria with presence of endotoxin 
on their outer membrane (Rizzatti et al., 2017). Endotoxin-induced inflammation is driven 
microbiota dysbiosis in these animals recognised by the fact that antibiotic treatment 
reduced circulating endotoxin, improved insulin sensitivity, and lowered systemic 
inflammation and oxidative stress caused by the immune system (Cani et al., 2008; Rizzatti 
et al., 2017).  
 
Epithelial tight junctions in the intestine are similar to the endothelial tight junctions of 
microvascular in the brain and are equally susceptible to endotoxin.  Circulating endotoxin 
can disrupt the blood-brain-barrier (BBB) and activate microglia in the brain via PRRs 
leading to the recruitment of leukocytes during neuroinflammation. Preventing the 
extravasation of autoreactive T-cells by blocking a4b1 integrin disrupts trafficking across 
the BBB and has yielded some clinical benefit in the treatment of RR MS. 
- aging microbiota and neurodegeneration  
 
There is a striking parallel between the onset of neurodegenerative disorders such as 
Parkinson’s Disease and Alzheimer’s and age-related changed within the intestinal 
microbiota. Age-related decline of the intestinal microbiota is associated with increasing 
proinflammatory cytokines and deteriorating IP in mice (Thevaranjan et al., 2017). The 
ageing intestinal microbiome appear to alter in composition with a reduction in alpha 
diversity, and increased presence of proteobacteria (Rizzatti et al., 2017). Significant 
decreases have been reported in Bifidobacteria, Bacteroides, and Clostridium cluster IV 
(Zwielehner et al., 2009). 
Enrichment of Proteobacteria are a common observation in inflammatory conditions 
(Rizzatti et al., 2017). Age-associated intestinal dysbiosis may arise as a consequence of an 
ageing immune system (immunosenescence) and potentially enhanced susceptibility 
towards infections, inflammation and autoimmunity.  Risk of neurological inflammatory 
driven pathologically increase as we age, susceptibility to diseases and increased morbidity 
and mortality due to low-grade inflammation caused by endotoxemia (Singh & 
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Newman 2011; Freund et al. 2010). The intestinal microbiota is potentially a large source of 
endotoxin. Concomitantly, ageing causes priming of microglial cells in the brain making 
them more sensitive to a secondary inflammatory stimulus (Perry & Holmes, 2014).  It is 
not understood why this occurs during a process what is termed inflammageing; however 
microglial susceptible to activation by circulating pro-inflammatory cytokines caused by a 
systemic trigger (i.e. infection) may facilitate a leaky blood-brain barrier (BBB) and 
trafficking of pathogenic T cells that promote various neurogenerative conditions 
(Bachstetter et al., 2015; Dilger & Johnson, 2008)(Blaylock & Maroon, 2011).  
- Parkinson’s Disease (PD) 
 
Sleep disorder, cognitive impairment and mood disturbance are common non-motor 
symptom in PD (Yu et al., 2018). However, the origins of Parkinson’s Disease (PD) may 
begin in the intestine. It has been suggest that GI symptoms, particularly constipation can 
precede motor symptoms up to 20 years prior to diagnosing PD and may predict onset of 
PD (Yu et al., 2018).  The production of SCFAs by the intestinal microbiota are known to 
modulate microglia and enhance PD in genetically susceptible mice (Sampson et al., 2016). 
Overexpression of a-synuclein (aSn) in these mice causes aggregation within neurons and 
culminates in progressive deficits in motor function as well as intestinal motility 
dysfunction (Sampson et al., 2016). 
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Figure 1.1.15 Microglial activation is induced by systemic inflammation and contributes towards 
behaviour adaptions to infection. Ageing and low-grade systemic inflammation causes progressive 
priming of microglial cells in the brain that alters their morphology and neural function. Later in life, 
viral/bacterial infections may cause irreversible activation of microglial cells that increases the risk of 
illnesses affecting memory, and cognition such as dementia, characterised by neuronal dysfunction, 
and activated of pro-inflammatory cytokines in the brain. From (Perry & Holmes, 2014). 
 
Microbial production of SCFAs during viral infection have been described as activating 
microglial cells, the resident tissue macrophage in the brain and CNS (Erny et al., 2015).  
Indeed, transfer of faecal material from human PD patient donor into aSn-overexpressing 
mice revealed an altered profile of SCFAs, which was capable of activating microglia alone 
within  PD disease-susceptible GF mice (Sampson et al., 2016). Activation of microglia 
passes the threshold known as priming of microglial, and induces neuroinflammation 
observed through morphological changes, including on specific administration of SCFAs in 
this experiment.  
 
- Increased intestinal permeability in Major Depression 
 
Major depression is a psychiatric disorder with a defined abnormal immune component 
and suspected changes in intestinal permeability. Patients display high serum IgM and IgA 
antibodies reactive with LPS (endotoxin) of multiple Gram-negative enterobacteria. The 
levels of these antibodies are associated with a global worsening of symptoms, including 
fatigue, autonomic and gastro-intestinal symptoms (Maes et al., 2008). These results also 
suggest ‘leaky gut’ plays a role by increasing the exposure of bacterial LPS causing an 
inflammatory immune response marked by proinflammatory cytokines IFN-γ and IL-6. 
Chronic low-grade inflammation or immune activation that underlies the aetiology of IBS is 
also a driving risk factor in mood disorders (O'Malley et al., 2011). 
- Increased intestinal permeability in ME/CFS 
 
Increased serum IgM and IgA responses have also been documented in CFS patients against 
the LPS of enterobacteria using an ELISA method (Maes et al., 2007). Given the year of 
publication of this article it is important to note that the Canadian ME/CFS and/or 
international ME criteria could not have been applied. As discussed earlier, Fukuda CFS 
criteria has significant overlap with psychiatric comorbidities. 
More recent studies that have assayed for surrogate markers of intestinal permeability, 
Including LPS, LBP, sCD14, I-FABP as well as surveying a number of pro-inflammatory 
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cytokines conclude that bacterial translocation in ME/CFS may be stimulating the immune 
system (Giloteaux et al., 2016). Together with recent data showing a reduction in the 
diversity of the ME/CFS microbiome appear to add further support to this concept, 
however, there is no additional information related to differences in local gut immune 
reactions towards intestinal microbes, or how these permeability markers reflect severity 
of ME/CFS. 
1.11 Leaky gut hypothesis in ME/CFS 
 
‘Leaky gut’ is an informal term used to described increase intestinal permeability that may 
result in bacterial translocation and exposure to the host immune system. It has been 
suggested that ‘leaky gut syndrome’ is a mechanism for immune dysfunction and auto- 
inflammation and autoimmunity (Fasano, 2012).  Indeed, there have been several reports 
of changes in intestinal permeability that are frequently in tandem with evidence for 
dysbiosis in a selection of  neurological and autoimmune diseases (Bosi et al., 2006; Fasano, 
2012; Manfredo Vieira et al., 2018; Pijls et al., 2013; Rojo et al., 2007; Sapone et al., 2006). 
Of course, details for how the microbiota cause the immune system to produce 
autoantibodies is unclear and in to response to which particular microbes in the gut. It is 
tempting to speculate an unknown infection in ME/CFS initiates neurological complications 
in some patients, similar to Guillain-Barré (GB) syndrome where LPS derived 
from Campylobacter jejuni elicit cross-reactive antibodies through molecular mimicry of 
host gangliosides (Yu et al., 2006). From this, the pathological consequences to the CNS and 
effects on behaviour appear to be precipitated by immune dysregulation driven by 
bacterial infection. However, serial pieces of evidence are missing to support this 
hypothesis.                                     
 
 
 
 
 
 
 
 
 
 
Figure 1.1.16 An explanation for ME/CFS incorporating intestinal dysbiosis, intestinal permeability 
and autoimmunity. Our hypothesis is that the pathogenesis of ME/CFS is driven by intestinal 
dysbiosis that results in increased Th1/Th17 immune responses towards intestinal microbes and 
ME/CFS 
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increased intestinal permeability. Increased anti-microbial reactivity to luminal microbes may 
engender cross reactivity through molecular mimicry with the CNS and brain that so far has not been 
established in ME/CFS. Identifying intestinal dysbiosis and alterations in intestinal permeability are 
plausible mechanisms for induction of autoimmunity and have been associated with several 
autoimmune diseases (Fasano, 2012).  
 
- Concluding remarks 
 
The cause(s) of ME/CFS is not known but is suspected to involve cytokine infiltration of the 
brain, neuro-inflammation, low NK cell function and frequently follows viral infections 
suggesting a link with the immune system. Environmental and/or microbiological triggers 
originating from the gastrointestinal tract are thought to be a cause of the disease or 
perpetuate symptoms and pathological illness.  
 
Autoimmune reactions lead to inflammation, increased permeability of blood vessels and 
migration of lymphocytes to sites of injury. Microglia within the brain can be primed during 
chronic inflammatory diseases but can then induce inflammation in the brain when they 
are triggered by a second inflammatory challenge such as a systemic microbial infection 
(Blaylock & Maroon, 2011). This raises the possibility that the damaging neuro-
inflammation seen during ME may be triggered by systemic infections. Indeed, several 
autoantibodies have been documented in some but not all ME/CFS patients. An interesting 
example are anti-5-HTA receptor antibodies since the majority of serotonin is produced in 
the gut (Maes et al., 2013b).  
Many ME patients have gastrointestinal disturbance, are more likely to develop irritable 
bowel syndrome, and may have a “leaky” gut barrier (Lakhan & Kirchgessner, 2010) 
Together these observations suggest that changes in intestinal barrier integrity, which may 
be driven by or are a consequence of intestinal dysbiosis, as a result, for example, of a gut 
infection could contribute to ME by increasing exposure of host mucosal and systemic 
immune cells to microbe-derived antigens and drive systemic inflammation and/or 
influences the microbiota-gut-brain axis. 
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1.1.12 Overall study aim, hypothesis & objectives 
 
 
- Central Hypothesis 
 
Severe ME/CFS patients have a compositionally and functionally altered intestinal 
microbiota compared to their house-hold relative, which promotes ongoing intestinal 
epithelial permeability and systemic, chronic (auto)-inflammation. 
 
- Thesis Aim 
 
The first aim was to recruit an apparently healthy, house-hold control participant to match 
with their respective house-bound, severe ME relative; the second, to characterise the 
composition and metabolic of activity of the intestinal microbiome and to test for evidence 
of intestinal epithelial permeability in these patients. 
   
Recent metagenomic and metabolomic studies have focussed exclusively on mild to 
moderately affected ME/CFS patients with respect to conventional age and gender 
matched healthy controls. If these findings translate into severe, house-bound ME/CFS 
patients in unknown. 
 
- Specific Objectives: 
 
Chapter 3: To compare metagenomic sequencing methods to characterise the composition 
of the intestinal microbiota in severe, house-bound patients, in order to determine: 
 
i) if there is evidence for intestinal dysbiosis; 
 
ii) the identify of key bacterial species belonging to a novel “microbial 
signature” which may help define severe, ME patients from those mild to 
moderately affected; 
 
iii)  the effect of the contribution of external environmental factors known to   
influence population-level microbiome variation by using house-hold 
controls 
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Chapter 4: To define the faecal and serum metabolome of severely affected ME/CFS 
patients, in order to determine if: 
 
i) altered microbial composition (dysbiosis) influences the faecal and blood 
serum metabolism;  
 
ii)  there is any evidence for alterations in aerobic energy metabolism or of a 
hypometabolic state, which have recently been reported in studies on mild 
to moderately affected ME/CFS patients; 
 
iii) severe, ME patients have a distinct bile acid metabolic profile using 
targeted HPLC-mass spectrometry. 
 
Chapter 5: To evaluate methods for detecting anti-microbial antibodies using solid phase 
and liquid phase assays by establishing: 
 
i)  if lab-cultured bacterial isolates, representative of the human intestinal 
microbiome, can be immobilised onto nitrocellulose-coated glass slides; 
 
ii) a whole cell bacterial microarray to rapidly screen serum using microarray 
scanner detection; 
 
iii)  the relative abundance of IgA-coated faecal microbes in severe ME/CFS 
patients versus matched house-hold controls using faecal flow cytometry; 
 
iv) the intestinal permeability status of severe ME patients versus house-hold 
controls based on serum detection of lipopolysaccharide (LPS) and LPS-
Binding Protein (LBP); 
 
v)  if IgA reactivity towards faecal microbes correlates with these existing 
measures of intestinal permeability. 
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  Chapter Two 
 
 
2 Overall study design 
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2.1 General study rationale 
 
This thesis project is a pilot study focussed on severe ME/CFS patients who were identified 
as being house and/or bed-bound. Housebound and bedbound ME/CFS patients account 
for approximately 25% of the patient population, yet fewer than 0.5% of studies carried out 
to date include these patients (Pendergrast et al., 2016). Studies of the intestinal 
microbiota of ME/CFS patients suggest a reduction in microbiota diversity and the number 
of species of bacteria (Fremont et al., 2013; Giloteaux et al., 2016; Nagy-Szakal et al., 2017).  
Other culture-based studies using the Fukuda criteria to identify patients, described an 
increased number of D-lactate producing Enterococcus and Streptococcus spp. in ME/CFS 
patients providing a plausible explanation for  neurological impairment (see symptoms fig 
1.1.3) in ME/CFS similar to patients with D-lactic acidosis (Sheedy et al., 2009).  
 
Relatively few studies compare the microbiota of patients with healthy same house-hold 
individuals as controls despite the benefit of controlling for important environmental 
factors. Various factors affect the microbiota, chiefly among are diet and lifestyle 
(Zhernakova et al., 2016). It is a reasonable assumption that members of the same house-
hold will share food and be exposed to similar habitat associated factors and microbes. To 
this end, house-hold members act as a useful environmental control. Finally, the majority 
of house-hold controls used in this study were relatives of the patient and share a similar 
genetic background which contributes to microbiota diversity shaping of the host immune 
response to commensal intestinal microbes.  
 
At the time of writing, this work represents the first insight of the intestinal microbiota of 
house-bound ME/CFS patients and disease-free members of the same house-hold. The 
data from this analysis is presented in the following chapter, chapter 4. Host and 
microbiota metabolism analysed through metabolomics-based approaches has identified 
alterations energy and lipid metabolism, amino acids and products of microbial metabolism 
including lactate and SCFAs (butyrate) derived from fermentation of dietary carbohydrates. 
However, none of these studies have included severe patients or healthy house-hold 
controls (Armstrong et al., 2015; Germain et al., 2017; Naviaux et al., 2016). In chapter 5 
detection of faecal IgA-coated bacteria is determined using flow cytometry as a surrogate 
for intestinal permeability that has previously been applied to assessing intestinal barrier 
dysfunction in colitis (Palm et al., 2014). 
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In total seventeen home visits were carried out across the South of London and 
neighbouring counties (see heatmap, figure 2.2.1) to collect faecal samples from 17 severe 
patients and 10 house-hold controls (two being full-time carers). Of these, additional faecal 
samples were provided by seven patients and five house-hold controls.  
 
During 2015 faecal samples were obtained from twenty-five mild/moderate severity 
ME/CFS patients recruited from the Chronic Fatigue Service (CFS) at the Epsom & St Helier 
NHS Foundation Trust University Hospital, Carshalton, UK. 
 
2.2 Study Participants 
 
All patients were registered at the St. Helier CFS service under direct supervision of Dr 
Amolak Bansal, Consultant Immunologist and Director of the CFS service. This has over 
more than 10 years registered more than 7000 patients enabling it to establish a 
substantial clinical history and clinical definition of ME/CFS leading to the development of a 
13-point scoring system (figure 1.2.1) based on the most frequent symptoms of ME/CFS 
(Bansal, 2016) and an absolute requirement for PEM symptom, which scores a maximum of 
3 points.  
 
 Since 2008 over 2000 patients have been diagnosed using this system and it has remained 
a robust and rigorous in that during the past decade with no other explanations for fatigue 
being forthcoming in any patients diagnosed with ME/CFS (Bansal, 2016). Common 
symptoms in the vast majority (>90%) of patients within this service includes aching 
muscles and muscles weakness, stress aggravated fatigue, impaired concentration and non-
restorative sleep (Bansal, 2016). Additional symptoms include an increased respiratory rate 
with 70% of moderate to severe and very severe patients presenting with persistent cold 
hands and feet (Bansal, 2016).  
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Table 2.2.1 Adapting Fukuda, CCC and ICC case definitions into a 13-point scoring system used by 
Epsom and St Helier CFS service List of symptoms and respective scores to characterise CFS/ME.  
 
- Inclusion criteria 
 
Patients diagnosed with ME/CFS must fulfil the Canadian, International Consensus and 
Fukada criteria to be part of the St. Helier CFS service. The selection of patients from this 
service for inclusion in this study were identified by Dr Bansal as described above (Bansal, 
2016) with symptoms persisting for a minimum 50% of any period (Jason et al., 2014). 
Patients must also score a minimum of 8 using this system. The results of previous clinical 
investigations including blood tests were used to exclude other common causes of 
persistent tiredness, including psychiatric illness. These tests include full blood counts, 
levels of C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), tests for renal, 
hepatic (LFT) and thyroid (TFT) function, presence of anti-nuclear antibodies (ANA) to 
exclude systemic lupus erythematosus (SLE), and serum immunoglobulin levels and gluten 
sensitivity tested. The patient's clinical and psychiatric history were also examined to 
identify potential causes for fatigue. The Hospital Anxiety Depression Scale (HADS) was 
used to assess any underlying depression and anxiety.  The Chalder Fatigue Scale and 
additional fatigue scale are used routinely to assess the degree of fatigue. 
 
Factor Score 
Delayed prolonged post-exertion malaise after increases in physical, mental 
and emotional activity 
 
3 
Non-restorative sleep with frequent difficult initiating and/or maintaining 
sleep 
 
2 
Impaired concentration that is reduced further by external stimuli 
 
1 
Reduced short term memory with word finding difficulty 
 
1 
New onset headaches (>2/mth and different in character from previous 
headaches) 
 
1 
Sore throat with cervical tenderness/recurrent flu-like episodes 
 
1 
Arthralgia affecting several joints with stiffness > 1 hr but no swelling 
 
1 
Myalgia affecting multiple groups and exacerbated by mild exertion 
 
1 
Postural instability feeling unstable on standing or sitting 
 
1 
Hypersensitivity to sounds and lights (smells and to a lesser degree taste 
also) 
1 
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- Exclusion criteria 
 
Antibiotic usage 4 weeks prior to enrolment was the only major exclusion criteria with 
patients given the opportunity to be recruited to the study after completing their antibiotic 
treatment and after recommendation by Dr Bansal. The other specific exclusion criteria 
was a HADS score of greater than 7. Anxiety and depression are known to affect the 
immune system causing stress and disturbances in sleep. Nonetheless, given the chronic 
state of this illness a degree of depression and anxiety, and stress, is likely to feature in all 
patients but is distinct from major depressive symptoms including guilt and low motivation. 
Probiotic consumption was not an exclusionary criterion as this would have restricted 
patient recruitment.  
 
 
- Disease severity  
 
Patients were grouped based on the severity of their ME/CFS defined by the St. Helier CFS 
service. Mild/moderate patients were distinguished from severe (house/bed-bound) 
patients by their ability to attend to repeat hospital visits. This is reflected by descriptions 
of daily living (ADL) activities used by the service (table 2.2.2).  Patients beyond the level of 
moderate severity cannot or rarely leave the house and are defined as severe in this study.  
 
Table 2.2.2 Definitions of Activities of Daily Living (ADL) determining the level of severity of 
symptoms in ME/CFS patients 
 
 
- Eligibility of House-Hold Controls (HHC) 
 
With the exception of 2 out of 10 HHCs, who were full-time carers of the patient, all these 
individuals were family relatives of each respective severe ME/CFS patient living in the 
same house-hold. These participants were recruited on the basis of their ‘apparent’ healthy 
status and could not be clinically assessed, or medical records obtained prior to their 
inclusion in the study. However, HHCs were advised not to participate with any known 
medical or psychiatric history, particularly associated with gastrointestinal symptoms. 
Mild Moderate Severe Very Severe 
Still working, mobile, 
reduction in family 
and leisure activities 
Not working, sleeping 
in daytime. Reduced 
mobility, but can leave 
the house 
House-bound, (rarely leaves 
house) with severe worsening 
of symptoms under physical 
and mental exertion 
Bed-bound, light and 
noise sensitivities. 
Requires someone else 
to wash and feed them 
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Figure 2.2.1 Heatmap of location of patient home visits 2016-2017 using Google Maps. A total of 
17 home visits were completed to severe, house-bound ME/CFS patients registered at the CFS 
service in Epsom and St Helier, Surrey.  
 
2.3 Research Ethics Approval 
 
The original study proposal was reviewed by the University of East Anglia Faculty of 
Medicine and Health Sciences (FMH) Research Ethics Committee in 2014 and subsequently 
approved (reference FMH20142015-28). This approval allowed for the inclusion of faecal 
and blood samples collected from patients within the Epsom and St Helier CFS Service using 
the Norwich Biorepository, approved from the Cambridge East Committee of the National 
Research Ethics Service (NRES). Copies of approval letters from the committee and the 
research and development department are provided in supplementary figures 2.1 and 2.2. 
 
The original research proposal included recruitment to assess the intestinal permeability of 
140 ME/CFS patients including 35 mild/moderate, 35 patients defined as severe, 35 
controls, and 35 ME/CFS with specific GI symptoms. It became apparent that this target 
was ambitious and could not be completed in the time allowed and it was later revised to 
focus exclusively on home visits severe patients.  
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- Informed consent 
 
Patient information sheets containing information about the study were provided to 
patients upon request at the St. Helier CFS service or discussed in routine consultation with 
Dr Bansal (see appendix). Severe patients were informed of the study by telephone 
consultation with Dr Bansal who forwarded the information and advised patients 
interested in participating to contacted myself using email or the study dedicated 
telephone number. Patients expressing an interest in participating were mailed study 
documents in advance of any home visit and advised to contact myself via email or 
telephone to discuss the study further. 
 
- Inclusion of House-Hold Controls (HHCs) 
 
The inclusion of a same household control was not an absolute study inclusion criteria in 
order to enable severe, house-bound patients to participate in this research. Prospective 
HHCs were approached by the patients themselves before contacting myself to discuss the 
research and provided with a stool samples kit. 
 
- Ethical considerations 
 
The study’s ethical approval did not allow any data collection such as the use of 
questionnaires for assessing level of functional GI disorders or clinical history to be 
obtained. As a researcher, it was not possible to conduct a physical examination of the 
patient to ascertain parameters such as an individual response to painful stimuli or 
sensitivity to light and sound. There were also several occasions where it was not physically 
possible to obtain a blood sample for patients. ME/CFS patients can exhibit collapsed or 
inaccessible veins. In other instances, blood samples could not be acquired without causing 
distress to the patient and therefore it was deemed unethical to obtain these samples. For 
example, in severe patients with extreme light sensitivity or with heightened sensitivity to 
touch and pain stimuli. 
 
2.4 Sample collection & Storage 
 
Samples were collected and stored within 1-6 h at -800C at St Helier prior to transfer to the 
Norwich Biorepository at a later date. All samples were processed and analysed together.  
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- Mild/moderate ME/CFS patients 
 
Twenty-five mild/moderate ME/CFS patients were recruited in 2015 from St Helier CFS 
service.  
 
- Home visits  
 
A minimum of 2 visits were carried out between 2016-2017 to each of the 17 severe 
patients, first to consent patient and provide them with the stool sampling kit and 
instructions for collection (see appendix).  
 
 
- Stool sample 
 
All study participants were instructed to collect their intact faecal sample in a FECOTAINER® 
(AT Medical B.V., Enschede, Netherlands), figure 2.2.2 no later than 24 hours prior to a 
scheduled home visit. Samples were stored at 40C prior to collection from the patient home 
and transported on ice to St. Helier hospital. Participants donating stool in 2017 collections 
were also provided with an AnaeroGenä Compact anaerobic sachet (Cat No. AN0010, 
Oxoid Ltd., United Kingdom) to activate as soon as they produced their sample to eliminate 
environmental oxygen conditions and promoting the survival of obligate anaerobic 
microbes. On return to the hospital, samples were manually homogenised with a sterile 
autoclaved metal spatula, aliquoted and either processed immediately or stored at -800C 
for future use.  
 
 
 
 
 
 
 
 
 
 
Figure 2.2.2 FECOTAINER® collection device used to collect stool sample. (Reproduced 
image accessed via www.fecotainer.eu on 12th September 2018). 
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- Blood sample 
 
Where possible patients and house-hold controls (HHC) were also bled using S Monovette® 
Z-Gel for serum collection (Cat No. 02.1388.001, Sarstedt AG & Co., Nümbrecht, Germany). 
For home visits, it was not always possible to attempt to collect blood from severe patients 
and HHCs due to unavailability of a phlebotomist to accompany myself.  
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 Chapter Three 
 
3 Characterising the composition of the gut microbiome 
associated with severity of ME/CFS 
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3.1.1 Introduction 
 
There is an urgent need to identify validated biomarkers for the diagnosis of ME/CFS. 
Altered intestinal microbiota composition (dysbiosis) has emerged as a feature of neuro- 
and immuno-inflammatory diseases, suggesting a causal relationship (Round & 
Mazmanian, 2009). Gastrointestinal inflammation is associated with abdominal pain and 
altered bowel movements (Neufeld, 2013). Stress, anxiety and depression are well known 
psychological disorders, which frequently make GI symptoms worse, particularly in IBS. 
Intestinal dysbiosis may be a driver of altered gut-brain signalling and pain perception. 
Thus, IBS is described as a functional disorder, and like ME/CFS appears absent of physical, 
structural or biochemical abnormalities and is instead identified by characteristic 
symptoms (Häuser et al., 2012). IBS-like symptoms are common among ME/CFS patients 
with as many as 92% of all ME/CFS having IBS at some time during the development of 
ME/CFS  (Lakhan & Kirchgessner, 2010). The mechanism for IBS-related abnormal pain and 
discomfort is thought to be driven by inflammatory derived immune signals, such as 
cytokines and release of prostaglandins in response to an infection and through direct 
bacterial activation of the nervous system.  
 
Chui and colleagues have shown that infection by  S. aureus activates nociceptors causing 
mechanical and thermal hyperalgesia in mice, the severity of which correlated with 
bacterial load (Chiu et al., 2013). Furthermore, LPS stimulation of afferent sensory neurons 
require TRPA1 ion channel mediated calcium influx and release of neuropeptides which 
enhance local inflammation and hyperalgesia (Meseguer et al., 2014).  Although sensory 
neurons express the receptor for LPS, TLR4, the sensory responses to LPS in tlr4-deficient 
mice did not differ (Meseguer et al., 2014). Visceral pain perception has become a target 
for pharmacological intervention using drugs to block or alter gut-brain signalling and 
neuroimmune pathways to alleviate symptoms (Farzaei et al., 2016).  Increased intestinal 
permeability in a subset of IBS patients with diarrhoea symptoms enhances severity and 
hypersensitivity to visceral stimuli (Zhou et al., 2009). Increased bacterial translocation 
would therefore facilitate direct contact with afferent sensory neurons, which further 
stimulate visceral hypersensitivity through engagement of bacterial antigens.  Given the 
role of intestinal bacteria in activating nociceptors, management of visceral hypersensitivity 
in IBS and other disorders with GI symptoms may benefit from targeting the intestinal 
microbiota as well as the (“leaky”) intestinal epithelial barrier.  
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The intestinal microbiota is significant in the development of post-infectious IBS in mice 
where probiotic preparation of Bifidobacterium and Lactobacillus strains ameliorate IP and 
inflammatory cytokine production, reducing intestinal inflammation and alleviating 
hypersensitivity (Wang et al., 2014). An overlapping profile of plasma cytokines has been 
reported in IBS and ME/CFS driven by IL-6, IL-8 IL-1ß and TNF (Scully et al., 2010). Systemic 
circulation of these cytokines to the brain induces sickness behaviour causing symptoms of 
extreme malaise and severe fatigue (Dantzer et al., 2008). 
 
- Dysbiosis linked to low-grade chronic inflammation 
 
Intestinal inflammation and bacterial translocation can lead to systemic infection and low-
grade chronic inflammation in ME/CFS (Lakhan & Kirchgessner, 2010). Changes in the 
intestinal microbiota in metabolic disorders are associated with higher plasma 
concentrations of LPS and development of endotoxemia (Cani et al., 2008). It is well 
documented that the relative abundance of Firmicutes exceeds Bacteroidetes in metabolic 
disorders. However, the increased prevalence of Proteobacteria is a potential microbial 
signature for inflammatory-dependent intestinal and extra-intestinal diseases (Rizzatti et 
al., 2017). In addition, the aging microbiota is represented by an increase in Proteobacteria 
and decrease in Bifidobacteria and may alter the balance between anti- and pro-
inflammatory responses of Treg/Th17 immune cells in the intestine (Biagi et al., 2010). 
 
Proteobacteria are Gram-negative and a potential source of LPS which could induce 
endotoxemia in the development of metabolic disorders. Beyond metabolic disorders, a 
more recent study has shown that Parkinson’s Disease patients have increased abundance 
of Proteobacteria, but it is unclear how dysbiosis enhances progression and impairment of 
motor control and decline in neurocognitive functioning. A possibility is that increased 
intestinal permeability may expose Proteobacteria to the internal environment. Indeed, 
faecal markers for intestinal inflammation and intestinal permeability, (including zonulin 
overexpression) are significantly elevated in a cohort of PD patients compared to age-
matched healthy controls (Schwiertz et al., 2018). Moreover, intestinal biopsies taken from 
9 PD patients showed a positive correlation between intestinal asynuclein aggregation and 
serum endotoxin in early PD in response to increase exposure to intestinal bacteria 
(Forsyth et al., 2011). Whilst these pathological features do not distinguish PD patients 
from other (neuro)-inflammatory disorders associated with GI barrier dysfunction, it does 
lead to speculation of a common cause for generating low-grade inflammation and 
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increased physiologic input from the microbiota in the activation innate immune receptors 
such as TLR4 and nociceptors in afferent sensory neurons behind a compromised intestinal 
barrier.  
 
- Microbiota-derived intestinal metabolites 
 
It is not known if or how intestinal dysbiosis influences the pathogenesis of ME/CFS. 
Many of the symptoms of ME/CFS, severe fatigue, malaise, unrefreshing sleep, cognitive 
impairment, memory deficits, autonomic disturbances including blood pressure changes, 
orthostatic intolerance, overlap with neurodegenerative and neuropsychiatric disorders, as 
discussed above. Significantly, an altered microbiota will impact on the profile of microbial 
products, particularly those with the capacity to act as neurotransmitters and modulators 
of inflammation. For example, secondary bile acid metabolism (see next chapter) is 
regulated by certain intestinal bacteria with specialised enzymes (bile salt hydrolases, BSH) 
modifying structural and chemical changes to primary bile acids produced by the liver. 
These secondary bile acids are lipophilic and can be absorbed across the intestinal barrier, 
interacting with cells beyond the intestinal epithelial barrier via TGR5 which has emerged 
as a key receptor in the mediation of bile acid neural-humoral signalling with an impact on 
energy homeostasis and inflammation (Bunnett, 2014).  
 
Altered microbiota in PD patients has been associated with alterations in the proportions of 
SCFAs (Unger et al., 2016). SCFA are significant metabolites produced by the microbiota, 
the most abundant of which are acetate, propionate and butyrate that are an important 
source of energy for intestinal epithelial cells. Understanding how the intestinal microbiota 
changes in disease states will help understand the impact dysbiosis may have on disease 
pathogenesis.  For instance, Bacteroides thetaiotaomicron is a major producer of acetate 
and propionate. Clostridium tyrobutyricum produces high levels of butyrate that inhibits 
HDAC activity and upregulation of TJs proteins such as zonulin, which if dissociated from 
the TJ complex leads to increased serum levels which is a useful marker for altered 
intestinal permeability (Bordin et al., 2004; Sapone et al., 2006). However, PD patients have 
an overall reduction in faecal SCFAs (Unger et al., 2016). In PD patients, members of the 
phyla Bacteroidetes which includes the family Prevotellaceae were reduced with increased 
abundance of Enterobacteriaceae which includes Proteobacteria (Unger et al., 2016). 
Significantly ASO mice, engineered to overexpress a-synuclein are genetically susceptible to 
PD, but do not develop the PD-like phenotype if maintained under germfree conditions or 
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are treated with antibiotics to eliminate gut microbes. Conventionalisation of these 
germfree or antibiotic-treated mice restored the PD phenotype, with the transplantation of 
faecal microbiota from PD patients greatly exacerbating the PD phenotype compared to 
animals conventionalised with faecal microbiotas of healthy individuals (Sampson et al., 
2016). Moreover, SCFAs derived stool samples from PD patients were sufficient alone to 
enhance motor dysfunction and activate microglial in GF ASO mice (Sampson et al., 2016).  
 
Defects in Blood Brain Barrier (BBB) permeability in the offspring from germfree mice have 
been observed after intravenous administration of Evans blue dye which accumulates in 
the brain parenchyma (Al-Asmakh & Hedin, 2015). However, the prior introduction of 
SCFAs producers, C. tryrobutyricum (butyrate) and B. thetataiotaomicron 
(acetate/propionate), enhanced BBB integrity via unknown effects on TJ complexes 
(Braniste et al., 2014).  SCFAs activate the GPR41 and GPR43 G-protein coupled receptors, 
with physiological effects including of reducing GI transit, energy balance, and anti-
inflammatory signals (Al-Asmakh & Hedin, 2015). Gpr43 deficient mice develop colitis, 
arthritis and asthma (Maslowski et al., 2009). Moreover, butyrate has a neuroprotective 
effect limiting neuronal damage and prevents a-synuclein accumulation by enhancing 
autophagy (Liu et al., 2017).  
 
Although the role of SCFAs in the pathophysiology of inflammatory diseases is unclear, 
associated intestinal dysbiosis appears to have a role in driving pathology in various 
neurodegenerative diseases (Mulak, 2018). a-synuclein aggregates form in the enteric 
nervous system many years prior to the onset of PD which raises the question, do 
neurodegenerative disease begin in the intestine? Mouse models demonstrate that the 
intestinal microbes contribute to driving neuropathology, further highlighting the need to 
understand how microbial compositional changes impact microbial metabolite production, 
for example SCFAs, that may contribute to pathogenesis.  
 
Unlike PD, RR, MS, NMO introduced earlier in chapter 1, there is no animal model for 
ME/CFS. The observations that the intestinal microbiota can have a wide range of 
physiology input in metabolic disorders, to neuro-immune and neurodegenerating 
disorders with similar symptoms including severe fatigue, cognitive deficits, visceral 
sensitivity and GI disturbances, warrants investigation into ME/CFS to establish potential 
aetiological causes.  
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- Treating intestinal dysbiosis 
 
Faecal Microbiota Transplant (FMT) is the practice of transferring a healthy donor stool 
sample into a patient in an attempt to treat intestinal dysbiosis by restoring a diverse 
intestinal microbiota (Borody & Khoruts, 2012). In clinical practice it has proven to be very 
effective in the treatment of recalcitrant Clostridium difficile infection (CDI), which arises as 
a result of antibiotic treatment leading to the loss of many members of the microbiota, 
leading to germination of C. difficile spores and bacterial overgrowth. 
 
Bacteriotherapy involving trans-colonoscopic infusion of 13 anaerobic enterobacteria has 
been trialled in 60 ME/CFS patients. Amongst the ME/CFS patients, 52 had IBS comorbidity. 
Just over half of these patients responded to an initial infusion, of which 88% no longer 
experienced GI symptoms. Ten patients that did not respond with significant improvements 
in refreshing sleep, lethargy, fatigue, did see some improvement in their GI symptoms. 
Although the initial success rate was encouraging, this trial did not adequately follow up 
the long term benefit this treatment in these patients. Twelve patients that were followed 
up of which 7 remained cured of CFS which the other 5 describing relapsing CFS symptoms 
between 18 months to 3 year following bacteriotherapy (Borody et al., 2012).  
 
3.1.2. Profiling the intestinal microbiota 
 
The relatively few studies that have profiled the composition of intestinal bacteria in 
ME/CFS are summarised in Table 2.2. It must be appreciated that these studies rely on a 
small number of patients defined by the use of the Fukuda (1994) criteria for CFS. 
Moreover, these studies have varied in their experimental approach and according to the 
technical capabilities at the time. Prior to recent advances in DNA sequencing technology, 
traditional culture-based techniques were used to study the human intestinal microbiota. 
In fact, the concept that the composition of the microbiota changes in health is not new 
and was first reported in 1973 using culture techniques (Tannock & Savage, 1974). 
However, in the past decade improvements and cost reductions in sequencing technology 
have made it possible to profile the bacterial composition across different microbiotas on 
and inside the human body. This is evidenced by the rapidly increasing number of 
publications shown as year on year increases in figure 3.1.1, as the technology has 
improved and reduced in cost.  
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The introduction of high-throughput (HTP) next-generation sequencing (NGS) technology 
has allowed researchers to exploit the highly conserved bacterial 16S gene for their reliable 
identification without the necessity of isolating and culturing them, on a massively parallel 
scale. Sequenced-based molecular identification of bacteria entails a choice 9 hypervariable 
regions of 16S rRNA gene using universal primers flanking these regions to amplify the DNA 
prior to high-throughput next generation sequencing. This generates sequences that are 
typically 250 base-pairs long, referred to as reads. Each read can then be processed and 
collectively analysed using bioinformatics software to such as Qiime, to assign each of the 
reads to their operational taxonomic units (OTUs) (D’Amore et al., 2016). The software 
utilises reference databases to identify each OTU.  
 
 
Figure 3.1.1 The rise in the number of microbiome-based studies between 2005 – 2016 Scientific 
Figure on ResearchGate. Available from: https://www.researchgate.net/Bibliometric-parameters-of-
microbiome-studies-Representations-were-limited-to-the-four_fig1_320728834 [accessed 10 May, 
2018] 
 
- Limitations of 16S gene-based sequencing studies 
 
16S rDNA gene amplicon sequencing has become the most widely used method of NGS to 
profile of the human gut microbiota. However, its domain is restricted to bacteria and 
archaea and it is limited to profiling bacteria at the genus level and therefore it is not 
possible to discriminate bacteria at a species or strain level (Jovel et al., 2016; Ranjan et al., 
2016). Furthermore, the choice of 16S hypervariable region and primers introduce a bias 
for particular bacteria taxonomic groups (Ghyselinck et al., 2013).  
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- Faecal DNA extraction 
 
Faecal samples are the most complex and diverse microbiome samples that can be isolated 
from on or inside the human body and therefore obtaining a good quality and high yield of 
DNA from all faecal bacteria can be challenging when studying such a diverse and complex 
community of microbes which have varying cell membrane and cell wall strengths 
encapsulating their DNA context. To that end, commercially available DNA extraction kits 
have been shown to vary in efficiency and quality of DNA extraction. A recent study 
compared 6 of these kits, including the MP Biomedicals FastDNA® Spin kit for soil used in 
this study (Turlej-Rogacka et al., 2017). For 16S-based studies all kits produced adequate 
DNA for PCR amplification, sufficient to provide a product which could be sequenced. 
However, the kits did vary significantly in obtained DNA concentration and purity using 
(A260/280) ratio (Turlej-Rogacka et al., 2017). For shotgun metagenomic studies high-
molecular weight genomic DNA will maximise the quality of output for downstream 
applications (Bag et al., 2016). However, total recovery of genomic DNA is a significant 
challenge for commercially available kits using minimal amounts (~250 mg) of faecal 
material and naturally these methods can have different biases towards the efficiency of 
DNA extraction from different bacterial species (Brooks et al., 2015). Accurately quantifying 
the concentration DNA in your sample can depend on the method of choice with more that 
10-fold higher DNA concentrations using NanoDrop versus Qubit (Turlej-Rogacka et al., 
2017). 
 
- Evidence of intestinal dysbiosis in ME/CFS using culture-based techniques 
  
Before the advent of NGS technology, investigators relied on traditional microbiology and 
bacterial cultures to grow and identified individual isolated bacteria. During an early 
investigation by Sheedy and colleagues, they likened the neurological impairments of 
ME/CFS to another condition where lactic acid producing bacteria are responsible for 
severe cognitive dysfunction. D-lactic acidosis is a metabolic disorder, which usually 
manifests in patients as a complication of having short bowel syndrome (SBS). SBS 
describes the inadequate absorption of nutrients by the small intestine, diarrhoea and 
dehydration enabling colonic bacteria to ferment carbohydrates causing excess D-lactic 
acid to accumulate in the blood. The effects of D-lactic acid on the CNS are apparent from 
other studies where it causes neurological impairments such as confusion, slurred speech, 
muscle weakness and inability to think. Faecal bacteria were grown in selective cultures 
from 108 CFS patients and 177 controls to generate viable counts (Sheedy et al., 2009). The 
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number of D-lactic acid producing Enterococcus and Streptococcus species were 
significantly higher in patients than controls (p=0.01) (Sheedy et al., 2009). The possible 
cause or mechanism for the accumulation of these bacteria is unclear, though their 
presence will lower the intestinal pH and may explain intestinal permeability increases 
associated with systemic endotoxemia (Henriksson et al., 1988; Maes & Maes, 2009). 
 
Another report in the same year, outlines the effect of a 4-week programme of 
administering twice daily (x2 20ml) probiotics containing 108 CFU/ml of Lactobacillus F19, L. 
acidophilus NCFB 1748 and B. lactis Bb12 in 15 CFS patients with high fatigue and disability 
scores (Sullivan et al., 2009). During the four-week follow up, 6 patients reported significant 
improvement in cognitive function, but not in fatigues or physical activity scores compared 
to pre-treatment, with no significant changes found in their intestinal microbiota PCR-
based methods for identification Lactobacilli and CFU counts (Sullivan et al., 2009). The 
authors remarked on the high variability in patient responses demonstrating the 
heterogeneity of the study group, moreover, the benefits were on a case by case basis, 
with those benefitting reporting sustainable improvement to cognitive function up to 70 
days later (Sullivan et al., 2009). 
 
The depression and anxiety characteristics in 39 CFS were studied in a separate cohort 
following an 8 week intervention consuming a daily dose of  2.4 x 1010 CFU of L. casei strain 
Shirota (LcS) spread across 3 smaller doses of 8 x 109 CFU after each meal (Rao et al., 2009). 
Overall, a significant rise in Lactobacillus and Bifidobacteria spp. was seen in patients 
receiving the probiotic treatment (n=19), as well as a reduction in levels of anxiety, versus 
those patients (n=16) who have received the placebo control (Rao et al., 2009). 
 
- 16S rDNA-targeted amplicon sequencing in ME/CFS 
 
Fremont and colleagues published the first ME/CFS study using HT 454 pyrosequencing 
performed on 16S V5-V6 region generating reads of at least 240 bp long (Fremont et al., 
2013). On average, 6000-7000 reads were obtained for each patient/control of which 98% 
could be assigned to specific phyla, and 129 different bacterial genera identified (Fremont 
et al., 2013). This ME/CFS cohort included patients from Norway and Belgium with 
respective healthy controls from the same countries. The majority of patients were female 
and diagnosed by Fukuda criteria. Dysbiosis was more significant in the Norwegian patients 
with a reduction in firmicutes: Roseburia, Syntrophococcus, Holdmania, Dialister and a x20 
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increase in Lactonifactor, and a 3.8 increases in Bacteroidetes genus, Alistipes (Fremont et 
al., 2013). Interestingly reduction of Roseburia, a Gram-positive butyrate producer, is 
reported to be a defining characteristic of dysbiosis in ulcerative colitis patients, and thus 
consistent with intestinal inflammation (Machiels et al., 2014). Moreover, Alistipes (and 
Enterobacteriaceace) were over-represented in patients with depression (Jiang et al., 
2015). In contrast, Belgian patients were less distinct from their respective healthy 
controls, except for x45 increase in Lactonifactor in patients thus remarkedly similar to the 
20 -fold increase of this genera in Norwegian patients (Fremont et al., 2013). 
 
Since this 2013 study, Roche® 454 sequencing has been replaced by the Illumina® MiSeq 
platform. The fundamental difference is an ability of 454 sequencing to achieve longer 
reads (up to 700 bp with 99.9% accuracy and 0.7Gb/run) compared on average with 
Illumina® NGS, between 150-300 bp (L. Liu et al., 2012). However, the Illumina® MiSeq v2 
platform offers 2 x 250 bp (paired-end, PE) reads yielding a total coverage of 44-50 million 
reads equivalent to 7.5-8.5 Gb of data per run (Goodwin et al., 2016). Thus, Illumina® 
provides much more sequencing depth and number of reads than earlier Roche® 454, as 
well as a more rapid turnaround time of as little as 4 h making it more cost-effective. It can 
now produce up to 15 Gb output making it the most widely used NGS platform to date 
(Ravi et al., 2018). 
 
High-throughput is further achieved by multiplexing and pooling samples in an individual 
sequencing run; allowing a large number of samples, up to 384, to be analysed 
simultaneously (Illumina, 2014). During DNA library preparation of each samples, 
specialised DNA adaptors and bar codes (or sequencing indexes) are hybridised to each 
DNA fragment. Each read sequenced is identified to a particular library representing a 
unique sample. For example, the Nextera XT library preparation kit manufactured by 
Illumina® provides 40 unique indexes; two are used in unique combination per DNA 
fragment enabling up to 384 samples to be analysed in a single sequencing run (Illumina, 
2014).  
 
A recent application of NGS Illumina® MiSeq sequencing performed in ME/CFS compared 
the 16S rDNA V4 sequences from faecal samples of 48 patients compared with 39 healthy 
controls (Giloteaux et al., 2016). Most of these patients (n=34) reported GI symptoms 
including constipation, diarrhoea, and abdominal pain/sensitivity (Giloteaux et al., 2016). In 
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total, 8,534,117 reads were obtained with an average of 98,093 reads per sample 
(Giloteaux et al., 2016). The primary finding was a reduction of bacterial diversity in 
ME/CFS patients, (P=0.004, W=1268; figure 2.2). To define the diversity of a sample, 
sufficient number of sequences must be obtained from each sample to identify all present 
bacterial taxa. The rarefaction curve in figure 2.2 shows as the number of reads increase 
the number of identifiable taxa increases up to a plateau. Beyond this point despite 
increasing the vast number of additional reads, very few or no additional taxa will be 
identified (Hanson & Giloteaux, 2017). However, too few reads (below 5000, green area) 
will cause underestimation of bacterial diversity.  This puts into perspective the relatively 
low number of reads achieved by Fremont and colleagues in the earlier study, where 6000-
7000 reads per sample did not distinguish a-diversity within ME/CFS samples compared to 
controls using the same indices of diversity within a sample (Shannon H evenness, Chaos1 
and PD richness). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.2 Sequence-based rarefaction curve of Phylogenetic diversity across ME/CFS and 
Control samples using 16S targeted rRNA sequencing. Based on the same number of sequences per 
sample, the diversity of assigned bacterial taxa (observed species) is higher in controls compared 
with ME/CFS patients. Figure reproduced from (Hanson & Giloteaux, 2017)). 
 
 
Gilateaux et al. reported a reduction in Bifidobacterium and Faecalibacterium species in 
ME/CFS patients (figure 2.3) (Hanson & Giloteaux, 2017). Individually the genera in fig. 2.3 
represent only 1% of the gut microbiome. At the phylum level, firmicutes were reduced in 
patients at 35% relative abundance (RA) versus 46% in controls with a relative increase in 
the abundance of proteobacteria, belonging to the family Enterobacteriaceae; 6% in 
ME/CFS versus 3% in controls (Giloteaux et al., 2016). 
       
 
 109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.3 Comparison of relative abundances of bacterial genera between ME/CFS patients and 
Healthy Controls. Shows relative abundance on a log10 scale. Figure reproduced from (Hanson & 
Giloteaux, 2017). 
 
The majority of 40 OTUs found to be different in ME/CFS were within Firmicutes; including 
Ruminococcaceae family members Oscillospira spp, F. prausnitzii, Ruminococcus; and 
Lachnospiraceae such as Coprococcus spp. (Giloteaux et al., 2016).Although butyrate 
production was not measured in this cohort, a reduction in butyrate producers and lactic 
acid promoting bacteria (beneficial to barrier function) is similar to individuals with IBD and 
IBS and will influence the production of PICs and consequently the risk of immune 
activation and increases in intestinal permeability demonstrated by higher levels of LPS, 
sCD14 and LBP in the plasma of ME/CFS patients (Giloteaux et al., 2016).  
 
- Whole-Genome ‘Shot-gun’ (WGS) sequencing 
 
 Whole genome sequencing, WGS (also called Shotgun metagenomics) is unrestricted to 
specific target amplicons, like 16S, and is able to resolve the microbiota beyond the genus 
level, including sequencing information derived from other members of the microbiota 
such as fungi and viruses.  WGS can determine low abundance species as well as functional 
capacity of the sample microbiome based on the mapping of individual genes (Ranjan et al., 
2016). From this, the potential metabolic pathways that enable the microbiota to function, 
and more critically identify pathways that are disrupted in disease can be deduced. This in 
combination with other ‘omics technologies, particularly metabolomics (in the next 
chapter) may provide a more informative description of intestinal dysbiosis in ME/CFS 
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patients according to the metabolic function of their intestinal microbiota rather than just 
changes in composition.  
 
The first WGS-based study was performed in ME/CFS sub-grouped according to the 
presence of IBS symptoms. Out of the 50 ME/CFS patients recruited, 21 had been 
diagnosed with IBS with no cases of IBS in 50 healthy controls. Shotgun metagenomic 
sequence data collected from this cohort is fundamentally different to earlier ME/CFS 
microbiome studies in that it will not be subject to amplification biases of 16S based 
sequences; furthermore species-level assignments are possible using MetaPhlan taxonomic 
assignment, in addition to identification of biological pathways. Increases in unclassified 
Alistipes and Faecalibacterium emerged as microbial markers of ME/CFS with IBS, whist 
robust statistical testing agreed decreased RA of B. vulatus defined ME/CFS without IBS 
(Nagy-Szakal et al., 2017). Differences with bacterial species in ME/CFS were driven by IBS 
co-morbidity including a reduction in RA of Faecalibacterium species, R. obeum, E. hallii, 
and C. comes (Nagy-Szakal et al., 2017). Table 2.1 lists the bacterial species taken from the 
Nagy-Szakal et al. (2017) study that are the strongest predictors for subgroups of ME/CFS 
with/without IBS.  
 
 
 
 
 
 
 
 
 
Table 3.1.1 Lists of bacterial species extracted from text of Nagy-Szakal paper, relevant to their 
predictive model to distinguish ME/CFS subgroups from controls  
 
Interestingly, there were significant correlations between certain bacterial species and 
symptom severity scores using the SF-36 and Multidimensional Fatigue Inventory (MFI). 
Decreased RA of Faecalibacterium spp, R. obeum, E. hallii, C. comes and Coprococcus spp 
were associated with IBS-like hypersensitivity, bloating and abdominal discomfort (Nagy-
Szakal et al., 2017).  
 
“ME/CFS” “ME/CFS + IBS” “ME/CFS – IBS” 
C. catus 
P. capillosus 
D. formicigenerans 
F. prausnitzii 
C. asparigiforme 
Sutterella wadsworthensis 
A. putredinis 
Anaerotruncus colihominis 
 
 
Faecalibacterium cf. 
Bacteroides vulgatus (decreased 
RA distinguishes from ME/CFS – 
IBS, on all statistical tests) 
 
Additional 9 added: 
F. cf. 
F. prausnitzii 
B. vulgatus 
A. putredinis 
C. catus 
A. caccae 
D. formicigenerans 
A. colihominis 
C. asparagiforme 
Bacteroides caccae 
P. capillosus 
P. distasonis 
Bacteroides fragilis 
Prevotella buccalis 
Bacteroides xylanisolvens 
D. formicigenerans 
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- Summary 
 
Both Giloteaux et al. (2016) and Nagy-Szakal et al. (2017) have used different methods to 
produce lists of bacteria at various taxonomic levels (partly on whether the data is 16S or 
shotgun) which are putatively overrepresented in either patients or controls. Both studies 
assess the size of the effect that each taxon has on the difference between groups, using 
the same method of Linear Discriminant analysis Effect Size, (LEfSE). Significant differences 
were found in 40 OTUs (out of ~1,330 OTUs per sample), but only appear to name 
corresponding species for some of them despite this being 16S data. Moreover, even if all 
taxa were distributed randomly between patients and controls, you are likely to get a small 
number, which appear, by chance, markedly more abundant in one group compared to the 
other. To that end, if this study were to be repeated it would be surprising if all of these 
genera listed were found to be significantly more/less abundant in ME/CFS again because 
of major environmental factors, such as diet known to contribute to population-level 
variation of the microbiota on a daily basis. Figure 2.4 is taken from Fig. S2 in this paper, to 
highlight the difficultly in equating these taxa to differences for separation of ME/CFS from 
Controls in these plots. 
 
The 2017 study additionally presents functional pathways overrepresented in ME/CFS with 
or without IBS compared with controls. In their statistical analyses, “ME/CFS” is referred 
distinctly from “ME/CFS + IBS”, and “ME/CFS – IBS”, and “controls” (no ME/CFS, no IBS), 
suggesting the “ME/CFS” is a supergroup being compared with subsets of itself. Critically 
this paper lacks an IBS-only disease control group. Parts of the methods to this work suffer 
ambiguity, particularly with respect to the tools used to create the topological data analysis 
(TDA) and machine learning approach to identify difference across groups; the lack of detail 
here does not makes this easily reproducible. The machine learning approach was 
successful in the Giloteaux et al. (2016) study as a way to see what combination of 
microbial taxa and various plasma markers could successfully predict whether a subject is a 
patient or control, using most of the data as a training set and then making predictions on 
the remaining samples. Finally, there is consistency between TDA, the rank-based test, the 
LEfSe, and features identified by machine learning for species belonging to 
Faecalibacterium, Roseburia, Dorea, Coprococcus, Clostridium, Ruminococcus, and 
Coprobacillus as significantly different in “ME/CFS” compared with “controls” (Nagy-Szakal 
et al., 2017). 
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Figure 3.1.4 Principal Coordinate Analysis (PCoA) plot of healthy controls versus ME/CFS based on 
32223 sequences per sample using targeted 16S rRNA gene sequencing. 16S rRNA derived 
microbial community analysis reveals no difference in beta-diversity between patients and controls.  
Clustering distances calculated with weighted UniFrac (a) and unweighted UniFrac (B). Figure 
reproduced from (Giloteaux et al., 2016), supplementary figure S2. 
 
- Confounders of microbiome diversity 
 
The differences found between Norwegian and Belgium ME/CFS patients highlight the 
importance influences the environment, diet and genetic background have on the 
composition of the intestinal microbiota (Fremont et al., 2013). Most studies offer gender 
and age matching of healthy controls to their patients, with no consideration of the above 
factors. Cohousing mice is a routine and regular practice in studying the effects of the 
intestinal microbiota and to control for dietary influences. Interestingly a recent paper 
studying the enteric virome in IBD in humans demonstrates the importance of having 
house-hold controls to increase the power of detecting disease-associated changes.  Then 
natural variability in intestinal bacteria and viruses in non-household controls and patients 
makes it more difficult to see such disease-specific alterations (Norman et al., 2015). It is 
also expected house-hold controls will more likely share a similar diet and will normally 
share a similar genetic background mother-daughter or father-son. In these circumstances 
age of course cannot be matched; however, researchers have to decide which factors to 
give the priority towards controlling and will depend upon individual study design and the 
hypothesis. So far, no study investigating the microbiome in ME/CFS has attempted to 
recruit house-hold controls. 
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Indeed, comparison of multiple studies in microbiome research is complicated by the fact 
that different researchers opt for different study designs, extraction methods, sequencing 
platforms and favour different bioinformatic tools to interpret the data (D’Amore et al., 
2016). Nagy-Szakal et al. (2017) acknowledge that their work cannot be directly compared 
to the earlier 16S rDNA analyses but support intestinal dysbiosis in ME/CFS based on 
increases/decreases of the RA of specific bacterial species (table 2.1). However, they have 
made a first attempt to correlate specific symptoms and severity with patterns of dysbiosis 
in ME/CFS although their study design did not make severity a focus. Impact of severity 
included scores associated with emotional wellbeing, motivation, fatigue and pain, 
however the relatively small cohort make it difficult to predict ME/CFS severity using their 
microbiome data in this study. 
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Table 3.1.2 Summary of microbiome studies performed in ME/CFS with relevant findings and overview of methods to determine these differences Up 
arrows denote increased relative abundance; down arrows denote reduction in relative abundance of bacterial taxa.
Study Sequencing 
method 
Recruitment 
criteria 
Sample size Platform Av. number 
of reads 
16S 
rRNA 
variable 
region 
Significant 
Observations/Conclusions 
Sheedy  
et al. 
(2009) 
 
Culture-based 
assays 
Holmes (1988) 
/Fukuda (1994)/ 
Canadian (2003) 
108 ME/CFS 
 
177 controls 
N/A N/A N/A   D-lactate Enterococcus and Streptococcus spp. 
 
 
 
Fremont 
et al. 
(2013) 
 
16S targeted 
amplicon 
Fukuda (1994) 43 ME/CFS 
 
36 controls 
454 
FLX 
(Roche®) 
6000-7000 per 
sample, min 
240 b.p.  
V5-V6 Belgian patients:  
x45 < Lactonifactor genus 
 
Norwegian patients:  
x20  <  Lactonifacor genus 
3.8 fold < in Bacteroidetes genus Alistipes 
Decreased Firmicute sub-populations 
Hanson 
et al 
(2016) 
 
16S targeted 
amplicon 
Fukuda (1994) 48 ME/CFS 
(34 report GI 
disturbances) 
 
39 controls 
Illumina® 
MiSeq 
2x250 bp 
 
98,093 ± 29,231 
reads per sample 
 
V4 Reduced Bifidobacteria and Faecalibacteria spp. 
 
Positive plasma markers for increased intestinal 
permeability: LPS, LBP, sCD14 
 
PD metric: ME/CFS less diverse than Healthy Controls 
Lipkin 
et al. 
(2017) 
 
Shotgun 
Metagenomic 
Fukuda (1994)/ 
Canadian (2003) 
50 ME/CFS 
 
50 controls 
Illumina® 
HiSeq 4000 
2x100 bp 
~35 million 
reads per sample 
 
10 samples/pool 
350 million reads 
per pool 
N/A Family level:     Lachnospiraceae &    Porphyro- 
monadaceae in ME/CFS 
 
Genus level:    Dorea,    Faecalibacterium,   
Coprococcus,    Roseburia, &    Odoribacter 
 
Clostridium and    Coprobacillus in ME/CFS 
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3.1.3 Aim and Objective 
 
There is limited evidence to suggest ME/CFS is associated with an altered intestinal 
microbiota and increased permeability. It is not known how well these findings replicate in 
other patient cohorts or according to disease severity. Existing published ME/CFS research 
has made no attempt to stratify patients based on specific symptoms and severity. Often 
such studies are indirectly comparable due to lack of protocol standardisation and 
agreement on the best inclusion and exclusion criteria to recruit patients.  
 
The aim for this first results chapter was two-fold. The first, to focus recruitment on 
patients who are house-bound with severe symptom severity, postulating that the severity 
of gut dysbiosis may be directly linked to extreme fatigue and neurological symptoms in 
these patients. The second, to compare house-bound patients with a house-hold control in 
order to: 
 
- control for environmental factors known to cause population-level variations in 
microbiome data; 
- use 16S targeted gene marker sequencing and whole genome “shotgun” 
metagenomic sequencing to assess for evidence of or any pattern of intestinal 
dysbiosis that may; 
- support conclusion from existing metagenomics studies in ME/CFS, and; 
- identify key bacterial species belonging to a novel “microbial signature” which may 
help define severe ME patients from those mild to moderately affected. 
 
3.3.4 Hypothesis 
 
Severe, house-bound ME/CFS patients have a distinct microbial signature for dysbiosis that 
is reflected by their profile of gut bacteria; the composition and reduction of diversity of 
which, separates them from house-matched healthy controls and when compared to 
existing metagenomics data from the general ME/CFS population.   
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3.2 Materials & Methods 
 
3.2.1 Patients 
 
For the work presented in this chapter, a total of 52 individuals (42 ME/CFS and 10 
controls) were recruited and consented between 2015-2017 to provide faecal samples to 
this study. Of these ME/CFS patients, 17 were severe, house-bound and 25 mild/moderate. 
An additional faecal sample one year on was available in 2017 from 8 previous participants 
(4 severe ME matched to 4 house-hold controls), bringing the total to 60 faecal samples 
processed for microbial DNA extraction and sequencing across 16S and whole genome 
metagenomic platforms.  
 
Prior to any home visits, mild/moderate ME patients were the first participants to be 
recruited and sequenced in 2015 using 16S rDNA V4 sequencing generating “Dataset A”. 
Home visits to severe patients were conducted in 2016 (“Dataset B”) and 2017 (“Dataset 
C”) with modifications made to stool sample collection method that have been used for 
mild/moderate patients (described below). All samples were initially stored at -80oC at St 
Helier Hospital, Carshalton, London. At the end of the study recruitment phase, all samples 
were packaged in dry ice containment and collected by an authorised courier for them to 
be deposited within the Norwich Biorepository. Samples were the accessible from the 
Biorepository to be used in experiments. 
 
- Stool sampling kits 
 
The original stool kit used for recruitment of mild/moderate patients included the following 
items: a ProtocultTM collection device (Product #500 Ability Building Centre, Rochester, MN, 
USA), OMNIGene® GUT stool device (OMR-200, DNA Genotek, ON, Canada), x4 30 ml 
Universal tubes with spatulas, and zipped bags for packaging. Using this method patients 
took samples from their own stool and equally divided as much of the sample as possible 
across the four tubes. As per instructions on the package insert of the OMNIGene® (figure 
3.1.1), patients were asked to transfer equivalent of a pea-sized amount of faeces into the 
yellow tube top and scrape horizontally. After replacing the purple cap, the device is 
shaken back and forth as hard as possible by hand, for a minimum of 30 seconds to allow 
mixing with the stabilising liquid. 
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Figure 3.2.1 Instructions for OMNIGene® GUT collection device used to collect mild/moderate 
ME/CFS samples in 2015. Patients collected their stool using the paper Protocult™ collection device 
(A), and then taking a ‘pea-sized’ spot sample from their stool transferred this to an OMIGene™ 
GUT® tube (B) and followed the visual instructions (1-4) as shown in this figure. The rest of the faecal 
sample was then divided equally across four 30 ml Universal tubes. Images obtained from: 
https://www.dnagenotek.com/us/products/collection-microbiome/omnigene-gut/OMR-200.html 
[assessed 10 March 2019]. 
 
 
 
 
1 2 3 
4 
A 
B 
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- Improvements to stool sample collection in 2017 
 
In 2017 changes were made to improve faecal sample collection to facilitate entire stool 
sample collection for the purposes of homogenisation. This step was particularly necessary 
for preparation of faecal water samples, as spot sampling from different areas of the same 
stool sample has been shown to produce varying results (Gratton et al., 2016a). Severe and 
house-matched participants were instructed to collect their entire faecal sample into a 
device called a FECOTAINER® (AT Medical B.V., Enschede, The Netherlands), figure 2.2.2 no 
sooner than 24 hours before a scheduled home visit, and to keep it in the fridge at 40C in 
double containted in plastic bags provided. This kit also contained an AnaeroGenä 
Compact anaerobic sachet (Cat No. AN0010, Oxoid Ltd., United Kingdom) to activate as 
soon as participants produced their sample to minimise oxygen conditions limiting any 
aerobic growth and activity. On return to the hospital, samples were manually 
homogenised with a sterile autoclaved metal spatula and processed according to their 
downstream application and stored at -80oC until required.  
 
3.2.2 Faecal DNA extraction 
 
The method for DNA extraction from human faeces was obtained from the Hall Lab at 
Quadram Institute Bioscience, with minor adaptions to the manufacturer’s kit protocol. 
Prior to experimenting, faecal DNA extracts were prepared from frozen faecal aliquots that 
had been pre-weighed (~250mg) into a sterile Lysing Matrix E tubes from the FastDNA SPIN 
kit for Soil (Cat. No. 116560200, MP Biomedicals, UK). Samples were stored at -80oC as 
soon as possible on the same day of collection. Earlier samples obtained using the 
OMNIGene GUT device began the exact same process to be described here, instead taking 
250 µl of faecal homogenate. 
 
On the day of the experiment, faecal aliquots were thawed, after which 978 µl sodium 
phosphate buffer and 120 µl MT buffer was added and homogenised using the FastPrep® 
Instrument for a duration of 45 seconds and repeated for a total of 3 cycles. Each cycle was 
separated by placing each sample in ice for 60 seconds to reduce heat. Following the 
mechanical destruction of bacteria cells within the faeces, cell debris and other faecal 
particulate were removed by centrifuging at 14,000 x g, for 15 min. The supernatant was 
transferred into a sterile 2.0 ml Eppendorf tube, to which 250 µl of PPS was added to 
precipitate protein from the solution. The supernatant was transferred in 15 ml tubes 
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containing 1 ml of Binding Matrix and inverted by hand for 2 minutes to allow DNA binding. 
Tubes where then placed in a rack and allowed to settle for 3 minutes after which 500 µl of 
the supernatant was discarded with care not to disturb the settled Binding Matrix. The 
remaining resuspended Binding Matrix solution containing bound DNA was passed through 
a SPIN filter tube at 14,000 x g, for 1 minute. DNA captured on the column was washed 
using DNase-free salt/ethanol wash (SEWS-M). Subsequently, a second dry spin was 
performed and each SPIN filter air dried for 10 minutes at room temperature to remove 
excess alcohol. Finally, DNA was eluted in 50 µl of DNase/Pyrogen free DNA water (DES) 
pre-incubated at 50 degrees to enhance DNA recovery and stored at 4oC short term, or at -
20oC for a longer period. DNA was quantified using Qubit® and Agilent Tapestation. 
 
3.2.3 Acquisition of 16S rRNA gene sequence data 
 
V4 16S rRNA gene sequencing was performed in two batches for mild/moderate patients in 
2015 and severe and house-hold controls in 2017. Following microbial DNA was extraction 
as described above, these samples were sent to sequencing companies for further 
downstream processing as described below:  
 
- Mild/moderate ME/CFS (n=25) 
 
DNA extracted from 25 faecal samples from mild/moderate ME/CFS patients was 
submitted to Animal Health and Veterinary Laboratories Agency (AHVL) for PCR 
amplification of the V4-V5 region of the 16S rRNA gene (primers: U515F, 5’-
GTGYCAGCMGCCGCGGTA-3’; U927R, 5’-CCCGYCAATTCMTTTRAGT-3’) and (Illumina MiSeq) 
sequencing. 16S rRNA gene sequence data were processed using QIIME 1.9 (Caporaso et 
al., 2010). Demultiplexed read files were supplied by the sequencing provider. For each 
read file, paired-end reads were joined using fastq-join (Aronesty, 2011); minimum 
acceptable Phred quality score was Q20; primers were removed from reads using cutadapt 
leaving reads of ~370 nt in length (Martin, 2011). The read files were concatenated and 
OTUs picked using usearch (99 % mapping, similarity, gg_13_8), which also performs 
chimera checking (Edgar, 2010). Sequences were aligned using PyNAST (Caporaso et al., 
2009). Taxonomy was assigned using gg_13_8 (99 %), with annotations for the 
representative sequence set checked and corrected where necessary (e.g. in Greengenes, 
members of the family Rikenellaceae are poorly annotated and newly described 
prokaryotes are not annotated). Singletons and reads representing < 0.001 % of total reads 
were filtered from the OTU table. For descriptions of data in terms of abundance, 
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rarefaction was performed on the OTU table (n = 8,750) so that the number of reads 
compared per sample was identical. 
 
- Severe ME/CFS (n=21) and House-hold controls (n=12) 
 
Faecal DNA extracted from severe house-bound patient and their respective house-hold 
controls were submitted to Novogene® for 16S sequencing. DNA concentration and purity 
were checked on 1% agarose gels. According to the concentration, DNA was diluted to 
1ng/μL using sterile water. The V4 region of the 16S rRNA gene were amplified using 
specific primers, U515: F, 5’-GTGYCAGCMGCCGCGGTA-3’; and U806, R, 5’-
CTACCRGGGTATCTAATCC-3’ (Caporaso et al., 2011). All PCR reactions were carried out with 
Phusion® High-Fidelity PCR Master Mix (New England Biolabs). PCR products stained with 
Sybr Green nucleic acid stain were separated on a 2% agarose gel and bands selected 
between 400-450bp of length. These PCR products were mixed in equidensity ratios. Then, 
the mixture of PCR products was purified with Qiagen Gel Extraction Kit (Qiagen, Germany). 
Libraries were generated using the NEBNext® UltraTM DNA Library Prep Kit for Illumina 
and sequencing performed on the Illumina® MiSeq platform. Paired-end reads was 
assigned to samples based on their unique barcode and truncated by cutting off the 
barcode and primer sequence. Demultiplexed read files were supplied by the sequencing 
provider. 
 
Acquisition of Shallow Shotgun Metagenomic sequence data 
 
- Dataset B 
 
DNA extracted from 11 severe ME/CFS patients and 8 house-matched controls were 
quantified using Qubit® Broad Range Assay and submitted to Dr Gemma Kay at the Bob 
Champion Biomedical Research Building, University of East Anglia, UK, for library 
preparation. An additional sample of containing 20 µl DES H2O was processed alongside the 
faecal samples to act a negative control and to highlight potential kit contamination. 
Illumina library construction was prepped using the Nextera XT DNA kit (Illumina Inc. USA) 
containing barcoding sequences and i5 and i7 primer adaptors. Raw sequencing reads were 
pre-processed using Trimgalore (v 0.4.4) for end trimming and filtered to exclude low-
quality and low-complexity reads. Adaptor sequences were removed using cutadapt 
contained with the Trimgalore wrapper. Human sequences were subtracted from the 
dataset using BBMap 38.06 to align them against the Human reference (hg38), keeping 
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only unaligned reads for further processing. Bacterial composition (relative abundance) 
was obtained from raw sequencing data using MetaPhlAn (v1.7.8). 
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Table 3.3.1 Summary and descriptions of metagenomic datasets (A-C) collected in 2015, 2016 and 2017.
Dataset Year Study type Sample Size  ME/CFS 
status 
Platform Av. number 
of reads 
Analytical methods & bioinformatics 
tools 
A 2015 16S rRNA 
targeted 
amplicon 
 
U515F, U927R 
n = 25 ME/CFS 
 
No controls 
Mild/ 
moderate 
Illumina® MiSeq 
x2 300 bp 
 
V4 region 
70,769 
(rarefied to 
8,750) 
16S rRNA gene sequence data were processed using 
QIIME 1.9, species annotation by Greengenes 
assigned 99% similarity OTU clustering  
Few Actinobacteria (Bifidobacteria and 
Coriobacteria 
B 2016 “Shallow” 
shotgun 
metagenomics 
n = 19 
 
11 female ME/CFS 
 
8 house-matched 
control 
(7 female, 1 male) 
Severe, 
bed bound 
Illumina® MiSeq  
 
x2 300bp  
960,260 
 
(ranges 253,000 
- 2,168,000) 
 
MetaPhlAn 2.0. 
 
Capacity to determine species level and functional 
capacity  
 
Microbial community analysis performed using 
MEGAN 6.0 
C 2017 16S rRNA 
targeted 
amplicon 
 
U515F; U806R 
n = 33 
 
21* females 
ME/CFS 
 
12* house-matched 
controls 
Severe, 
bed bound 
Illumina® HiSeq 
2500 
x2 250 bp 
 
V4 region 
150,882 
(rarefied to 
47,985) 
QIIME 1.7 
 
97% similarity OTU clustering, species annotation by 
SILVA database 
 
Microbial community analysis performed using 
MEGAN 6.0 
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Sample Summary: 
Dataset A (2015) 
 
 
 
 Status Sex Age DV** Reads Observed OTUs 
28 Mild/Moderate M 54 22 68,165 310 
30 Mild/Moderate F 28 15 58,752 289 
31 Mild/Moderate M 41 24 48,775 142 
32 Mild/Moderate F 65 17 66,839 278 
33 Mild/Moderate M 48 18 65,459 222 
35 Mild/Moderate M 37 21 64,504 284 
37 Mild/Moderate F 60 1 140,262 238 
38 Mild/Moderate F 43 2 91,835 352 
39 Mild/Moderate F 39 3 82,192 338 
40 Mild/Moderate F 44 4 118,137 283 
41 Mild/Moderate F 54 5 77,531 238 
42 Mild/Moderate F 45 6 87,229 318 
43 Mild/Moderate M 47 7 77,101 366 
44 Mild/Moderate F 25 8 106,107 113 
45 Mild/Moderate F 48 10 58,552 332 
46 Mild/Moderate F 72 11 71,712 345 
47 Mild/Moderate F 30 12 61,424 225 
48 Mild/Moderate F 55 13 54,967 336 
49 Mild/Moderate F 33 14 46,834 306 
50 Mild/Moderate M 58 16 68,534 300 
51 Mild/Moderate F 53 19 9,064 229 
52 Mild/Moderate F 27 20 75,622 235 
53 Mild/Moderate F 32 23 76,883 327 
54 Mild/Moderate F 21 26 57,916 216 
55 Mild/Moderate F 59 27 34,851 171 
 
Table 3.3.2 Sample summary of dataset A containing 25 mild/moderate patients (44.72 ± 13.40 
years old). Note: these samples were processed using OMNIGENE gut collection tube prior to DNA 
extraction and 16S gene sequencing. 
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Sample Summary:  
Datasets B & C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3.3  Sample summary of datasets B & C consisting of 17 Severe, house-bound patients 
(42.88 ± 15.16 years old) and 10 house-hold control (55 ± 13.62 years old). Samples obtained 
during 2016 and 2017. This table also highlights the cross over between datasets B and C in terms of 
DNA sequencing technology used to survey the ME microbiome. 
 
 
 Status Sex Age ‘Shallow” 
Shotgun 
      2016 
16S (V4 region) 
 
   2016          2017 
1 Severe F 63 ME_8 F26  
2 Severe F 56 ME_5  F15 
3 Control F 55 CTR_4 F31 F6 
4 Control F 69 CTR_17 F30 F4 
5 Severe F 44   F3 
6 Control F 70   F20 
7 Control F 55 CTR_18  F19 
8 Severe F 38 ME_13  F2 
9 Severe F 21 ME_3 F33 F10 
10 Severe F 37   F9 
11 Control F 64   F11 
12 Severe F 18 ME_12 F27 F7 
13 Severe F 61   F1 
14 Severe F 40   F17 
15 Severe F 54   F18 
16 Severe F 58 ME_1 F21 F13 
17 Control M 60 CTR_2 F22 F14 
18 Severe F 27 ME_6 F23 F12 
19 Control F 60 CTR_16 F28 F8 
20 Severe F 63   F5 
21 Severe F 32 ME_7 F24  
22 Severe F 31 ME_11 F25  
23 Control F 54 CTR_15   
24 Control F 29 CTR_14   
25 Severe F 56 ME_10 F32  
26 Severe F 30 ME_19 F29  
56 Control F 34 CTR_9 F34  
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3.3 Results 
 
3.3.1 16S phylogenetic abundance in mild/moderate ME patients (n=25) 
 
- Dataset A 
 
Phylogenetic abundance data was generated from 21 females and 6 male mild/moderate 
patients. It was not possible to obtain samples from suitable control subjects. Raw 
sequences were trimmed using cutadapt to remove primers. In total, 1, 769, 247 reads 
were generated across 25 samples.  The mean number of paired end (PE) reads at 250bp 
long obtained was 70,770 ±25,581 S.D. per sample. Reads which clustered together with 
99% sequence homology generated a total of 686 Operational Taxonomic Units (OTUs) 
across all samples. Sequenced-based rarefaction curves were produced at 8750 (figure 
3.3.1) and 34000 reads per sample, which demonstrated diversity of all 25 samples was 
covered by sampling at 8750 reads. A minimum number of 2 samples were required for 
each particular OTU to be observed in order for that OTU to be retained. After filtering 
OTUs of less than 0.01% relative abundance, on average, 272 ± 52 SD OTUs were obtained 
per sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.1 Rarefaction curve for the intestinal microbiota of 25 mild/moderate ME patients 
recruited from walk-in appointment at the CFS service. Each sample has been rarefied to 8750 
reads. As the gradient of each curve increases less species are discovered within each sample. The 
higher the curve the greater number of species have been found within that sample. 
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Figure 3.3.2 Alpha diversity plots showing community evenness (Shannon H) A, and richness 
(Chao1, and PD), B and C, of 25 mild/moderate ME/CFS faecal samples derived from dataset A. As 
the gradient of each curve decreases and reaches a plateau the diversity (number of species 
identified) within that sample does not increase.  
  
All samples were rarefied to 8750 reads, which was below the sample with the least 
number of reads, sample DV19 (table 3.3.3). The number of observed “species” 
represented by number of reads clustering with 99% sequence similarity to form unique 
OTUs was used to calculate the alpha diversity within the mild/moderate ME/CFS group. 
Figure 3.3.2 shows the respective curves for community evenness using the Shannon H 
index, and indices for community richness; Choa1 and Phylogenetic Diversity (PD). These 
plots show as the number of reads increases the curve approaches a plateau beyond which 
the diversity of each sample does not increase with increasing number of sequence reads. 
Based on rarefying to 8750 read per sample, Shannon indices produced a value of H = 5.68 
± 0.70 SD, whilst indices for community richness produced 309.92 ± 59.12 SD, and 12.18 ± 
2.20 SD for Choa1 and PD respectively. 
A B 
C 
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Of the 686 OTUs found across all samples, 62 were assigned to bacterial genera using the 
Greengenes database. OTUs which could not be assigned were classified as unknown. The 
relative abundance of all OTUs and assigned OTUs were outputted into Microsoft™ Excel® 
to provide tables at each different taxonomic level from kingdom to the genus level.  Four 
samples DV2,6,7,23 had detectable Archaea ranging from 0.01% - 0.38% of all 
classifications. 
 
- Phylum level observations 
 
Compositional taxonomic analysis based on bacterial phyla (figure 3.3.3) identified 
Firmicutes and Bacteroides as the most abundant members of the microbiota at 49.02% 
and 47.80% respectively. Tenericutes were found in relative high abundance in two samples 
DV7 and DV23, 5.94% and 14.56% respectively. 
 
 
 
Figure 3.3.3 Relative abundance (%) of bacterial phyla provides a community composition profile 
of 25 mild/moderate ME/CFS patients. Bacteroidetes (red) and Firmicutes (turquoise) are the most 
dominant bacterial phyla within all samples 
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- Genus level observations 
 
Genus abundance is the highest taxonomic level that can be achieved in 16S-based 
microbiome studies. On average 41.12 ± 3.62 SD genera (figure 3.3.4) were identified per 
sample, ranging from the lowest, 32 genera in sample DV27, to the highest, 47 genera in 
sample DV2. Four samples were distinguished by high abundance of Prevotella, particularly 
DV4 at 60.27% of all genera present. Few Actinobacteria which include members of 
Bifidobacterium (0.04%), Coriobacteria (0.19%) and Eggerthella (0.02%) were identified 
across all samples. On average, 12.27% ± 8.61 SD of genera (purple bars, fig 3.3.4) were 
classified as unknown. 
 
 
Figure 3.3.4 Genus-level abundance data produced sampling at 8750 reads per sample from faecal 
samples obtained from 25 mild/moderate ME/CFS patients collected in 2015.  
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Figure 3.3.5 Summary of 34 top genera observed in 25 mild/moderate ME/CFS patients based on 
16S V4 region sequencing identification. Circle size relative to percentage abundance. 
 
 
The raw abundance tables were imported into MEGAN 6.0 for composition community 
analysis to visualise and compare each sample with the rest of the group. The top 34 most 
abundant genera are presented in figure 3.3.5. Bacteroides was the most abundant genus 
present in 24 samples at 28.06% ±12.60 SD. This genus was not detected in sample DV27; 
however, this sample had the third lowest number of reads. Faecalibacterium was 
prevalent in almost all samples at 9.27% ± 3.86 SD. No healthy sample control group 
processed at the same time of this sequencing to compare this data to. However, this data 
highlights some qualitative difference between patients that may influence the ME/CFS 
microbiota. For example, Roseburia is more abundant (6.01% ± 4.82 SD) in some patients 
than others ranging from 0.38% to 22.42% RA of the total ME/CFS microbiome. A similar 
pattern was seen for Oscillospira and Ruminoccoccus observed at 3.06% ± 2.04 SD and 
3.54% ± 1.96 SD RA respectively. 
 
Taxonomic profiles for all 25 samples was analysed using MEGAN which performed analysis 
of overall compositional differences samples within the group using multiple comparison 
tests for beta-diversity and applied to Principal Coordinate Analysis (PCoA) using Bray-
Curtis dissimilarity. Near-neighbour network representation was generated to reveal any 
sample grouping (fig 2.3.6).  
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Figure 3.3.6 Principal Co-ordinate Analysis using Bray-Curtis dissimilarity and Nearest-Neighbour 
network analysis comparing all 62 genera across 25 mild/moderate ME/CFS patients. Figures 
created using MEGAN 6.0. Left, PCoA separates samples into clusters, the closer samples cluster 
together the more compositionally similar they are. Right, Nearest-neighbour network groups. 
 
Bray-Curtis is influenced by the most abundant taxa within a sample. For example, DV4, 
DV18, DV19 and DV20 form a discrete cluster due to the higher RA of Prevotella in these 
samples 45% ± 19.72 SD. Other outliers include DV7 represented by 41.39% of unknown 
genera, and DV8 with the highest (35.93%) RA across all samples for Alistipes.  
 
3.3.2 Shallow shotgun metagenomics 
 
- Dataset B 
 
Shotgun metagenomic sequencing of 11 severe, house-bound ME/CFS patients and 8 same  
house-hold healthy controls (HHC) relatives generated FASTQ files accumulating to 19.24 
GB of sequence data from 300 bp, paired end reads from a single lane on the Illumina™ 
MiSeq® platform.  The range of sequence reads obtained was between 230,000 and 
2,168,000 for these samples.  After QC clean up, there were no reads associated with 
sample CNEG-20 which was a blank control to exclude any DNA extraction kit 
contamination and ‘kitome’ effect. A high number of human-associated reads were found 
in all samples ranging from 7-44% of all reads and removed before analysing sequences 
using MetaPhlAn. A total of 152 species of bacteria were observed across all samples of 
which 143 were from within the severe ME/CFS groups compared to 88 found in the HHC 
group. On average the number of species per sample was 38.64 ± 6.28 and 34.62 ± 8.97 in 
ME/CFS and HHCs respectively. 
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- Phylum level observations 
  
Firmicutes were the most abundant bacterial phyla within most samples for patients and 
HHCs, in figure 3.3.7 (turquoise bars) at 58.17% ± 21.6 in ME and 56.11% ± 12.92 SD in 
HHC. Bacteroides were less dominant at 17.90% ±  15.26 SD in ME versus 26.66% 13.54 SD 
in HHC. Actinobacteria (blue bars) were more abundant in ME compared with HHC, at RA of 
14.59% ± 8.41 SD versus 11.72% ± 6.72 respectively. Euryarchaeota (yellow bars) were 
found in 3 ME/CFS samples, the highest RA in 1_ME at 15.89%, and in a single HHC sample, 
4_HHC at 2.05% RA. These samples were not from the same house-hold. Sample 4_HHC 
was also notable for having the highest number of human reads at 43.77% of all 253, 484 
reads generated. After filtering human reads only 169,707 were useable for metagenomic 
characterisation. Table 2.3.2 present summary of number of reads associated with each 
sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.7 Relative abundance of bacterial phyla observed across all 19 samples (severe ME=11, 
HHC=8) using Illumina™ MiSeq® sequencing platform. There are no proportional differences in 
these bacterial phyla  between both groups.
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Figure 3.3.8 Statistical plots for bacterial phyla: Bacteroides, Firmicutes and Actinobacteria in ME 
and HHC. Top left, box plot of all phyla observed, central line represents median percentage of 
group severe vs. house-hold control; error bars indicate max and min values for each observation. 
Top right and bottom, each dot represents a single sample; central line is mean percentage, error 
bars are the standard error (SE). No significant differences.  
  
The RA of Bacteroides, Firmicutes and Actinobacteria were plotted in graphs (figure 3.3.8) 
and statistically analysed with the non-parametric Mann-Whitney test for differences 
between ME and HHC. There were no statistically differences for observed relative 
abundances across the bacterial phyla between ME and HCC at 5% significance level. 
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Figure 3.3.9 : Comparison of relatives abundance (%) of bacterial genera in severe (n=11), 
mild/moderate (n=25) ME/CFS compared with HHCs (n=8).  
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- Genus level observations 
 
Genus-level abundance detail of the severe ME microbiome is of qualitative comparative 
interest to the earlier mild/moderate ME/CFS dataset (figure 2.3.9). A total of 57 bacterial 
genera were identified across severe ME and HHC samples. These observations were 
correlated with bacterial genera observed in mild/moderate ME/CFS, of which 29 genera of 
these were not identified in either severe ME or HHCs. Table 2.3.4 lists the 57 bacterial 
genera found and their RA in Severe ME and HHCs. This approach highlighted possible 
genus-level trends across sample groups. For example, Bacteroides (fig. 3.3.9, brown) 
abundance is follows for the trend M>H>S, at 28.06%, 16.14% and 13.1% respectively.  
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Table 3.3.4 Genus-level abundance data from dataset B. Values expressed in this table are an 
average percentage (%) of the relative abundance (RA) of genera across groups: severe, house-hold, 
mild/moderate A total of 58 genera were observed across all samples from severe patients and 
house-hold controls. Of these, only 34 out of 62 matched to genera from 16S analysis of 
mild/moderate patients (dataset A). ND, not detected 
Bacterial Genus Severe House-Hold Mild Moderate 
Acidaminococcaceae_unclassified 0.0063 0.0000  ND 
Acidaminococcus 0.1592 0.0000 0.09 
Adlercreutzia 0.0927 0.1505  ND 
Akkermansia 3.4569 1.4131 0.01 
Alistipes 2.5854 7.4204 5.17 
Alloscardovia 0.1686 0.0000  ND 
Anaerostipes 0.2074 0.1067 1.23 
Atopobium 0.0192 0.0000  ND 
Bacteroidales_noname 0.2808 0.7948  ND 
Bacteroides 13.110 16.140 28.06 
Barnesiella 0.7925 1.1171 0.49 
Bifidobacterium 10.186 6.5995 0.04 
Bilophila 0.2289 0.0921 0.01 
Blautia 5.9221 5.7447 3.30 
Burkholderiales_noname 0.0000 0.0888  ND 
Butyricicoccus 0.0014 0.0000 0.10 
Butyrivibrio 0.0000 0.6657  ND 
Citrobacter 0.0183 0.0000  ND 
Clostridium 0.9115 0.0079 0.69 
Collinsella 2.7422 4.5425 0.06 
Coprobacillus 0.0822 0.0000 0.02 
Coprococcus 2.8474 2.4623 1.13 
Coriobacteriaceae_noname 0.1021 0.0000  ND 
Dialister 0.8483 0.5147 0.56 
Dorea 1.9255 3.2903 0.37 
Eggerthella 0.9899 0.4304 0.02 
Enterobacter 0.3085 0.0000  ND 
Enterobacteriaceae_noname 0.0177 0.0000  ND 
Enterococcus 0.0285 0.0000  ND 
Epsilon15likevirus 0.0700 0.0000  ND 
Erysipelotrichaceae_noname 0.4662 0.1554  ND 
Escherichia 0.4830 3.1811 0.33 
Eubacterium 12.152 11.868  ND 
Faecalibacterium 2.9294 10.233 9.27 
Flavonifractor 0.0028 0.0000 0.27 
Gordonibacter 0.1350 0.0148  ND 
Holdemania 0.0374 0.0000 0.07 
Klebsiella 2.6349 0.0706  ND 
Lachnospiraceae_noname 0.6953 0.6304 1.39 
Lactobacillus 0.6840 0.0000  ND 
Methanobrevibacter 1.9334 0.5275 0.03 
Methanosphaera 0.0421 0.0000  ND 
Odoribacter 0.0112 0.0076 0.28 
Oscillibacter 0.4695 0.0797  ND 
Parabacteroides 0.9784 1.0373 2.43 
Paraprevotella 0.1379 0.1425 0.18 
Parasutterella 0.0000 0.0079 0.37 
Peptostreptococcaceae_noname 0.2556 0.0000  ND 
Roseburia 2.1468 1.3018 6.01 
Ruminococcaceae_noname 0.0569 0.1169 0.01 
Ruminococcus 11.931 8.5893 3.54 
Scardovia 0.0344 0.0000  ND 
Slackia 0.1176 0.0000  ND 
Streptococcus 2.3592 1.2583 0.39 
Subdoligranulum 10.799 9.0340 0.09 
Sutterella 0.1550 0.1134 0.48 
Turicibacter 0.0208 0.0000 0.06 
Veillonella 0.2164 0.0451  ND 
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The Faecalibacterium genus, shown in pink in this figure, was found lowest in severe ME 
(2.93%) compared with mild/moderate and HHCs at RA of 10.24% and 9.27% respectively. 
Finally, Alistipes spp. (fig. 3.3.9 pale blue) were diminished in Severe ME at 2.59% versus 
7.42% in HHC and 5.17% in the mild/moderate 16S-derived microbiota. 
 
Using the 25 most abundant genera found in severe ME and HHCs, a heatmap was 
generated in MetaPhlAn. In this figure (3.3.10), samples to the right of ME-3 tend to 
feature more controls (6) versus samples to the left are more dominated by ME samples 
with the exception of 2 HHCs. Based on the low number of samples collected in this cohort 
is difficult to identify any findings that distinguish the severe ME microbiome separate from 
HHC. The Bacteroides genus tends to be more abundant in HHCs, whilst Collinsella spp. is 
absent in some ME samples and at low-high abundance in HHCs. In addition, Coprococcus 
spp. is identifiably more abundant (dark blues) in at least 4 of severe ME patients and one 
ME patient higher (red). Notably, Oscillibacter spp. was found present in 8 of the severe ME 
patients whilst only one HHC had this genus. 
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Figure 3.3.10 Heatmap of 25 most abundant bacterial genera seen in severe ME (n=11) and 
matched house-hold controls, HHC (n=8). Genera list (g_name) on the right of map. Red colours 
indicate this genus is present at a higher RA in samples, whereas blue genera are less abundant and 
black indicates absence of this genera. CNEG-20 is water, used as a kit control (kitome) for 
sequencing. 
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- Species level observations 
 
A total of 152 species were classified across all samples using MetaPhlAn 1 in 2016. The 
same raw sequencing data was re- analysed with the more update version of MetaPhlAn 
2.0 in 2018. However, this did not significantly alter the outcome of this data. Table 3.3.5 
summaries the total number reads associated with each sample and the total number of 
species observed in it. DNA concentration was measured and recorded prior to dispatch to 
the sequencing provider who also performed in-house QCs checks for DNA fragment 
length. The lowest quantity of DNA sent for sequencing was 700 ng of total DNA in 20µl 
water, in sample CTR-15. The highest number of observed species was 52 in ME-10, and 
the lowest number 20 in CTR-9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3.5 Sample sequencing statistics for extracted DNA concentration from 250 mg of raw 
faecal stool and number of paired end reads obtained following QC and trimming. This data was 
generated from 20µl of undiluted DNA sent to an external sequencing provider. Number of reads 
obtained after removal of human sequences. Number of species assigned to reads using MetaPhlAn 
2.0. 
Sample DNA (ng/µl) Reads Species 
ME-1 172 1,188,807 44 
CTR-2 196 765,785 40 
ME-3 372 818,307 43 
CTR-4 73 169,707 24 
ME-5 294 1,324,046 41 
ME-6 548 1,468,535 38 
ME-7 76.4 1,258,690 46 
ME-8 468 480,512 23 
CTR-9 137 345,280 20 
ME-10 300 1,038,416 52 
ME-11 47 990,786 37 
ME-12 270 1,222,374 40 
ME-13 65.2 1,267,583 39 
CTR-14 199 344,530 24 
CTR-15 35 1,185,795 40 
CTR-16 324 1,090,871 40 
CTR-17 264 1,511,959 47 
CTR-18 144 873,110 42 
ME-19 78 899,956 22 
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Ü Figure. 3.3.11 Bubble chart summary of 59 bacterial species and 9 genera in 11 severe ME 
patients versus 8 House-Hold Controls. Colours representative of individual genera or species. (A) 
Size of circle is proportional to the relative abundance (RA) of that genus or species with the 
individual total microbiota. (B) Size of circle represent RA values on a square-root scale to reveal 
differences between less abundant and minor members of the intestinal microbiota. 
 
Figure 3.3.11 A and B were produced using MEGAN 6.0 to summarise composition 
differences between species in ME and HHC; which reveals several HHCs had a higher RA of 
Faecalibacterium prausnitzii (pink circles) 10.23% ± 6.04 SD versus 2.93% ± SD 3.15 in 
HHCs. Ruminococcus bromii (brown circles) was higher in 3 of the ME patients; 41.24%, 
23.04% and 33.15% respectively in figure 3.3.11B. This part of the figure also shows 
Bacteroides vulgatus (pale blue circles) was missing is 6 patients compared to just two in 
the HHCs. However, ME-19 had a RA of 36.79% for this species compared to an average of 
2.70% ± 1.62 in across all HHCs. Almost half of the relative abundance of species within 
ME-12 was attributed to Bifidobacterium adolescentis (orange circles, fig.  3.3.11B) at 
45.39% which was absent in most ME patients and only appear in a single HHC at RA of 
3.71% (CTL-17). 
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Ü Figure 3.3.12 Twenty-five most abundant bacterial species across all samples identified using 
MetaPhlAn 2.0 in 2018.  
 
Sequnce read originally analysed in 2017 were re-analysed using a more recent version of 
MetaPhlAN. Additional species were identified in most samples; however, this did not 
exceed 12 per sample. It is important to note that these were not new species and instead 
represented assigning of previously identified species to more samples across both groups. 
A heatmap was generated in Figure 3.3.12 from MetaPhlAn 2.0 to compare the RA of the 
top 25 species which varied the most between patients and HHCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.13 Status by bacteria genus reveals differences between severe ME and house-matched 
controls for Eggerthella, Faecalibacterium & Oscillibacter. Statistical analysis and graphical output 
completed using RStudio®. 
Genus P value 
Eggerthella 0.0466 
Faecalibacterium 0.0184 
Oscillibacter 0.0183 
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- Statistical comparison of bacterial genera in severe ME versus HHC 
 
Taxonomic abundance tables were analysed using R Studio for significance testing between 
ME and HHC at the genus level. Figure 3.3.13 presents the statistical plots generated for 
this analysis using an unpaired Mann Whitney U test with Benjamin Hochberg p value 
adjustment. This identified three bacterial genera with a p value <0.05. Members of 
Oscillibacteria spp. and Eggerthella spp. were statistically more abundant (p values 0.0183 
and 0.0466, respectively) in the severe ME microbiota compared with the HHC group. 
Conversely, the genus Faecalibacterium were significantly lower (p=0.0184) within the 
severe ME microbiota compared to HHCs. No species belonging to the genus of 
Oscillibacteria or Eggerthella were identified whilst F. prausnitzii was the only species 
found within Faecalibacterium spp.  
 
- Bray-Curtis Dissimilarity Analysis 
 
The beta-diversity between the microbiotas of severe ME and HHCs was calculated using 
MEGAN 6.0. PCoA of taxonomy using Bray-Curtis distances are based on measures of the 
most abundant bacterial taxa within that sample. Figure 3.3.14 the direction of clustering 
of samples and has been labelled with the dominant species within these samples driving 
this spatial separation. Significantly, Facalibacterium prausnitzii emerges as the main 
principle component in most CTR samples. Other discrete clusters are for ME samples 
driven my Ruminoccus bromii and Bacteroides uniformis however, these are explained by 
typically one of two outlier ME samples compared to the rest of the group, see fig. 3.3.11b. 
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Ü Figure. 3.3.14 PCoA analysis using Bray-Curtis dissimilarity to compare compositional 
differences in beta-diversity between severe ME and HHCs groups. Analysis draws conclusion of 
most abundant bacterial species (annotated in figure) associated with separations of samples, e.g. 
Faecalibacterium prausnitzii is more abundant in CTR-2, CTR-4, CTR-9 & CTR-16.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.15 PCoA analysis using Hellinger distances to measure the difference in compositional 
taxa between severe ME and HHCs. Plot annotated with bacterial species relevant to driving 
separation of samples. 
 
PCoA analysis was also performed using Hellinger distances to separate samples based on 
proportions of taxa observed between each dataset and is considered more representative 
of proportional differences between taxa between groups of samples. Sample which 
cluster together are more compositional similar. Another standard tool for microbial 
community analysis is Unweighted Pair Group Method with Arithmetic Mean (UPGMA) 
based on UniFrac distances which is a hierarchical clustering method for sample 
classification used in ecology studies. Samples with the closest distance cluster together as 
a node. Unweighted UPGMA (figure 3.3.16A) considers the clustering of samples on 
composition alone, whilst the weighted version (figure 3.3.16B) consider both abundance 
and composition. 
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Figure 3.3.16 UPGMA clustering unweighted (A) versus (B) weighted UniFrac distances performed 
in MEGAN using severe ME and HHC samples. Matched severe ME (red circles), unmatched severe 
ME (blue circles); matched house-hold controls (green triangles); negative control (yellow circle). 
 
 
- Comparison of severe ME and HHC core microbiomes 
  
Core microbiomes were calculated as a feature of MEGAN 6.0 using a sample threshold of 
50% and class threshold of 1%. This analysis provided an interesting output and revealed a 
distinct difference in the number of species determining the core microbiome in patients 
compared with HHCs. Patients have 6 members of a core microbiota (fig 3.3.17A), 
represented by Bacteroides uniformis, Verrucomicrobiales, Bifidobacterium longum, 
Eubacterium spp., Dorea spp., Ruminococcus spp. and Subdoligranulum spp. Figure 3.3.17B 
shows there are 8 members within the core microbiome of HHCs distinct from ME and 
include Bacteroides vulgatus, Alistipes putredinis, Streptococcus salivarius, Coprococcus 
comes, Dorea longicatena, Ruminococcus bromii, Faecalbacterium prausnitzii, and 
Ruminococcus bromii. 
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Figure 3.3.17 Phylogenetic trees featuring the members of bacterial taxa identified as part of a 
core microbiome within 11 severe ME sample and 8 HHCs. Size of circle is proportional to the 
relative abundance of taxa within these samples. A: represents common features shared between 
11 severe, house-bound ME patients. B: represents 8 house-hold controls related to severe, house-
bound patients. 
 
A 
B 
  
 
147 
 
 
Figure 3.3.18 Phylogenetic tree representative the comparison between the shared core 
microbiome of 11 severe patients and 8 house-hold controls. Colours and size of circles are 
proportional of the RA contributing to the microbiome. Patients are in light blue versus HHCs in 
purple.  
 
Figure 3.3.18 provides shared features of a core microbiome in patients and HHCs 
compares the compositions of these members between groups. For example, ME (light 
blue) is less abundant in Bacteroides vulgatus, Alistipes putredinis, Coprococcus comes, 
Faecalibacterium prausnitzii, and Ruminococcus bromii but highly more represented by 
Eubacterium spp.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe ME 
House-Hold Control 
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16S phylogenetic abundance in severe ME and HHCs 
 
- Dataset C 
 
This final data provided insight into the 16S V4 region microbiome of 17 female severe, 
house bound patients and 8 HHCs recruited in 2016/2017 using the enhanced methods for 
faecal sample collection which required the entire intact stool and was protect using 
Anaerogen™ Compact® sachet to limit oxygen exposure. Left over sample from the 
previous year (2016) in conjunction with additional samples produced in 2017 available 
from 4 patients and their respective HHCs bringing the total number of samples to 21 ME 
versus 12 HHC.  
 
Table 2.3.6 shows faecal DNA extraction yield was notably lower in samples that had been 
stored in the -800C freezer. The minimum concentration yielded was 12 ng/µl in a total 
volume of 65 µl of ddH2O.  The average number of reads per sample was 150,882 ± 35,890.  
A total 2520 OTUs were observed across all samples. Of these 2282 (figure 3.3.19) were 
clustered together with ≥97% DNA sequence similarity and annotated to 866.15±75.80 SD 
bacterial genera across both groups. OTU abundance was normalised corresponded to 
sample F4 with the least number of reads at 47,985. On average the number of genera 
observed per sample in each group was 877±56.40 SD in ME versus 847±108 SD in HHCs. 
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Table 3.3.6 Summary of sample status and number of paired-end reads, including quality score 
(Q20 and Q30), DNA concentration, GC% content obtained per sample from 33 samples supplied 
to sequencing provider.  
 
 
 
 
 
 
 
 
 
 
 
Sample Status DNA 
(ng/µl) 
Year Reads Ave 
Len(nt) 
Q20 Q30 GC% Assigned 
OTUs 
F1 ME 803 2017 243,161 253 99.34 98.68 53.14 910 
F2 ME 466 2017 163,179 253 99.37 98.71 53.9 926 
F3 ME 731 2017 223,279 253 99.36 98.71 53.39 877 
F4 HHC 448 2017 47,985 253 99.34 98.68 55.47 467 
F5 ME 648 2017 222,044 253 99.4 98.77 54.03 932 
F6 HHC 610 2017 182,173 253 99.37 98.73 52.68 825 
F7 ME 515 2017 150,931 253 99.36 98.72 54.25 865 
F8 HHC 544 2017 195,424 253 99.39 98.74 52.95 903 
F9 ME 403 2017 117,136 253 99.36 98.7 53.04 934 
F10 ME 526 2017 109,282 253 99.37 98.71 52.67 842 
F11 HHC 2154 2017 172,826 253 99.4 98.78 53.13 1265 
F12 ME 244 2017 166,377 253 99.35 98.7 52.21 805 
F13 ME 171 2017 213,772 253 99.33 98.65 53.12 896 
F14 HHC 978 2017 135,073 253 99.34 98.66 53.49 935 
F15 ME 326 2017 188,528 253 99.34 98.68 53.41 915 
F17 ME 233 2017 219,965 253 99.37 98.71 55.02 881 
F18 ME 822 2017 163,722 253 99.37 98.72 52.89 799 
F19 HHC 576 2017 116,316 253 99.36 98.71 53.56 884 
F20 HHC 476 2017 171,177 253 99.35 98.68 53.21 894 
F21 ME 336 2016 107,094 253 99.36 98.68 53.18 876 
F22 HHC 385 2016 101,151 253 99.36 98.69 52.99 849 
F23 ME 147 2016 150,529 253 99.38 98.75 53.47 1215 
F24 ME 90.2 2016 148,620 253 99.34 98.67 52.56 812 
F25 ME 66.5 2016 196,539 253 99.35 98.68 53.86 830 
F26 ME 44.9 2016 141,569 253 99.36 98.7 54.11 823 
F27 ME 466 2016 190,187 253 99.33 98.66 53.85 785 
F28 HHC 454 2016 92,279 253 99.38 98.73 53.18 782 
F29 ME 12 2016 159,789 253 99.4 98.77 53.21 859 
F30 HHC 351 2016 144,861 253 99.38 98.73 52.91 732 
F31 HHC 672 2016 101,084 253 99.37 98.71 53.35 812 
F32 ME 237 2016 159,332 253 99.37 98.71 53.25 794 
F33 ME 183 2016 91,557 253 99.35 98.68 53 843 
F34 HHC 29.2 2016 84,446 253 99.36 98.7 52.89 816 
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Figure. 3.3.19 Venn diagram of observed OTUs in severe ME (n=21) and HHCs (n=12) samples. 
Values in overlapping parts represent common OTUs. The numbers refer to specific OTUs unique to 
that sample group. 
 
Rarefaction curves were plotted for each sample (figure 3.3.20A) using reads rarefied to 
47,985 reads. As the number of sequenced reads increases the number of observed species 
gradually reaches a plateau. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.20 Rarefaction curves per sample (A) and averaged species abundance (B) and alpha 
diversity (C) measured using the Shannon Index, H.  
Severe ME 
HHC 
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Figure 3.3.21 WPGMA cluster analysis using weighted UniFrac distances to reveal hierarchical clustering of samples based on composition and relative abundance of bacterial 
phyla in 21 severe ME patients and 12 House-Hold Controls. Weighted pair group method with arithmetic mean (WPGMA) is a hierarchical clustering tool used in ecological studies 
to classify samples.  The clustering tree (left) is constructed on the basis of sequence similarity among different samples. The Weighted Unifrac Distance is calculated as an average 
between clusters of samples with similar sequences forming a node, followed by branching and clustering of samples with more distant sequences.
Severe ME 
 
House-hold control 
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Figure 3.3.22 Box plot of Alpha Diversity indices between 21 severe ME patients and 12 House-
Hold Controls using the Shannon (H) index. Plot highlights no intra-individual sample differences for 
species diversity within patient and control groups. Diversity of severe ME appears no different from 
house-hold control samples. 
 
Alpha diversity is used to assess the diversity of microbial composition. This was performed on this 
dataset using the cut-off of 45,995 reads per sample assigned to OTUs at 97% similarity in DNA 
sequencing. Classification of these OTUs provides microbial composition. The Shannon H index 
measures microbial composition in each individual sample (figure 3.3.20C). The difference in H 
indices obtained from samples within both groups, severe ME and HHCs are presented in figure. 
3.3.22.T-test and Wilcox tests were performed on this data and showed no significant difference 
between these groups in terms of microbial composition. 
 
- Phylum level observations  
 
Weighted UniFrac distances were applied to PGMA to visualise clustering of samples at the 
phylum level. Figure 3.3.21 is the output from this analysis and shows a proportion of 
severe ME patients cluster at this level. However, averaging the RA of phyla between 
groups shows there were no significant observations in terms of RA at the phylum level. 
Firmicutes, Bacteroides, Proteobacteria and Actinobacteria were observed the most 
abundant bacterial phyla in that order within both groups (figure 3.3.23).  
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Figure 3.3.23 Relative abundance ratio of bacterial phyla observed in severe ME versus HHC. 
“Healthy” refers to House-Hold Controls (HHCs). There is no significant or observable difference in 
the proportions of bacterial phyla comparing severe ME with a respective house-hold control. 
 
 
- Genus level observations  
 
The abundance of the most dominant 35 genera among all samples was investigated in 
terms of distribution between severe patients and HHCs. The majority of the most 
dominant genera were found within Firmicutes. This was based on the analysis of clustering 
of samples as well as taxa.  Interestingly the most abundant dominant genera were found 
in individual severe ME samples, including Holdemanella, Streptococcus, Anaerostipes, 
Prevotella, Dialister, Bifidobacterium, Subdoligranulum, Collinsella, Lachnospiraceae, Dorea, 
Escherichia-Shigella and Mucilaginibacter. 
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Figure 3.3.24 Heatmap of relative abundance of the most dominant genera in 21 severe ME versus 
12 HHCs. The abundance distribution of the dominant 35 genera among all samples was displayed in 
this species abundance heatmap. Based on the clustering results of samples and taxa, samples may 
be clustered or not according to their similarity or differences, observed in this heatmap. Names on 
right side of heatmap represent bacterial genus. The absolute value of Z represents the distance 
between the raw score and the mean of the standard deviation across all samples in that group. Z is 
negative (blue) when the raw score is below the mean and vice versa when the score is above the 
group mean (red) for that sample. 
 
 
- Statistical analyses 
 
Principle component analysis (PCA) uses complete multivariate data based on OTUs from 
each sample to compare the structure of the data from the two groups. PC1 (17.19%) and 
PC2 (PC 7.42%) in figure 3.3.25 show the maximum variation in this data. The similar the 
microbial composition between samples, the closer the distance corresponding to their 
position of the plot. Most samples cluster together suggesting a similar microbial 
composition is shared in both groups. However, four patients and one HHC are 
compositional distinct from this cluster and appear as outliers. 
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Figure 3.3.25 Principal Component analysis based on differences of composition of assigned OTUs 
to bacterial taxa in 21 severe ME patients and 12 HHCs. Each dot represents a sample plotted 
against principal components, PC1 (17.19%) versus PC2 (7.42%). Samples which share a similar 
community composition of bacteria, the closer they are represented on the plot. Based on similar 
group clustering of ME and HHC samples, plot reveals no difference between the beta-diversity of 
patient and control group. 
 
 
A series of comparisons between patients and HHCs using ecological indices explored in 
PCoA plots using Bray-Curtis dissimilarity, Chi-Square and Goodall similarity index to 
determine pair-wise similarity between observations of composite multivariate OTU 
datasets in the two groups. As discussed earlier, Bray-Curtis measures focus on the most 
abundant bacterial taxa, which were found to be Bacterdoides vulgatus, Turicibacter spp. 
and Clostridium celatum. Patients in the plot (figure 3.3.26) are represented by dark blue 
red are matched, whilst un-matched ME patients are the dark blue circles. All HHCs (green 
triangles) are matched to their respective severe ME patients.  
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Figure 3.3.26 PCoA using Bray-Curtis distances to separate 21 severe ME patients from 12 HHCs 
High species composition similarity between samples are plotted closer together. There appears to 
be a reduced similarity comparing between severe ME patient samples, compared to both 
unmatched and house-hold controls which appear much more similar to one another. Red circles, 
matched severe ME; dark blue circles, unmatched severe ME; green triangles, house-hold controls. 
Plot annotated with bacterial species relevant to driving separation of samples. 
 
MEGAN 6.0 was also used to compute PCoA plots using Chi-Square distances and the 
Goodall’s similarity index. The former (figure 3.3.27) has the added advantage over Bray-
Curtis for considering the differences in proportions of the taxa instead of summarising the 
most abundant. Using this method, the same bacterial taxa emerge samples in the 
respective region of the plot. In both methods, un-matched ME patients cluster more 
closely as do HHCs with exception to CRL-4, -22 and -34. 
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Figure 3.3.27 PCoA plot using Chi-Square distance separation between 21 severe ME patients and 
12 HHCs. Conventional unmatched controls (blue) cluster together revealing similar proportions of 
bacterial taxa. Contrastingly, severe ME samples (red) display more dissimilarity within their own 
group and with their respective House-Hold control (HHC), green triangles. Fewer than expected 
HHCs share similar proportions of the same bacterial taxa identified in their ME patient counterpart. 
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Figure 3.3.28 PCoA plot using Goodall’s similarity index to compare 21 severe ME patients and 12 
HHCs. This measure assigns greater similarity between severe ME (red) and HHCs (green) identifying 
the sharing of rarer bacterial genera regardless of the high abundance of other genera. These less 
represented genera found in severe ME and HHCS are much less likely to be found in samples from 
the conventional (unmatched) control group. 
 
Goodall’s similarity index (figure 3.3.28) is an non-parametric measure designed to examine 
pairwise similarity between observations of composite multivariate data and is used to give 
more weight to differences between rarer bacterial taxa rather than comparing the most 
abundant genera within a group (Mitra et al., 2010). This had the dramatic effect of 
reducing the clustering of samples compared to the other PCoA plots. Finally, UPGMA was 
used to visualise the distances between the clustering of samples according to the 
unweighted and weighted UniFrac method and is frequently used to compare 
microbiological community structures. In contrast to Bray-Curtis, the relative relatedness of 
community members by observation of phylogenetic distances between observe species 
within a sample is used to compare samples. This analysis was performed using MEGAN 6.0 
and presented in figures 3.3.29A (unweighted) and 3.3.29B (weighted). Unweighted only 
accounts for clustering of OTUs compared to weighted which considers the RA in addition.  
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A,    Unweighted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B,    Weighted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.29 UPGMA clustering based on unweighed (A) and weighted UniFrac (B) distances 
between 21 severe ME patients and 12 HHCs. Analysis represents the comparing of microbial 
ecological communities across all samples using phylogenetic distances to generate a tree. 
Unweighted corresponds to differences in low-abundance taxa, whereas weighted calculates branch 
length according to the observed abundance of shared and unshared bacterial taxa across both 
groups and is less sensitive to lower abundance taxa.  Red circles, matched severe ME; dark blue 
circles, unmatched severe ME; green triangles, house-hold controls. 
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A 
B 
- Species variation between severe ME and HHC 
 
T-test was performed to determine species with significant variation between groups (p 
value < 0.05) at various taxonomic ranks including phylum, class, order, family, genus, and 
species. 
 
Figure 3.3.30 shows the significant species variation in abundance between both groups. 
The class of Bacilli spp. appear more (p = 0.004) in severe ME. Conversely, the phylum 
Sphingobacteria was higher (p = 0.045) in the HHC group.  Significant intra-group variation 
were detected using MetaStat produced in RStudio which used multiple hypothesis-test for 
sparsely sampled features and Benjamin Hochberg false discovery rate (FDR). Fusobacteria 
spp. emerged from this analysis as significant (q < 0.05) in severe ME patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.30 The bacterial phylum, Fusobacteria are significantly more varied in ME and absent in 
HHCs (A) Intergroup variation: left panel, each bar represents the mean value of the abundance in 
each group of the species showing significant between group variation. The right panel shows the 
confidence interval between these group variations. The centre each circle represents the difference 
of the mean value. (B) Intra-group variation detected Fusobacteria were significantly (q <0.05) more 
varied within patient compared to HHCs were they were absent. 
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As a final summary of this data, MEGAN was used to generate a phylogenetic tree (figure 
3.3.31) of the top 10 most RA genera across also samples and to highlight the relative 
contribution these have within the two groups. This revealed Collinsella spp., Blautia spp. 
and Lachnospiraceae spp. were more common in some patients (fig. 3.3.32). Conversely, 
Bifidobacterium spp., Subdoligranulum spp. were more common in HHCs. Interestingly, 
Faecalibacterium spp. was similarly abundant in both groups. 
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Figure 3.3.31 Top 10 bacteria genera found common in 21 severe ME patients and 12 HHCS. The size of circle 
represents the size of its relative abundance in samples. Each colour represents a sample group and the 
proportion of dominance that taxa has within the sample group. The first number below the taxonomic name 
represents the percentage in the whole taxon, while the second number represents the percentage in the 
selected taxon.  Tree highlights no observable differences between these top 10 genera in patients and HHCs; 
Collinsella; Bifidobacterium; Bacteroides; Clostridium; Blautia; Lachnospiraceae; Roseburia; Faecalibacterium 
Subdoligranulum; Turicibacter.
Severe ME 
 
House-Hold Control 
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Severe ME House-Hold 
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Ü  Figure 3.3.32 Bubble plot summary of 21 selected genera across 21 severe ME patients and 12 
HHCs. Analysis provides individual sample summary of bacterial abundance. There are no obvious 
differences in abundance of these shared genera between patients and HHCs. Plot generated using 
MEGAN 6.0. Colour corresponds to bacterial genera listed to the left. Size of bubble given 
proportional the square root scale of the relative abundance in each sample.  
 
3.4 Discussion 
 
The initial design and concept for this microbiome study was conceived in late 2013. At this 
time there was very little published guidance on designing the perfect microbiome study. 
The overwhelming majority of intestinal microbiome research uses faecal samples 
collected by the participant and DNA extracted using a range of commercially available kits.  
Since 2013 several reports have highlighted that sample collection represents a crucial step 
in ensuring uncompromised sample integrity and that stability is maintained for 
downstream application of Next-Generation Sequencing (NGS) (Panek et al., 2018). Prompt 
downstream processing of faecal samples should be completed within 2-3 hours with 
immediate stabilisation for longer term storage (Panek et al., 2018). Relatively short term 
exposure to room temperature for up to 2 h prior to DNA extraction does not affect the 
stability of the microbiota composition according to comparison with samples that had 
been frozen immediately (Guo et al., 2016).  
 
Freezing the faecal sample at -800C as soon as possible after collection is regarded as the 
most appropriate method for preserving microbial composition (Choo et al., 2015). This 
was not possible considering the majority of samples were obtained from house-bound 
patients who had collected their sample within 24 hrs of a scheduled home visit. Last 
minute house visits could not be conducted to minimise this time because of the 150-mile 
distance between the research laboratory and patients living in the South London area. 
Instead patients were asked to store their sample in the fridge until collection. 
Refrigeration of up to 72 hours has been shown not to adversely affect the microbiota 
diversity of composition and is reassuring that this covers the time required to collect the 
faecal samples from the patients home (Choo et al., 2015). However, all samples were left 
without refrigeration between collection from the patient’s home and delivery to the 
hospital laboratory, before storing at -800C. The time delay was dependent on a number of 
factors including traffic delays and distances between patient’s homes and the hospital and 
could be between 1-6 hrs until the sample was frozen may contribute to changes microbial 
composition. This study also praised OMNIgene GUT® as an alternative method to 
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refrigeration. These devices contain a patented stabilisation mixture and where initially 
used in 2015 for the collection of faecal samples from 25 mild/moderate patients in dataset 
A. Early attempts to extract faecal DNA from  -800C frozen OMNIgene GUT devices failed to 
produce a readable concentration of DNA using the MOBIO Powersoil® DNA extraction kit 
and Nanodrop. Instead, the FastDNA® Spin kit for soil was found to extract the minimum 
5ng/µl for PCR 16S V4 amplification performed by the sequence provider. 
 
Storage of the OMNIGene GUT at -800C is only recommended up to 1 month (DNAGenotek, 
2017). Samples from mild/moderate patients (dataset A) were kept at the hospital at -800C 
for much longer (~9 months) before they were received at the institute for DNA extraction. 
Notably, these samples have very low abundance of Actinobacteria which includes 
members of Bifidobacterium spp. and Coriobacteria spp. This observation was found not to 
be the case in dataset C (fig. 3.3.7) in severe ME patients who had 14.59±8.41% RA of 
Actinobacteria and may be regarded as a technical artefact.  The turnaround time dataset C 
was much quicker, as these samples had their DNA extract within 3 months of being stored 
at -800C. Interestingly Table 3.3.6 shows some of samples from 2016 collections yielded a 
lower DNA concentration compared to 2017 samples. Studies of long-term storage of 
faecal material at -800C has been investigated for samples stored for 2 years and 14 year 
showing they can be used for 16S but with a reduction in observed OTUs and increased 
abundance for Lactobacillus spp. and Staphylococcus spp., none of which were detected in 
our mild/moderate ME patients (Kia et al., 2016; Shaw et al., 2016; Vandeputte et al., 
2017). Long term freezing causes substantial DNA shearing compared to fresh faecal 
extractions and may have greater implications for shotgun metagenomic studies which 
require high quality input DNA (Kia et al., 2016).  
  
Following sample collection and storage, several processing steps can introduce data bias 
caused by the DNA extraction protocol and during 16S rDNA library preparation (Rintala et 
al., 2017). For example, detection of Gram-positive bacteria, particularly Bifidobacterium 
spp. requires adequate bead-beating during sample DNA extraction and optimisation using 
modified primers targeting V1-V3 regions (Walker et al., 2015). 16S microbiota profiles are 
based on the reported relative read abundances of OTUs derived from 16S amplicons; thus 
PCR amplified DNA can only be representative of the quantitative abundance of all bacteria 
in faeces if this step is efficient for all strains of bacteria (Wintzingerode et al., 1997). 
Universal primers U515F and U927R/U806R in datasets A and C respectively, were chosen 
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to span the 16S V4-V5 region for highest taxonomic resolution of bacterial and archaeal 
ribosomal gene (Wang & Qian, 2009). This leads to the assumption that the PCR primers 
have equal access for hybridisation to a specific 16S-targed V region in all bacteria, 
however DNA extraction also determines this property depending on how sufficiently the 
extraction kit causes bacterial cell disruption in order to access the genetic material 
(Wintzingerode et al., 1997).  
 
Since 16S-based microbiome studies are restricted to short nucleotide (nt) read lengths 
(100-300bp) on the Illumina platform (compared to 250-400bp using 454 methods), the 
outcome of the relative abundance of amplicons can also favour different bacteria 
depending which variable region of the 16S gene is targeted and the specificity of primer 
sets used. For example, primers spanning hypervariable regions V1-V2 do not adequately 
reproduce proportional abundance of reads that reflect the contribution of all species in 
the female genital tract compared to the V3-V4 region which identifies a greater number of 
taxa (Graspeuntner et al., 2018). There is also consensus that targeting V4-V5 regions in 
intestinal microbiome studies produces a greater number of recognised OTUs and 
observed microbial diversity compared to V3-V4 using the Shannon H index (Rintala et al., 
2017).  Elsewhere, sequencing regions V4-V6 have been suggested to represent the 
majority of diversity of bacterial phyla for taxonomic classification (Yang et al., 2016).  
 
Amplicon sequencing is suggested to be more sensitive to lower abundant species since 
utilities a PCR application step in preparation of a library of amplicons to be sequenced 
(Edgar, 2017). However, primer bias and mismatches can occur during PCR amplification 
and can bias the relative abundances of amplicon produced in the library (Robinson et al., 
2016). Although datasets A and C are 16S-derived sequencing of the same V4 region they 
were collected by different methods and do not contain overlapping samples to determine 
the batch effect and therefore cannot be directly compared. Moreover, the library 
preparation of these datasets use different PCR protocols provided by the sequencing 
provider at the time. It has been suggested PCR primer length, amplicon length, reaction 
temperatures and number of cycles, and different polymerases can influence the efficiency 
for amplification and shown to provide contrasting estimates for community structure (Wu 
et al., 2010).  
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The design of the perfect 16S study cannot be achieved because different microbiotas have 
vastly different microbial structures which makes deciding the most suitable V-region, set 
of optimal primers and recommended read length a substantial challenge to accurately 
reflect the correct community profile. Mock microbial community analysis using 16S 
amplicon read abundances have been independently compared with shotgun metagenomic 
sequences showing significant deviation away from the 16S estimated bacterial 
composition compared to the known community structure (Edgar, 2017). To obtain 
accurate measurement of the full taxonomic diversity within a complex community sample 
such as human faeces, near complete characterisation of the 16S gene is needed to assign 
specific bacterial species (Yarza et al., 2014). Therefore species-level abundances using 16S 
have no meaningful use because they are based on such short read lengths of 250-300bp 
compared to the available length of the 16S rRNA is around 1400-1900bp (Karst et al., 
2018) Closely related bacteria are more difficult to resolve using V4 alone. To that end the 
species-level assignment given in figure 3.3.31 are not reliable based on this sequence 
information. Another problem encountered can be 16S copy number variation which will 
bias the PCR amplification step and influence the predicted microbial composition (Edgar, 
2017). Moreover, the choice of storage method, DNA extraction protocol, primer design 
and sequencing platform will influence the outcome of the result. For consistency, the 16S-
derived microbiota in datasets A and C were processed using the same extraction kit and 
targeted at the V4 of 16S PCR amplification. In future, to avoid any batch effects samples 
must be analysed together using the same experimental PCR protocols, conditions and at 
the same time.  
 
Dataset C produced on average 80,122 more reads per sample than those in dataset A, 
which allowed over 4 times the number of classifiable OTUs to be taxonomically assigned. 
This fact demonstrates how the collection method, primer sequences, PCR protocols and 
sequencing length can affect data output and has been explored more in depth using mock 
microbial populations highlight a need for a standardised approach (Fouhy et al., 2016).  
Alpha diversity (figure 3.3.22) and beta diversity measurements were not found to be 
significantly different between Severe ME patients and HHCs. Actinobacteria were present 
in all samples (figure 3.3.21), as they were also in the “shallow” shotgun, dataset B (figure 
3.3.7), adding further convincing evidence that the lack of these species in dataset A, 
mild/moderate patients is not a genuine finding. In contrast to findings from Giloteaux et 
al. (2016), the number of observed species in patients was higher than in HHC (figure 
  
 
168 
3.3.20A and 3.3.20B). A key difference between this study and theirs are the inclusion of 
controls living within the same house-hold of the patient. It was expected that similar 
features in microbiota populations would be shared between the microbiotas of patient 
and their respective HHC. It was expected PCoA analysis would show closer distances 
between patient and their matched control based on overall community composition. The 
reverse is found in figures 3.3.26 and 3.3.27 which show house-hold controls are more 
compositionally related to un-matched ME patients. Goodall’s similarity test was chosen as 
it specifically considers the fact these samples are paired. It can be seen from figure 3.3.28 
that the patient and HHC group are positioned in an overlapping ring formation with some 
unmatched patients within the centre of the plot. To that end, given the description of this 
analysis by (Mitra et al., 2010), Goodall dissimilarity more accurately reflects the 
relationship between severe ME and HHCs. The lack of forming discrete clusters within this 
PCoA plot also demonstrates how compositionally diverse both patients and HHCs from 
other members within their respective group. UPGMA UniFrac considers the presence or 
absence of OTUs distances and did show clustering of some severe ME patient that 
matched HHCs (fig. 3.3.29) (Jovel et al., 2016). However, UniFrac is a method of 
determining the phylogenetic relationship tree structures compared between samples, and 
so given the shallow sequencing and number of observed OTUs this method is perhaps not 
the most suited to this data, whereas non-phylogenetic measures of ß-diversity, including 
Bray-Curtis (fig 3.3.26) which does account for zero abundances within the raw data, but is 
still heavily influenced by more dominant OTUs which overshadow smaller changes in less 
abundant, rarer OTUs (see supplementary S2.1 and S2.2) (Bray & Curtis, 1957; Jovel et al., 
2016). Among the top 10 genera highlighted from MEGAN in figure 2.3.31 that shared 
between ME and HHC, includes Lachnospiraceae, Roseburia, and Faecalibacterium, that 
have previously been associated with the ME/CFS (Giloteaux et al., 2016; Nagy-Szakal et al., 
2017). Lachnospiraceae the family to which the genus Lactonifactor belongs, found to 
increased x20 in Norwegian CFS patients and x40 in Belgian CFS patient compared to 
healthy controls, did not differ between patients and HHCs in dataset B (table 3.3.4) and 
dataset C (fig. 3.3.11B) (Fremont et al., 2013).  
 
Finally, dataset C did not reproduce findings from dataset B, for significant changes in the 
relative abundances for Faecalibacterium prausnitzii, Oscillibacter and Eggerthella. 
Fusobacteria were associated with 1-3 OTUs (figure. 2.3.30) per sample, in patients only. 
These were samples ME_5, ME_17, ME_27 and ME_29. Fusobacterium are increased in 
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colorectal cancer (CRC) and have diagnostic relevance as an additional microbial marker for 
faecal immunochemical testing patient faeces increasing sensitivity of testing to 92.3% 
from 73.1% to supplement diagnosis of advanced  CRC (Wong et al., 2017). 
 
- Shotgun metagenomics attempt 
 
In order to overcome the potential biases of 16S gene marker approaches and achieve 
better taxonomic resolution, shotgun metagenomics (dataset B) was attempted from 2016 
visits to 11 house-bound patients. Unfortunately, the term “shallow” shotgun 
metagenomics was adopted to describe the low sequencing depth of reads with this 
dataset. Lipkin et al. 2017, acquired on average 7GB of sequence data per sample 
equivalent to around 35 million reads, compared to our lowest sample which had 253, 484 
raw sequencing reads (Nagy-Szakal et al., 2017). This may partly be due to MiSeq platform 
used to sequence these samples which is limited to 15GB of data with a maximum output 
of 44-50 million 300bp PE sequencing reads with the MiSeq Reagent Kit v3 (Illumina, 2015). 
It is difficult to advise exactly how many reads are required to generate an accurate 
representation of the total microbiome which also includes members of archaea, fungi and 
viruses. Cost is a significant factor per sequencing run, individual coverage of these samples 
is balanced by the total number of samples processed simultaneously in each run by 
multiplexing up to 96 or 384 samples at a time using dual indexes (barcodes) during library 
preparation (Quince et al., 2017). Based on the number of reads obtained, this dataset 
exceeds both average number of reads for 16S in the other datasets. Significantly as it is 
SMS, it is not restricted to the 16S gene and therefore contains random sequencing across 
the total microbiome which MetaPlAn has compared against reference genomes available  
from (www.bitbucket.org/biobakey/metaphlan2). This has had some benefit in being able 
to apply a species-level identification to dataset B.  
 
As highlighted already, application of SMS to metagenomic studies of diverse microbiotas 
requires high-quality molecular weight DNA. This aspect was not considered during 
preparation of dataset B; at the time DNA was quantified using Qubit, which uses a 
fluorescent dye to hybridise with the sample DNA and is considered superior at providing 
more accurate concentration than the NanoDrop. Added to this, lack of sequencing depth 
has since been explained by the fact that libraries were prepped using Illumina® Nextera 
XT, which is recommended for use in low-biomass starting material of 1ng/µl. As with 16S 
studies, the choice of method for preparation of library preparation for shotgun 
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metagenomic sequence data has been evaluated in faecal samples which show Nextera XT 
performs poorly in these samples with 28% low quality reads compared the more expense 
Illumina TruSeq PCR-free kits  (Jones et al., 2015). The low DNA input for Nextera XT is 
possible because of a whole genome amplification (WGA) step, but given the diversity of 
the intestinal microbiome, there will be the familiar amplification biases that will also cause 
the RAs of different bacteria to change (Probst et al., 2015). It has been proposed that PCR-
free approaches to metagenomic library prep are implemented, however, these are more 
expensive but will likely be more representation of the true community structure of the 
faecal microbiota (Quince et al., 2017). 
 
Another explanation for the loss of sequencing depth may be a result of the beat betting 
used by the FastDNA® spin kit which would create shortened DNA fragments that are 
suitable enough for 16S, but not for shotgun library preparation with the Nextera XT kit 
which uses a technique called “tagmentation” (Quince et al., 2017). This causes enzymatic 
fragmentation of sample DNA and transfers transposons (tags) onto the both ends of 
dsDNA to allow partial overhang of Illumina® sequencing adaptors. The concentration of 
the kit’s reagents and the concentration of sample DNA can limit transposome complex 
transposase activity (figure 3.4.1) and tagging of DNA fragments. Thus, the distribution of 
tagged DNA within the library will influence the proportion of the library that gets 
sequenced. For example, samples that are >1ng can therefore lead to under-tagmentation 
(Caruccio et al., 2009; Holmes et al., 1988; Illumina, 2014; Syed et al., 2009). Prior to 
sending samples to the sequencing provider for dataset C, they were analysed on the 
Bioanalyzer™ Tapestation® which produces gel images to assess DNA fragment sizes. 
Although this dataset produced 16S data, DNA quality can also affect tagmentation. The 
Nextera XT transposome requires minimum of 300bp to efficiently cut the DNA into 
fragments for transposon tagging and therefore if the sample DNA is degraded this will 
cause few tagmented fragments to be sequenced and will cause an under-representation 
of species diversity (Illumina, 2014).  
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Figure. 3.4.1 Nextera XT fragmentation causes breaks within dsDNA and transposon tagging across 
the sample DNA. Diagram adapted from, (Caruccio et al., 2009) 
 
Despite the technical issues with this data, there were some interesting findings comparing 
severe patients with HHCs. The first is the lower RA of Faecalibacterium prausnitzii in 
patients shown in figure 3.3.11. This is in agreement with another report of this species 
being significantly reduced in ME/CFS patients with IBS (Nagy-Szakal et al., 2017). It is 
suggested to account for 5% of the total bacteria resident in the intestinal microbiota and a 
reduction in this species in linked to dysbiosis in intestinal inflammatory diseases such as 
Crohn’s Disease (Miquel et al., 2013). Significantly higher RA of Eggerthella spp. 0.98% ME 
versus 0.43% HHC (table2.3.4) was seen comparing across the genus level using non-
parametric Mann-Whitney U test in figure 3.3.13. The abundance tables for this dataset are 
included in the supplementary section (S3.1 and S3.2).  Eggerthella spp. are Gram-positive 
anaerobes belonging to the phylum Actinobacteria normally found in the human intestinal 
microbiota but have been associated with abdominal sepsis (Gardiner et al., 2014).This 
finding in severe ME patients was also something reported by Lipkin et al (2017) in ME/CFS 
without IBS (Nagy-Szakal et al., 2017).  
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- Summary 
Seventy-seven samples were analysed using next generation sequencing to determine 
differences in the composition of the intestinal microbiota between ME/CFS patients and 
house-hold controls. The composition of the intestinal microbiome of ME/CFS patients has 
been suggested to be less diverse than that of healthy controls (Fremont et al., 2013; 
Giloteaux et al., 2016; Nagy-Szakal et al., 2017).  We compared and contrasted sequencing 
of the V4 hypervariable region of the 16S gene, a single genetic marker against recovery of 
non-targeted, random 150bp DNA sequences representing the entire (meta)genome 
content extracted from faeces. The data generated from these two methods did not show 
variation in the diversity of species identified in ME/CFS and HHCs.  However, using shallow 
shotgun sequences, patients had a 5-fold reduction in Faecalibaterium prausnitzii 
compared to HHCs. Other significant differences were at the genus level included increased 
abundance of Oscillibacter and Eggerthella in severe ME compared to HHC.  Comparison of 
the members of the core microbiota (defined by bacterial taxa appearing in 50% of all 
samples) revealed qualitative and quantitative differences between severe ME and HHCs 
based on 16S sequencing. Severe ME patients have few members of the core microbiota 
than HHC. No evidence for increased abundance of Proteobacteria (a source of bacterial 
LPS) was found in any of the datasets. The genus contains several known human pathogens 
and is suggested as a microbial signature for low-grade inflammation sustained by 
exposure to LPS (Rizzatti et al., 2017).  
 
A recent review highlights the need for best practices for designing and analysing 
microbiome studies which address some of the issues surrounding reproducibility of 
microbiome data (Knight et al., 2018). Several sources of confounding factors are 
generated through every step of a microbiome study. Every microbiome study faces 
challenges for establishing an experimental design to generate the best source of data and 
relies on the of methods of sample collection, protocols to standardise faecal DNA 
extraction and library preparation and PCR biases, choice of sequencing platform, pre-
processing of reads, and bioinformatics pipelines to analyse sequence data to generate a 
microbial profile. Therefore, the output of multiple metagenomics studies is very difficult 
to compare without establishing good practices to address these differences.  
 
In conclusion, the total data in this chapter represents a pre-screening of the composition 
the intestinal microbiota of severe ME patients compared to HHCs.  We have shown the 
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taxonomic capabilities of 16S sequencing does not allow sufficient taxonomic resolution to 
reveal differences between patients and house-hold controls. Our shallow shotgun data 
utilised non-targeted, random “shotgun” sequencing of the intestinal microbiome but 
failed to provide adequate coverage based on the low number of sequence reads 
generated. Despite this, the number of reads generated far exceed the output of both 16S 
datasets and were processed using MetaPlAn to compare sequences against known 
bacterial reference genomes. Here, we did reveal a significant reduction in the relative 
abundance of Faecalibacterium and increased Eggerthella and Oscillibacteria in severe ME 
compared to HHCs. This study represents the first of its kind to explore the microbiota 
composition in severe patients matched with their respective healthy house-hold control. 
We consider this an important strength to this study, but future work should sample from 
patients diagnosed with IBS to exclude to possible dysbiosis by this cause. Our analysis did 
not sufficiently replicate those of other ME/CFS metagenomic studies carried out in mild to 
moderately affected ME/CFS patients. Given the known impact diet has of the microbiota, 
future studies should give consideration to recording food intake. Future work should also 
resolve both technical and logistical concerns raised throughout this discussion.  
 
 
 
 
 
 
 
 
  
174 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter Four 
 
 
4 Profiling the faecal and serum metabolome in house-
bound, severe ME patients 
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4.1.1 Introduction 
 
The human metabolome is complex, particularly within the gut since factors including diet, 
lifestyle, age, medications, and environmental contact with microbes influence 
experimental data and outcome. Metabolomics, a major contributor among the ‘omics’-
based technologies, is being exploited to better understand the role of the functional 
capacity of gut microbes in the context of health and disease. The majority of research on 
the intestinal microbiota has focused on genome-based studies that have led to 
associations of changes in the composition of intestinal bacteria in a broad spectrum of 
(auto)-immune/inflammatory disorders from: obesity, type II diabetes, cancer, and (neuro)-
immune/endocrine pathologies such as multiple sclerosis, autism and depression and 
anxiety-based disorders. Gradually metagenomics has started to become integrated with 
metabolomics to functionally annotate the microbiota and characterise its metabolic 
activity and relative contributions in health and disease. The advent of NGS metagenomics 
over the last decade has evolved in its high-throughput capacity to identify thousands of 
targets within the complex samples such as human faeces for a comprehensive sequenced-
based identification of a diverse range of bacterial species. Previously it was suggested 
bacteria outnumber cells in the human body by a ratio of 10:1, however this estimate has 
been downgraded to be in the same order of the number of cells in the body (Sender et al., 
2016). The Human Microbiome Project and MetaHIT have shown the taxonomic diversity of 
the human microbiota through the number of bacterial species varies enormously from 
person to person  (Ehrlich, 2011; Human Microbiome Project, 2012). However, a number of 
different communities of bacteria as well as individual bacterial species within the 
microbiota are able to perform exactly the same metabolic biochemical functions in a 
healthy microbiome. This functional redundancy allows the microbiota to adapt to 
environmental changes, or perturbations by changing gene expression to continue to 
deliver the same functional benefits to the host (Heintz-Buschart & Wilmes, 2018). Nearly 
10 million genes have been catalogued from the human gut microbiome with little known 
about their biochemical function and contribution towards host metabolism (Li et al., 
2014). The functional benefits of the microbiota are being recognised in faecal microbiota 
transplants from healthy donors and has been suggested to be successful in treating some 
ME/CFS patients (Borody & Khoruts, 2012). Understanding the composition of intestinal 
bacteria alone is not enough to understand the complex relationship between the 
intestinal microbiota and host. Depending on the method of prediction between 40-70% of  
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the protein-coding metagenome has unknown function and is a limitation to metagenomic 
approaches to unravel disease mechanisms (Heintz-Buschart & Wilmes, 2018). The shift 
towards shotgun metagenomic provides an overview of the genetic information encoded 
by the microbiota however, additional ‘omics technologies need to become integrated with 
this strategy to address the expression of this metagenomic material and characterise its 
metabolic features which interact with the host and relate to its functions in health and in 
disease.  
 
The principle technologies of metabolomic profiling uses a combination of platforms 
including Nuclear Magnetic Resonance (NMR), Gas Chromatography /Mass Spectrometry 
(GS/MS) and Liquid Chromatography/Mass Spectrometry (LC/MS) in non-targeted and 
targeted experiments to cover a range of metabolites with accuracy and sensitivity. The 
aim of this is to combine metabolite profiles with a functionally annotated intestinal 
microbiome to help identify diagnostic biomarkers as well as unravel diseases mechanisms 
associated intestinal dysbiosis with limited bias and data-driven approach to biomarker 
discovery.  The biggest challenge remains in the extent of metabolite coverage in a single 
experiment. In fact multiple methodologies are needed because of the physical 
biochemical diversity of metabolites ranging from hydrophilic to hydrophobic compounds 
(Dias & Koal, 2016). The experimental design and choice of workflow to quantify 
metabolites, as well as differences in the range of signal detection, when comparing NMR 
data derived from a 600 MHz  versus 750 MHz magnetic field strength machine,  will alter  
the signal to noise ratio in NMR spectra and sensitivity towards metabolite detection. 
Indeed, this can make inter-study comparison difficult not least because of the 
heterogenous patient cohorts used in ME/CFS research but also differences in size of 
reference compound libraries to compare against experimental spectra can vary between 
studies. This is made further difficult in non-targeted experiments when it is not clear 
which metabolites are of particular interest to that cohort. A combination of targeted and 
non-targeted approaches using multiple metabolic platforms is for example preferred to 
identify and quantify as many metabolites as possible. As a result, studies often examine 
different sets of metabolites and number of metabolites that can be identified can make it 
challenging to compare studies linking metabolites variation to a particular disease state. 
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4.1.2 The metabolome in ME/CFS 
 
Suppression of general energy metabolism and mitochondrial dysfunction are thought to 
be involved in the aetiology and long-term maintenance of the two most significant and 
highly debilitating symptoms in ME/CFS patients: chronic persistent fatigue and post-
exertional malaise (Fluge et al., 2016). Whilst onset of ME/CFS is often described by a flu-
like illness, many potential pathogens that have been linked with the disease are not 
consistently found in all patients, suggesting that they may be acting as a potential trigger 
to a series of pathological events yet to be defined rather than being a direct cause in itself 
(Buckwold et al., 1996). The gut acts as a major player within the immune system, since its 
epithelial cell surface barrier remains exposed to the microbiota. Microbial dysbiosis 
resulting in altering the diversity profile of gut bacteria has been reported in ME/CFS, but it 
is unknown how microbial metabolites may conspire to alter local intestinal (and systemic) 
homeostasis or contribute to the severity of fatigue.  
 
Given that a key microbiota function is in digestion and extracting energy from food and 
current research highlighting metabolic disruption in energy and lipid metabolism in ME; 
additional insights may be obtained from studying the severest, most fatigued patients, 
would provide a test for reproducibility and further substantiate confidence in these 
findings. Severe patients represent the most fatigue and disabled individuals within the ME 
spectrum and may represent a subset of patients whom fundamental changes have 
occurred within their energy metabolism as a product of immune activation (Hornig et al., 
2015), on-going inflammation, neuroendocrine dysregulation, autonomic dysfunction 
and/or cardiovascular anomalies. This highlights the complexity of multi-system 
dysfunction that have been found to occur in ME/CFS. It is a reasonable assumption to 
suspect that blood metabolism may be exerting homeostatic shifts across these systems. 
Moreover, blood metabolism is influenced by gut metabolism and diet, and in general, 
increasing evidence suggests gut health plays a significant part in many extra-intestinal 
diseases, including neuro-psychological and neuro-inflammatory disorders (Carding et al., 
2015; De Punder & Pruimboom, 2015; Kelly et al., 2016; Moos et al., 2016; Sampson et al., 
2016). For example, a study between the relationship of the intestinal microbiota and 
plasma metabolites show strong correlations, (e.g. microbiota-derived plasma levels of 
Trimethylamine N-oxide (TMAO)) with microbial community structures and an individual’s 
body mass which influenced the risk of developing glucose tolerance (Org et al., 2017). 
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4.1.3 Faecal metabolome in ME/CFS 
 
The relationship between host and changes in gut bacterial populations within the ME/CFS 
are currently at the correlation level with very little previous reports to comment on the 
faecal metabolome in these patients. One study by Armstrong et al. (2017) examined the 
faecal metabolites from 34 female patients using 750MHz 1H-NMR (see table 4.1.1) to 
correlate the data with changes in bacterial populations and systemic metabolism by taking 
blood serum and urine samples (Armstrong et al., 2017). Their findings were consistent 
within ME/CFS for a decrease in faecal lactate and increase in faecal butyrate, isovalerate 
and valerate. Small Chain Fatty Acids (SCFAs) such as these, particularly butyrate are 
utilised by intestinal epithelial cells as an energy source as a by-product of the 
fermentation of indigestible food in the colon (Inoue et al., 2014). They act by binding to G 
protein-coupled receptors (GPR41 and GPR43) to signal conversion of adenosine 
monophosphate-activated protein kinase (AMPK) to the phosphorylated (pAMPK) (Kimura 
et al., 2014). This facilitates increased fatty acid oxidation and expression of glucose 
transporter (GLUT4). Moreover, increased gut permeability thought to be present in 
ME/CFS, and may be exacerbated by higher levels of SCFAs and will enter the blood 
circulation in increased concentration and have further influence on systemic energy 
metabolism, but particularly in liver and muscle cells (Armstrong et al., 2017; Giloteaux et 
al., 2016) . Armstrong’s observations support this idea, since propionate from the gut can 
enter gluconeogenesis via succinyl-CoA in the liver to generate aspartate and glucose which 
were positively correlated within serum and urine metabolomic profiles, respectively 
(Armstrong et al., 2017).  
 
To summarise, the faecal metabolite differences found SCFAs in ME/CFS suggest increased 
bacterial fermentation that appears facilitated by changes within the microbiome profile. 
Armstrong used traditional culture methods to simultaneously analysis bacterial species, as 
such, Clostridium spp. were increased and are interestingly shown to ferment lactate and 
amino acids in the production of butyrate (Smith & MacFarlane, 1998). Indeed, acetate,  
propionate and butyrate were all increased in the ME/CFS faecal metabolome, with 
butyrate being the most significant. Lactate was unexpectedly found to have decreased 
despite an earlier finding which found an increase in lactic acid producing bacteria in 
ME/CFS (Armstrong et al., 2017; Sheedy et al., 2009). 
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4.1.4 Systemic metabolome in ME/CFS 
 
Blood serum and plasma have previously been studied in ME/CFS using NMR and LC-MS 
and produced intriguingly consistent results that is even more surprising given the extreme 
heterogeneity which is normally a drawback in studies of these sizes, (see Table 4.3.1) 
(Armstrong et al., 2015; Germain et al., 2017; Naviaux et al., 2016). Such consistency may 
be indicative of the blood metabolome being fundamentally different in ME/CFS. 
Armstrong first reported anomalous energy and oxidative stress pathways in ME/CFS 
derived from serum NMR experiments 2015 (Armstrong et al., 2015). Using this 2015 data 
of 29 metabolites identified and quantified in sera, these were later combined with faecal 
metabolite concentrations in 2017 to conclude SCFAs maybe entering the circulation, 
especially propionate to cause mitochondrial dysfunction and oxidative stress and may 
further be exacerbated by increased gut permeability ME (Armstrong et al., 2015, 2017; 
Giloteaux et al., 2016). Further correlations were made between the faecal and blood 
metabolomes summarised in table 4.1.1. 
 
In conclusion, current evidence points towards suppression of energy metabolism, fatty 
acid metabolism and oxidative stress as common pathways altered in ME/CFS and to which 
there is some consistency within the literature. But it is not clear how these pathways 
relate to the context of severity of ME or from observations of the faecal microbiome or 
why these observations are so consistent given the heterogeneity of the ME population 
included in these studies so far. Naviaux et al. published a landmark paper in 2016 detailing 
abnormalities within 20 metabolic pathways from plasma, including reduced lipid 
metabolism, amino acid metabolism, and purine metabolites, and mitochondrial 
metabolism (Naviaux et al., 2016). Another study using the Fukuda CFS criteria suggested 
that the ratios of plasma metabolites pyruvate/isocitrate and ornithine/citrulline, related 
to the TCA and urea cycles, respectively, may have diagnostic relevance (Yamano et al., 
2016). Germain et al., who later published from a much smaller pilot cohort using distinct 
mass spectrometry techniques (see Table 4.1.2), supported the vast range of conclusions 
drawn from Naviaux’s earlier work targeting 612 metabolites in total. Among the 361 
detected, 74 metabolites were significantly different with a similar trend to Naviaux’s 
finding for a hypometabolic state with 80% of these altered metabolites being lower in 
ME/CFS versus controls. 
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4.1.5 Investigating bile acid metabolism in ME 
 
As a follow up to NMR, targeted High-Performance Liquid Chromatography-mass 
spectrometry (HPLC-MS) was used in faecal water and serum to accurately quantitate 26 
bile acids – based on previous observation of decreased taurine in ME/CFS plasma (Niblett 
et al., 2007). Taurine conjugates with bile acids to form bile salts necessary for lipid 
absorption which were also found to be negatively affected in patients belonging to the 
Germain study (Germain et al., 2017). To date, no other studies have targeted the role of 
bile acids within ME/CFS metabolism; especially in severe, house-bound patients. 
Moreover, the gut microbiota provides a functional role in the regulation of bile acid 
metabolism which is vitally important in host lipid and energy metabolism. 
 
Bile acids (BA) are steroidal compounds synthesised in the liver from cholesterol and 
regulated via negative feedback through their binding to nuclear farnesoid X receptors 
(FXRs) in the liver and gut, see figure 4.1.1.  There are two pathways that have been 
identified for BA synthesis: the “classical” and “alternate” pathways also shown in figure 
4.1.1. The classical pathway is responsible for most BA synthesis and is controlled by the 
enzyme cholesterol 7α-hydroxylase (CYP7A1) which is inhibited by FXR activation through 
expression and binding of FGF15/19 to FGF4/ßKlotho receptor. As much as 95% of the total 
BAs secreted are reabsorbed from the gut and delivered to the liver via the hepatic portal 
vein. Chenodeoxycholic acid (CDCA) and cholic acid (CA) are the two most abundant 
primary bile acids produced by humans in the liver which serve to facilitate lipid 
emulsification and digestion. Upon secretion into the duodenum, the bile acid pool may be 
further altered by the gut microbiota to produce secondary bile acids (Wahlström et al., 
2016). Indeed, the gut microbiota can therefore alter the distribution of bile acids as a 
consequence of dysbiosis within its community structure. In fact, several disease states 
including inflammatory bowel disease (IBD), liver disease, C. difficile infection, metabolic 
syndrome, and various cancers are now associated with changes to bile acid metabolism 
(Staley et al., 2017). Thus, alterations within bile acid metabolism may be indicated by 
changes of the ratio of primary to secondary bile acids, could be indicative of a disease-
associated microbiome.    
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Figure. 4.1.1 Bile acid synthesis is dependent on expression of CYP7A1 in the liver and is regulated 
by a negative feedback loop mediated by the induction of FXR. Primary acids are produced in the 
liver. CYP7A1 codes for the enzyme 7a-hydroylase which converts cholesterol to 7a-
hydroxycholesterol. FXR activation inhibits CYP7A1 and is activated by hydrophobic (non-polar) 
primary and secondary bile acids (CDCA, CA, DCA, LCA). Intestinal activation of FXR induces the 
release of FGF15/19 into enterohepatic circulation back to the liver where it binds to GFR4/bKlotho 
receptors on hepatocytes to inhibit CYP8B1, another hydrolase involved in BA synthesis. FXR – 
farnesoid X receptor; FGF -fibroblast growth factor. (Shapiro et al., 2018) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 182 
 
 
Figure 4.1.2 Summary of “Classical” and ‘Alternative” pathways for bile acid synthesis in humans 
and mice. Classical pathway occurs in hepatocytes and accounts for 90% of total bile acid production 
in humans. Cholic acid (CA) and chenodeoxycholic acid (CDCA) are the predominant primary BAs in 
humans; whereas CDCA is converted in muricholic acids (MCAs) in mice. Whilst in the liver, BAs are 
conjugated to either glycine or taurine regulated by bile acid-amino acid transferases (BAT) and bile 
acid CoA ligase (BAL) prior to bile secretion into the duodenum. Genes coloured in red have been 
identified as being under the regulation of the intestinal microbiota. The major difference in mice is 
the conversion of CDCA into αMCA and b-MCA in the mouse liver. Figure has been reproduced from 
an open access publication – access to this is available from: 
https://www.researchgate.net/Schematic-overview-of-pathways-involved-in-the-hepatic-synthesis-
of-primary-bile-acids-in_fig2_317376112 [accessed 11 Jul, 2018]. 
 
BA composition differs significantly in mice, due to the conversion of CDCA through 
hydroxylation at the 6b-position to form alpha-muricholic acid (αMCA), whereas bMCA is 
formed from ursodeoxycholic acid (UDCA) (Takahashi et al., 2016). Whilst UDCA is a 
secondary bile acid in humans, in mice produce is as a primary bile acid (Wahlström et al., 
2016). It has been shown in the absence of a microbiota in germ-free mice, the bile acids 
pool is largely made up of primary conjugated bile acids, including MCAs such as T- αMCA 
and T-bMCA which are typically more hydrophilic in comparison to human BAs where the  
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total bile acid pool is more hydrophobic (Wahlström et al., 2016).  However, the 
biochemical pathway for this conversion from CDCA to MCA is unclear; but a recent report 
suggests Cyp2c70 is a gene required for MCA synthesis in mice which leads to this  
 
 
species variation (Takahashi et al., 2016). Human primary bile acids are mostly conjugated 
to glycine in the liver but can also include taurine (more frequently in mice), via an 
enzymatic step involving bile acid-amino acid transferase (BAT) before they are released in 
the duodenum (Claus et al., 2008). The human gut microbiota influences the bile acid pool 
from a functional perspective by providing enzymes for deconjugation, dehydrogenation 
and dehydroxylation of primary bile acids. In the liver primary BAs are found to have 
hydroxyl groups attached  at the 3, 7, 12-carbon positions under regulation of at least 14 
enzymes, of which some of these are shown to be under the regulation of unknown factors 
derived by the gut microbiota.  (Sacquet et al., 1983; Sayin et al., 2013). Further 
biochemical modifications can involve oxidation of these hydroxyl groups and reversible  
Fig. 4.1.3 Secondary bile acid metabolism. Microbial metabolism facilitates transformation of 
primary bile acids via deconjugation and 7a/b-dehydroxylation. Further heterogeneity can be 
introduced into the BA pool through step-by-step epimerization, oxidation and reduction by 7a/b-
hydroxysteroid dehydrogenases to produce stereochemical distinct oxo-bile salts. Upon 
recirculation to the liver, DCA and LCA are conjugated to glycine or taurine just as primary bile acids 
are synthesised before being reintroduced into the bile acid pool. In mice, CDCA is converted to 
muricholic acids (MCAs) and contributes to a distinct secondary bile acid profile compared with 
humans. Figure has been reproduced from an open access publication – access to this is available 
from: https://www.researchgate.net/Schematic-overview-of-pathways-involved-in-the-hepatic-
synthesis-of-primary-bile-acids-in_fig2_317376112 [accessed 11 July, 2018]. 
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epimerization by microbial enzymes which alter their stereochemical orientation during 
transformation providing a heterogenous secondary bile acids pool within the gut (Staley et 
al., 2017). The biochemical steps involved in secondary bile acid metabolism is summarised 
in figure 4.1.3. The small quantity of BAs that do not get reabsorbed, undergo 
deconjugation of taurine and glycine by hydrolases ubiquitous throughout the microbiota, 
and various oxidation steps which serve to alter the chemical properties, particularly the 
toxicity and hydrophobicity of each bile acid.  For example, deoxycholic acid (DCA) is a 
secondary BA transformed in the large intestine following deconjugation to free cholic acid 
(CA) and subsequent 7α-dehydroxlyation by intestinal clostridia. Deconjugation enhances 
detergent properties which lead to the greater disruption of bacterial cell membrane 
potential (Ridlon et al., 2014). Furthermore, accumulation of DCA has been reported to be 
associated with a “Western diet” (Dermadi et al., 2017).  
 
Increased concentrations of bile acids appear to favour gram-positive bacteria belonging to 
the firmicutes which also include Clostridium cluster XVIa bacteria capable of 7α- 
dehydroxylation to generate secondary bile acids, DCA from CA, and LCA from CDCA. 
Conversely, gram-negative bacteria are less resistant to bile acids and prefer lower BA 
concentrations (Ridlon et al., 2014). Such observations are based on patients presenting 
with hepatic encephalopathy. These patients exhibit certain neuro-psychiatric 
abnormalities as a result of liver failure during its severe stages. During these stages, 
bacterial dysbiosis was observed and linked to low bile acid concentrations and reduction 
of gram-positive bacteria Blautia and Rumminococcaceae (Bajaj et al., 2014). 
 
BAs are also recognised as important signallers, which act as steroid hormones associated 
in the regulation of triglyceride and glucose homeostasis. To that effect, BA metabolism has 
come under increasingly scrutiny to better understand how microbial dysbiosis may 
contribute in various disease states including type 2 diabetes, cardiovascular disease, non-
alcoholic fatty liver disease and cancers. However, a substantial amount of research on BA 
metabolism to date has been performed in germ-free, specific knock-out and conventional 
mice; and given the differences between mice and humans, these experimental outcomes 
limit any translation benefit in human disease and future development of therapies 
targeting bile acid metabolism. For this reason, it was decided to explore the BA profile for 
the first time in severe, house-bound ME patients. 
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4.1.6 Experimental design overview 
 
Various platforms (NMR versus MS) and methods lead to great differences in the power of 
discovery in the field of metabolomics (Dias & Koal, 2016).  Greater accuracy for 
quantification of metabolites is needed, but it is also desirable being able to detect a 
greater number of metabolites in a single run. For instance, at the time of writing, the 
Serum Metabolome database contains 4651 small molecules identified in human serum 
(Psychogios et al., 2011). The expanse of metabolites which can be targeted falls 
dramatically short of expectation in comparison to genomics-based technologies which can 
identify millions of target genes in a single experiment, although 40-70% of their 
biochemical function is not known (Heintz-Buschart & Wilmes, 2018). This makes current 
observations and consistencies within the ME/CFS metabolome even more interesting 
given its heterogenous nature. Here, the result of a small pilot study is presented 
examining the faecal and serum metabolome profiles from 11 severe, house-hold ME/CFS 
patients using 600 MHz 1NMR spectroscopy.  
 
Where possible, each patient was matched with a house-hold control, and both samples 
collected and processed for analysis simultaneously. Only samples collected during 2017 
were included in this work due to changes made to sample collection protocols requiring 
faecal homogenisation and faecal water extraction on the day of sample collection. It is  
important to note that sample preparation and processing were performed in accordance 
to the methods described by Armstrong et al., 2017. It is highly important to make every 
endeavour to control for method variation to give more power in comparing studies and 
towards unravelling multiple aetiologies conspiring to cause ME/CFS symptoms.  
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Table 4.1.1 Summary of publications relating to the study of the metabolome in ME/CFS *Hydrophilic Interaction Liquid Chromatography-ElectroSpray Ionization-Tandem 
Mass Spectrometry 
Study Selection Criteria Cohort Size Biofluid Type Metabolites 
targeted 
Observations/Conclusions 
Naviaux et al.  
(2016) 
IOM (2015), Canadian 
(2003), & Fukuda 
(1994)  
 
45 ME/CFS (n = 22 men and 
23 women)  
CFS males were 53 (±2.8) y 
old vs. females 52 (±2.5) y old  
39 control subjects (n = 18 
men and 21 women) age- and 
sex-matched.  
Blood 
Plasma 
HILIC-ESI-
MS/MS* 
612 (from 63 
biochemical 
pathways) 
Abnormalities in 20 metabolic pathways – 80%       
consistent with hypometabolic syndrome:  
   plasma sphingo- and glyco- sphingolipids in patients who 
had CFS  
Diagnostic accuracy in males using 8 metabolites versus 13 
in female. Posit ME is hypermetabolic response to stress 
from environment similar to dauer. 
Germain et 
al. (2017) 
Fukuda (1994) 17 female ME/CFS 
(age 53.9±8.6y) 
 
15 female controls (age 
51.9±6.2y) 
 
Blood 
Plasma 
Q-Exactive ME 
(QE-MS) 
method  
 
361 (74 altered in 
ME) 
20% of metabolites disrupted in ME/CFS 
 
31 metabolites    in ME incl. lipid metabolism and several 
amino acids,     glucose,     ATP,     ADP 
 
   primary bile acids & taurine,     palmitate 
Armstrong et 
al. (2017) 
Canadian (2003) 34 females with ME/CFS 
(34.9±1.8 SE) y old 
 
25 female controls (33.0±1.6) 
y old 
Faeces, 
Blood 
serum & 
urine 
 
1H NMR – 
(800MHz) 
Bruker Avance II 
US 
Total of 83 
identified 
metabolites in: 
faeces (24), urine 
(30) & serum (29)  
14 metabolites altered,    faecal lactate,    faecal butyrate 
   microbial fermentation of fibre and amino acids to 
produce SCFA  
 
Vipond 
et al.  
(unpublished) 
Canadian (2003), 
International 
Consensus (2011) & 
Fukuda (1994) 
11 severe female ME/CFS 
 
8 house-matched controls (7 
female, 1 male) 
 
14 mild/moderate CFS 
Faeces 
& blood 
serum 
1H NMR 
(600MHz) 
 
Targeted 
HPLC-MS 
45 in faeces 
53 in serum 
 
 
26 Bile Acids 
Faecal gamma-butyrobetaine notably    in 3 patients 
Faecal taurine detected only in 2 patients 
   Glycocholate in severe patients (p=0.03)  
 
No significant findings from serum.  
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4.1.7 Aim & Objective 
 
The aim of this chapter was to define the faecal and serum metabolome of severely 
affected ME/CFS patients compared to house-hold controls, in order to understand how 
metabolic features may be related to neurological and behavioural aspects associated with 
greater severity compared to mild and moderately affected patients.  
 
Three recent independent studies on the general ME/CFS population have contributed 
consistent data revealing various biochemical pathways and metabolites in patients that 
are associated with a reduction in lipid and energy metabolism (Armstrong et al., 2017; 
Germain et al., 2017; Naviaux et al., 2016). Whilst these metabolomics-based studies of 
mild to moderately affected ME/CFS patients have identified such alterations, it is not 
known if these findings translate to severely affected ME/CFS patients.  In order to 
determine this, the following objectives were established: 
 
- to address the functional capacity of the severe ME/CFS microbiome using NMR 
spectroscopy to measure low molecular weight metabolites;  
- by preparing faecal water and serum samples in accordance to methods set out by 
a previous NMR study by Armstrong and colleagues in 2017; 
- to determine if an altered microbial composition (dysbiosis) influences faecal and 
serum metabolism in severe ME compared with house-hold controls; 
- to determine if severe ME patients display a distinct bile acid metabolic profile 
using targeted HPLC-mass spectrometry which may described altered energy 
metabolism in these patients.  
 
4.1.8 Hypothesis 
 
The functional capacity of the intestinal metabolome in severe ME/CFS patients is altered 
through a decline in the compositional diversity of intestinal bacteria to the detriment of 
host metabolism, causing the faecal and serum metabolomes of severe, house-bound 
ME/CFS patients to reflect a hypometabolic state in accordance with altered energy and 
bile acid metabolism. 
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4.2. Materials & Methods 
 
4.2.1 Sample preparation and storage 
 
Briefly, the entire stool sample was collected in a FECOTAINER® collection device (AT 
Medical B.V., Enschede, Netherlands), figure 2.2.2 no sooner than 24 hrs before visiting the 
patient’s home for collection. During this time before our arrival to collect, patients were 
advised to keep their sample inside the fridge in double containment using the packaging 
provided. An AnaeGenTM Compact anaerobic sachet (Cat. No AN0010, Oxoid. Ltd.) was also 
provided for insertion and activation inside the FECONTAINER® as soon as the sample was 
produced by the patient. 
  
On return to the hospital the entire stool sample was homogenised manually using a sterile 
autoclaved metal spatula. Faecal water was extracted from homogenate of each sample 
with a 2:1 ratio of molecular grade water. It is recommended ~15g of faecal material is 
used with 30 ml of water but is dependent of amount of original sample provided. This 
mixture was vortexed for 5 min and centrifuged at 18,000 x g, for 10 min, or 3,500 x g, for 
30 min. The supernatant is then divided in to multiple aliquots and stored at -80 degrees 
prior to analysis. 
 
4.2.2 Preparation for 1H NMR spectroscopic Analysis 
 
- Preparation using serum samples 
 
Samples were prepared for NMR using a method modified from a previous study (Armstrong et al., 
2017). Serum samples were thawed from -800C, from which 250µL of serum was added to 
250µL ice cold deuterated chloroform and 250µL ice cold deuterated methanol and mix by 
vortexing. Samples were then left on ice for 15 mins before centrifuging (16100 x g) at 40C 
for 10 mins to produce hydrophilic phase of water/deut. methanol and lipophilic phase of 
deuterated chloroform. 300µL of the top hydrophilic layer was transferred to 300µL of 
NMR buffer (0.26g NaH2PO4,1.44g K2HPO4,17mg TSP, 56.1mg NaN3 in 100 ml D2O), and 
mixed mix before transferring 550µL to NMR tube. In addition, 0.9% saline solution (0.9g 
NaCl in 100ml D2O) was made to combine with serum, using 200µL serum mixed with 
400µL saline solution, before transferring 550µL in to NMR tubes. 
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- Preparation using faecal water extracts 
 
Samples were prepared for NMR using a method modified from a previous study 
(Armstrong et al., 2017). One millilitre aliquot from each sample were thawed from -800C. 
250µL faecal water was transferred in 250µL ice cold deuterated chloroform and 250µL ice 
cold deuterated methanol. Samples were mixed by vortexing and left on ice for 15 mins 
before centrifuging at 16100 x g at 40C for 10 mins to produce hydrophilic phase of 
water/deuterated methanol and lipophilic phase of deuterated chloroform. 300µL of the 
top hydrophilic layer was transferred in to 300µL of NMR buffer (phosphate buffer, pH 7.4 
in D2O, containing 1mM d4-TSP), and mixed thoroughly before all samples were transferred 
into NMR tubes. Additional faecal extracts were prepared without chloroform/methanol 
extraction from 300µL of faecal water in 300µL NMR as described above.  
 
- Acquisition of NMR data 
 
High resolution 1H NMR spectra of faecal water extracts were recorded on a 600 MHz Bruker 
Avance III HD spectrometer fitted with a 5 mm TCI cryoprobe and a 60 slot autosampler 
(Bruker, Rheinstetten, Germany). Sample temperature was controlled at 3000K and the D2O 
signal was used as lock. Each spectrum consisted of 1024 scans of TD = 65,536 data points 
with a spectral width of 20.49 ppm (acquisition time 2.67 s). The noesygppr1d presaturation 
sequence was used to suppress the residual water signal with low power selective irradiation 
at the water frequency during the recycle delay (D1 = 3 s) and mixing time (D8 = 0.01 s).  A 
900 pulse length of approximately 8.1 µs was used, with the exact pulse length determined 
for each sample by the Bruker automation routine (au_prof1d). Spectra were transformed 
with 0.3 Hz line broadening and zero filling and were automatically (proc_prof1d) phased and 
referenced (to TSP) using the TOPSPIN 3.2 software. The noesygppr1d sequence avoids the 
need for a first order (PHC1) phase correction or for baseline correction. The resulting Bruker 
1r files were converted to Chenomx (.cnx) format using the ‘Batch Import’ tool in the 
Processor module of Chenomx NMR Suite v8.12. The only additional processing during 
conversion was a shim correction to remove any line-shape irregularity and the 
concentration of the reference compound, TSP, was set to 0.5 mM.NMR spectra of serum 
extracts were recorded and processed in exactly the same way except that the number of 
scans was 512 and the 900 pulse length was approximately 8.6 µs. NMR spectra of the serum/ 
saline solution samples were also obtained using the diffusion edited pulse sequence to 
emphasise signals from lipoproteins and other large molecules.  
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Metabolites were identified from the Chenomx library (337 compounds) with in-house 
additions (ca. 40 compounds), the HMDB database (http://www.hmdb.ca), literature and 
by use of the 2D-NMR methods, COSY, TOCSY, HSQC and HMBC on selected samples. The 
2D methods were useful in obtaining precise chemical shifts which could differ slightly from 
literature values since the samples contained some methanol in addition to water. 
Concentrations of up to 45 compounds per sample were obtained using the Chenomx 
Profiler module and the concentrations of all samples were exported to an excel file. 
Diffusion edited spectra were analysed using variable width buckets (added graphically to 
spectra using Bruker AMIX software). 
 
- Data analysis 
 
Statistical analysis for individual compounds was carried out in GraphPad Prism v5.01 
(GraphPad Software, San Diego, CA) using the Mann-Whitney test for comparison of two 
groups or the Kruskal-Wallis test for three groups, followed in the latter case by Dunn’s 
Multiple Comparison test for pairwise comparison. Data plots were also produced for the 
compounds showing the median and interquartile range for each group.  
 
Multivariate statistical analysis (Principal Component Analysis, PCA) was carried out using 
the PLS Toolbox v8.01 (Eigenvector Research Inc., Wenatchee, WA) running within Matlab 
R2015a (The Mathworks Inc., Natick, MA). For the PCA any missing values (zero 
concentrations) in the data table were replaced with a very small value, the rows were 
normalised (sum of concentrations made the same for each sample) and the columns 
(compound concentrations) were scaled to unit variance. 
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4.2.3 Targeted bile acid quantification by mass spectrometry 
 
Faecal water extracts and serum were analysed using HPLC – mass spectrometry operated 
in multiple reaction monitoring (MRM) mode. Each sample (5 µl) was analysed using an 
Agilent 1260 binary HPLC coupled to an AB Sciex 4000 QTrap triple quadrupole mass 
spectrometer.  HPLC was achieved using a binary gradient of solvent A (Water + 5mM 
Ammonium Ac + 0.012% Formic acid) and solvent B (Methanol + 5mM Ammonium Ac + 
0.012% Formic acid) at a constant flow rate of 600 µl/min. Separation was made using a 
Supelco Ascentis Express C18 150 x 4.6, 2.7µm column maintained at 40°C.  Injection was 
made at 50% B and held for 2 min, ramped to 95% B at 20 min and held until 24 minutes.  
The column equilibrated to initial conditions for 5 minutes. 
 
The mass spectrometer was operated in electrospray negative mode with capillary voltage 
of -4500V at 550°C.  Instrument specific gas flow rates were 25ml/min curtain gas, GS1: 40 
ml/min and GS2: 50 ml/min. Dwell time for each MRM was 20 ms. Quantification was 
applied using Analyst 1.6.2 software to integrate detected peak areas relative to the 
deuterated internal standards. 
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4.3. Results 
 
4.3.1 Patient cohorts and datasets obtained 
 
This chapter presents various datasets using faecal water and blood serum samples 
collected from 2016- 2017. Table 4.3.1 summarises the types of samples collected and from 
which group of participants. This has given rise 4 distinct datasets (4A-4D), which have 
displayed and described in table 4.3.2. Each dataset here is presented in its order collection 
and the result of each described in the following text in that order. All samples within each 
dataset have been included in the same experiment. 
 
4.3.2 Identification of faecal metabolites using NMR  
 
Proton Nuclear magnetic resonance (1H-NMR) spectroscopy was used to identify 
metabolites within faecal water from 11 female severe house-bound ME patients (42.1 ± 
4.8 SE years) versus 6 house-matched controls (63 ± 2.4 SE years). The resultant cohort was 
matched on the basis of each healthy control living with a patient. With the exception of 
one matched healthy control, paired samples were gender matched and typically represent 
mother as control, and daughter as patient. Due to this relationship it was not possible to 
control for age differences. A total of 45 compounds were examined and quantified as 
absolute concentrations down to the low micromole per litre range. Figure 4.3.1 shows the 
multiple spectra obtained using AMIX (Bruker) to colour individual spectra by group (e.g. 
patient/control). The peaks were used to determine concentrations of individual 
metabolites by fitting the spectra of known single compounds from the reference library to 
the experimental spectra. Ice cold methanol/chloroform was mixed with serum to create 
biphasic separation of upper hydrophilic layer containing low molecular weight 
metabolites. It is this fraction in which the data has generated from. 
 
Prior to statistical testing no assumption was made on distribution of individual metabolite 
concentration; to this end p-values were determined with the non-parametric Mann-
Whitney test in GraphPad prism. In some samples the compound concentrations were 
below the limit of detection were set at 0.0001 mM to avoid having zeroes for the 
statistical analyses. The outcome of these p-values is summarised with the table included 
as part of figure 4.3.2. 
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Table 4.3.1  Summary of participant samples acquired for metabolic profiling.  
15 Severe (age 42.9± 4.04 SE years), 15 Mild/Moderate (age 44.7±3.49 SE years), and 9 
Control (age 57.3±4.04 SE years). Status for each participant is given. ‘X’ identifies year 
sample was collected and the analysis performed.  
 
 
 Status Sex Age Faecal 
water 
Serum NMR           
2016        2017 
Bile Acid analysis 
faeces        serum 
1 Severe F 63  X   X 
2 Severe F 56 X X X X X 
3 Control F 55  X X  X 
4 Control F 69 X   X X 
5 Severe F 44 X  X  X 
6 Control F 70 X  X X X 
7 Control F 55 X  X X X 
8 Severe F 38 X X  X X 
9 Severe F 21 X X X X X 
10 Severe F 37 X     
11 Control F 64 X   X  
12 Severe F 18 X  X X X 
13 Severe F 61 X   X  
14 Severe F 40 X   X  
16 Severe F 58 X X  X X 
17 Control M 60 X X  X X 
18 Severe F 27 X X  X X 
19 Control F 60 X X  X  
20 Severe F 63 X  X X X 
22 Severe F 31  X   X 
23 Control F 54  X   X 
24 Control F 29  X   X 
25 Severe F 56  X   X 
26 Severe F 30  X   X 
27 Mild ME F 30  X   X 
28 Mild ME M 54  X    
29 Mild ME F 26  X   X 
30 Mild ME F 28  X   X 
31 Mild ME M 41  X   X 
32 Mild ME F 65  X   X 
33 Mild ME M 48  X   X 
34 Mild ME M 43  X   X 
35 Control M 37  X   X 
36 Mild ME F 43  X   X 
37 Mild ME F 60  X   X 
49 Mild ME F      X 
50 Mild ME M 58     X 
57 Mild ME F 60     X 
58 Mild ME M 54     X 
59 Mild ME F 27     X 
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Table 4.3.2 Overview of datasets presented in this chapter and metabolite coverage generated using NMR and HPLC-MS metabolomic profiling of 
participants recruited between 2015-2017. Datasets are organised in chronological order for each experiment: “A” represents the first dataset; and “D” 
being the final dataset to be completed.  
Dataset Biofluid Platform Sample size ME/CFS  
status 
Sample prep. Metabolite  
coverage 
Summary of findings 
 
 
4A 
 
 
Faecal 
water 
 
 
1H-NMR 
(600MHz) 
 
n=17 
11 ME/CFS, 
6 House-matched 
controls 
 
 
Severe 
Ice-cold deuterated 
Methanol/chloroform 
Extraction of hydrophilic phase 
 
As described by Armstrong et al. 2015 
 
 
45 
Increased glycocholate (p=0.03) 
Hypoxanthine (p=0.05) 
Methylsuccinate (p=0.06) 
 
 
4B 
 
 
Faecal 
water 
 
 
HPLC-MS 
 
n=14 
8 ME/CFS 
6 House-matched 
controls 
 
 
 
Severe 
200µl faecal water  
 
26 
Bile acids 
No significant findings 
Kruskal-Wallis 
 
Traces of muricholic acids 
High concentration of HDAC in some patients 
 
 
4C 
 
 
Blood 
Serum 
 
 
1H-NMR 
(600MHz) 
 
n=34 
25 ME/CFS, 
9 House-matched 
controls 
 
 
Severe (n=14), 
Mild/moderate 
(n=11) 
Ice-cold deuterated 
Methanol/chloroform 
Extraction of hydrophilic phase 
 
Diff. edited NMR: 
Saline-diluted serum 
 
 
53 
No significant findings 
Kruskal-Wallis with Dunn’s test 
 
 
4D 
 
 
Blood 
Serum 
 
 
HPLC-MS 
 
n=46 
26 ME/CFS, 
7 House-matched 
6 IBD  
 
Severe (n=14) 
& 
Mild/moderate 
(n=14) 
 
 
200µl undiluted serum 
 
 
26 
Bile acids 
Significant variances across samples within dataset 
Traces of muricholic acids 
HDCA higher in some severe ME patients 
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- dataset 4A 
Scatter dot plots were generated in GraphPad Prism for each metabolite for comparison 
between the severe ME group and matched healthy controls. These have been summarised 
and presented as supplementary figures (S4.1 and S4.2) included within the appendix.  The 
horizontal lines indicate the max, median and min.  
 
In an attempt to separate severe ME (S) from House-Hold Controls (H), principal 
component analysis (PCA) was performed to identify any metabolites as a source of 
variation between the two groups (figure 4.3.5). The first principal component 
(PC1(41.69%)) represents the largest possible variance. This is determined to a large extent 
by interindividual differences, particularly samples with unusually higher values, although 
an attempt was made by normalising the sum of concentrations in each sample to the 
same value. PC3(8.92%) versus PC4(6.80%) in the right plot of figure 4.3.5 shows severe (S) 
in red separates from house-matched (H) in green. The numbers refer to the individual 
samples driving these differences. In order to understand the source of this variation, 
figure 4.3.6 provides an annotated PCA plot with specific faecal metabolites. This is useful 
in identifying specific metabolites within individual samples causing the variance. Here 
compounds: formate, ethanol, lactate, succinate, methylamine, glutarate, methylsuccinate, 
taurine and 3-phenylpropionate are found higher in patients 6, 14 and 15 and not in the 
severe (S) groups in general. To that end, there is very little statistical power based on the 
observations made in this experiment. For many compounds there are one or two samples 
with very high values – often these come from the same sample, for example sample 9 
(and 12) is high in amino acids and sample 15 is very high in succinate and lactate, (figures 
4.3.7 & 4.3.8). 
  
The conclusion is that a weak separation is found between patients and control. Of the 45 
compounds examined only one showed p<0.05. This compound was the nearest calibrated 
standard that was available in our reference library, which was “glycocholate”, although it 
should be considered of as a general bile acid signal. The inclusion of this compound along 
with another seen in very high concentration in 3 of the severe patients was g-
butyrobetaine. This present in very low concentration in patients and controls and is a gut 
metabolite of L-carnitine and intermediate in the conversion of carnitine to trimethylamine 
and TMAO (Koeth et al., 2014). L-carnitine is associated with a lot of meat in the diet, 
however it is more likely that these patients have been taking L-carnitine supplements. PCA  
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separation with the addition of these compounds is included in figure 4.3.7. In this plot, 
PC1(39.99%) demonstrates that severe (S) samples 6, 9, 12, 14, 15 in red, are the source of  
this variation of which, the compounds have been annotated to the plot in figure 4.3.8. 
Metabolites shown in the positive region f PC3 are more likely to be in higher 
concentration in severe (S) patients, versus the negative region which reveals compounds 
more likely to be higher in house-matched (H) control. A more detailed analysis of the bile 
acids by mass spectrometry in a targeted analysis appears later in this chapter as a follow 
up to the apparent bile acid signal detected significantly higher in patients. The next 
nearest significant difference was hypoxanthine (p=0.05) and methylsuccinate (p=0.06), see 
box plot in figure 4.3.3. 
  
A box plot summary presents the entire dataset was and highlights the lack of evidence for 
differences in individual metabolites (figure 4.3.3). Some of the trends identified are at 
variance with earlier publications suggesting short chain fatty acids are in higher 
concentration within the ME/CFS populations. The data obtained for this in figure 4.3.4 
shows no evidence of this in severe ME patients. No differences were found for pyruvate or 
ornithine or any of the detected amino acids in this experiment. Alas, these other studies 
had more participants, but nevertheless the clinical severity of patients used in our study 
made this finding even more disappointing. From Armstrong et al. (2017), table in Fig 1e 
and Sec 3.4 in this paper find significant differences between patients and controls for 
isovalerate, lactate and valerate – in each case with a higher level in patients. Although not 
significant they also report a higher level of total SCFA in patients. Although none of these 
are found to be significant in this small cohort of severe patients there does appear to be a 
trend for all of them to be higher in controls (isovalerate, valerate, acetate, butyrate, 
propionate), but not in patients. The PCA loadings with figure 4.3.8 agree with this since all 
these metabolites appear in the negative region of PC3 and are likely to be higher in house-
matched (H) samples, according to this experiment.  
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Faecal Water 1H-NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.1 Partial 600 MHz 1H-NMR spectra from faecal water extractions used for biphasic separation in methanol/chloroform to extract the 
hydrophilic layer for small metabolites quantification.  1-17 are shown. Severe (S) are in blue. House-Matched (H) are green. g-gain increased to reveal 
smaller peaks. All metabolites assigned to the reference spectra using Chemomx software. “BA” = bile acid peak, quantified as “glycocholate”.  
 
 
BA 
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Metabolite p-value 
1,3-Dihydroxyacetone 0.3361 
2-methylbutyric 0.2913 
3-Phenylpropionate 0.2901 
5-Aminopentanoate 0.9599 
Acetate 0.8016 
Alanine 0.5804 
Aspartate 0.8802 
Butyrate 0.725 
Caprate 0.6537 
Caproic acid 0.3112 
Ethanol 0.0779 
Formate 0.9599 
Fumarate 0.8404 
Glutamate 0.9599 
Glutarate 0.6503 
Glycerol 0.8397 
Glycine 0.451 
Hypoxanthine 0.0561 
Isobutyrate 0.2478 
Isoleucine 0.3654 
Isovalerate 0.3397 
Lactate 0.7992 
Leucine 0.1193 
Lysine 0.3397 
Methionine 0.6468 
Methylamine 0.5136 
Methylsuccinate 0.0628 
Nicotinate 0.222 
Phenylacetate 0.2913 
Phenylalanine 0.0786 
Proline 0.3549 
Propionate 0.9599 
Serine 0.5947 
Succinate 0.1193 
Taurine 0.3237 
Threonine 0.9195 
Trimethylamine 0.5804 
Tyrosine 0.2478 
Uracil 0.58 
Valerate 0.2478 
Valine 0.3397 
Glucose 0.2657 
p-Cresol 0.2823 
Gammabutyrobetaine 0.2478 
“Glycocholate” 0.0347 
* (p=0.03) 
 “Bile Acid” 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.2  The 45 metabolites detected across 
faecal water samples using 600 MHz 1H-NMR 
spectroscopy. Table (left) provides the name of each 
metabolite compound and p-value generated from 
the Mann Whitney test. Out of the 17 faecal water 
samples from (11) severe, house-bound ME/CFS 
patients and (6) house-matched control, the only 
significant difference was reported from a potential 
bile acid signal. The scatter plot for this compound 
display the absolute concentrations in mM from 
individual samples. Severe mean = 0.015mM vs 
control = 0.0058mM 
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Figure 4.3.3 Box plot representation of 42 out of 45 faecal water low molecular weight 
metabolites in severe (s) red, versus House-matched (H) green samples. The magnitude of the 
concentration of the other 3 metabolites could not be presented in this plot. Each household control 
(H) is matched to an individual severe (S) ME patient. Both samples were collected and analysed 
simultaneously on a 600MHz 1H-NMR Bruker machine. Central line of each box represents the 
median. Width denotes the interquartile range, with error bars positioned to show Min and Max  
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concentration detected across that group. “Glycocholate” has been labelled with inverted commas 
as the closest assigned bile acid fitting the experimental spectra. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.4 Summary of Short Chain Fatty Acid (SCFA) compounds whose range of concentrations 
detected across all samples were too extreme to include with other low molecular weight 
metabolites quantified using NMR spectra. Box plot with whiskers. Concentrations were analysed 
using the Mann-Whitney test at 5% significance level. Severe (n=11) versus House-Matched (n=6). 
Acetate: severe mean = 4.21±0.64 SE mM versus House-Matched mean = 5.00±1.25 SE mM. 
Butyrate: severe mean = 0.97±0.19 SE mM versus House-Matched mean = 1.21±0.38 SE mM. 
Propionate: severe mean 1.15±0.19 SE mM versus House-Mathced mean = 1.14±0.21 SE mM. P 
values were 0.80, 0.73 and 0.96 respectively. 
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Figure 4.3.5 PCA plots showing interindividual variation of faecal water NMR metabolomic profiles 
based on 45 absolute concentrations for low molecular weight metabolites. PC1 vs PC2 & PC3 vs PC4 
scores. Severe (S), red, House-Matched (H), green. Separation between severe and control group is 
seen on PC3. Data Row normalised and autoscaled.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.6 Metabolite labelled PCA plot identifying metabolite compounds influencing 
spatial separation. Row normalised and autoscaled. PC3 vs PC4 Loadings. 
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Figure 4.3.7 PCA plot showing a weak separation between severe (S) and House-Match (H) groups 
including glycocholate and gammabutyrobetaine. Row normalised and autoscaled. PC1 vs PC3. 
Severe (S), red, House-Matched (H), green. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.8  Metabolite labelled PCA plot showing individual metabolites influencing group 
separation between severe (S) and House-Match (H). Analysis includes glycocholate and 
gbutyrobetaine. Row normalised and autoscaled. PC1 vs PC3 Loadings. Metabolites in the positive 
part of PC3 are expected to be higher in patients and those in negative part to be higher in controls. 
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4.3.2. Serum metabolome 
 
- dataset 4C 
 
Direct quantification of a total of 53 metabolites was conducted in a slightly larger patient 
cohort representing 14 severe (S), as well as 11 mild/moderate (M) ME patients and 9 
house-matched (H) controls. Table 4.3.1 highlights that paired samples 3 and 9 where 
included twice in this dataset due to the availability of further serum collected 
approximately one year later.  
 
A similar and more comprehensive set of metabolites were measured using the same 
method of extraction in methanol/chloroform, producing a biphasic with a top hydrophilic 
layer, as in Armstrong et al., (2015). They found significant difference for acetate, glucose, 
glutamate, hypoxanthine, lactate and phenylalanine. Scatter plots presented in figure 4.3.9 
highlight the fact that none of these findings were replicated within severe (S) patients. 
Indeed, following a log transformation of all absolute metabolite concentrations across 
groups and summary of the distribution of all data points within a box plot demonstrates a 
lack of evidence for differences, figures 4.3.12 and 4.3.13. Many of the bars show extreme 
overlapping variation in all groups: (S), (M) & (H). The three groups were analysed 
statistically according to the response variable of absolute metabolite concentration in 
millimolar (mM). As with the earlier data on the severe ME faecal metabolome, no 
assumption was made about the distribution of concentration values. In order to not 
assume statistical significance by chance, a non-parametric analysis of variance was carried 
out using the Kruskal-Wallis (KW) test. A post-hoc Dunn’s multiple comparison test was 
applied since the response variable in this case in ordinal (severe(S)/mild-moderate 
(M)/house-matched (H)) rather than nominal, i.e. treatment. This allows for determination 
of which pairs of groups (S v M, S v H, M v H) is significantly different from the other.  
 
Out of all the tests only one was found to be significant – 2-hydroxyisovalerate, which had 
a p value of 0.02 with S v M as the pair that was significantly different (M>S). This has been 
identified in urine and is associated with lactic acidosis, where lactic acid accumulates in 
the body and can result in the lowering of blood pH. It is also among several 
hydroxycarboxylic acids which form ketone bodies from the ketogenesis of amino acids 
valine, leucine and isoleucine (Liebich & Först, 1984). Unfortunately, none of the other  
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observations for these amino acid concentrations were helpful in supporting any form of 
hypothesis surrounding this finding, except that is likely that these patients were in a 
fasting period during the sample was taken. Although no diet information or pattern of 
eating was recorded during the study. 
 
With respect to glutamate, one of the healthy samples appeared as an obvious outlier at 
0.15mM. In figure 4.3.10 this sample has been removed to resolve any visible separation 
across the groups. On repeat of a KW test, there was a significant difference across the 
groups for glutamate (p=0.03), however Dunn’s multiple comparison did not confirm which 
paired groups were significantly different. An attempt to view the data with other clear 
single outliers within scatter plots for hypothanthine (within the Mild group) and 
phenylalanine (within House-Matched group) were excluded and re-plotted (not shown). 
These outliers did not make any difference to reveal at specific trend.  Tau-methylhistidne 
included in this figure, is another increased metabolite that may be slighter higher within 
some severe (S) patients, however, given the distributions of concentrations derived from 
house-hold controls (H) and the small ranges in concentration difference it is hard to 
conclude anything from this. Suffice to say, Tau-methylhistinde is an amino acid largely 
present in actin and myosin, and can be used as a surrogate for indirect determination of 
muscle myofibrillar protein degradation (Lowry et al., 1985; Röuthig et al., 1984). Indeed, in 
the context of severe, house-bound patients, this is not a surprising finding. 
 
Two other metabolites from serum did appear interesting based on the possible subset 
distribution of concentration in severe (S). Figure 4.3.11 presents the scatter plots for an 
unknown metabolite at 2.69ppm, and for acetoacetate. In both these plots, there appears 
to be an emergence of two discrete, severe (S) patient populations. Higher levels of 
acetoacetate are indicative of ketosis during a fasting state. Indeed, many of the severest 
patients, who remain bed-bound the entire time, eat very little and at inconsistent times of 
the day. Dehydration is also common among them and is reflected by the Bristol scores, 
most which score 1, being the most dehydrated stool presenting difficult to pass for the 
patient.  
 
Finally, as a statistical summary for all metabolite concentrations measured in serum, table 
4.3.3 provide mean concentrations (mM) and the standard error for each of 53 metabolites  
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measured in serum along with their respective p value for KW test performed with Dunn’s 
multiple comparison test. Despite a more comprehensive overview of the coverage of 53  
serum metabolites none of the previous findings based of just 24 serum metabolites could 
be replicated (Armstrong et al., 2017). Armstrong et al. acknowledged no investigation was 
performed on their serum samples using the apolar layer extracted during 
methanol/chloroform extract. In the next result section, for the first time in ME/CFS 
research, an attempt has been made to study the lipid profile of ME/CFS serum. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.9 Selected scatter plots of 8 metabolites previously reported to be altered within the 
ME/CFS patient population but were not observed to be significant altered in this study. Plots 
were generated using GraphPad Prism. Each dot represents a single participant. Horizontal line 
represents the median concentration (mM) value. Error bars represent the Max and Min values 
observed from each experimental group. 
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Figure 4.3.10 Amended scatter plots excluding extreme values included in the initial plot (Fig. 
4.3.11) for Glutamate and Tau-MeHis. Glutamate (p=0.03, M>H). Tau-MeHis (p=0.07) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.11 Scatter dot plots for unknown small metabolite and acetoacetate. Significance tested 
using Kruskal-Wallis test with Dunn’s post-hoc test, no significances observed. Distribution of 
concentrations (mM) plotted appear to indicate a trend in metabolite concentration across groups, 
S>M>H for both metabolites. (p=0.81 and p=0.66 respectively). 
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Figure 4.3.12 Box plot summary including 25 of 53 serum metabolites detected using 600MHz 1H-
NMR. Frozen storage (-80oC) serum collected from severe (S), mild/moderate (M) and House-
Matched (H) were analysed simultaneously. Analysis was performed blinded using experimental 
spectra compared with reference spectra of known small compounds. Absolute concentrations were 
obtained in milli-molar (mM) before undergoing log transformation and plotting data using 
GraphPad Prism. Three groups S, M, & H were analysed for statistical significance using the Kruskal-
Wallis test with Dunn’s post correction. *(2-hydroxyisovalerate, p=0.02). 
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Figure 4.3.13 Remaining 26 out of 53 metabolites found in serum. All samples were analysed 
simultaneously using 600 MHz 1H-NMR. Central line of boxes represents median value for each 
compound; error bars show samples were the max and min concentration was detected. Width of 
box shows the interquartile range. Absolute concentrations were determined from measurement of 
peak intensity. Compounds were identifiable based on comparison of the experimental spectra with 
known reference spectra in the library. No significant differences were observed across groups: (S), 
(M) & (H). 
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Metabolite    P 
value 
Severe 
  
Mild/moderate 
  
House Matched 
  
    Mean   St. Err       Mean   St. Err.         Mean St. Err. 
2-Aminobutyrate 0.95 0.0062 0.00082 0.0062    0.00077 0.0063 0.001247 
2-Hydroxybutyrate 0.94 0.0106 0.00149 0.0104    0.00155 0.0117 0.002476 
2-Hydroxyisovalerate 0.02* 0.0017 0.00013 0.0030    0.00046 0.0018 0.000260 
2-Oxoisocaproate 0.25 0.0076 0.00066 0.0092    0.00076 0.0075 0.001112 
3-Hydroxybutyrate 0.75 0.0179 0.00385 0.0125    0.00353 0.0151 0.005106 
3-Hydroxyisobutyrate 0.57 0.0039 0.00052 0.0043    0.00061 0.0043 0.000524 
3-Methyl-2-oxovalerate 0.13 0.0056 0.00052 0.0070    0.00054 0.0055 0.000684 
3-methyl-2-oxobutyrate 0.65 0.0034 0.00021 0.0037    0.00031 0.0034 0.000352 
Acetate 0.62 0.0144 0.00203 0.0143    0.00149 0.0362 0.020025 
Acetoacetate 0.66 0.0056 0.00106 0.0041    0.00058 0.0041 0.001024 
Acetone 0.58 0.0019 0.00025 0.0016    0.00022 0.0014 0.000305 
Alanine 0.29 0.1264 0.00800 0.1493    0.00994 0.1420 0.024365 
Arginine 0.67 0.0171 0.00115 0.0178    0.00244 0.0236 0.006239 
Asparagine 0.36 0.0128 0.00065 0.0123    0.00099 0.0102 0.001357 
Aspartate 0.76 0.0092 0.00086 0.0081    0.00067 0.0105 0.002707 
Betaine 0.78 0.0096 0.00090 0.0103    0.00095 0.0094 0.000712 
Carnitine 0.75 0.0128 0.00047 0.0116    0.00151 0.0130 0.001132 
Choline 0.99 0.0057 0.00042 0.0060    0.00052 0.0542 0.048057 
Creatine 0.09 0.0124 0.00140 0.0087    0.00151 0.0128 0.002179 
Creatinine 0.82 0.0153 0.00092 0.0168    0.00088 0.0168 0.000576 
Dimethylamine 0.2 0.0005 4.93681E-05 0.0006    3.9207E-05 0.0005 5.34522E-05 
Ethanol 0.53 0.0103 0.00224 0.0364    0.01350 0.0505 0.029978 
Formate 0.49 0.0083 0.00048 0.0079    0.00053 0.0092 0.000870 
Glutamate 0.03* 0.0230 0.00242 0.0274    0.00238 0.0343 0.016630 
Glutamine 0.39 0.1460 0.00552 0.1354    0.00807 0.1312 0.019423 
Glycerol 0.35 0.0262 0.00242 0.0218    0.00398 0.0807 0.054000 
Glycine 0.47 0.0855 0.00669 0.0980    0.00886 0.1034 0.017186 
Histidine 0.57 0.0250 0.00084 0.0238    0.00082 0.0284 0.004210 
Hypoxanthine 0.94 0.0035 0.00038 0.0041    0.00111 0.0035 0.000429 
Isoleucine 0.48 0.0184 0.00238 0.0194    0.00166 0.0193 0.002131 
Isopropanol 0.08 0.0014 0.00030 0.0008    0.00010 0.0022 0.001138 
Lactate 0.11 0.7062 0.06555 0.8540    0.06157 0.7263 0.105928 
Leucine 0.58 0.0385 0.00372 0.0400    0.00324 0.0493 0.011746 
Lysine 0.88 0.0440 0.00237 0.0434    0.00272 0.0481 0.008200 
Mannose 0.29 0.0157 0.00095 0.0131    0.00099 0.0162 0.002826 
Methylamine 0.45 0.0026 0.00044 0.0020    0.00043 0.0021 0.000534 
Ornithine 0.06 0.0145 0.00148 0.0179    0.00145 0.0148 0.003233 
Phenylalanine 0.76 0.0190 0.00081 0.0192    0.00095 0.0251 0.005307 
Proline 0.34 0.0635 0.00616 0.0678    0.00618 0.0575 0.006659 
Propylene glycol 0.97 0.0039 0.00232 0.0016    0.00094 0.0014 0.000472 
Pyruvate 0.19 0.0157 0.00369 0.0177    0.00249 0.0124 0.003852 
Sarcosine 0.23 0.0004 3.69564E-05 0.0004  4.52724E-05 0.0005 4.9099E-05 
Serine 0.39 0.0435 0.00304 0.0391    0.00392 0.0519 0.010921 
Threonine 0.84 0.0387 0.00267 0.0366    0.00354 0.0434 0.008674 
Tryptophan 0.31 0.0139 0.00042 0.0154    0.00086 0.0160 0.001569 
Tyrosine 0.42 0.0237 0.00222 0.0244    0.00253 0.0295 0.003739 
Urea 0.19 0.1878 0.01646 0.1940    0.01734 0.2247 0.015689 
Valine 0.85 0.0672 0.00392 0.0695    0.00463 0.0695 0.005800 
Citrate 0.12 0.0158 0.00102 0.0166    0.00136 0.0203 0.001703 
Glucose 0.1 1.0639 0.06742 1.1821    0.08797 1.2798 0.134884 
β-Alanine 0.44 0.0012 0.00065 0.0010    0.00022 0.0013 0.000386 
τ-Methylhistidine 0.07 0.0027 0.00086 0.0009    0.00020 0.0024 0.000827 
 
Table 4.3.3 Summary statistical for absolute concentration (mM) of low molecular weight 
(hydrophilic) metabolites in serum.   Mean values and standard error were calculated using 
Microsoft Excel. Data was plotted using Prism (see scatter plots in supplementary materials). 
Kruskal-Wallis test was applied for determining level of significance at 5% followed by Dunn’s 
multiple comparison test to compare across groups: (S) vs (M) vs (H).
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4.3.4 Diffusion edited NMR using saline diluted serum 
 
- dataset 4C 
 
A separate dataset was collected using saline-diluted serum to explore spectral 
contributions from lipoproteins and other macromolecules as opposed to small molecular 
metabolites. Diffusion edited NMR spectra were analysed by summing the intensities 
within each variable width bucket. As far as possible each bucket was assigned by 
comparing spectral features with reference spectra in the literature. At the time of writing, 
no previous data using 1H-NMR has looked at the contribution of lipoproteins in this 
disease.  Blood serum contains various proteins and lipoproteins which contribute strongly 
to 1H-NMR spectra with smaller metabolites such as amino acids superimposed as sharp 
peaks. The larger molecules generate much broader resonances figure 4.3.14 compared 
with the earlier NMR generated spectrum (figure 4.3.1). This is characteristic of larger 
macromolecules such as lipoproteins due to their faster relaxation properties of protons 
associated with aromatic and aliphatic chemical groups. By alternating the NMR pulse 
sequence during the acquisition of the samples this generates a diffusion edited NMR 
spectrum (figure 4.3.15). This approach utilises an echo phenomenon to recover certain 
signals after a delay in diffusion - as such, macromolecules behave as ‘sluggish’ movers.   
 
The data provides a spectral overview of CH groups of lipids within lipoprotein particles, 
table 4.3.4. This was then analysed by summing the intensities within each variable width 
bucket, shown as black bars along the chemical shift axis in figure 4.3.15.  Each bucket is 
labelled with a chemical shift at the centre of each bucket (ppm). The integrated intensities 
from each sample are presented in dot plots comparing Severe (S), Mild/moderate (M) and 
House-Matched (HM) – see supplementary figure (S 4.3) in appendix.  These intensities 
were normalised by setting the sum of intensities in each spectrum to 1 to allow for 
concentration difference. Table 4.3.4 presents the identities of the chemical shifts relating 
to each variable width bucket. These have been assigned using the resonances  observed 
from high resolution 750 MHz 1H-NMR using normal human blood plasma (Foxall et al., 
1995).
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Figure 4.3.14 600 MHz 1H diffusion edited NMR spectra of all serum samples (n=34) with patient codes and colouring: severe (S) – blue; mild (M) – green; healthy (H) – 
red.  
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Figure 4.3.15 600 MHz 1H ‘diffusion edited’ NMR spectrum of saline diluted serum (sharp lines from low mol. wt. metabolites are suppressed). The data are analysed by 
summing the intensities within each variable width bucket (black bars below the spectrum). Each bucket is labelled with the chemical shift at the centre, e.g. the arrowed 
bucket is labelled ‘2.03’ in the supplementary statistical plots. 
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Table 4.3.4  Experiment spectra peak assignment based on observed chemical shift and reference to known lipid molecules detected in normal human plasma. Using 
750MHz 1H-NMR.
Metabolite Chemical Structure Chemical shift 
(ppm) 
Assigned Observed 
Unsaturated lipid =CHCH2CH2 5.31690001 5.31 1D, COSY, HMQC 
Glyceryl of lipids  CHOCOR 5.1967001 5.2 COSY 
Glyceryl of lipids  CH2COR 4.26854992 4.25 HMQC 
myo-inositol  CH2 4.08055019 4.06 JRES 
Unknown 
 
3.98484993 3.98 JRES 
Unknown 
 
3.93875003 3.93 JRES 
Glycerol C2H 3.88940001 3.87 JRES, COSY 
Unknown 
 
3.81389999 3.83 JRES, COSY, HMQC 
Choline (lipid)  NCH2 3.67209995 3.66 JRES, COSY, HMQC 
Glycerol 
 
3.56110001 3.56 1D, COSY, HMQC 
Choline  N(CH3) 3.22959995 3.21 JRES, HMQC 
Albumin lysyl  e-CH2 3.000000 3.01 1D, JRES, COSY, HMQC 
Lipid  C=CCH2C=C 2.74849999 2.72 1D, COSY, 
Lipid  CH2CO 2.23970008 2.23 COSY 
Unknown 
 
2.07934999 2.08 1D, JRES, COSY  
Glycoprotein (acetyls)  NHCOCH3 2.03464997 2.04 1D, COSY, HMQC 
Lipid  CH2C=C 1.98540002 2 COSY 
Lipid  CH2CH2C=C 1.71249998 1.69 COSY, HMQC 
Lipid  CH2CH2CH2CO 1.3513 1.32 JRES, COSY, HMQC 
Lipid (mainly VLDL)  CH2CH2CH2CO 1.29580003 1.29 1D, CPMG, JRES, COSY 
Lipid  CH3CH2CH2 1.23405004 1.22 HMQC 
Cholesterol C21 C21 0.89815 0.91 HMQC 
Lipid (mainly VLDL)  CH3(CH2)n 0.8364 0.84 1D, JRES, COSY, HMQC 
Cholesterol C18 C18 0.70524999 0.7 HMQC 
Lipid (mainly VLDL)  CH2CH2CO 1.57999998 1.57 JRES, COSY, HMQC 
Unknown 
 
1.509 
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The only significant difference discovered was across two groups (p=0.009, S>H) for a signal 
at 2.03ppm. This signal was identified as N-Acetyl groups from a1-acid glycoprotein (figure 
4.3.16). The next closest significant signals were detected at 2.24ppm, 1.23ppm and 
1.58ppm. The signal at 1.58ppm (figure 4.3.17) appears to follow a trend (S>M>H) and 
appears to correspond to citrulline based on the observed resonances recorded in 
Nicholson & Foxall, (1995). However, in this particular experiment small molecules such as 
citrulline are known to be excluded. The earlier set of samples processed using 
methanol/chloroform extraction would have detected low molecular weight metabolites 
such as this, but unfortunately did not detect citrulline either.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.16  N-acetyl group from glycoproteins The points in the statistical plot shows the 
integrated intensities of the bucket labelled with a chemical shift of 2.03ppm. These intensities have 
been normalised i.e. the sum of intensities in each spectrum has been set to 1 to allow for 
concentration differences. (p=0.009). 
 
 
 
 
 
 
 
 
 
 
 
 
* p = 0.009 
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Figure 4.3.17 Integrated signal intensities within bucket width at 1.58ppm. No significant 
p value. There appears to be a trend (S>M>H). 
 
Citrulline was detected in2D NMR experiments used for signal identification but it was too 
low in concentration and lacked clear-cut signals that could be used for quantification by 
NMR. Armstrong et al., claim to have quantified it using the same method as they had 
access to a 900 MHz NMR, the 600 MHz machine. Citrulline has previously been suggested 
as a surrogate marker for increased intestinal permeability as well as intestinal insufficiency 
relating to short bowel syndrome in patients (Curis et al., 2007; Fragkos & Forbes, 2018). In 
a 2018 review, the authors conclude citrulline is ‘quite reasonably’ a marker of intestinal 
function and absorption (Fragkos & Forbes, 2018). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 216 
 
4.3.5 Targeted bile acid mass spectrometry 
 
- dataset 4B 
As an extension to the 45 metabolites identified using 1H-NMR in severe ME faecal water; 
additional aliquots for available samples were used for a targeted analysis of 26 bile acids 
(Table 4.3.5) using Liquid-Chromatography – Mass Spectrometry (LCMS) in multiple 
reaction mode (MRM). A total of 14 samples were analysed including 8 severe ME (S) 
patients versus 6 House-Matched (H) controls. The range of concentrations observed 
across the 26 bile acids varied dramatically and for the purposes of summarising this data 
across the two groups (S v H), log transformation of absolution bile acid concentrations 
enabled visualisation on a box plot (figure each bile acid, 4.3.18). Individual metabolites 
were compared between severe (S) and house-matched (H) using the Mann-Whitney test, 
except where multiple samples gave zero concentrations, using GraphPad Prism. Beta-
muricholic acid (b-MCA), a primary bile acid that is one of the main forms of major bile 
acids found in germ-free mice, was significantly higher in severe patients, p value = 0.0416) 
(Eyssen et al., 1976). The literature is clear that the presence of this bile acid is not expect 
in humans but been reported to be detected in low concentrations in urine (Goto et al., 
1992). Tauro-conjugated forms of alpha- and beta- muricholic acids were also detected in 
(S) and (H) faecal metabolomes. Table 4.3.5 provides statistical summary of mean bile acid 
concentrations (ng/ml) and standard errors and respective p value.  
 
The bile acid, temporarily designated as ‘glycocholate’ based on earlier collected NMR 
spectra which showed a weak separation between severe (S) and house-matched (H), did 
not produce any significant result, with a recorded p value of 0.4162. For some bile acids, 
one or two severe ME (S) samples were observed to have unusually higher concentration 
values outside the rest of the group (see Figure 4.3.19).  
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Figure 4.3.18 26 Bile Acid targeted Mass Spectrometry analysis of faecal water from 8 
severe (S) and 6 House-matched controls (H) Box plot used to compare range of log of 
concentrations (mM) detected within (S) and (H) groups. Line inside each box represent the 
median. Error bars indicate the extreme Max and Min values.  
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Figure 4.3.19 Summary scatter plot for 8 out of the total 26 Bile Acids (BA) targeted faecal water in 
8 severe ME patients versus 6 House-Matched controls. Horizontal lines indicate the max, median, 
and min. Patient numbers 12 and 15 were consistency revealed as outliers across at least 3 BAs. 
Data was analysed by Mann-Whitney test at the 5% significance level. Plots are labelled with the 
abbreviated name of each BA listed in Table 4.3.5. 
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Figure 4.3.20 Faecal metabolome concentration of HDCA (ng/ml) in severe (S) ME versus House-
Matched controls. No significant different report by Mann-Whitney test (p=0.15). 
 
Hyodeoxycholic acid (HDCA) showed a cluster of patients with almost double the 
concentration detected within the House-matched (H) group. The scatter plot in figure 
4.3.20 has been annotated with a red box to highlight these patients. It has been 
documented that HDCA is formed from muricholic acid and hyocholic acid by an unknow 
Gram-positive rod shaped bacterium originating from the gut of rodents (Eyssen et al., 
1999). It is therefore considered to be a secondary bile acid formed in humans as a 
metabolic by-product of intestinal bacteria. It is not normally present in the urine of 
healthy humans (Almé et al., 1977); but most interesting has also been cited as being 
absorbed well across the gut barrier based on its excretion in urine (Sacquet et al., 1983) in 
patients with cholestatic disease and others with purported intestinal malabsorption (Almé 
et al., 1977; Summerfield et al., 1976) . Interestingly, HDCA has been shown to be effective 
in treating rodents for metabolic disorders and a diet enriched in HDCA was protective of 
atherosclerotic plaque formation in LDL receptor knockout mice by reducing intestinal 
absorption of cholesterol (Shih et al., 2013).  
 
ng
/m
l 
 
  
 220 
Bile Acid Abreviation Type   Faeces Un-paired t test            
            Severe (S) 
 
     House-Matched (H)      
P value Mean St. Err. Mean St. Err. 
 
alpha-muricholic acid a-MCA Primary (mouse) 
 
0.0631 21.90 9.20 7.0 3.60 
 
beta-muricholic acid b-MCA Primary (mouse) 
 
0.0416* 43.75 20.37 5.6 3.30 
 
Cholic acid CA Primary (mouse) 
 
0.3948 661.90 20.00 59.4 36.50 
 
Chenodeoxycholic acid CDCA Primary (mouse) 
 
0.3397 355.40 16.60 19.7 9.10 
 
Deoxycholic acid DCA Secondary 
 
0.8786 639.80 373.20 1076 615.10 
 
Glycocholic acid GCA Glyco-conjugated 
 
0.4162 165.10 3.10 24.6 12.50 
 
Glycochenodeoxycholic acid GCDCA Glyco-conjugated 
 
… 3.00 1.40 3.30 1.60 
 
Glycodeoxycholic acid GDCA Glyco-conjugated 
 
0.2583 17.20 3.60 4.60 2.50 
 
Glycocholic acid GHCA Glyco-conjugated 
 
… 0.00 0.00 4.20 2.50 
 
Glycohyodeoxycholic acid GHDCA Glyco-conjugated 
 
… 5.70 0.00 1.10 0.70 
 
glycolithocholic acid GLCA Glyco-conjugated 
 
… 0.00 0.00 0.00 0.00 
 
Glycoursodeoxycholic acid GUDCA Glyco-conjugated 
 
… 11.70 0.50 0.00 0.00 
 
Hyodeoxycholic acid HDCA Secondary 
 
0.1511 1128.50 598.90 757.7 422.3 
 
Lithocholic acid LCA Secondary 
 
0.7645 621.50 287.70 681.9 409.7 
 
Muricholic acid MCA Primary (mouse) 
 
… 53.60 12.00 0.00 0.00 
 
Tauro-a-muricholic acid Ta-MCA Tauro-conjugated 
 
0.3989 27.10 18.90 78.6 47.70 
 
Tauro-b-mucricholic acid Tb-MCA Tauro-conjugated 
 
0.983 169.70 130.90 128.1 69.20 
 
Taurocholic Acid TCA Tauro-conjugated 
 
0.9303 127.50 91.60 97.3 50.30 
 
Taurochenodeoxycholic acid TCDCA Tauro-conjugated 
 
… 5.60 3.50 29.9 18.00 
 
Taurodeoxycholic acid TDCA Tauro-conjugated 
 
… 7.20 2.20 165.9 99.6 
 
taurodehydrocholic acid TDHCA Tauro-conjugated 
 
… 0.00 0.00 0.00 0.00 
 
trihydroxycoprostanic acid THCA Secondary 
 
… 0.00 0.00 0.83 0.50 
 
Taurohyodeoxycholic acid THDCA Tauro-conjugated 
 
… 0.00 0.00 3.80 2.10 
 
Taurolithocholic acid  TLCA Tauro-conjugated 
 
… 0.00 0.00 7.20 4.30 
 
Tauroursodeoxycholic acid TUDCA Tauro-conjugated 
 
… 8.25 5.70 5.70 2.60 
 
Ursodeoxycholic acid UDCA Secondary 
 
0.2567 179.10 116.00 49.20 30.1 
 
 
Table 4.3.5 Statistical summary table for 26 bile acids (BA) quantified in faecal water samples from severe (S) ME patients versus house-matched (H) controls. Mean 
concentrations are provided in ng/ml with standard error in measurements. Both groups were compared for statistical significance at the 5% level using the Mann-Whitney 
test, p values are displayed in table 
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Table 4.3.6 Statistical summary of serum bile acid concentrations (nM) in Severe (S), Mild/moderate (M), Healthy, and IBD. Included 26 targeted bile acids quantified 
using mass spectrometry. Significant p values are in bold. Colour shading for ease of separation of values corresponding to 12 severe ME (red), 14 mild/moderate ME 
(yellow), 7 healthy (green) and 6 IBD (blue) samples. Mean concentrations and standard error per metabolite, per group. P values calculated using Kruskal Wallis test at 5% 
significance: *denotes p < 0.05, ** denotes p < 0.01.
Bile Acid Abbreviation Type P value Severe (S)  Mild (M)  Healthy  IBD  
   KW Mean St. Err Mean St. Err Mean St. Err Mean St.Err 
alpha-muricholic acid a-MCA Primary (mouse) 0.55 30.12 2.77 25.21 1.91 27.5 1.98 33.00 6.01 
beta-muricholic acid b-MCA Primary (mouse) 0.16 11.12 9.21 0.00 0.00 11.25 4.81 9.67 9.67 
Cholic acid CA Primary (mouse) 0.01* 78.29 14.79 102.21 29.43 155.91 58.29 240.33 54.77 
Chenodeoxycholic acid CDCA Primary (mouse) 0.003** 57.21 12.11 109.5 37.65 137.00 49.06 233.00 65.45 
Deoxycholic acid DCA Secondary 0.33 267.07 106.47 189.5 55.78 230.25 54.37 130.67 24.05 
Glycocholic acid GCA Glyco-conjugated 0.47 143.64 23.58 185.57 49.04 188.75 33.51 172.83 27.00 
Glycochenodeoxycholic acid GCDCA Glyco-conjugated 0.59 354.86 67.04 553.86 107.18 453.33 85.75 439.17 105.08 
Glycodeoxycholic acid GDCA Glyco-conjugated 0.19 270.00 60.85 225.64 44.62 267.33 68.02 87.83 21.28 
Glycocholic acid GHCA Glyco-conjugated 0.02* 0.64 0.64 6.92 2.49 1.00 1.00 0.00 0.00 
Glycohyodeoxycholic acid GHDCA Glyco-conjugated 0.27 14.29 0.54 11.36 1.34 13.42 1.48 9.67 3.15 
glycolithocholic acid GLCA Glyco-conjugated 0.16 16.07 2.04 16.42 1.94 21.67 4.72 10.83 1.28 
Glycoursodeoxycholic acid GUDCA Glyco-conjugated 0.15 15.21 1.33 13.71 0.79 16.00 1.00 16.67 0.92 
Hyodeoxycholic acid HDCA Secondary n/a 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Lithocholic acid LCA Secondary 0.10 59.57 47.91 1.71 1.71 32.42 24.22 0.00 0.00 
Muricholic acid MCA Primary (mouse) 0.84 75.5 16.87 136.29 38.63 105.41 28.43 88.67 32.71 
Tauro- -muricholic acid T -MCA Tauro-conjugated 0.21 17.86 8.69 2.07 1.42 5.50 3.00 20.83 9.51 
Tauro- -mucricholic acid T -MCA Tauro-conjugated 0.06 319.93 126.3 124.93 18.66 220.08 48.64 122.83 28.32 
Taurocholic Acid TCA Tauro-conjugated 0.11 123.21 24.16 77.14 10.36 149.5 32.2 147.83 56.52 
Taurochenodeoxycholic acid TCDCA Tauro-conjugated 0.93 90.71 24.22 81.5 18.8 98.25 25.88 79.17 24.36 
Taurodeoxycholic acid TDCA Tauro-conjugated 0.13 85.43 17.71 50.57 8.32 73.67 21.79 30.50 6.17 
taurodehydrocholic acid TDHCA Tauro-conjugated 0.30 0.00 0.00 2.07 2.07 0.00 0.00 6.50 6.50 
trihydroxycoprostanic acid THCA Secondary n/a 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Taurohyodeoxycholic acid THDCA Tauro-conjugated 0.13 15.07 0.66 12.57 12.3 13.58 0.50 15.17 1.08 
Taurolithocholic acid TLCA Tauro-conjugated 0.17 16.00 0.94 13.79 1.41 17.00 1.79 12.33 1.02 
Tauroursodeoxycholic acid TUDCA Tauro-conjugated 0.60 21.21 2.89 15.00 2.13 16.83 1.98 15.67 3.61 
Ursodeoxycholic acid UDCA Secondary 0.36 17.57 4.35 39.93 11.77 30.67 6.95 36.50 10.89 
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4.3.6 Bile Acid analysis of ME serum 
 
- dataset 4D 
 
Targeted HPLC mass-spectrometry of the same 26 bile acids was accurately quantified in a 
total of 46 serum samples collected between 2015-2017. This represents the largest and 
final dataset (designated 4D, Table 4.3.2) acquired during the study. Twenty-six ME/CFS 
patients where included in the experiment were categorised as follows: 12 severe (S), 14 
mild/moderate (M). In addition, 7 House-Matched (H) and 6 IBD serum samples were also 
included. Sera collected the previous year (2016) was available at the time, for 2 of the 
severe patients (n=12+2, severe) and their respective House-Matched control (n=7+2). A 
further 3 conventionally healthy samples were provided as a gift along with the 6 IBS serum 
samples kindly given by Dr Alistair Noble (Imperial College London, UK), bringing the total 
sample size to 46. 
 
The synthesis of primary bile acids takes place within the liver where major bile salts are 
produced when conjugated with taurine and glycine, forming tauro-chenodeoycholate 
(TCDCA) and glycochenodeoxycholate (GCDCA) respectively (Germain et al., 2017). Both of 
these have been reported significantly reduced in ME/CFS patients. In contrast, within 
severe (S) and Mild/moderate (M) patients there was no statistically relevant difference for 
either. However, upon review of the scatter plot for GCDCA (fig. 4.3.21), it does appear as if 
severe patients have a lesser concentration compared with the other groups which would 
be in agreement with these previous reports. Although it is worth noting that this trend 
was not identified in the faecal water metabolome of the same participants (figure 4.3.19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.21 Concentration (ng/ml) of glycochenodeoxycholic acid (GCDCA) across 4 groups. KW 
test revealed no significant differences at 5% significance.  
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Figure 4.3.22 Mass Spectrometry targeting on 26 bile acids in serum. Four groups compared: 14 
severe (S), 14 Mild/moderate (M), 14 House-Matched (H) and 6 IBD serum. Statistical analysis was 
performed in GraphPad Prism using one-way ANOVA with Dunnett’s Multiple comparison to House-
Matched (H). No significance was observed. 
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Figure. 4.3.23 Scatter plots summarising concentrations found of tauro-deoxycholic acid 
(TDCA) found across the 4 groups labelled. Kruskal-Wallis with Dunn’s multiple comparison 
test reveal the following values (left plot) p= 0.132, (right plot) p=0.047.  
 
Another interesting trend emerged from a primary bile acid produced in the liver called 
taurodeoxycholic acid TDCA. The initial Kruskal-Wallis (KW) test performed for this bile acid 
did not show significant differences in accumulation between different groups. Review of 
the scatter plot highlighted 3 healthy outliers. These samples were subsequently removed 
from the plot (figure 4.3.23), given the limited criteria for the condition of healthy was 
based on participants ‘apparently healthy’. After which, the KW test re-applied to show 
higher, significant difference between groups, at a p value of 0.047. Alas, Dunn’s multiple 
comparison was unsuccessful is demonstrating which pair of groups were significantly 
different, but the trend appears to be S>M>H. Tauro-congutated bile acids are more 
typically found in mice, compared to human bile acids which more frequently conjugate 
with glycine.  
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In an attempt to summarise this work, as with previous datasets 4A-C, a box plot was 
constructed comprising serum bile acid concentrations (ng/ml) across severe (S), 
mild/moderate (M), house-matched (H) and IBD groups. Statistical summary of the data is 
provided by Table 4.3.6 with mean BA concentrations and standard errors, including p 
values determined by individual KW tests.  As with the faecal metabolome, several 
muricholic derived bile acids were detectable and quantified in serum, with possibly the 
highest concentrations detected in a few of the severe (S), see table 4.3.6. However, in a 
recent metabolomic study profiling bile acids in human plasma from patients with 
Alzheimer’s disease (AD) various muricholic acid forms were below the limit of detection 
(Pan et al., 2017). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.24 Selected scatter plots for absolute bile acid concentration across 4 bile acids in 
serum. Consistently the same patients are the represented as outliers within their respective group 
(S), (M), (H) for these particular bile acids. No clinical information was provided for IBD serum 
samples used in this analysis. KW test revealed GHCA group differences generative p value of 0.02, 
but failed Dunn’s multiple comparison. CDCA **p=0.003 CA *p= 0.01 
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Chenodeoxycholic acid (CDCA) and cholic acid (CA) are considered primary bile acids that 
undergo synthesis in both the livers of humans and mice before conversion by intestinal  
microbes to lithocholic acid (LCA) and deoxycholic (DCA) respectively (Hu et al., 2014). 
CDCA is usually abundant in human bile, but is not compared with mice where is it 
converted to muricholic acids (Zhang & Klaassen, 2010). Higher serum concentration of 
CDCA and other bile acids such as GCA, GCDCA, TCDCA are noted with respect to liver 
injury and disease (Luo et al., 2018). No evidence, as such, is presented within these data to 
suggest severe (S) ME or mild/moderate (M) patients display signs of liver injury or disease.  
On the contrary, the CDCA scatter plot presented in figure 4.3.24 was highly significantly 
different (p=0.003) based on KW test and Dunn’s multiple comparison, for the following 
trends, S<IBD, M<IBD. CDCA is normally abundant in human bile compared with mice 
where is converted to muricholic acid. Indeed, the earlier observation of higher faecal 
HDCA is also intriguing as it can be formed from MCAs. 
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4.4 Discussion 
 
Metabolomics was used to profile metabolites derived from serum and the faecal 
microbiota of ME/CFS patients compared to HHCs. The composition of the intestinal 
microbiota was explored in the previous chapter in ME/CFS using metagenomics 
increasingly interprets the functional gene diversity, rather than its taxonomic profile, 
needed to carry out important functions including vitamin, short chain fatty acid 
production, amino acid synthesis, secondary bile acid metabolism and fermentation of non-
dietary carbohydrates (Vernocchi et al., 2016). Metabolomics is able to compliment 
functional metagenomic interpretations, by providing a metabolic profile as an 
intermediate between microbiota-host interactions.  Until now recent metabolome studies 
to date, have suggested some consistencies for alterations with the ME/CFS faecal and 
blood metabolome. These findings have been substantiated by independent research 
groups and by the application of different metabolomics methods using 1H-NMR and Mass 
Spectrometry (MS). Based on this, it was expected that the severe ME patient cohort 
examined here would exhibit similar metabolic disturbances relating to their energy and 
lipid metabolism. Furthermore, given their severity of clinical status it was hypothesised 
that the scale of such metabolic difference may be accentuated in severe ME compared 
with the general mild/moderate ME patient population. The data presented in this chapter 
based on serum did not support this hypothesis. Indeed, the lack of any particular finding in 
either faecal and serum metabolome was surprising and appear to reject our hypothesis.   
 
Faecal water collected from 11 severe ME patients and 6 house-matched controls were the 
first samples to be examined. These samples were collected in 2017 following changes 
made to sample collection where the patient was asked to provide samples from their own 
stool specimen which, did not allow for control of location of the sample from the entire 
stool. In an attempt to address the issues around the lack of standardisation frequently the 
case in microbiome-based studies, it was decided to collect the entire stool sample from 
each participant. Gratton et al. (2016) show that faecal homogenisation is an important 
step in overcoming sample variability according to where you sample even within same 
stool specimen (Gratton et al., 2016b). Transport time was also an additional factor when 
attempting to conduct patient home visits. There was considerable journey time for some 
sample collections depending on where they lived with respect to the site of sampling 
processing.  
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There may be a consensus regarding reduced butyrate production in the faecal 
metabolome in ME/CFS patients, although this was not seen in this study. No assumptions 
were made about the distribution of metabolite concentrations prior to statistical testing. 
To that end, a conservative approach was made in the decision to use non-parametric 
testing to compare differences across different groups. In contrast to parametric testing, 
this approach is more stringent, with less assumption but also does not account for the fact 
that each house-matched control is paired with a severe ME patient. However, this does 
not negate that upon review of the data in figures 4.3.3. there is great overlap in individual 
metabolite concentrations between the groups. Earlier work by Armstrong et al., (2017) 
using 900MHz 1H-NMR, provided the most relevant incite in to the ME systemic 
metabolome since it also used ME/CFS serum, but only had the capacity to detect 29 
metabolites. With the emphasis on the severity of ME with our patient cohort, the lack of 
any result is puzzling given that in the analysis of serum 53 metabolites there were 
detected and quantified in severe ME, again, no significant conclusions can be justified. 
 
The lack of reproducibility continues to be a challenge for ME research, however this is 
layered with further challenges when considering potential methodological differences 
may be contributing dramatically to the outcome of the result. As discussed, sample 
collection and processing must also be controlled. Review of table 4.1.1 highlights serum 
versus plasma as the most obvious factor in accounting for variability with respect to small 
metabolites that appear to be more stable in plasma than in serum based on the lack of 
any consistent findings that have previously reported. Both serum and plasma analyses 
have been performed in ME patients using mass spectrometry but only those done using 
plasma highlight significant overlap in observed differences in metabolic pathways. 
Unfortunately, it was not possible to include plasma in this work since serum collection was 
originally prioritised for the purposes of identifying the presence of (auto)-antibodies 
towards gut microbes in future work. Serum is the preferred standard for antibody-based 
discovery. Moreover, serum collected from house-bound patients experienced variable 
delays (1-4 hrs) in transport to the laboratory for processing and storage at -80oC. It is 
unknown if this causes further enhanced loss of some metabolites or if plasma would be 
more resilient. For future sample collection is would be highly preferably to include mobile 
refrigeration during transportation to maintain constant temperature of all samples.  
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Other methodological difference include NMR platform technology and equipment used. 
Armstrong et al. produced their data on a 900 MHz 1H-NMR machine – which is 1.5 times 
stronger than the 600 MHz machine used in this chapter. Briefly, when a sample is placed 
in a strong magnetic field the nuclear spins allocate themselves to two energy levels: low 
(‘spin up’) and high (‘spin down’). The energy level difference is small compared with 
thermal energy so the difference in number of nuclei in the lower and upper energy levels 
is very low e.g. 1 in a million. It is only this difference that we can detect. The difference in 
energy levels is greater and more detectable using 900 MHz machine versus 600 MHz. 
Moreover, signals are 1.5x more spread out at 900MHz, across 0-10 ppm, the full range of 
signals for hydrogen. For these reasons, a signal of interest that is overlapped with an 
interfering signal at 600 MHz may be better resolved at 900 MHz. 
 
Contrary to Armstrong et al. (2017), no evidence has been found for increased 
fermentation within this severe patient cohort. Particularly no difference was found for 
faecal butyrate or any other SCFAs. Often the faecal specimen provided by the patient was 
significantly less than that from house-matched control and appear very hard and 
dehydrated. Taking into account the disabling nature which confines these patients to the 
house and bed, often patients eat very little and do not drink enough. This most likely 
decreases gut transit and is a process that is known to increase the pH in the gut 
environment (Thursby & Juge, 2017). Studies have documented the effect of higher pH to 
show increased SCFA production and a decrease in lactate concentration, another 
metabolite in which no significant difference was observed (Belenguer et al., 2007). 
 
One interesting metabolite detected was gbutyrobetaine. This could be measured at a low 
level in most samples (patients and controls) but was notably higher in 3 of the patients. It 
is a gut microbial metabolite of L-carnitine (Koeth et al., 2014) and an intermediate in the 
conversion of carnitine to trimethylamine and TMAO. L-carnitine is found in meat, fish and 
eggs, however could also suggest these patients are taking a supplement with carnitine. 
Another possible explanation could be these patients lack bacteria that effect the 
conversion to TMA or TMAO. Increased Lactonifactor spp. belonging to the family 
Lachnospiraceae spp. and Ruminococcus spp. can produce TMAO, whilst Bacteroides spp. 
has been found to be less abundant in its presence (Wang et al., 2015).   Another 
metabolite that was only found in two patients was taurine. Taurine may be relevant since 
it is known to conjugate to primary bile acids in the liver whose function is important in 
lipid metabolism and consequently energy homeostasis. Like, L-carnitine, taurine is also 
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found in many health and energy supplements which we were unable to obtain any 
information regarding their consumption by ME or control subjects included in this study. 
 
The liver is the site for bile acid synthesis from cholesterol. Tauro-chenodeoxycholate 
(TCDCA) and glyco-chenodeoxycholate (GCDCA) have already been reported to be reduced 
in ME/CFS, which may suggest potential liver damage, although more the status of more 
conventional markers for this are unknown in ME/CFS (Germain et al., 2017). Bile acids are 
an important aspect to lipid metabolism since they facilitate the digestion and absorption  
of lipids within the small intestine. Interestingly, high fat diets may lead to partial intestinal 
permeability dysfunction; thus, bile acid metabolism was explored in these severe ME  
patients in the context of a role for a leaky gut in ME/CFS as providing a potential 
mechanistic role in these circumstances. Moreover, an unidentifiable suspected ‘bile acid’, 
to which the closest reference match was glycocholate, appeared significantly higher in 
severe patients (fig. 4.3.2) based on NMR resonances observed from their faecal water. Out 
of the 45 metabolites, this unknown bile acid was the only significantly different metabolite 
(KW, p=0.03).  
 
Global metabolite profiling uses an untargeted approach in the field of biomarker discovery, 
however different platforms can be limited to the size and chemical properties of 
metabolites they detect.  Increasing the number of metabolites identified requires 
authenticated standards included in the analysis to compare mass spectra and retention 
time with sample metabolites (Roessner, 2001). The choice of sample extraction solvent can 
allow for separation of polar and apolar metabolites. With our NMR work, 
chloroform/methanol was used for biphasic solvent extraction, thus our focus was on small 
soluble metabolites in serum and faeces. The sensitivity and resolution of NMR is considered 
inferior the MS-based methods, therefore better coverage of the metabolome uses both of 
these in combination. Together 1H-NMR and MS are the most powerful metabolomic 
techniques that define the number of metabolites in clinical samples (Collino et al., 2013). 
Other published ME/CFS studies have been able to detect a wide variety of metabolites with 
a range of physical chemical properties. Germain and colleagues used plasma to quantify 361 
metabolites using Q-Exactive MS (QE-MS) and found ADP, ATP, pyrimidines and many amino 
acids were significantly decreased in ME (Germain et al., 2017). Indeed, it would be 
interesting to undertake similar sophisticated workflows and MS, as previously described, to 
examine these pathways in severe ME patients. However the majority of the “signature” 
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metabolites identified from the analysis of much larger numbers of metabolites (Armstrong 
et al., 2017; Germain et al., 2017; Naviaux et al., 2016) whose abundance was altered in mild 
and moderately affected ME/CFS patients; whilst of those metabolites overlapping with our 
study were found unaltered in severe ME/CFS patients. 
 
The previous chapter discovered that severe ME patients tended to have less F.prausnitzii 
compared to HHCs.(fig. 3.3.11B). A reduction in this species has been well-established with 
IBD and considered an important contributor to intestinal health (representing 5% of the 
total  microbiota) providing energy to colonocytes through butyrate production and 
simulating anti-inflammatory signalling pathways (Arumugam et al., 2011; Cao et al., 2014; 
Miquel et al., 2013; Qiu et al., 2013). Our expectation was to find a reduction in faecal 
butyrate. However, Armstrong and colleagues suggested ME/CFS patients to display 
increased microbial fermentation correlated with Clostridium spp. and Bacteriodes spp. 
producing higher levels of SCFAs, valerate, isovalerate and butyrate (Armstrong et al., 
2017). None of these were found any different between our severe patients and HHCs, 
(figure 4.3.3) or from our sequencing data. Microbial volatile organic acids may be better 
targeted using GS/MS compared to NMR as the current agreement between metabolic 
studies in ME/CFS have been focused on using MS techniques (Germain et al., 2017; 
Naviaux et al., 2016). 
 
Targeted bile acid mass spectrometry did not reveal any significant changes in bile acid 
composition between patients and controls and was not helped by the relatively low 
sample group sizes. This was in exception to serum CDCA found significantly lower in 
severe ME patient serum and is known to be reduced in fasting states (J. Zhang et al., 
2017). Surprisingly, the alpha and beta forms, as well as tauro-conjugated murichoIic acids 
were detectable across all samples in faecal water and serum even though it has been 
suggested that the human gut microbiota is unable to metabolize CDCA into βMCA (Martin 
et al., 2007, 2008; Sacquet et al., 1984, 1985). Conversely, mice can hydroxylate 
chenodeoxycholic acid (CDCA) in the liver at the 6β-position to form α-muricholic acid 
(MCA) and ursodeoxycholic acid (UDCA) to form βMCA. Cyp2c70 is the principal enzyme 
involved in MCA production and is responsible for the differences in bile acid metabolite 
profile between humans and mice with further heterogeneity introduced in secondary bile 
acid metabolism by intestinal microbiota where taurine/glycine conjugated primary bile 
acids undergo deconjugation by intestinal bacteria using bile salt hydrolases (BSHs).  Tauro-
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alpha/beta-muricholic acids (T- α/βMCAs) were also detected in patients and controls, 
despite also normally being considered as species-specific primary bile acids in mice that 
are lacking in humans. Notably, tauro-beta-muricholic acid has been studied as a farnesoid 
X receptor (FXR) antagonist in mice models for metabolic disorders including obesity and 
insulin resistance, where reduction of bacteria with BSH activity protected against obesity 
and improved insulin sensitivity (Prawitt et al., 2011). Further work is needed to explore 
the BA profile in ME/CFS due to it roles in participating in different signalling pathways 
involved in lipid, glucose, and energy metabolism. 
 
Targeted analysis conducted in this way does have a drawback in that other less abundant, 
minority isoforms may go unnoticed in humans, such as muricholic acids. For instance, 
(García-cañaveras et al.,, 2012) were able to detect for the first time T-αMCA in healthy 
human serum using UPLC MRM MS, where in mice MCAs form >80% of the total primary 
acid pool (García-cañaveras et al., 2012). Analysis of faecal bile acid composition  
also revealed high levels of a mouse secondary bile acid, hyodeoxycholic acid (HDCA) 
shown in figure 4.3.20, in some severe ME patients. Although this result is not statistically 
significant, it appears convincingly higher in concentration for five severe patients (red 
box), at over twice the median concentration compared to the control group. In fact the 
conventional mouse gut microbiome is able to convert T-βMCA through bile salt hydrolase 
(BSH) and bile acid 7α-dehydroxlase forming β-MCA and hyodeoxycholic acid (HDCA; 
3α,6α-Dihydroxy-5β-cholan-24-oic acid) respectively (Ridlon et al., 2014) . The higher levels 
of HDCA in severe patients is unusual and obscure when reviewing the current published 
literature which purport hydroxyl groups in human primary bile acids to mainly occupy the 
3, 7, 12-position, whilst only mice can also add hydroxyl groups at the 6-postion forming 
HDCA and α/β/y-MCAs (Sacquet et al., 1983).  Indeed, the only difference between 
deoxycholic acid (DCA) and HDCA is the position of the hydroxyl group, which is at the 12-
postion in DCA.  To that end, HDCA is considered to be a major murine secondary bile acid, 
absent in humans, that is microbially generated from the primary bile acids αMCA and 
βMCA (Studer et al., 2016).  
 
The microbiome is a source of various bile salt hydroxylases (BSHs) that can perform 
deconjugation of glycine and taurine to liberate free primary bile acids and 7α-
dehydroxylating bacteria facilitating bile acid conversion. Member of Lactobacillus spp. and 
Bacteroides spp. are known to produce BSH, none of which we found correlations in our 
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earlier discussed sequencing of the ME/CFS metagenome (De Smet et al., 1995; Stellwag & 
Hylemon, 1976).  An unidentified Gram-positive rod-shaped bacteria capable of 
dehydroxylation of the 7β-hydroxy group and epimerization of the 6β-hydroxy group into a 
6α-hydroxy group converting βMCA into HDCA was isolated from rat intestines (Eyssen et 
al., 1999). Therefore, this makes the higher levels on detection in some severe samples, in 
tandem with low levels of MCAs a possible interesting finding. HDCA does not appear to be 
used as a substrate for further conversion by intestinal bacteria and has been reported to 
be well absorbed in the human intestine, although serum levels were unremarkable in 
severe ME serum (Sacquet et al., 1983). 
 
Thus, mice and humans have different bile acid pools that may affect signalling through bile 
acid receptors and host physiology very differently across species further highlighting the 
microbiome’s role interaction in host species metabolism. This warrants caution when 
translating the bulk of research literature performed in mice to explain human disease 
states.  For instance, germ-free mice have revealed that a lack of a gut microbiota not only 
changes the bile acid pool within the entero-hepatic circulation and serum but also reduces 
availability of SCFAs, such as butyrate used as an energy substrate by colonocytes (Bäckhed 
et al., 2007; Wichmann et al., 2013).  Consequently, these animals display hyperglycaemia 
and insulin resistance causing disruption to glucose metabolism. SCFAs are considered 
necessary for gut health, since lack of butyrate-producing bacteria has been associated 
with type 2 diabetes. Furthermore, in a recent report using mice with a disrupted 
microbiota caused by antibiotic treatment there was improved glucose homeostasis and 
insulin sensitivity compared to their GF counterparts. (Zarrinpar et al., 2018). Conflicting 
reports such as these and the known metabolic difference between mice and man highlight 
the complexities of microbial metabolic interactions with host metabolism and physiology. 
More observation led studies must be applied in human disease states, such as this work in 
severe ME to decipher how apparent changes in the gut microbiota may be altering host 
metabolism and physiology particularly with respect to host lipid and energy metabolism.  
 
Our data is most relevant for comparison with Armstrong and colleagues, based on 1H-NMR 
measurements in faecal water and serum, whereas the other studies use plasma and MS in 
in combination with different workflows. Serum versus plasma is another consideration 
that has to be made when comparing studies and the respective metabolomic profile will 
be different (Yu et al., 2011). The coagulation and separation of serum within the gel 
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collection tube can alter the metabolite profile and, as with metagenomic research, 
highlights the important for sample collection and processing standardisation (Liu et al., 
2018). Moreover, blood transport time and storage were significant cofounding factors 
given that these samples were obtained from home visits and had various delays in 
processing for long term storage (Jobard et al., 2016). The drawback is that we have been 
unable to detect and quantify a large number of metabolites that have been reported to 
alter various aspects of ME/CFS metabolism. Targeted acquisition of metabolites in these 
pathways can be sought with more sophisticated workflows using MS, as previously 
described (Germain et al., 2017). As an example, we targeted bile acids in our analyses, and 
acknowledge their biological importance to energy metabolism and glucose homeostasis 
(Shapiro et al., 2018; Wahlström et al., 2016). Blood serum levels of BAs are difficult to 
interpret given the known impact diet and the time of taking the sample. However, TDCA 
was significantly higher (p = 0.047) in severe ME (fig. 4.3.22) and may directly inhibit colon 
motility and slow intestinal transit time and gastric emptying as shown in mice (Abdu & 
Albaik, 2016). Interestingly, bile acids can inhibit LPS-induced TNFa secretion, while 
conjugated bile acids can act as signalling molecules for TGR5 pathways to modulate 
inflammation (Chang et al., 2018). Moreover, TCDA may also decreases systemic 
inflammatory cytokines  by increasing immune-regulatory cells (Chang et al., 2018). 
 
In conclusion, despite the adoption of similar sample processing and acquisition of NMR 
metabolic profile, we were unable to replicate the observations reported by Armstrong and 
colleagues. Despite the relative reduction in F. prausnitzii in severe ME patients reported in 
the previous chapter, faecal butyrate concentration was not decreased compared to house-
hold controls. Of note, the levels of muricholic acid and their derivatives cholic acid and 
chenodeoxycholic acid (CDCA), which are the most important human primary bile acids, were 
significantly lower in the serum of severe ME/CFS patients. Analysis of faecal bile acid 
composition also revealed high levels of a mouse-associated secondary bile acid, 
hyodeoxycholic acid (HDCA) in severe ME. HDCA is considered to be a major murine 
secondary bile acid, absent in humans, that so far, has only reported to be microbially 
generated within the rat intestinal microbiome from primary bile acids αMCA and βMCA 
(Eyssen et al., 1999; Studer et al., 2016). Further work exploring the significance of specific 
alterations of bile acid profile in ME/CFS may yield new mechanistic insights into how the 
alterations in primary bile acids impacts on signalling pathways involved in lipid, glucose, and 
energy metabolism that are a general feature of ME/CFS. 
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5.1 Introduction 
 
Increased intestinal permeability, or “leaky gut” is not currently recognised as a standalone 
medical disorder that can be diagnosed and treated. In health, the intestinal epithelial 
barrier acts as a physical barrier protected by a immunologically active mucus layer with 
bacteriostatic and bactericidal properties, such as anti-microbial peptides, called defensins, 
to stop invasion and translocation of harmful microbes and toxins that may elicit 
inflammatory damage from infection injury (Khounlotham et al., 2012). Increased gut 
permeability represents a major loss of this barrier function causing increased exposure of 
intestinal microbes to the intestinal immune system with the risk of translocating bacteria 
entering the systemic circulation and other sites in the body triggering widespread systemic 
immune system activation (Fasano, 2012). Finally, the intestinal microbiota represents an 
entity that can be manipulated with diet and pre-/probiotic interventions, and in extreme 
cases with faecal transplantation of the microbiota in an attempt to treat a “leaky gut” and 
ameliorate inflammatory-driven intestinal barrier tissue damage.  
 
Bacterial and viral infections are commonly reported prior to, and during the onset of 
autoimmune disease where intestinal permeability may increase the exposure of immune 
cells to intestinal microbes and environmental triggers (e.g. food, medications) which does 
not normally occur in good health (Fasano, 2012). This can then be contributing to a 
mechanism where reactivity against foreign bacterial and viral antigens leads to cross-
reactive antibodies towards self-epitopes which share a common protein sequence 
similarity during a process referred to a molecular mimicry (Oldstone, 1998). The concept 
of molecular mimicry was first described in 1983 where monoclonal antibodies to measles 
virus P protein (MV-P) were found to react with intermediate filament protein, vimentin 
(Fujinami et al., 1983). Neurological symptoms are triggered during Campylobacter jejuni 
infection in some individuals. This food-borne pathogen is a major cause of gastroenteritis 
that can trigger Guillain-Barre syndrome (GBS). During the infection antibodies are made 
reactive to lipooligosaccharide (LOS) structures on the outer surface membrane of C. jejuni. 
Structural analysis of LOS includes sialyated moieties homologous to human gangliosides 
leading to antibody cross-reactivity directed against peripheral nerves as well as 
Campylobacter (Heikema et al., 2010).  Infection appears to initiate these pathological 
events, but after pathogen clearance autoimmunity persists suggesting there are additional 
perpetuating factors which drive this phenomenon, which may be explained by long lived 
auto-antibodies and/or persistent regeneration of new autoantibodies. 
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Less than 10% of persons with a genetic risk for developing type 1 diabetes develop 
disease. Antigen presenting cells, such as macrophages and dendritic cells, are in close 
proximity to the intestinal barrier and their responsiveness is dependent on individual 
genotypes of HLA class I and II molecules for presentation of antigen to T cells. To that end, 
a genetic predisposition is not sufficient for disease development. Increased intestinal 
permeability may have a key role in a pre-autoimmune mechanism which initiates or 
progresses autoimmunity in T1D patients causing auto-destruction of insulin producing 
pancreatic b cells (Visser et al., 2009).  
 
Evidence for existence of leaky gut in patients with type 1 diabetes (T1D) and their 
relatives, is based on expression of the tight junction protein, zonulin which is frequently 
upregulated in autoimmune disease and causes disassembly of tight junctions between gut 
epithelial cells (Fasano, 2011; Sapone et al., 2006). This is further correlated with increased 
intestinal permeability measurements of sugar absorption greater in 42% out of 339 
diabetic patients in comparison to age-matched controls (Sapone et al., 2006). A separate 
independent study also found increased intestinal permeability preceding clinical onset of 
T1D by comparing the intestinal permeability to sugars in 18 preclinical subjects with 28 
new onset and 35 long-term with 40 healthy controls (Bosi et al., 2006). These findings 
underpin the concept that a leaky gut may shift the balance towards contribution of 
various environmental factors including changes in the gut microbiota, in conjunction with 
genetic factors and immune responsiveness which conspire to cause the pathogenesis of 
T1D. However, the detail of the precise order these events following increased intestinal 
permeability is not known and therefore in the various conditions associated with 
increased permeability it is not known how important altered intestinal permeability 
relates as a cause or consequence across these disease pathologies. 
 
T1D patients have also shown high titres of antibodies against glutamate decarboxylase 
(GAD), an enzyme found in pancreatic b cells, which has sequence similarity to coxsackie B 
viral protein p2-C suggesting a viral trigger for this disease. Interestingly, PBMCs isolated 
from patients with autoantibodies to islet cells proliferated in response to GAD and this 
viral peptide. However, it is unclear what are the most significant environmental triggers 
are or the sequences of such events in the development of T1D although there is some 
evidence that diabetogenic T cells are initially primed in the intestine in response to dietary 
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gluten and is therefore associated in pathogenesis (Antvorskov et al., 2014; Visser et al., 
2009).  
 
- Measuring intestinal permeability in patients 
 
The current method to assess intestinal permeability in patients is not routinely used in 
NHS clinical practice because it is invasive and requires medical supervision with delayed 
sample collection of urine to measure the rate of excretion of low to high molecular weight 
sugars, lactulose/mannitol/sucralose (Andre et al., 1988). High molecular weight molecules 
such as lactulose rely on much slower transcellular uptake across the epithelial barrier as 
opposed to paracellular transit of smaller sugar probes such as mannitol into the 
circulation. Determining the ratio between the concentrations of these two molecules in 
the patient’s urine after 5-6 hrs requires sophisticated analytical equipment such as 
HPLC/MS not found in conventional NHS hospital laboratories.  Moreover, results obtained 
generally reflect changes in small intestinal permeability as lactulose is degradable by 
bacteria in the colon (Bischoff et al, 2014). 
 
In their review Bischoff et al., 2014 described at almost 100 publications linking intestinal 
permeability to disease. In the 4 years since their review on this topic the majority of the 
methods used to assess intestinal permeability have not advanced in attempt to address 
their limitations. Another common choice of method is to examine patient serum/plasma 
for levels of bacterial endotoxin (LPS) using the lysate from horseshoe crabs, which is highly 
sensitivity to bacterial endotoxins forming a gel clot. This is known as the Limulus-
Amoebocyte Lysate (LAL) assay. Such assays can be technically challenging to perform since 
the enzymes in the clotting cascade in this crab can be inhibited by various protein factors 
in human blood in addition to EDTA and heparin anticoagulants found in blood collection 
tubes can all effect endotoxin recovery. Manufactures of LAL kits do not recommend its use 
in clinical samples without undertaking special precautions to minimise these effects. In 
addition to circulation levels of LPS, other surrogate markers such as soluble CD14 and LPS-
Binding Protein (LPB) which bind help to and sequester LPS have been documented for 
many diseases (Buscarinu et al., 2017; De Kort et al., 2011; Irvine & Marshall, 2000; Maes et 
al., 2007; Rojo et al., 2007). LPS measurement may be the preferred surrogate marker for 
intestinal permeability for its obvious advantages over the L/M test which requires 
significant patient intervention. Despite the technical complications assaying for LPS in 
plasma, data published comparing the disease activity of IBD patients correlated increased 
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LPS with clinical worsening of the patients’ condition (Rojo et al., 2007). Plasma LPS level 
could also separate patients in inactive and active Crohn’s disease which had significantly 
higher circulating LPS compared with inactive and active Ulcerative Colitis (UC) patients.  
In the pursuit of diagnostic biomarkers, systemic antibodies reactive towards intestinal 
microbes, as well as autoantibodies resulting from intestinal inflammation, have been 
explored in the context of leaky gut in IBD where increased intestinal permeability has 
been associated in the onset of pathology as well as the relapse or progression of disabling 
symptoms (Macpherson et al., 1996; Mitsuyama et al., 2016; Palm et al., 2014; Sapone et 
al., 2006; Tibble et al., 2000). A predisposition to increased intestinal permeability may 
explain why certain individuals are prone to developing IBD since mice genetically 
engineered to lack junctional adhesion molecule A (JAM-A) and adaptive immune cells 
develop colitis (Khounlotham et al., 2012). Whereas JAM-A deficiency alone did not cause 
colitis because of compensatory mechanism leading to an enhanced adaptive immune cell 
response and increased IgA secretion (Khounlotham et al., 2012). The combined loss of 
barrier and adaptive immune cells exaggerated acute mucosal injury in these mice 
(Khounlotham et al., 2012). Many IBD patients report stressful life events prior to episodes 
of illness. Stress has been implicated with negative consequences for the immune system 
and increasing intestinal permeability and may be an etiological factor in promoting a leaky 
intestinal barrier (Ait-Belgnaoui et al., 2012; Glaser & Kiecolt-Glaser, 2005; Vanuytsel et al., 
2014). 
It has been proposed that autoantibodies reactive with the intestinal microbiota and 
intestinal epithelial tissue be useful markers in IBD patients and provide insight to its 
immune-mediated pathogenesis. Indeed, a diagnostic test to differentiate IBD from non-
IBD, and Crohn’s from Ulcerative colitis, has been commercialised by Prometheus® 
Laboratories (Nestlé Health Science) called IBD sgi Diagnostic®. Now its 4th generation of 
this screening panel including 9 serological markers (Prometheus Laboratories, San Diego, 
CA). The test uses the ELISA platform to quantify anti-microbial antibodies such as anti–
Saccharomyces cerevisiae antibody (ASCA), antibody to Escherichia coli outer membrane 
porin C (OmpC), antibody to Pseudomonas fluorescens–associated sequence (anti-I2), and 
antibody to flagellin Cbir1 (anti-CBir1) (Targan et al., 2005).  A report by Benor et al. in 2010 
highlighted an earlier version of this test, IBD7, based on 7 serological markers without any 
genetic or inflammatory markers now included in the up-to-date version, was not 
successful at predicting IBD in children referred for suspected IBD and initial clinical 
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evaluation and diagnostic by conventional endoscopy and histopathology (Benor et al., 
2010); Here, detection anti-flagellin antibodies only had a specificity of 53%. Elevated IgG 
antibody titres have been reported in 120 Crohn’s patients compared with 120 non-IBD, 
age-matched controls, against a cocktail antigen preparation derived from B. vulgatus and 
another using 20 mucosal-associated gut bacteria, and is consistent with loss of barrier 
function causing increased exposure to microbial antigens and an altered immune response 
(Adams et al., 2008).  It still remains that clinical diagnosis of IBD requires invasive 
endoscopy and histopathology to inform differential diagnosis of clinical forms such as 
Crohn’s Disease and Ulcerative Colitis. 
 
- Antimicrobial antibodies to assess intestinal permeability 
 
Despite substantial evidence for increased intestinal permeability in 
neurological/neuropsychiatric pathologies such as MS, Parkinson’s disease, stress, anxiety, 
depression, autism spectrum disorders, as well as in ME/CFS, there is limited data available 
on systemic antibody responses towards intestinal commensal bacteria in health and 
disease  (Hollander, 1999; Vanuytsel et al., 2014). How intestinal permeability contributes 
towards a disease mechanism is poorly understood in these conditions although there is 
some evidence to suggest increase intestinal permeability precede years before onset of 
diabetes and Parkinson’s Disease and first degree relatives of these patients also have 
higher intestinal permeability (Bosi et al., 2006; Forsyth et al., 2011). Anti-microbial 
antibodies may be more informative and evident of decreased compartmentalisation 
between the local intestinal immune system and systemic immunity, which may increase 
the presence of anti-microbial antibodies to intestinal bacteria in samples of peripheral 
blood. Indeed, systemic IgA, IgG and IgM antibodies reactive against E.coli, E. faecalis, E. 
coli Nissle, B. fragilis, K. pneumoniae, and B. thetaiotaomicron have been measured in 29 
IBD patients (a combination of mild/active and active CD and UC) and 19 controls using live 
bacterial fluorescence activated cell sorting (FACS) (Haas et al., 2011). It is perhaps not 
surprising that severe chronic enteropathy is associated with IBD patients to have higher 
antibody titres in IBD patients probably due to increased exposure in the gut arising from 
damage caused to the intestinal barrier. The same study highlights chronic HIV-1 infection 
association with enteropathy and B cell disturbances, with data suggesting bacterial 
translocation arises from circulating LPS, sCD14 and butyrate potential driving chronic 
immune activation. However, comparison of systemic antibodies to gut commensals in 
these patients to healthy controls were no different and did not support their hypothesis 
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for gut bacteria driving this chronic immune activation. The authors acknowledge lack of 
data on local immune responses in the gut of these patients since faecal samples were not 
available to study IgA-responses to gut commensals where distinct reactivity to certain 
members of the intestinal microbiota provides an IgA +/- index of specific antibodies that 
have been identified in IBD (Palm et al., 2014). As a result, the earlier reports of increased 
bacterial translocation and LPS exposure in HIV-1 appear misleading since Haas et al. did 
not replicate increased LPS or endoCAb levels. To that end, increased intestinal 
permeability does not appear relevant cause for immune activation in chronic HIV-1 
infection.  
 
The gut bacteria in the lumen do not normally cause a systemic immune response as the 
gut is considered a separate closed compartment (MacPherson & Uhr, 2004).  On the basis 
a leaky gut reduces the compartmentalisation between the gut immune system and 
systemic immunity, blood serum is becoming an attractive sample for quantifying 
antibodies against gut commensals. Previously where elevated LPS, sCD14, LPS-bind 
protein (LBP) in serum has indicated leaky gut, by identifying high titres of commensal 
antibodies in peripheral blood as well as confirming a series of specific Here there is a 
requirement for a rapid, high-throughput method for simultaneous detection of multiple 
commensal antibodies in a single serum sample.  
 
Current methods such as live bacterial FACs and traditional ELISA can only quantify 
antibody titres towards a select number of commensal isolates whilst it is estimated that 
there are 1000 species of gut bacteria present in a healthy gut (Qin et al., 2010). In an 
attempt to address this problem, in this chapter a new technique for a leaky gut microarray 
chip is presented as well as a flow cytometry to measure anti-microbial antibodies to faecal 
bacteria. This technique uses existing DNA microarray printers to deliver whole cell bacteria 
onto a glass slide coated with substrate designed to immobilise cells. Following incubation 
with a minimal amount of patient serum, such slides can be screened with a secondary 
anti-human IgG antibody for reactivity against several candidates of the microbiota, figure 
5.1.1 using a standard microarray scanner. 
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Figure 5.1.1 Comparison of methods used in this chapter for detecting antibodies against intestinal 
microbes in faeces (top) and serum (bottom). Top: isolated faecal bacteria suspended in liquid can 
be incubated with IgA-specific and binding detected using a flow cytometer. Bottom: in adaptation 
to a method reported by Thirumalapura et al., 2006 simultaneous screening of serum against 
multiple intestinal bacteria immobilised onto nitrocellulose can be assessed using a conventional 
DNA microarray scanner and microarray printing equipment. 
 
 
Bacteria have previously been immobilised onto nitrocellulose-coated glass slides used for 
the detection of antibodies in sera of dogs infected with Francisella tularensis 
(Thirumalapura et al., 2006).  The method used both Gram positive and Gram-negative 
bacteria and reported successful immobilisation onto commercially available nitrocellulose-
coated glass slides. An immunoassay of this kind has not been reported for use in human 
serum antibody detection. As a platform, microarrays offer high-throughput capability that 
would favour screening multiple serum samples for reactivity against potentially hundreds 
of bacterial isolates from the human gut microbiota. In a single experiment this format 
would aid simultaneous antibody and help identify specific titres of antibody relevant to 
disease pathology and the status of the immune system. This assay would not only be 
useful for ME/CFS research but may also facilitate other areas of research with difficultly in 
establishing a causative role for increased gut permeability.  
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- Evidence of increased intestinal permeability in ME/CFS 
 
Evidence of raised concentrations of serum IgA and IgM against LPS in CFS patients for a 
limited number of enterobacteria isolates has been obtained in several studies, concluding 
that serum IgA levels to selected isolated bacterial species also correlated with severity of 
illness using the Fibro-fatigue scale (Maes et al., 2007). These isolates include Hafnia alvei, 
Pseudomonas aeruginosa, Morganella morganii, Proteus mirabilis, Pseudomonas putida, 
Citrobacter koseri, and Klebsiella pneumonia (Maes et al., 2007). It has been proposed that 
severity of symptoms of fatigue, IBS symptoms, and failing memory/concentration in some 
ME/CFS patients originated from having a leaky gut which drives inflammation and cell 
mediate immune activation and altered cytokine production (Maes & Maes, 2009). In a 
case report on a 13 year old girl who showed high titres for IgM against LPS of 
enterobacteria, normalisation of leaky gut led to complete remission of her symptoms 
using a combination of antioxidants, zinc and glutamine, with immunoglobulin therapy 
(Maes et al. 2007).  Maes also report higher serum antibody titres for the same 
enterobacteria in patients with major depression disorder (MDD). In 2013, Maes reported 
autoimmunity in some ME/CFS patients and increased IgA responses towards commensal 
enterobacteria, all of which were associated with increased fatigue, neurocognitive and 
autonomic symptoms, sadness and a flu-like malaise (Maes et al., 2013). Leaky gut may 
well support autoimmunity but with limited data of the types of antibodies made to only a 
few commensal bacteria it is difficult to decipher the source of this phenomenon. 
 
In summary, the current methods for defining intestinal permeability are not without 
limitation, open to misinterpretation, and are not widely used in clinical practice. Without 
improved methods to assess intestinal permeability and the role of the microbiota in 
disease, current therapeutics such as prebiotic and probiotics, and especially faecal 
microbiota transplantation may be ineffective. Detection of systemic IgG and gut mucosal 
IgA antibodies towards commensal bacteria as a surrogate for intestinal permeability in 
patients has yet to be explored in ME/CFS.  
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- The role of mucosal IgA antibody in protecting the intestinal barrier 
 
The intestine generates several grams of IgA per day, secreted from large numbers of 
plasma cells from beneath the surface of the layer of epithelial cells which form the 
intestinal barrier and is the main mediator of intestinal mucosal immunity (Pabst, 2012).  
IgA antibody responses can be produced by T cell dependent and independent pathways 
(Macpherson et al., 2012).  The majority of commensal bacteria have been found to mostly 
stimulate IgA production in a T cell independent manner resulting in low affinity or non-
specific “natural” IgA antibodies which contribute to the shaping of the gut microbiota 
(Bunker et al., 2015; Rescigno, 2014). In contrast, T-cell dependent mechanisms for IgA 
production lend towards reactivity against non-self, bacterial derived specific antigenic 
proteins presented by dendritic cells and macrophages in Peyer’s patches and mesenteric 
lymph node (mLNs) during infection (Bunker et al., 2015). Mucosal IgA also appears to have 
as significant role in immune compartmentalisation between the local and the systemic 
immune system since mice deficient in IgA produce higher serum antibodies towards gut 
commensals (Macpherson & Uhr, 2004; Sait et al., 2007).  
 
More recently, in mice, the majority of the reactivity of sIgA appears to be naturally 
polyreactive against the commensal microbiota instead of being specific to individual 
bacteria taxa (Bunker et al., 2017). Whilst its primary function is to promote immune 
exclusion of intestinal pathogens by neutralising them for phagocytosis, the commensal 
member B. fragilis adapts it outer-membrane surface structures to promote IgA-binding, to 
gain access and colonise mucosal niches providing intimate contact with gut barrier 
epithelial cellular innate immune receptor such as TLRs (Donaldson et al., 2018).  Another 
study found a proportion of the IgA repertoire contains reactivity towards specific 
commensal antigens that appears to be dependent on T cell pathways (Benckert et al., 
2011). T cell independent pathways obliterated by MyD88/TRIFF double KO mice are 
deficient in ‘naturally’ polyreactive IgA antibodies and instead show systemic antibodies 
reactivity towards the intestinal microbiota (Slack et al., 2009). Supportive of systemic 
antibody production are Th1 and Th2 cytokines IFNγ and IL-4 known to trigger CSR to IgG1 
and IgG2a and IgE in allergy, respectively (Mitsdoerffer et al., 2010) Finally, in the event of 
increased intestinal permeability, we hypothesis exposure to the intestinal microbiota will 
initiate pro-inflammatory T cell mediated responses that are known support B cell 
proliferation and affinity maturation within the gut-associated lymphoid tissue (GALT) 
enhanced antibody production (Mitsdoerffer et al., 2010). In humans, CD27+ and CD27- 
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IgA+ circulating memory B cells are known to exist which operate under T-cell dependant 
and independent pathways, respectively (Berkowska et al., 2015). T cell dependent CD27+ 
IgA+ circulation memory B cells may become activated in a pro-inflammatory milieu and 
secrete more sIgA. Conversely, CD27- IgA- circulating memory B cells are T cell independent 
and their IgA reactivity profile has shown to be polyreactive towards commensal members 
of the intestinal microbiota (Berkowska et al., 2015). Under normal homeostatic conditions, 
T(reg) and DCs derived cytokines IL-10 and TGFB would favour T cell independent B cell 
proliferation and CD27- IgA+ memory B cell production of “natural” polyreactive antibodies 
against the commensal microbiota, thus support the immunological barrier against 
bacterial translocation (Berkowska et al., 2015).  
 
Based on studies carried out in animal models in a healthy gut microbiota, Foxp3+ T 
regulatory cells promote immune tolerance toward the commensal microbiota by 
supressing inflammation and regulating the diversity of IgA repertoire through selection in 
Peyer’s patches enriched with antibody secreting B cells  (Kawamoto et al., 2014). Foxp3+ T 
cells differentiate into T-follicular helper (Tfh) cells in germinal centres where they interact 
with naïve B cells to stimulate differentiation into gut homing IgA-secreting plasma cells 
whose quantity of IgA antibody production and specificity influences the composition of 
the gut microbiota (Kawamoto et al., 2014; Rescigno, 2014). Absence or dysregulation of 
IgA production severely impacts the composition of the gut microbiota (Kawamoto et al., 
2012; Suzuki et al., 2004; Wei et al., 2011). M cells have a major role in the uptake of 
luminal antigens presented by APCs in Peyer’s Patches and in their absence GCs in mice fail 
to maturate causing a decline in the total production of sIgA (Rios et al., 2016). Tolerogenic 
DCs suppress Th7/Th19 inflammatory responses through releasing retinoic acid, IL-10 and 
TGF-B with promote Foxp3+ T regulatory cells and can further differentiate into Tfh cells 
with express CD40L and IL-21 to induce B cell mediated IgA production in the germinal 
centres (GCs) (fig 5.1.2) (Gutzeit et al., 2014). A disrupted microbiota can also lead to 
altered antigen presentation and loss of tolerance potentially overwhelming the regulatory 
T cell maintenance of GCs and instead activate pro-inflammatory Th1/Th17-cell dependent 
IgA production. Further, increased intestinal permeability would facilitate increased uptake 
of bacterial luminal antigens by DCs which migrate to LNs where they interact with naïve T 
cells to trigger clonal expansion and differentiation into Th1/Th2/Th17 T cell subsets with 
their associated cytokine profiles influencing B cell interactions.  
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Elevated levels of secretory IgA are an apparent compensatory mechanism for 
compromised intestinal permeability and has been reported in mice deficient in junctional 
adhesion molecule A (Khounlotham et al., 2012). Interestingly in IBD the identification of 
taxa-specific levels of IgA-coating faecal bacterial has revealed distinct patterns of the 
colitogenic microbiota in IBD (Palm et al., 2014). Therefore, measurement of IgA-coated 
bacteria may be a future diagnostic marker for the outcome of the interactions between 
the immune system and gut bacteria. The status of IgA+/IgA- coated bacteria in addition to 
specific systemic antibody responses to gut microbes are not known in ME/CFS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.2. A healthy intestinal microbiota promotes Foxp3+ regulatory T cells to interact with B 
cells to undergo class switch recombination (CSR) and somatic hypermutation (SHM) in germinal 
centres to generate polyreactive or “natural” IgA antibodies to maintain microbial diversity. B cells 
residing in germinal centres interact with T-follicular cells which migrate to germinal centres (GCs) 
by expressing CXCR5 chemokine receptor (King et al., 2008) to stimulate B cell maturation into long-
lived IgA-secreting plasma cells. Graphical abstract taken from Kawamoto et al., 2012 
 
- Experimental approach 
 
Observations of IgA-coated faecal bacteria can be easily assessed with minimal 
invasiveness to the patient since no blood extraction is needed. Intestinally secreted IgA 
antibody can be visualised using an anti-human IgA secondary antibody conjugated to APC 
and measured by flow cytometry as a proportion of total faecal bacteria (Palm et al., 2014). 
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With the necessary antibody isotype control for excluding nonspecific binding, flow 
cytometry has a major advantage over traditional ELISA methods and western blotting 
techniques, which usually test single bacterial antigen (LPS) extracted from bacterial lysate 
as opposed to whole cell bacteria which maintain the integrity and full complement of 
bacterial cell antigens to which the host immune system would be exposed to in vivo.  
 
Patient antibodies which target bacterial surface antigens in pure culture and in human 
faeces have been explored using flow cytometry (Moor et al., 2016; van der Waaij et al., 
1994). This has an added advantage over more traditional techniques such as an ELISA 
since the bacteria are in liquid suspension and do not require immobilisation to a micro-
titre plate or glass slide. It is also much easier to adjust bacterial densities in liquid phase 
and to detect discrete bacteria populations within a faecal bacteria suspension to which 
antibodies have bound to. Moreover, faecal flow cytometry examines the entire faecal 
bacteria cell population unique to that individual which can lead to the identification of 
specific bacterial subpopulations.  Until now, faecal IgA production has not been explored 
in the ME/CFS population and may be useful additional marker for increased intestinal 
permeability. The benefit being this is a potential non-invasive method that can determine 
this status without the need a blood sample. 
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5.1.2 Aims & Objectives 
 
The first aim of this chapter was to determine the suitability of a whole-cell bacterial 
microarray (“chip”) to assess ME/CFS patient serum antibody reactivity against 
representatives of the intestinal microbiota using immunofluorescence and high-throughput 
microarray scanning.   
 
In order to achieve this aim, the following objectives were set out: 
 
- to determine the stability of lab-cultured intestinal bacteria once immobilised onto 
nitrocellulose-coated glass microscopy slides; 
- establish an assay protocol using a microarray scanner to detect polyclonal anti-
microbial antibodies generated in rabbit from a stool sample provided from a 
healthy donor (positive control); 
- following validation of the microarray, screen blood serum from severe ME/CFS 
patients and house-hold controls; 
- to detect serum antibody reactivity against this microarray to determine intestinal 
permeability status in ME/CFS versus house-hold controls. 
 
The second aim of this chapter was to assess intestinal IgA reactivity against faecal 
microbes, isolated in a faecal liquid suspension from patients and house-hold controls using 
a modified method of flow cytometry:  
 
- to exclude faecal contaminants by using a nuclei acid stain to resolve microbes; 
- in order to determine if severe ME patients have a higher relative abundance of 
IgA-coated faecal bacteria compared with their house-hold controls; 
- to assess faecal IgA reactivity against intestinal bacteria with serological markers 
such as LPS and LBP, to see how IgA-bound faecal bacteria may serve as a surrogate 
marker for interpreting intestinal permeability in patients. 
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5.1.3 Hypothesis 
 
Patients with severe ME/CFS have increased intestinal permeability, which causes a loss of 
compartmentalisation between the intestinal and systemic immune systems (fig. 5.1.4). 
This exposes the intestinal microbiota to the immune system leading to increased T-cell 
dependant mucosal IgA production and reactivity towards faecal bacteria. Secretory IgA is 
therefore a potential biomarker for intestinal dysbiosis and increased barrier permeability 
(fig 5.1.3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.3 Secretory IgA regulates gut microbiota composition and protects the intestinal 
barrier. IgA is the predominant antibody isotype found in the intestine and recognises a broad range 
of members of microbes. Levels of IgA coating intestinal bacteria may be a marker for increased 
intestinal permeability in an attempt to neutralise commensal bacteria as well as enteric pathogens 
that may be relevant to ME/CFS pathophysiology. Increased IgA-bound bacteria may also indicate 
dysbiosis resulting from the interactions between intestinal microbes and the immune system in 
these patients.
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 Ü Figure 5.1.4 Increased intestinal permeability facilitates translocation of bacterial endotoxin 
(LPS) and exposure of mucosal-associated bacteria.  Antigen presenting cells (APCs) interact with 
members of the microbiota to present bacterial antigens to T-helper cells which stimulates 
polyclonal B cells activation and expansion to produce antibodies towards these members of the 
intestinal microbiota.  Flow cytometry can be used to identify IgA-bound bacteria within mixed 
faecal bacterial suspensions obtained from patients and their house-matched control.  Higher levels 
of IgA-coated bacteria may a valid indicator of intestinal permeability in accordance with other 
serological marker for evidence of bacterial translocation. Diagram created in Microsoft® 
PowerPoint® by Daniel Vipond 
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5.2 Materials & Methods 
 
5.2.1 Solid versus liquid phase assay for bacterial antibody detection 
 
The methods used in this chapter attempt to probe human serum and faeces to elucidate 
immunoreactivity against whole cell faecal bacterial surface antigens presented on a solid 
slide and in liquid suspension. 
 
5.2.2 Bacteria Microarray  
 
The protocol for a whole cell bacterial microarray was based on the method of 
Thirmulalapura and colleagues using Gram positive and Gram negative bacteria 
immobilised onto nitrocellulose-coated glass slides to detect antibodies in canine infected 
serum (Thirumalapura et al., 2006).  
 
- Strain preparation 
 
Bacterial cells were resuscitated from a -800C glycerol stock and grown for 16 h under 
appropriate growth conditions. Cells were harvested by centrifuging at 6000 x g for 10 min. 
Cells were washed in PBS and adjusted to an optical density (OD) of 1.0 ± 10% at 600 nm 
and plated onto solid agar media for CFU counting. For visualisation purposes, bacteria 
were fluorescently stained using 1μl/ml Baclight® Red or Sybr Green nuclei acid (x10,000) 
stain, diluted 1:10,000 for 30 min. Bacteria were inactivated by fixing in 1% 
paraformaldehyde (PFA) for 15 min to preserve whole cells structure before use in 
experiment. Based on colony counting experiments, one millilitre of cell suspension 
represents approximately 108 cells.  
 
- Microarray construction and use 
 
The ProPlate® microarray slide module (Grace Bio-Labs, Sigma cat. GBL204839) was 
inserted onto the surface of a SuperNitro Microarray substrate glass slide containing a 150 
µm layer of nitrocellulose (Arrayit® item no. SNM) to create 64 discrete wells for pipetting 
sample. 50 μl of fixed bacterial cells in PBS suspension was pipetted into each well and any 
remaining wells filled with PBS. The slide coupled with its silicone gasket was held in place 
with snap clips before being placed into a makeshift polystyrene block enclosed within a 
centrifuge swing bucket and monitored whilst operating at 700 rpm (99xg) for 15 min to 
pull down cells onto the slide surface. The slide was left overnight at 40C to facilitate 
binding of bacteria to the nitrocellulose coating on the slide.  
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Figure 5.2.1 Grace-Biolab ProPlate® 64-well microarray slide module to create wells on a 
nitrocellulose glass microscope slide. Dimensions are given in millimetres (mm).  
 
 
- Primary antibody/rabbit serum slide incubation 
 
The printed bacterial microarray was blocked with 2-10% BSA (Sigma cat. no. 05470) in PBS 
(pH 7.4) for 1 h on a gently shake at 4oC inside sterile a Petri dish. If using serum, the 
sample was heated to 560C in a heat block for 30 min to inactive complement proteins and 
kept on ice afterwards.  All primary antibody/rabbit serum dilutions were performed in 
sterile-filtered PBS, 2%BSA, typically at dilutions of 1:50, 1:100, 1:200. Primary antibody or 
rabbit serum was pipetted into each well and left overnight at 40C.  The next day, the slide 
was washed twice with sterile-filtered PBS in Petri Dish for 5 min, while gently shaking.  
 
In later experiments, the slide was spin dried using a makeshift polystyrene insert for swing 
bucket modules designed for that specific centrifuge. These slides were then incubated with 
the rabbit OmpA monoclonal antibody or rabbit serum samples for 30 min at room 
temperature. After incubation, the slides were washed twice for 10 min each with PBS-T.  
 
Bound antibody was detected using 50 μl/well secondary goat anti-rabbit-IgG antibody 
conjugated to Dylight® 550 (5µg/ml) at 1:200 in PBS, 2% BSA for 30 min. The ProPlate® 
gasket was retained on the glass slide throughout the entire experiment and through a 
single PBS wash bath step and dried at 500C. The slides were then immediately scanned for 
fluorescence on the GenePix® 4000B Microarray Scanner using 635 nm and 532 nm lasers, 
and the images acquired using the scanner’s native GenePix® Pro 6.0 software. 
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- Anti-faecal microbe anti-sera 
 
Rabbit polyclonal antibodies were generated by CovalAb UK (Cambridge, United Kingdom) 
against faecal bacteria isolated from a single healthy human stool sample. Two female 
rabbits were immunised accordingly to the regime over 67 days in table 5.2.1 and included 
four injections per animal.  
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Table 5.2.1 67-day immunisation protocol used in rabbit to generate polyclonal antibodies against 
human faecal bacteria isolated from a single healthy donor.  
 
Faecal bacteria were extracted from 1g of fresh human stool by homogenisation with PBS 
and centrifuging at 300 x g for 5 min to remove large particulates. One millilitre of the 
bacterial supernatant was taken and washed twice in PBS (3,500 x g, 10 min) to produce a 
biomass of 400 μg for immunisations. 
 
- Validating of rabbit sera anti-microbial activity 
 
Faecal bacteria from the same donor were extracted in PBS and diluted across the slide in a 
series of 1:10 dilutions and blocked with 2% BSA for 1hr before being incubated with serum 
at a dilution of 1:100 for a further 1hr. Slide washes were performed for removal of 
blocking and after each primary and secondary antibody incubation using a 0.5l PBS bath 
The slide was developed with a secondary goat anti-rabbit IgG-conjugated to Dylight®650 
for 1 hr. Dylight® 650 provides far-red fluorescence with excitation/emission at 652/672 
nm respectively. 
 
 
 
Day 0 
Pre-immune bleed (4 - 5 mL) and storage at -20°C 
Intradermal injection (1 mL / rabbit) 
0.5 mL of 106 fixed bacteria + 0.5 mL incomplete Freund's adjuvant 
Day 14 Intradermal injection (1 mL / rabbit) 
0.5 mL 106 fixed bacteria  + 0.5 mL incomplete Freund's adjuvant 
Day 28 Intradermal injection (1 mL / rabbit) 
0.5 mL  106 fixed bacteria + 0.5 mL incomplete Freund's adjuvant 
Day 39 Test bleed (4 - 5 mL) and storage at +4°C Dispatch of sera D0 & D39 - 
15/09/2015 
Day 42 Subcutaneous injection (1 mL / rabbit) 
0.5 mL of 106 fixed bacteria  + 0.5 mL incomplete Freund's adjuvant 
Day 53 Test bleed (10 - 15 mL) and storage at +4°C Dispatch of sera D53 - 
29/09/2015 
Day 67 Terminal bleed (50 - 70 mL) and storage at +4°C 
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- Microarray assay validation  
 
Polyclonal antibody generated in rabbit for outer-membrane protein A (OmpA) 
(1.74mg/ml) was kindly provided by Dr Régis Stentz (Quadram Institute Bioscience, 
Norwich). OmpA is widely expressed among Gram-negative bacteria. In addition, a strain of 
Bacteroides thetaiotaomicron engineered to lack OmpA protein, GH290, was also made 
accessible as a negative control species for immobilisation on the microarray in 
experiments to enable determination of optimal assay conditions as well as the limit of 
antibody detection. In a further attempt to provide proof-of-concept an E.coli RaFC “deep 
rough” mutant was also immobilised and used as an additional control, onto a slide and 
probed used an anti-E coli FITC antibody (1:500) for 1hr at RT. The slide was imaged 
immediately using the 532 nm (green) laser on the microarray scanner and signal gain 
adjusted in relation to wells left as blanks.   
 
5.2.3 Patient and control serum 
 
Bacterial endotoxin (LPS) and LPS-Binding Protein (LBP) were quantified in patient and 
house-hold control (HHC) serum samples collected into 9 ml polypropylene blood collection 
tube using the S-Monovette® Z system containing a clotting activator (Sarstedt, Germany, 
order: 02.1063.001).  Collection tubes were centrifuged 2000 x g for 15 min to extract the 
serum. Serum samples were kept stored at -800C until required.  
 
- Serum Endotoxin 
 
Endotoxin testing was performed on severe ME (S), House-Hold Control (HHC) and earlier 
Mild/moderate ME/CFS (M) samples using the same batch of reagents provided the 
Kinetic-QCL Limulus-Amoebocyte Lysate (LAL) kit manufactured by (Lonza Ltd., Switzerland, 
Cat. No. 50-650U). Serum was diluted 1:10 in LAL water certified as pyrogen-free and 
inactivated by heating to 560C for 30 min. After cooling, serum was then kept on ice and 
stored overnight at 40C. Endotoxin standards were made using E. coli 055:B5 by 
reconstituting the supplied vials in a volume of LAL water provided on the certificate of 
analysis. All serum samples, endotoxin standards and a negative control (LAL water) were 
dispensed in a volume of 100 µl into wells on endotoxin-free microplate and preincubated 
in the microplate reader at 370C for 10 min. Reconstituted LAL reagent was prepared by 
adding 2.6 ml of LAL water to lyophilised mixture of lysate prepared from circulation 
amoebocytes from the horseshoe crab and kept at 40C and used on the same day. 100 µl of 
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LAL reagent into each well on the microplate as quickly as possible before activating the 
microplate reader. This assay has been designed to measure DOD over time, (Reaction 
Time, RT) to increase the initial absorbance measurement by 200 mOD. To this end, each 
well was simultaneously measured for absorbance OD at 405 nm every 50 seconds for 2 hr 
on the BioRad® Benchmark Plus plate reader using Microplate Manager software. 
Individual OD readings for each well was then exported to a Word® Excel® file and kinetic 
plots generated for each sample and controls. A standard curve of known endotoxin 
concentration ranging from 0.005 EU/ml to 50.0 EU/ml was established. Using a four-
parameter linear regression model, a mathematical formula representing the kinetic plots 
from each serum sample was generated to calculate the precise Reaction Time (RT) for a 
DOD of 200mOD. The concentration of endotoxin is inversely proportional to the RT.  
 
- Serum LPS-Binding Protein (LBP) 
 
The same aliquots of serum analysed for endotoxin that had been kept at 40C overnight 
were used to measure LPS-binding protein (LBP) by a Human LBP ELISA kit according to kit 
instructions (RayBio® Inc., item code: ELH-LBP). Briefly, serum samples were diluted in LAL 
water to a final 1:100 concentration. Duplicate testing was performed on 100 µl of diluted 
serum per sample well and concentrations of LBP ranging from 0.819 ng/ml to 200 ng/ml 
and a zero standard after transferral to the LPB microplate immobilised with anti-human 
LBP. Following a 2.5 hr incubation at room temperature, a secondary biotinylated anti-
human LBP antibody was added for 1 hr at room temperature with gently shaking. The 
plate was then washed four times before incubating with HRP-streptavidin for 45 min at 
room temperature. After plate washing, 100 µl of the supplied 3,3,5,5’-
tetramethylbenzidine (TMB) was added as a substrate for 30 min in the dark. 50 µl of 0.2M 
sulfuric acid was added per well to stop the reaction, and readings for each well measured 
at 450 nm using the BioRad® Benchmark Plus and native Microplate manager software. 
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5.2.4 Faecal bacteria flow cytometry  
 
- Sample preparation 
 
Stool samples were homogenised manually using a metal spatula for 5 min. Six aliquots 
containing 100 mg of raw faecal pellet was prepared from each stool sample and 
designated use in flow cytometry experiments. These were stored at -800C before the  
experiment. On the day of the experiment, a single 100 mg aliquot of raw faeces was taken 
for each study participant and initially thawed whilst resting on wet ice and then gradually 
up to room temperature to mitigate any protease activity causing degradation of IgA 
antibody. It is estimated that 1g of healthy stool contains anywhere between 109-1010 
bacteria cells. Based on this, all 100 mg faecal homogenates were diluted to 1:100 which is 
equivalent to 106 cells in a final volume of 4 ml and stained with Sybr Green (1:10,000) and 
anti-human IgA-APC (1:100). To do this, 1ml of sterile-filtered Dulbecco’s phosphate-
buffered saline (Sigma, cat. D8537) was used to homogenise each 100 mg of faeces using a 
plastic pestle and mot for 5 min. This faecal homogenate was then centrifuged at 300 x g 
for 5 min to produce a faecal bacterial suspension. This suspension was then further 
diluted 1:10 in PBS before staining. Sybr green nuclei acid stain was provided as a gel stain 
at a x10,000 concentration in DMSO (Sigma, cat. S9430) and diluted in each sample to a 
final concentration of 1/10,000 and added to 20 µl sample of the faecal bacterial 
suspension in PBS to a FACS tube containing 80 µl PBS containing SYBR green to make a 
further 1:10 dilution.  To this, 1 µl of anti-human IgA-APC antibody (Miltenyi Biotec, order 
no. 130-116-879) was incubated at room temperature for 30 min before fixing in 350 µl of 
1% PFA and temporarily placed onto ice whilst awaiting to be analysed.  
 
- Flow cytometry data acquisition  
 
Flow cytometric analysis was performed on faecal bacteria suspensions stained with Sybr 
green (1:10,000) and anti-human IgA-APC (1:100) using the BD FACSCanto™ II and BD FACS 
Diva software for data acquisition. Forward and side scatter voltages were adjusted to 
capture events within the space of the plot. Non-fluorescently labelled cells were used to 
set PMT voltages for APC (IgA-detection) and FITC (Sybr Green) and position these events 
on the bottom left area of the plot. Events captured in the bottom right of the plot were 
positive for Sybr green, and events observed top left were IgA-APC position. Anti-human 
IgG-APC (1:100) was used in each sample as an isotype control for non-specific binding. 
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5.3 Results 
 
5.3.1. Sample acquisition  
 
Home visits were conducted during May 2016 and at the end of February 2017. A total of 
17 severe ME patients were recruited and included in this chapter (Table 5.3.1) Nine house-
hold controls were recruited and linked to their respective ME participant. It must be noted 
that out of these nine house-matched controls, two were unrelated full-time carers of 
these severe ME patients. This was the best achievable environmental control in these 
instances, since these carers worked long hours in close contact with the patient and in the 
preparation of meals. 
 
Figure 5.3.1 shows a map of the locations of the 11 home visits carried out in 2016.  Due to 
the availability of a suitably trained medical profession, it was not possible to obtain blood 
samples from all these home visits.  Blood taking from these patients proved difficult for 
most severe patients and was deemed unethical to pursue further attempts to take blood. 
The difficulties in obtaining blood was another turning stone to switch strategies from 
systemic microbial antibody detection, to using less invasive faecal samples to access IgA 
reactivity in faecal bacteria. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 5.3.1 Maps of locations for 11 home visits attended across South London, UK, during 2016  
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Sample Collection Summary 
 
Sample Status Age Sex Collection year 
2016      2017 
Paired samples 
1 Severe ME 63 F X X  
2 Severe ME 56 F X X  
3 House Control 55 F X X 1 
4 House Control 69 F X X 2 
5 Severe ME 44 F  X 3 
6 House Control 70 F  X 3 
7 House Control 55 F X X 4 
8 Severe ME 38 F X X 2 
9 Severe ME 21 F X X 1 
10 Severe ME 37 F  X 5 
11 House Control 64 F  X 5 
12 Severe ME 18 F X X 4 
13 Severe ME 61 F  X  
     14 Severe ME 40 F  X  
15 Severe ME 54 F  X  
16 Severe ME 58 F X X 6 
17 House Control 60 M X X 6 
18 Severe ME 27 F X X 7 
19 House Control 60 F X X 7 
20 Severe ME 63 F  X  
21 Severe ME 32 F X  10 
22 Severe ME 31 F X  8 
23 House Control 54 F X  8 
24 Carer 29 F X  9 
25 Severe ME 56 F X  9 
26 Severe ME 30 F X   
56 Carer 34 F X  10 
 
Table 5.1.1 Patient Demographics: Severe ME (n=17) plus House-Hold controls (n=9) 
“X” denotes sample collected. Severe ME (age 42.9±13.2 years) and House-matched controls (age 
57.3±8.8 years). Yellow highlights patients followed up for a second sample 
 
 
In 2017, additional faecal samples were made available from 7 of the original severe ME 
patients recruited in 2016, with another 6 new severe ME patients included in final home 
visits to conclude the entire study. Again, owing to the difficulties of organising a suitable 
trained clinical professional to take blood as well as these patients being exceptionally 
challenging to acquire a suitable vein for bleeding, not all severe ME patients and their 
controls contributed blood serum to this study.  
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5.3.2 Bacterial Microarray 
 
Attempts to design and develop a useful bacterial microarray for patient systemic serum 
antibody detection was carried prior to research ethics approval and therefore these 
experiments were conducted in advance of any patient or control sample collections.  The 
rationale for its design was to allow for ease of detection of serum antibodies in human 
serum against multiple faecal bacterial isolates and for the simultaneous detection of these 
antibodies using high-throughput microarray printing and array scanning. 
 
Early attempts used single cultured intestinal isolates immobilised onto a nitrocellulose-
coated slide. Bacteroides thetaiotaomicron VPI 5482 was chosen for its ability to withstand 
oxygen exposure on the lab bench and due to the availability from within the research 
group culture collection and that of an outer-membrane protein A deficient strain, GH290 
(OmpA-). This was also one of the species used for anti-microbial detection by Haas et al., 
2011 in HIV-1 infection and IBD patients (Haas et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.1. Bacteroides thetaiotaomicron OmpA+ and OmpA- can be immobolised onto a 
nitrocellulose-coated glass microscope slide. Baclight Red® stain was incubated with cells before 
transfer of 10 μl to slide. Slide was dual laser imaged on the GenePix Microarray scanner. Fluorescence 
cells appear detectable, read at wavelength of 635 nm versus 532 nm .   
 
In preparation to access the effect of CFU numbers on the detectability of Baclight® Red 
signal during the microarray scan; PBS suspended VPI5482 (109 cells/ml) and GH290 (109 
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cells/ml) cells were stained with Baclight® Red (100 μM, working dye solution) in a final 
1:1000 dilution. The desired cell number (ranging from 109, 108, 107 or 106 cells per array 
spot) was achieved by serial dilution in PBS.  Figure 5.3.1 shows an example of these cells 
deposited onto the microarray using a 10 μl printing volume. The Baclight® red fluorescence 
intensity was recorded using the red laser (λ = 635 nm).  The slide was also scanned for 
fluorescence on the green channel of the microarray scanner (λ = 532 nm) and shows 
background fluorescence may interfere with downstream signal detection of antibodies on 
this channel. It was difficult to quantitate the intensity of Baclight® fluorescence at this stage, 
however OmpA- cells did appear more fluorescent from this image.  
 
In slide-independent studies using flow cytometry (figure 5.3.2), Baclight® Red was 
demonstrated to only have fluorescent properties when it was associated with both Gram 
positive and negative bacterial cells, confirmed also by the manufacturer’s protocol and gave 
reassurances that Baclight® detection was a reliable visual indicator of the presence and 
location of cells on the microarray slide. Figure 5.3.2 shows E. gallinarum (Gram positive) and 
A. muciniphila and B. thethaiotoamicron (both Gram negative) cells can be sort for 
fluorescence using Baclight signal intensity. 
 
 
 
 
 
 
 
Figure 5.3.2 Visualising bacteria stained using Baclight® red by flow cytometry. Threshold set to a 
minimum of <100 ets/s based on sterile-filtered PBS (left plot). Bacterial cells were positioned within 
the plot using forward (FSc) and side scatter (SSc) light properties which are proportional the size of 
SS
C-
A 
FSC-A 
E. gallinarum A. muciniphila 
B.thetaiotaomicron 
SS
C-
A 
FSC-A 
Sterile-filtered PBS 
Pure culture faecal isolates 
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individual cells (FSc) and intracellular complexity (SSc). Histogram measured the Baclight® intensity, 
cells accumulate to the right of this plot are positively stained. Pseudo-colour represents 
concentration of cells where a region of interest (gate) has been added to exclude culture debris and 
non-specific events. Number inside gate is a percentage of all events processed. These were then 
gated and measured for Baclight signal in the histogram (red). 
 
- Microarray assay validation 
 
Immobilisation of OmpA+/- strains of Bacteroides thetaiotaomicron on nitrocellulose-coated 
glass slides was used to optimise the antibody detection protocol using a polyclonal anti-
OmpA antibody and a secondary goat anti-rabbit-IgG conjugated to Dylight®550 (Thermo-
Scientific) for green fluorescence that could be detected on the microarray scanner’s second 
laser at 532 nm. To facilitate multiple antibody conditions on single glass slide, a multiarray 
chamber (fig. 5.2.1), was integrated with the glass slide to produce 64 individually spaced 
wells similar to a microtiter plate. Binding of the OmpA antibody would be expected using 
the wild-type VPI5482 strain, with GH290 (OmpA-) representing a negative control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.3 Slide washing causes loss of bacterial cells. 10 μl of bacterial suspension (109 CFU/ml) 
of stained and unstained VPI5482 and GH290 cells per well (108 cells) was air dried onto slide and 
subjected to three separate washing steps by submersing slide in a 5L bath of PBS-T (0.05% Tween 
20) and left to dry in between each wash. After the final wash the slide was left to dry at 370C before 
scanning. 
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An experiment was required to test if immobilised bacteria can withstand a minimum of 
three PBS-T wash steps to allow for application and removal of (1) a suitable blocking 
reagent, (2) serum/antibody, and (3) removal of unbound primary/secondary antibody. 
Bacteroides thetaiotaomicron strains remain partially immobilised onto the slide after three 
washing steps (figure 5.3.3). Efficiency and stability of cells immobilisation appears to vary 
across different regions of the slide since loss of fluorescence occurs more to wells at the 
ends of the slide. There appeared to be no differences between OmpA+ or OmpA- cells.  
Using the ProPlate 64-well gasket configuration, VPI5482 and GH290 cells were immobilized 
onto separate slides with the application of primary OmpA antibody concentrations (1:100, 
1:200, 1:500) titrated against secondary goat anti-rabbit IgG-Dylight®550 (1:100, 1:100, 
1:500). Figure 5.3.5 shows two slides with annotations for antibody incubated against 
OmpA+/- Bacteroides. Cells incubated with antibody were not stained with Baclight® Red to 
avoid any signal bleed over onto the 532 nm laser used to detect secondary antibody binding. 
Both slides contained 108 cells per well which were deposited onto the slide in 10 μl 
volume/well in an attempt to coat the entire well surface. Six wells did contain 109 cells 
stained with Baclight® Red as a control and for the purposes of monitoring following slide 
washing.  
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Figure 5.3.4 Polyclonal rabbit OmpA antibody was used to test for specificity and reactivity against 
immobilised VPI5482 bacteria. 
 
Several attempts were made using OmpA antibody to provide proof-of-concept for this 
method of antibody detection. A makeshift polystyrene insert for a centrifuge swing bucket 
was created to introduce centrifugal force to maximise contact between cells and the slide 
surface. Blocking with BSA was attempted at 2% and increased to 10% to minimise slide 
background signal in fig. 5.3.4. However, scanning of both slides at 532 nm did not reveal 
specific binding of antibody to the wild-type (OmpA+) Bacteroides. 
BT VPI5482 (OmpA+) 
BT GH290 (OmpA-) 
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Figure 5.3.5 Reactivity of polyclonal anti-microbial rabbit serum tested against faecal bacteria 
extracted from human faeces. Donor faecal bacteria used to immunise rabbit was used on this slide, 
starting at 108 cells diluted across the slide using PBS. Top: slide map shows the position of cell 
dilutions and antibody staining concentration. (A) single (red)laser, λ = 635 nm, scan of slide to 
detect secondary antibody binding produced no reactivity. (B) single (green) laser, λ = 532 nm 
measures background fluorescent activity. (C) dual laser (λ = 635/532 nm) with increased gain show 
no specific antibody reactivity to faecal bacteria. 
 
λ = 635 nm 
λ = 532 nm 
Ratio λ = 635/532 nm 
A 
B 
C 
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Rabbit sera raised against faecal bacteria isolated from a single human donor was tested 
using this microarray format in figure 5.3.5. However, no fluorescence was detected on the 
array scanner at 635 nm.  
 
An attempt using pooled serum from rabbits “17” and “20”. In this experiment, blocking was 
increased by using 10% BSA and the serum was left overnight at 40C. The slide was then 
processed and developed as previously performed and scanned for fluorescence (figure 
5.3.6). Detection using the green channel shows the slide surface to be highly auto-
fluorescent. Combined post-immune sera was compared directly with the pre-immune bleed 
for anti-microbial activity to donor faecal bacteria titrated against cell number, but this 
produced little or no detectable antibody binding (fig. 5.3.6, right). 
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Ü Figure 5.3.6 Post-immunised rabbit sera shows no anti-microbial reactivity using donor faecal 
bacterial immobilised onto a nitrocellulose-coated glass microscope slide. Anti-microbial reactivity 
towards faecal bacteria was compared using pre- and post-immune rabbit sera. Faceal bacteria were 
diluted from 109 – 101 cells using PBS only as a negative control. Slide was imaged on separate laser 
channels, λ = 635 nm, green (left) and λ = 635 nm, red (right). Regions of interest (boxes) indicate 
wells created to deliver cells onto slide.  
 
- Automated microarray printing 
 
A microarray printer was used to deliver cells onto the nitrocellulose-coated slide in the same 
fashion described by Thirumalapura and colleagues. To that end, a microarray printing buffer 
was recreated using PBS containing 20% Ficoll 400 and 4% glycerol to suspend VPI5482 
bacterial cells at a density of 109 cell/ml.  Figure. 5.3.7 shows example of cells printed with 
each array spot representing ~25,000 cells. PBS/Ficol/Gycerol was compared with PBS alone, 
which provided a better quality of array spot. The bottom image in fig. 5.3.7 shows a scan of 
the entire slide surface and the differences in the quality of spotting. During imaging of the 
slide, signal gain was adjusted in relation to areas of the slide out of range of the microarray 
printer and was kept constant during re-imaging of the same slide following slide washing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C 
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Ü Figure 5.3.7 Automated microarray printing of Baclight® Red stained Bacteroides 
thetaiotaomicron VPI5482 (OmpA+). Cells were robotically printed onto a nitrocellulose-coated 
glass slide and imaged using a microarray scanner. (A) Entire slide surface imaged using single (red) 
laser, λ = 635 nm. (B) represents enlarged view of area in white box in A. (C) Compared Baclight® 
signal intensity (λ = 635 nm) from bacterial cells suspended in either PBS and PBS/Ficol/Glycerol 
printing buffer  
 
Baclight® signal was quantified using pre-defined analysis modes within the native 
GenePix® software on the array scanner. Based on the microarray printing pattern, regions 
of interest could be placed around each array spot and its fluorescent signal recorded and 
exported into an Excel file.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.8 Washing causes the majority of cells to be lost from the microarray slide surface. Two 
printing buffers, PBS and PBS/20%Ficol/4% glycerol were used to robotically print bacterial cells 
from Bacteroides thetaiotaomicron (Gram negative), Enterococcus gallinarum (Gram positive), E.coli 
(Gram negative), and Akkermansia muciniphilia (Gram negative) on to a nitrocellulose glass slide. 
Cells were stained with Baclight® Red according to different conditions; either before or after fixing 
cells overnight or staining unfixed cells and printing on the same day. Blue bars indicate Baclight® 
Red fluorescence pre-wash, compared to the red bars at post-wash. Mean fluorescence values were 
recorded in arbitrary units (AU) following scanning of entire slide surface. Error bars give the range 
of standard deviation. 
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Figure 5.3.8 (blue bars) compares the intensity of Baclight® signal in PBS versus PBS/20% 
Ficoll/4% Glycerol. Given the final version of this assay would require tens or even 
hundreds of different representatives of the human gut microbiota, such an assay would 
require advanced preparation and staining of these bacteria before they could be 
immobilised onto the array. Baclight® intensity was a third higher in cells printed in PBS 
alone for B. thetataiomicron. However, it did not make any notable difference if cells have 
been stained the previous day and kept at 40C compared to staining these cells the same 
day to be printed. The order of fixing cells before or after Baclight® staining did not make a 
difference for B. thetaiotaomicron or E.gallinarum; with the exception for E.coli that was 
more advantageous to stain these cells on the same day of printing. Interestingly the 
difference in fluorescence between the printing buffers for Akkermansia muciniphila was 
the least in contrast to the other strains that performed better in PBS, highlighting optimal 
printing and staining conditions are dependent on the bacterial strain. Reimaging the slide 
following washing revealed complete loss of Baclight® signal from all strains suggesting 
these cells have been lost from the slide surface.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 5.3.9 Anti-E.coli-FITC antibody reactivity towards for wild-type E.coli ATCC 700926 and 
DRaFc ‘deep rough’ mutant E.coli immobilised onto nitrocellulose-coated slide. 5x106 cells 
transferred onto slide and diluted in series 10-1-10-5. Each row of the slide indicates condition of cells 
prepared (1) unstained and unfixed, or Baclight® Red stained in unfixed (2) and 2% formalin (3).  
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A final attempt was made to generate a working slide assay using a ‘deep rough’ mutant 
raFC mutant E.coli. A FITC-conjugated goat polyclonal anti-E.coli antibody was tested 
against ATCC 700926 cells, including a K-12 like E.coli strain and a ‘deep rough’ mutant 
E.coli. This antibody reacts with most E.coli given the 95% homology across all strains. It 
was anticipated this experiment would work based on reducing the number of washing 
steps since no secondary antibody was required, however figure 5.3.9 is a scan of result of 
this experiment at 532 nm and show no specific antibody reactivity towards wild-type 
E.coli. Non-specific binding appeared to have occurred but was due to bleed over of 
Baclight® Red signal, as previously observed in figure 5.3.1. Fixing did appear to reduce this 
effect. Based on independent experiments using rabbit serum, OmpA and E.coli antibodies 
it was determined that this assay, in our hands, was not suitable to continue for future 
detection of serum antibodies in patient samples. At this time in the study it became 
apparent an alternative method was needed to evaluate anti-bacterial antibodies in patient 
samples. 
 
5.3.3 Faecal detection of IgA-coated faecal microbes  
 
Sybr green was used to label faecal bacteria isolated from homogenised stool samples of 
patients and house-hold controls. Figure 5.3.10 is an early experiment with faecal bacteria 
isolated from a single healthy donor stool. The flow plots reveal a subpopulation of cells 
that are Sybr green positive. Bacterial cells can also be identified using light scatter 
characteristics alone providing an adequate threshold of detection has been established so 
that no more than a rate of 100 events per second are detected using sterile-filtered PBS 
alone. PBS containing unstained/stained bacterial cells were diluted to an approximate 
range of 5000 events per second to minimise risk of clogging the cytometer.  
 
The protocol for visualising faecal bacteria using Sybr green in a flow cytometer was based 
on a protocol used by Dr Alistair Noble (Imperial College London) to stain intra-epithelial 
microbes isolated from biopsy samples of patients with inflammatory bowel disease (IBD). 
Here, Sybr green staining has been used as a refinement to earlier published work using 
faecal flow cytometry where no attempts have been made to separate faecal bacteria from 
other particulates within stool (Palm et al., 2014).   
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   FSc vs. SCc       30 min        60 min 
Figure 5.3.10 Optimisation of concentration required to visualise faecal bacterial cells with Sybr 
Green nucleic acid staining using flow cytometry.  Faecal bacteria were extract from a single donor 
provided as 100 mg aliquot for homogenisation and diluted 1:100 in PBS. FSc and SSc properties 
were used to identify faecal microbes from faecal debris. Identifying faecal bacteria was enhanced 
with with Sybr green staining diluted to 1/10,000 versus 1/100,000 for 30 min or 60 min and 
inspected on the flow cytometer.  
 
Further optimisation of Sybr green was performed with anti-human IgA and compared 
against faecal bacteria in an ME and HHC sample, by 1:100 and 1:1000 dilution of faecal 
bacteria in sterile-filtered PBS. We found 1:100 dilution most suitable for staining (see 
supplementary figures 5.1 and 5.2). 
 
A total of 19 samples were analysed from 2016 collections. The method for faecal IgA 
detection presented here was tested in an early experiment using a single matched severe 
ME patient and house-hold control. The percentage of IgA+ bacteria in the severe ME (57, 
F) patient was 21.3% compared to 6.37% in the HHC (60, M) (figure 5.3.11). The percentage 
of non-specific binding was 0.16% and 0.27% from patient and HHC respectively. The Sybr 
green staining was recorded at 52.7% in the patient versus 81.9% in the HHC. Although the 
percentage of Sybr Green is higher in the control, this should not make any difference to 
the percentage recorded for IgA detection.  
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The effectiveness of the Sybr green positive staining appeared to vary in both patients and 
HHCs. As an example, Sybr green staining pattern did not appear consistent in identifying 
bacteria within the faecal homogenate shown in the house-hold control (HHC), although 
the percentages suggested more were identified in the ME (21, F) patient compared to the 
HHC (55, F) at 54.8 % in ME and 66.4% in HHC (figure 5.3.12). In this pair, the percentage of 
isotype non-specific bind was recorded at 0.17% for the patient and 3.60% for the HHC. The 
percentage of IgA+ bacteria was the second highest in its group at 36.6%, over double the 
percentage compared to 16.5% measured in the HHC.  This pair represented the greatest 
difference in percentage between patient and HHC. This patient is also the second 
youngest at 21 years old and remains entirely bed-bound. 
 
As a third example of this dataset, another female ME (38, F) and HHC (69, F) pair showed 
more consistent Sybr+ green positive staining for faecal bacteria at 51.8% versus 70.1% in 
ME and HHC respectively (figure. 5.3.13). This patient presents the third highest percentage 
at 31.8% IgA+ bacteria compared with 17.0% IgA+ in the HHC control.  Sybr Green positive 
staining was 51.8% versus 70.1% for ME and HHC respectively. Non-specific bind with 
isotype antibody was 4.85% in ME versus 0.72% in HHC.
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ME, F (57)  IgA+ 21.3%  
Control, M (60)  IgA+ 6.37%  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.11 Flow cytometry data using faecal bacteria isolated from severe ME patient (top row) and their house-hold control (bottom row). Bacteria are gated using 
Sybr green fluorescence and measured for anti-IgA-APC binding to these cells recorded in the top right quadrant of IgA plots. Isotype control provides indicator for non-
specific binding events. Pseudo-colour shows areas of increasing cell numbers.  Numbers within each gate, represent the percentage out of total events recorded. 
Isotype Control Anti-IgA-APC 
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B 
A 
ME, F (21)  IgA+ 36.6%  
  Control, F (55)  IgA+ 16.5%  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.12 Flow cytometry data using faecal bacteria isolated from severe ME patient (top row) and their house-hold control (bottom row). Bacteria are gated using 
Sybr green fluorescence and measured for anti-IgA-APC binding to these cells recorded in the top right quadrant of IgA plots. Isotype control provides indicator for non-
specific binding events. Pseudo-colour shows areas of increasing cell numbers.  Numbers within each gate, represent the percentage out of total events recorded. 
Isotype Control Anti-IgA-APC 
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ME, F (38)  IgA+ 31.8 %  
  Control, F (69)   IgA+ 17.0 %  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.13 Flow cytometry data using faecal bacteria isolated from severe ME patient (top row) and their house-hold control (bottom row). Bacterial are gated using 
Sybr green fluorescence and measured for anti-IgA-APC binding to these cells recorded in the top right quadrant of IgA plots. Isotype control provides indicator for non-
specific binding events. Pseudo-colour shows areas of increasing cell numbers.  Numbers within each gate, represent the percentage out of total events recorded. 
Isotype Control Anti-IgA-APC 
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Figure 5.3.14 Summary of the relative abundance of IgA-coated faecal bacteria in 8 pairs of severe, 
house-bound ME/CFS patients versus house-hold (control) and 3 unmatched patients. Right, 
paired and unpaired samples; left, lines indicate pairing between patient and house-hold control, 
red line represents patient 9, see table 5.3.1. Paired t-test did not show any significance difference 
between the two groups. 
 
 
In summary, the percentage of IgA-coated faecal bacteria all 19 samples analysed was 
determined by subtracting non-specific antibody staining as measured using isotype 
antibodies (figure 5.3.15). The average percentage of IgA+ bacteria found in severe ME 
patients was 25.87 ± 7.42% SD versus 20.32 ± 7.35% SD in HHC. Although the differences 
with mean IgA+ coated bacterial was not significant when using a paired t test (p = 0.09). 
Non-specific binding events were similar across both groups at 3.56 ± 2.40% SD for ME 
versus 2.67 ± 2.35% in HHC. When matching patient with their HHC in figure 5.3.14 (right-
side plot), there appears to be an emerging trend for severe patients to have more IgA-
coated faecal microbes than that of their designed house-hold control. The red line in 
figure 5.3.14 highlights a severe patient (21, F), and HHC (55, F) (flow data plots shown in 
figure 5.3.12), which had greatest difference between measured IgA+ bacteria compared 
the other pairs.  
 
- Proportion of observed IgA+coated faecal bacteria changes with time  
 
In 2017 an additional 20 faecal samples were studied including some samples from a 
second stool sample collected from patients and their house-hold control almost a year 
since the previous collection and analysis. Table 5.1.1 summaries 12 of the original 19 
samples visited in 2016 (highlighted in yellow) that were revisited almost a year later 
n.s. 
 2016 collection 
9 
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(2017). In addition, 6 new severe ME patients were recruited in 2017 as well as 2 new 
house-hold controls contributing 2 matched pairs. 
 
In the following chosen examples of this flow data the acquisition of samples has been 
adapted to show proportions of Sybr green negative (Sybr-) events to establish the 
proportion of IgA antibody reactivity in each sample that may have occurred in instances 
where Sybr green staining has been less effective. The percentage of IgA+ bacteria in figure 
5.3.15 shows 27.3% IgA+ in ME (27, F) compared to 11.3% IgA+ in the HHC (60, F). Review of 
the first samples from this pair in 2016 (supplementary S5.2) revealed a profile of 21.5% 
versus 26.5% IgA+ in patient and control, respectively.  The percentage of Sybr- IgA+ events 
were 6.56% in ME and 10.6% in HHC. Isotype antibody reactivity was higher in HHC at 
5.71% compared to 1.54% in ME. 
 
The youngest ME patient within this group was 19 years old in 2017. The patient had also 
previously donated to this study alongside the same HHC. The samples they provided in 
2017, showed similar profile of IgA+ coated bacteria within both persons, figure 5.3.16. The 
percentage of IgA+ bacteria was closely similar, as before, at 11.8% in ME (18, F) and 13.0% 
in HHC (55, F).  In 2016, both these samples had a higher proportion of IgA-coated faecal 
bacteria with the patient’s sample profile was recorded at 29.5% compared to 21.1% in the 
control (supplementary figure S5.6). Once again, the Sybr+ green staining in figure 5.3.16 
appears greater in HHC at 66.7% versus 53.1% in ME. Interestingly, 11.2% of IgA+ events for 
HHC were recorded in the Sybr- region, compared to 4.48% in ME (fig. 5.3.16). Non-specific 
binding is also higher in HHC sample at 3.95% versus 1.24% in ME.  
 
Figure 5.3.17 is another example of a follow up a year later showing the profile of IgA+ can 
change from sample to sample. In this most recent sample, the percentage of IgA+ bacteria 
was recorded at 5.09% in ME (38, F) compared with 6.56% in HHC (69, F). The HHC has a 
greater proportion of Sybr- IgA+ events at 11.5% compared with 8.45% in the patient. This is 
contrasted to the 2016 data obtained for this pair shown previously in figure 5.3.13 which 
showed 31.8% in the patient compared to 17.0% IgA+ in the control. Both samples showed 
low non-specific antibody reactive: 0.27% ME versus 0.55% HHC. Less non-specific antibody 
binding was seen in the HHC compared to 4.85% in the previous year (figure.5.3.13) 
 
  
 
 
 
 278 
Two non-paired severe ME patients revealed interesting IgA+ antibody staining patterns. 
The percentage of Syb+ IgA+ in the first patient (40) was 17.9% compared to 2.40% Sybr- 
IgA+ events (figure 5.3.18A). The Sybr+ IgA+ pattern was the clearest from all samples 
demonstrating an obvious subpopulation of IgA+ faecal bacteria. The percentage of non-
specific antibody reactivity was all low at 1.03%. This other patient (54) who entirely bed 
bound (figure 5.3.18B) showed a similar percentage of Sybr+ IgA+ bacteria at 17.3% and 
more Sybr- IgA+ events recorded 11.4%. Although the staining in this patient was not as 
discrete as in the previous patient. Isotype antibody reactivity was slightly higher at 4.83%. 
No data had been collected for these patients the previous year since these patients had 
not yet been recruited part of the study.
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A ME, F (27)     27.3 %  
B Control F (60)    16.5 %  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.15 Flow cytometry data using faecal bacteria isolated from severe ME patient (top row) and their house-hold control (bottom row). Bacteria are gated using 
Sybr green fluorescence and measured for anti-IgA-APC binding to these cells recorded in the top right quadrant of IgA plots. Isotype control provides indicator for non-
specific binding events. Pseudo-colour shows areas of increasing cell numbers.  Numbers within each gate, represent the percentage out of total events recorded. 
Anti-human IgA Isotype Control 
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Anti-human IgA Isotype Control A 
B 
A  ME, F (18)   11.8%  
B  Control (55)   13.0%  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.16 Flow cytometry data using faecal bacteria isolated from severe ME patient (top row) and their house-hold control (bottom row). Bacteria are gated using 
Sybr green fluorescence and measured for anti-IgA-APC binding to these cells recorded in the top right quadrant of IgA plots. Isotype control provides indicator for non-
specific binding events. Pseudo-colour shows areas of increasing cell numbers.  Numbers within each gate, represent the percentage out of total events recorded. 
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A  ME, F (38)    5.09%  
B  Control, F (69)    6.56%  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.17 Flow cytometry data using faecal bacteria isolated from severe ME patient (top row) and their house-hold control (bottom row). Bacteria are gated using 
Sybr green fluorescence and measured for anti-IgA-APC binding to these cells recorded in the top right quadrant of IgA plots. Isotype control provides indicator for non-
specific binding events. Pseudo-colour shows areas of increasing cell numbers.  Numbers within each gate, represent the percentage out of total events recorded.
Anti-human IgA Isotype Control 
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Figure 5.3.18 Discrete IgA-coated bacterial subpopulations measured from faecal suspensions in 
two unpaired, severe ME patients recruited in 2017. Top (A), F (40) bottom (B), F (54).  
 
The flow cytometry data from the 2017 collections is summarised in figure 5.3.19. The 
range of IgA-coating of faecal bacteria in severe ME is greater than for house-hold control 
samples. This is due to one particular ME patient (highlighted as the red line in figure 
5.2.19B. The data for this HHC (60) and patient (27) pair is presented in figure 5.3.15. This 
pair previously studied in 2016 (see supplementary figure 5.2) revealed 26.5% (ME) versus 
21.5% (HHC) IgA+. Comparison of the two time points for the ME patient show the profile is 
similar at 26.5% in 2016 compared to 27.3% in 2017. Conversely, the HHC decreased from 
21.5% in 2016 to 11.3% in 2017. Unfortunately, as can be seen from figure 5.3.19, a reverse 
trend is found in 2017 showing most ME patients have less of a percentage of IgA+ faecal 
bacteria compared to their HHC: mean % IgA+ in ME was 10.72 ± 4.95 SD versus 9.73 ± 4.14 
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SD in HHC. There was very little difference on average between non-specific antibody 
reactivity in ME (1.87 ± 1.15% SD ME compared to 1.46 ± 2.90% SD in HHC). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.19 Summary of the relative proportion of IgA+ faecal bacteria detected in 14 severe, 
house bound ME patients versus 6 House-Hold Controls (HHC) recruited during 2017. (A) 
Percentage abundance of IgA-coated faecal bacteria in samples collected in 2017. (B) lines indicated 
pairing between severe ME patient and house-hold control. 
 
 
5.3.4 Serological markers of a leaky gut 
 
Thirty-eight complement inactivated serum samples were used to measure endotoxin (LPS) 
concentration and LPS-binding protein (LBP) as surrogate markers for intestinal 
permeability. Both screening assays were performed consecutively on same aliquot of 
serum per patient and house-hold control sample. The endotoxin screen was performed 
firstly, followed by the LBP assay within 24hrs on serum kept at 40C.  The serum samples 
had undergone one freeze-thaw cycle in total. Samples from mild/moderate ME/CFS were 
more freely available since these patients were able to attend the hospital during a pre-
arranged visit during 2015. The data obtained for LPS and LPB in these samples showed no 
clear differences between these groups (figure 5.3.20).  
 
 
 
 
 
 2017 Collection 
18 
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Figure 5.3.20 Serum endotoxin activity and LBP concentrations measured in 14 Severe (S), 14 
Mild/moderate ME (M) and 10 House-Hold Controls (HHC) as markers for bacterial translocation. 
The horizontal bars in both plots for LPS and LPB in figure 5.3.20 represent the median values for 
reaction time (RT) and concentration (μg/ml) respectively. Error bars represent the standard 
deviation 
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5.4 Discussion 
 
The results from this chapter provides a new insight into the pattern of IgA-coated faecal 
microbes in severe, house-bound ME patients. To date, there are no clinical biomarkers 
reflecting the status of the intestinal immune system and its interactions with luminal microbes. 
Previous studies have assessed the composition of the ME/CFS microbiome with data limited to 
the general ME/CFS population and no information about how changes in the microbiome may 
relate to severity of ME. Giloteaux et al. and others have reported a general reduction in 
microbial diversity in the general ME/CFS population as well as increases in Gram negative 
Proteobacteria which are more abundant in inflammatory environments such as IBD and 
provide source of bacterial LPS (Giloteaux et al., 2016; Sartor, 2011). Based on the current 
available data, there is a lack of consensus on the precise pattern of dysbiosis and how this is 
related to causality in ME/CFS. Indeed, any disturbances within the ME microbiome will alter 
dynamic feedback mechanisms with the gut immune system and reactivity to certain microbes 
that may give indications of underlying mechanisms driving changes in the immune system. This 
needs to be addressed in further studies of additional immune parameters for possible 
additional biomarkers, such as leaky gut.  
 
We hypothesised that severe ME patients have increased intestinal permeability which can 
impact immunity by allowing intestinal microbes to be exposed directly to the local and 
subsequently systemic immune systems. The mucosal immune response was examined for 
production of secretory IgA (sIgA) reactive with faecal bacteria isolated from the patient’s own 
stool. Indeed, faecal bacterial flow cytometry has been established for some time with different 
variations in faecal sample preparation and staining (van der Waaij et al., 1994). To refine the 
method used by Palm et al., 2014, faecal microbes were stained with Sybr Green nucleic acid 
stain to exclude faecal debris, electronic noise and small bubbles registering as events within the 
flow cytometer. This appeared to work well in most samples, however IgA+ reactivity was also 
apparent in Sybr green negative fractions suggesting some microbes may not stain as effectively. 
The effectiveness of Sybr green staining it likely to depend on the stool consistency and the 
composition of an individual’s microbiota as many bacteria have differences in the structure and 
design of their cell wall. This is a similar problem to the one discussed earlier regarding DNA 
extraction from bacteria within complex samples such as human faeces where the diversity and 
complexity of the community structure of the microbiota is the greatest compared to any other 
site in or on the human body.  
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The protocol for detection of IgA-bound faecal bacteria was trialled and optimised with 
Sybr green staining using one of the first patient/house-hold control samples collected in 
2016. The IgA profile in this patient and house-hold control (fig 5.3.11) showed a higher 
proportion of IgA+ coated bacteria in ME: 21.3% versus 6.37% in the HHC. This result was 
encouraging and demanded further investigation using more samples, since potentially, 
IgA-coating might be a useful immune marker to describe interactions between microbes 
and the immune system and may have relevance in the context of the status of the 
integrity of the intestinal barrier. On the latter point, inflammation in active IBD causes 
tissue damage and destruction of the intestinal barrier and as discussed in the introduction 
to this chapter, anti-microbial antibodies may have some diagnostic relevance in this 
process (Mitsuyama et al., 2016; Strober & Fuss, 2011). The integrity of the intestinal 
barrier is essential for innate immunity via PPRs displayed on the epithelial cells to which 
commensal bacteria can bind and signal anti-inflammatory immune responses as well as 
producing anti-inflammatory molecules such as butyrate which further enhance T(reg) 
responses and HDAC activity to promote changes in gene expression that support epithelial 
barrier integrity and tolerance to intestinal bacteria (Bordin et al., 2004; Vanhoutvin et al., 
2009; Zhou et al., 2018). Without the proper regulation and exclusion from the luminal 
environment, commensal bacteria can infiltrate the intestinal epithelial barrier providing 
non-self antigen simulating inflammation and tissue damage by increasing activation 
immune cells such as DCs and macrophages to produce pro-inflammatory cytokines which 
favour Th1/Th17 proliferation.  
 
Under normal conditions in the intestine, T-cell independent IgA production is supported 
through interaction of B cells with DCs which produce retinoic acid inducing α4β7 integrins 
and chemokine receptor 9 expression on circulating B cells to home to the intestinal 
mucosa and differentiate within the lamina propria into plasma cells secreting sIgA 
(Fagarasan et al., 2010; Mora et al., 2006).  DC-derived factors such as BAFF and APRIL 
further bind to B cells and enhance class switch recombination (CSR) from IgM to the IgA 
isotype (Berkowska et al., 2015).  However, an altered pro-inflammatory T cell environment 
driven by increases in intestinal permeability could led to more T cell dependent 
production of mucosal IgA secreted by plasma cells in the lamina propria governing somatic 
hypermutations and enhancing antibody affinity towards specific microbial antigens in the 
intestine. For example, T-follicular helper (Tfh) cells interact with B cells in the GCs of the 
lamina propria through CD40L presented on activated CD4+ T cells increasing CD40 
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intracellular signalling which causes activation-induced cytidine deaminase (AID) within B 
cells to undergo affinity maturation and CSR to IgA antibody production (Berkowska et al., 
2015; Muramatsu et al., 2000; Rescigno, 2014; Shulman et al., 2013). Moreover, Th17 cells 
and their associated cytokines IL-17, IL21, and IL22 have been shown to induce strong 
proliferative responses in B cells triggering CSR and increased antibody production with 
blockading of IL-17 signalling leading to reduction in the size and number of germinal 
centres where naïve B cells encounter antigen and undergo affinity maturation 
(Mitsdoerffer et al., 2010). IL-17 has been shown to promote intestinal IgA responses to 
intestinal infection although it did not affect the development of IgA+ memory B cell 
responses (Huang et al., 2017). Under homeostatic conditions, DC and Treg cell derived 
cytokines,  TGFβ and IL-10, represent a major T cell independent pathway which leads to 
the differentiation of B cells into antibody secreting plasma cells with affinities for lipid and 
carbohydrate structures on bacterial cell surfaces that are consider to be ‘natural’ of innate 
antibodies which help stop microbial translocation across the epithelial barrier (Berkowska 
et al., 2015; Litinskiy et al., 2002; Macpherson et al., 2000). Finally, it has been documented 
that serum level of IgM and IgA reactive antibodies against bacterial LPS have been found 
to be higher in patients with CFS as well as in major depression disorder (Maes et al., 2012; 
Maes, Mihaylova, et al., 2007).  
 
Leaky gut is commonly associated in IBD as a consequence rather than a direct cause with the 
majority of current IBD therapies target inflammatory pathways with limiting degrees of efficacy 
(Shimshoni et al., 2015). Potential therapies directed at modulating the microbiome and 
restoration of the gut barrier are highly likely important targets in future treatments.  This is 
further substantiated by the fact that a high percentage of IgA-coated microbes have been 
reported in IBD patients and subsequently isolated and sequenced to identify specific bacterial 
taxa associated with driving inflammation in germ-free mice (Palm et al., 2014). Whilst IBD is an 
extreme example of loss of intestinal barrier integrity; the increases in the proportion of IgA-
coated bacteria may be a new marker for intestinal permeability that can be applied to other 
diseases associated with permeability and intestinal immune system defects. 
 
A total of 11 severe ME patients and 8 house-hold controls were recruited in 2016. The original 
recruitment target of 35 patients had previously been determined using a statistical power 
calculation based on the differences in endotoxin measurements found serum from IBD patients 
versus healthy controls (Rojo et al., 2007). Home visits required a significant amount of 
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organisation and coordination to ensure samples were collected and processed as quickly as 
possible. Unfortunately, it was not possible to perform experiments on fresh samples, so faecal 
aliquots were processed and stored at -800C on the day of collection and examined at the end of 
the recruitment phase. Simultaneous processing of all these samples occurred in a single day 
and were analysed in a blinded fashion.  An emerging trend for increased IgA-coating was found 
in the majority of severe ME patients compared with their respective house-hold control (HHC), 
fig. 5.3.14. Most interestingly is patient 9 in this figure which had the second highest proportion 
of Sybr+ IgA+ bacteria (36.6%) and the biggest increase compared with the HHC. This patient was 
visited in a completely darkened room and was highly sensitive to any light and sound and 
speech was difficult. Even though all the patients considered in this work are referred to as 
severe, there is still considerable variation between them. Whereas, some have no sensitivity to 
light or sound and are able to manoeuvre around the house, others are almost entirely bed-
bound. It is important to note that the conception of this study occurred prior to the 2015 when 
the Institute of Medicine gave a recommendation to change ME to systemic exertional 
intolerance disorder (SEID) (IOM et al., 2015). New diagnostic criteria are continuously being 
reviewed with no consensus on the best criteria to use in ME research. 
 
With the exception of one matched pair, all samples used in this work were gender matched, 
see table 5.2.1. Age is a confounding factor in this study and is known to be important for the 
immune system (Magrone et al., 2013), but emphasis should be given to the fact that 
environmentally matched samples obtained from the same house-hold were made a priority for 
microbiome analysis. Unlike mice, diet and housing factors are almost entirely difficult to control 
in humans. Therefore, the inclusion of healthy same house-hold controls was an attempt to 
control for important co-variants of microbiome variation, lifestyle, diet and behaviours. Many 
of the paired samples are relatives of one another therefore share genetic similarities as well as 
exposure to the same house-hold environment. Joosens et al. were the first to show unaffected 
relatives of patients living with Crohn’s disease exhibit distinct pattern of intestinal dysbiosis 
with evidence for decreased species Collinsella aerofaciens and Escherichia coli-Shigella group 
and increase RA of Ruminococcus torques compared with healthy controls (Joossens et al., 
2011). Intestinal permeability has been reported at a two-fold increase in Crohn’s and relatives 
compared to conventional healthy controls suggesting this to be a contributing factor and 
potential disease mechanism (Hollander et al., 1986). Indeed, first degree relatives of IBD 
patients have a 1 in 10 risk of developing the condition and taking together with current 
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microbiome data indicate a significant role for gut dysbiosis and leaky gut in causing disease 
(Russell & Satsangi, 2004). 
 
The availability of a second stool sample from some of the patients studied in 2016 gave 
opportunity to re-examine IgA reactivity to faecal microbes in these patients and their HHCs. 
The level of IgA+ microbes was similar or decreased in ME. Out of the 12 ME patients revisited, 
only 6 were included with a HHC. Patient 18, a daughter aged 27 matched with her mother aged 
60 in figure 5.3.16 was convincingly higher on this occasion but had previously showed no 
difference the previous year (supplementary figure 3). The result highlights the dynamic nature 
of IgA production against intestinal microbes and raises significant questions. For example, are 
there qualitative differences in the bacterial taxa coated with IgA in severe ME compared with 
HHC; do systemic IgG antibodies exist against these IgA-coated bacteria? This list is not 
extensive; however, further work is needed to see how faecal IgA-coated bacteria proportional 
differ over time and if this can be attributed to disease worsening. 
 
Many of the severe ME patients produced visibly smaller amounts of stool which were compact 
and hard to manipulate indicating dehydration. This will have an impact of the total number of 
bacteria within the sample, however IgA measurements are provided as a percentage of total 
faecal bacteria is not affected by the variation of the numbers of events recorded in each 
sample. Other research has examined the role of serum IgA against a limited number of 
enterobacteria using an indirect ELISA containing the LPS of 7 different species (Maes et al., 
2007). This work has been further extended to suggest that treatment of a leaky gut can 
improve ME symptoms based a ‘leaky gut diet’ and supplementation with L-carnitine, CoQ10, 
lipoic acid and taurine (Maes et al., 2007). In this case study, this diet focused on exclusion 
certain dietary allergens, such as dairy, as well as adherence to low-carbohydrate and gluten-
free food in a single 13 year old girl who was already lactulose intolerant (Maes et al., 2007). 
 
During the process for obtaining research ethical approval, a new method was explored to 
help determine if alterations in intestinal barrier permeability exist in ME/CFS patients. 
Using a novel whole cell bacterial microarray-based approach to screen patients’ serum for 
antibodies against intestinal bacteria immobilised onto a nitrocellulose-coated glass slide. 
Bacteroides thetaiotaomicron, Enterococcus gallinarum, Escherichia coli and Akkermansia 
muciniphila were assessed for their ability to be printed on a microarray, figures 5.3.8 & 
5.3.9. Microarray printing offers huge scope to include hundreds of representatives of the 
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human gut microbiota compared with relative few microbes have been targets for 
seroreactivity using flow cytometry (Haas et al., 2011). The growth kinetics for each strain 
enabled calculation of the growth rate, μ, and estimation of the time-point at which cells 
had reached mid-exponential growth phase for subsequent immobilisation on to the 
microarray (data not shown). Mid-exponential growth phase was chosen for the purposes 
of obtaining a high cell viability count so that upon fixing cells in 4% formaldehyde the 
majority of cells would remain intact (“whole-cell”) when screened against patient serum. 
Thus, any serum antibody reactivity detected will be against bacterial surface antigens such 
a LPS, fimbriae, or pili etc. 
 
The rationale for using whole cell bacteria immobilised onto a microarray slide, follows that 
the bacterial cell surface is decorated with an array of molecules such as outer membrane 
proteins, lipopolysaccharide, flagella (H-antigens), capsules and fimbriae or pili and that the 
surface molecules are involved in bacterial adherence and are important in establishing an 
infection (Thirumalapura et al., 2006). Finally, antibodies directed against the bacterial 
surface antigens can neutralise the bacteria and afford protection particularly against 
invading extracellular bacteria leaking from the gut.  
 
Systemic priming to intestinal microbes has been documented in IBD and suggested to drive 
chronic immune activation and consequently disease progression via translocation of intestinal 
bacteria, including their products such as LPS (Haas et al., 2011; Elkadri et al., 2013). 
Experiments performed in specific-pathogen free mice demonstrate compartmentalisation 
between the intestinal mucosal immune system and systemic immunity where IgG responses to 
commensal bacteria are undetectable unless these mice have been engineered with deficiencies 
in bacterial sensing through toll-like receptor signalling (Slack et al., 2009). On the contrary, 
antimicrobial antibodies have been measured healthy humans against a limited number of 
representatives of commensal bacteria using flow cytometry (Haas et al., 2011). More evidence 
suggests gram-negative commensals can stimulate systemic immune responses to produce IgG 
antibodies reactive against commensal antigens, and murein lipoprotein (MLP) on Gram 
negative bacterial cell walls (Zeng et al., 2016). MLP was found as a major source for stimulating 
IgG responses in mice and humans. Passive transfer of anti-MLP IgG antibodies in mice to 
demonstrated protection against Salmonella infection (Zeng et al., 2016). This study underpins 
commensal driven immune response have widespread systemic consequence for the protection 
against pathogens. 
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Failed attempts to successfully validate the bacterial array using wild-type OmpA positive 
and negative stains was further compounded by the time home visits became underway 
with challenges confronted in obtaining blood necessary to perform this type of screening 
assay. To that end, the solid phase bacterial microarray assay was abandoned in favour for 
the ease of availability of stools samples to explore anti-IgA responses to faecal bacteria. 
LPS-Binding Protein (LPB) is another indicator of LPS leakage into systemic blood serum 
which could be an effect of microbial translocation. LBP increases binding of circulating LPS 
to soluble CD14, but its quantification can be more advantageous than detection of LPS 
alone, since it does not suffer of interference from blood that have been well documented 
using LAL assays. We found no evidence of these markers being any different in ME 
patients compared to house-hold controls. This result is in contrast to an earlier report 
which suggests ME patients have increased bacterial translocation based on elevated 
plasma LPS, CD14 and LBP concentration in 48 ME/CFS patients and 39 controls, compared 
to just 12 severe patients and 10 HHCs (Giloteaux et al., 2016). Interestingly we observed 
much less LBP in both patients and HHC ranging from 8 ng/ml to 4.38 μg/ml compared to a 
median of 12.38 μg/ml for healthy controls in this previous study. However, our 
observations for LBP concentration are within the range of healthy humans reported to be 
between 1.85 – 17.4 μg/ml in serum in a study of serum LBP concentration analysed in 63 
severe sepsis and septic shock patients whose level of LBP was found to increase 10 fold in 
range from 11.8 μg/ml to 275 μg/ml which also reduced LPS activity as expected (Zweigner 
et al., 2001). 
 
To conclude, the representation of anti-microbial antibodies in patients compared with healthy 
controls is proposed as an additional marker for interpretation and understanding of how the 
intestinal microbiota interacts with the immune system in pathological circumstances. Flow 
cytometry is a well-established technique, shown in this chapter to be suitable for measuring 
anti-IgA-coating in faecal samples. Skill of the flow cytometer operator is needed to confidently 
lower the threshold voltages to determine the relatively small size of bacterial cell within the 
area of the data plot. Bacteria are approximately 1 µm with pure cultures successfully 
demonstrating light scatter characteristics that were used to examine faecal suspension of 
bacteria.   This can be achieved using forward and side scatter light properties alone, although it 
is worth noting particles of a similar size that or not microbial, e.g. food particles may also be 
detected. Thus, the data here has shown that Sybr green appears to be a useful refinement to 
examine faecal microbes and should be used regularly, but it must also be acknowledged that 
composition of the microbiota will also impact the success of this labelling. Where possible we 
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have tried to include data for Sybr- IgA+ fractions of the microbiota. From our analyses the 
differences between the percentage of IgA+ coated to total faecal bacteria between severe ME 
patients and HHCs is inconclusive but quantitative differences are distinct from qualitative 
differences.  Therefore, an outstanding question remains, what are these IgA antibodies specific 
towards? Future work is needed to isolate these bacteria and identify their taxonomic profile as 
well as the status of IgA-coated microbes in relation to worsening of symptoms severity for 
ME/CFS. In the first dataset, from collections made during 2016, we identified a non-significant 
trend of increased IgA-coated faecal microbes in severe ME compared to house-hold controls. 
Repeat sample collection, in 2017, reversed this trend. Whilst sample collections for both years 
were conducted during the season of spring/summer, it is worth noting age, gender and 
seasonal variations influence SIgA and are indeed reported lower in females, increasing in both 
genders with age (Weber-Mzell et al., 2004). Certainly, faecal IgA concentration and microbial 
specificity appear relevant in the context of IBD pathology and gut permeability defects in these 
cases (Adams et al., 2008; Hollander et al., 1986; Palm et al., 2014; Targan et al., 2005; 
Viladomiu et al., 2017). The data presented here in severe ME warrant further investigation in 
larger, better defined patient cohort, preferably taking multiple samples to assess the dynamics 
of intestinal secreted IgA reactivity over time.  
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6.0 General Discussion 
 
The original hypothesis for this study suggested increased intestinal permeability exposes 
the local intestinal immune system to a quantity of non-self-bacterial antigens that 
facilitates low-grade chronic inflammation and possible autoimmunity (Kelly et al., 2015). 
The mechanism behind this theory is that chronic immune activation in ME/CFS causes 
oxidative and nitrosative stress (O&NS) and prolonged levels of pro-inflammatory cytokines 
via activation of NF-kB (Morris & Maes, 2014).  Serum IgM levels against damaged lipid cell 
membrane components such as palmitic and myristic acid present as neo-epitopes, 
previously hidden from the immune system (Maes et al., 2006).  ROS such as peroxides and 
superoxides (H2O2 and 2O2-) are generated by the immune system to kill pathogens injected 
by phagocytes (Fang, 2011). Recently a linked has been proposed between chronic immune 
activation of ROS in serum causes mitochondrial dysfunction (Blomberg et al., 2018). 
Critically, oxidation of cysteine residues in pyruvate kinase M, an enzyme associated with 
the pyruvate dehydrogenase complex (PDC) can block production of pyruvate which 
supplies energy in to the citric acid cycle (Anastasiou et al., 2011). 
 
We anticipated to replicate recently reported disturbances in severe patients, in particular 
aerobic energy metabolism affected in ME/CFS with increased lactate production (arising 
from pyruvate) and breakdown of amino acids as an alternative energy source for the citric 
acid cycle to produce ATP (Fluge et al., 2016; Germain et al., 2017; Naviaux et al., 2016; 
Yamano et al., 2016). Many individual serum metabolites others have reported were found 
to be no different in our severe ME patients. In some cases, one or two samples were 
distinctly separate from the rest of the group and these have been marked with their 
sample number. Our study is most comparable with Armstrong and colleagues who also 
used 1H-NMR to analyses serum and faecal water metabolomes (Armstrong et al., 2015, 
2017). They, and others, have suggested disturbed energy metabolism through inhibition of 
glycolysis that may be linked to mitochondrial dysfunction through chronic immune 
activation of oxidative stress pathways (Armstrong et al., 2017; Fluge et al., 2016). We did 
not find elevated glucose, or reduced lactate (fig. 4.3.11), glutamate and pyruvate in 
patients as suggested by Armstrong et al, and therefore cannot conclude glycolysis is being 
affected. Another metabolite we were expecting to find reduced was hypoxantine, a 
breakdown product of ATP. Several amino acids were expected to be reduced in the event 
of them being used as an alternative to carbohydrate energy sources (gluconeogenesis) for 
the citric acid cycle, but this was not replicated either. To this end, serum citrate 
  
 
 
 
 295 
concentration was the same for all groups, (table 4.3.3). Interestingly, faecal y-
butyrobetaine was notably higher in 3 severe ME patients, and is a metabolite of L-
carnitine which is essential for transfer of acetyl-CoA into the mitochondrial matrix for 
energy production from the beta oxidation of fatty acids. Increased lactic acid producing 
bacteria have been reported in CFS patients, but we did not measure any differences in 
both faecal and serum concentrations for lactate (Sheedy et al., 2009). Based on the serum 
profile we cannot provide evidence for increased intestinal permeability since microbial-
derived metabolite butyrate was not detected. The suggestion of increase amino acids in 
serum was also not replicated in our cohort, nor were they reduced due to increased 
bacterial fermentation to reproduce SCFAs (Armstrong et al., 2015).  
 
Both our faecal water and serum metabolome profiling used a small number of samples. 
Fourteen was the maximum group size, used in serum, for severe ME compared to 34 
ME/CFS patients included in Armstrong and colleagues work. The number of patients we 
analysed the faecal metabolome in was just 11 severe patients and 6 HHC as these samples 
were collected in 2017. Again, we found no significant changes in the faecal metabolome of 
ME/CFS patients with respect to increased SCFA production entering energy metabolism, 
as previously reported (Armstrong et al., 2017).  The sequence data (dataset C) for these 
samples also provided no significant findings, based on 16S V4 amplicon sequences (fig 
3.3.32). Earlier collections in 2016 analysed using shotgun metagenomics did provide some 
significant changes for reduced F. prausnitzii and increased Eggerthella spp. and 
Oscillibacter spp. in severe ME. Table 3.3.2 compares the overlap of the same patients and 
HHCs providing samples in 2016 and 2017 to produce both datasets. We had expected to 
find the opposite of increased SCFAs, particularly the anti-inflammatory mediator butyrate, 
given its production is associated with F. prausnitzii and protection against colitis in rodents 
(Zhou et al., 2018). Despite re-analysing a different aliquot from some of the same samples 
collected in 2016 from the same patient, and repeated collections from these patients in 
2017 as well as recruiting brand new patients, we did not see a reduction of F. prausnitzii in 
patients based on 16S amplicon sequencing. Many of the patients and HHCs did appear to 
associate according to their respective pairing based on 16S composition (fig. 4.3.28), 
which does reflect house-hold exposure and a degree of shared diet can influence the 
microbiota, although we could not request dietary information. 
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To perform correlations between the composition of the ME/CFS intestinal microbiome 
and the faecal and serum metabolomes, we would have needed to compare dataset C with 
our NMR data, as samples in these datasets were collected at the same time. To that end, 
we found insufficient difference between severe patients and controls for concentration of 
metabolites and differences in microbial composition to use a machine learning approach 
to produce a predictive model for diagnosing severe ME patients from house-hold controls. 
The relevance here to explain how the structure and metabolic role of the microbiota in 
various pathophysiological mechanisms, likely to exist in ME/CFS, may more severely 
disrupt host metabolism in some patients more than others. Such an approach would 
require many more data points, and a different study design integrating shotgun 
metagenomics with mass spectrometry to cover ten times more the number of metabolites 
based on comparison of the number of observations made by Germain and Naviaux. Under 
half the number of species of bacteria were observed in our shotgun metagenomic dataset 
compared to Nagy-Szakal and colleagues. The reasons for this were explained earlier, 
however, it is worth noting we observed 38.64±6.28 SD and 34.62±8.97 SD species in 
ME/CFS and HHCs, respectively, compared to 74.24±1.67 SE and 77.5±2.07 SE in their 
ME/CFS cohort and controls, respectively. We were unable re-perform shotgun 
metagenomics and instead produced dataset C using 16S-targeted amplicon sequencing. 
The two methods cannot be compared but it is apparent that 16S sequencing does not 
provide detailed functions of the microbiome and should be replaced with more 
informative shotgun metagenomic studies which provide functional pathway information 
that others have reported disturbed in ME/CFS which can then be better integrated with 
interpretation of faecal and blood metabolomes in patients.  
 
Nagy-Szakal and colleagues reported IBS status significantly altered the composition of the 
intestinal microbiome in ME/CFS. We did not objectively assess the IBS symptoms in our 
patients, but it is worth mentioning that all patients did have IBS-like symptoms, 
particularly abdominal pain and dietary intolerances in most cases to diary. Stress and 
anxiety are cofounding factors which influence the microbiota and are highly prevalent in 
ME/CFS patients and may predispose them to IBS (Lakhan & Kirchgessner, 2010).  At the 
genus level, Faecalibacterium, Roseburia, Dorea, Coprococcus, Clostridium, Ruminococcus 
and Coprocobacillus were associated  with ME/CFS with an emphasis on Faecalibacterium 
and Alistipes (Nagy-Szakal et al., 2017). Although, dataset A contains no controls, figure 
3.3.5 showed the biggest differences in RA for individual mild/moderate ME/CFS patients 
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was in the genera, Faecalibacterium, as well as Roseburia, Alistipes, and Oscillospira. 
Interestingly, we found the Eggerthella genus was more abundant in our severe ME 
patients (figure. 3.3.13A) which Nagy-Szakal and colleagues report one of its members 
Eggerthella lenta may be a marker for patients with IBS (Nagy-Szakal et al., 2017). We did 
not find a significant difference in the relative abundance of the genus Blautia between 
severe patients and HHCs (figure. 3.3.32) despite this being reported to drive separation of 
ME/CFS without IBS from controls (Nagy-Szakal et al., 2017). Blautia can account for 
anywhere between 2.5% to 16% of the total intestinal microbiota but is usually more 
abundant in IBS due to higher levels of gases produced as by-products of bacterial 
fermentation (Eren et al., 2015; Rajilić-Stojanović & de Vos, 2014; Vernocchi et al., 2016). 
Higher abundance of Blautia may also be reflective of Dorea spp. as a major contributor of 
hydrogen and carbon dioxide gas production, which Blautia can convert into acetate 
(Rajilić-Stojanović & de Vos, 2014). To that end, it is important to separate IBS co-morbidity 
as a cofounding factor influencing the ME/CFS microbiota and makes it more likely an 
ME/CFS associated profile will be influenced by low in abundance individual species. In 
addition to the lack of being able to reproduce increased SCFA production in ME/CFS we 
did not find any evidence for increased microbial fermentation based on relative 
abundances of Clostridium spp. or Bacteroides spp. either. Finally, we cannot conclude 
there is any difference in the diversity or number of bacteria found in ME/CFS and HHCs. 
 
Germain and colleagues performed pathway analysis on 74 altered metabolites they found 
using mass spectrometry. This showed taurine metabolism had the highest impact factor in 
ME/CFS given its decrease in patients, 3 end products in primary bile acid biosynthesis in 
this metabolic pathway that were also found reduced in ME/CFS patients (Germain et al., 
2017).  In our severe patient cohort, faecal taurine was only found in 3 patients in high 
concentration (supplementary 4.1), and importantly none of the HHCs. In these patients it 
may suggest increased bile salt hydrolysis. Bile salts enable emulsification and digestion of 
dietary fat, uptake of vitamins, and maintenance of intestinal barrier function, but can 
become metabolised into secondary and tertiary bile acids by members from diverse 
genera including  Bacteroides, Clostridium, Lactobacillus, Bifidobacterium, Enterobacter, 
Eubacterium and Escherichia (Vernocchi et al., 2016). Microbial deconjugation of taurine is 
the first step which prevents active uptake to the liver for recirculation. High concentration 
of free bile acids can then become metabolised into secondary bile acids that are able to 
diffuse lipid bilayers causing disruption to the cell membrane and regeneration of ROS 
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which can cause DNA damage and mutation and mitochondrial dysfunction that have been 
associated with a risk of colon cancer (Ajouz et al., 2014; De Boever et al., 2000). 
Observations of changes in bile acids metabolism in ME/CFS are relevant given they 
participate in energy regulation, glucose and lipid metabolism (Wahlström et al., 2016). 
CDCA was lowest in severe ME serum (fig. 4.3.32A) but compared with HHCs does not 
support evidence of liver toxicity damage as suggested by Germain and colleagues. 
Conversely active IBD serum provide in the same experiment was statistically higher for 
CDCA and CA compared to the other groups and may reflect increased bile acid re-uptake 
due to intestinal barrier breakdown. CDCA concentration may well be expected to be 
lowest in the severe group given these patients undergo significant periods of fasting or 
eating very little. This was also reflected by on average less faecal material provided at 
sample collection compared with HHCs. 
 
In summary, we have been the first to achieve shot metagenomic sequencing in severe, 
house-bound ME/CFS patients. The rapid evolution of next generation sequencing, 
guidance in designing the perfect microbiome study from methods of sample collection to 
analysis have arrived largely after they could be applied to this work. In the previous 
discussion chapters, it has emerged designing a study on ME/CFS is not straightforward and 
must be carefully thought out as there are many possible cofounders in these types of 
studies and is further complicated by the range of symptom complexes within ME/CFS 
which patients could be selected for and against, e.g. patients with or without IBS or PEM. 
The choice of these is dependent of the nature of the study and the available resources and 
methods to clinical assess these patients. The work presented in this thesis attempts to 
explore the impact of severity of ME/CFS symptoms. How these symptoms are objectively 
measured along with interpretation of symptoms questionnaires is not agreed 
internationally. Arranging home visits to patients and coordinating sample collections was 
enormously time consuming and expensive but did reveal severity of ME/CFS is still largely 
dependent on a matter of opinion and can have different interpretations and meaning 
from patient to patient. For example, out of the 17 patients visited, 4 demonstrated 
extreme hypersensitivity to light and sound. One patient in particular was bed-bound living 
in the basement to avoid sources of natural or artificial light and was extremely sensitivity 
to the quietest of sounds. Other severe patients were more mobile around the house, with 
symptoms vary from day to day. 
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Our efforts to minimise cofounding factors influencing the microbiome are demonstrated 
by the inclusion of house-hold controls. We have also taken the approach to adopt a more 
functional understanding of the microbiome in ME/CFS with the acquisition of 1H-NMR 
metabolomic profiling from faecal water and serum in an attempt to re-produce findings 
that have only recently populated the ME/CFS literature in the last two years. Again, these 
recent findings have come at a time when they could not influence our study design, 
particularly targeting known compounds in energy and lipid metabolism, as well as 
controlling for sampling methods and standard operating procedures used in these studies. 
For example, we originally set out to use serum for anti-microbial detection instead of 
plasma, which is the biofluid of choice in mass spectrometry studies. To address our 
hypothesis patients with ME/CFS have increased intestinal permeability we measured the 
proportion of IgA-coated faecal bacteria, based on the assumption increased IgA 
production to neutralise intestinal bacterial in a mechanism known as immune exclusion.  
Although we measured surrogate markers, LPS and LBP, and found no evidence of 
increased permeability, we gained an insight into the immune system interactions with the 
intestinal microbiota through sIgA interaction with the patient’s own faecal material versus 
microbes cultured and LPS alone. These results initially showed a trend for increased IgA-
coated bacteria in ME/CFS versus HHCs. Almost a year later this trend appeared to reverse. 
Further work is needed to measure the abundance of bacterial taxa with IgA+ and IgA- and 
to see if these correlate with increased antibodies in serum. This analysis recently been 
performed in adults versus the elderly and found differences in abundances of 
Clostridiaceae and Enterobacteriaceae were lower in the IgA+ for the elderly group 
(Sugahara et al., 2017).   
 
- Summary  
We draw this thesis work here to a conclusion with the suggestion that more focus is 
needed for longitudinal shotgun metagenomic studies in ME/CFS to see how functional 
pathways change in the ME/CFS microbiome and impact the disease with an emphasis of 
symptom severity and recommendation for the inclusion of house-hold controls. We set 
out to replicate existing findings of mild to moderately affected ME/CFS patients and to 
identify significant evidence for intestinal dysbiosis This is the first metabolome-based 
study of severely affected ME/CFS patients that incorporates the unique feature of same 
household healthy control subjects to mitigate against major environmental factors that 
contribute to population-level microbiome variation. On contrary to previous reports in 
  
 
 
 
 300 
ME/CFS, our findings fall short of a reduction in the diversity of the severe, house-bound 
ME microbiome when we compared them with this form of control. Indeed, several applied 
indices for measuring similarity between groups showed both severe ME and house-hold 
controls were more compositionally heterogenous than unmatched controls. Based on the 
current sample size, no clear pattern emerged from this data to suggest a role for specific 
members on the intestinal microbiome, except for the low abundance of F. prausnitzii. 
However, this species is not specific to ME/CFS and is well associated with IBS symptoms, 
also highly prevalent amongst the ME/CFS patient population. For that reason, more 
functional based studies examining the relationship between microbes and the host are 
encouraged, particularly with respect to microbial-immune and gut-brain signalling. As 
such, transcriptomic and proteomic analyses may further probe the metabolic activity, 
beyond the  predictive capability of whole-genome sequencing analysis. 
 
Based on comparing more than 50 metabolites in serum and faecal samples our findings do 
not replicate those of other ME/CFS metabolomics studies. Indeed, the lack of any 
particular finding consistent with altered metabolism in either faecal and serum 
metabolome of severe ME/CFS patients was surprising and appears to reject our earlier 
hypothesis. The only significantly altered serum metabolite we detected was the N-Acetyl 
groups from a1-acid glycoprotein which was significantly (p=0.009) increased in severely 
affected ME/CFS patients. This has previously been identified as a circulating biomarker 
predictive of the short-term risk of death and of possible relevance to ME/CFS, has been 
implicated in various pathophysiological mechanisms including inflammation, lipoprotein 
metabolism, and metabolic homeostasis (Fischer et al., 2014). 
 
Other methodological divergencies include the use of serum, in which small metabolites 
may be less stable than in plasma, and mass spectrometry in combination with different 
workflows with the capability of detecting much higher numbers (up to 600 or more) of 
metabolites (Germain et al., 2017; Naviaux et al., 2016). Targeted acquisition of 
metabolites in the future should be undertaken using more sophisticated workflows and 
MS, as previously described (Germain et al., 2017). Our targeted bile acid mass 
spectrometry analysis and quantitation in ME/CFS patients is a unique aspect of our study 
and has not been the focus of metabolome studies carried out to this date. However, 
consideration should be given to food intake and timing of the sample. Therefore, it is 
recommended integration of targeted metabolomics to characterise the status of energy, 
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lipid, and amino and bile acid metabolism in severe ME/CFS should also be a priority for 
future investigation. 
Finally, the pathogenesis of ME/CFS is likely to involve disruption of neural, neuro-
endocrine and immune signalling pathways communicating along the gut-brain axis. 
Indeed, GI symptoms and intestinal dysbiosis co-associate in several neurological and 
(auto)immuno-inflammatory disorders, including ME/CFS. It is apparent the difficulty 
excluding environmental influences known to cause microbiota population-level changes 
which make it challenging to identify specific ‘diagnostic’ microbial signatures. More 
information is needed to establish models for interaction between microbes and host 
physiology. Of interest for future studies, are microbial-immune interactions as a key 
regulator of microbiota-gut-brain communication. To that end, the final chapter of this 
thesis has shown it is possible to isolate faecal microbes from stool, to evaluate the 
proportion of faecal microbes bound by intestinal IgA which, we suggest, may be cell sorted 
and extracted for DNA sequence-based identification.  A future objective may be to 
elucidate specific members of the ME/CFS microbiota eliciting strong mucosal derived and 
systemic antibody production found in serum, compared with house-hold relatives. A 
reasonable aim would be to determine the subset phenotype and specificity of T cells for 
reactivity towards intestinal microbes.  Various assays can be used to measure cytokines 
associated with T-cell induction and proliferation in response towards the patient’s 
endogenous microbiota extracted from faecal samples. Indeed, we hypothesise a leaky gut 
causes induction and priming of immune cells within the intestinal submucosa which 
stimulates trafficking of encephalitogenic T cells to cross the blood-brain barrier in to the 
CNS. Here, flow cytometry would be a powerful method to explore the expression of 
gut/brain homing markers expressed on the cell surface of these immune cells. This would 
be a significant attempt to go beyond the descriptive nature of high-throughput ‘omics 
technologies to better understand the potential for microbial-immune interactions to 
influence ME/CFS pathology, in addition to the metabolism as a feature of the intestinal 
microbiota.  
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Chronic Fatigue Syndrome – Symptom list   Date…….……… 
 
 
Name..…………………………………………     DoB…………………………… Occupation………...................... 
 
Onset of Fatigue:    Acute or Gradual onset  Viral symptoms   
 
 
Brief history of Fatigue: 
 
 
 
Main worries now:  Getting better Finances    Work    Serious illness    Wasting 
life   
Employment/School                          F/T P/T – hours/wk……. Nil….….since………….  
 
 
SYMPTOMS Y/N COMMENTS 
Post Exertional Malaise 
(PEM) 
 Time to onset                        Duration                        Severity 
 
Non-Restorative sleep  Difficulty getting off to sleep                Frequent wakening 
Early morning wakening                        Daytime sleeping 
Obstructive Sleep Apnoea                      Restless Legs 
New Headaches  Frequency              Severity              Location 
Sore throat +/- LN  Frequency 
Fever and Sweats  Frequency                         Mild    Mod    Severe 
Impaired 
Concentration 
 Brain fog 
Reduced STM   
Arthralgia  Joint swelling                                              Joint stiffness 
Myalgia  Never           Sometimes         All the time          Any muscle 
tenderness? 
Intol of sound & light  Overload 
Postural instability   
Depression  Mood                Anhedonia            Libido         Appetite            
Worthlessness             Tearful 
Anxiety  Persistent Anxiety                                   Episodic anxiety 
Panic attacks 
Fibromyalgia  Severity                                   How many areas 
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Activities               How far can you walk at maximum? 
   
Can you prepare a meal?   Y    N 
   
Can you wash yourself    Y    N 
Any leisure activity?Walking / Cinema / Eating out  / Visiting friends / Other 
For how long can you read a book?                      Watch a film?  
 
Personality before CFS: 
 
 
Treatments used to date: 
 
GET Yes No  When:   Helpful:  Yes No 
CBT Yes No  When:   Helpful:  Yes No 
SSRI Yes No  Which drugs  When  How long  
 
Alternative Therapies 
 
Reflexology Homeopathy Acupuncture Pilates      Meditation   Head Massage 
          
Yoga 
 
Dietary manipulation: No Yes What was this? 
 
Echinacea  Ginseng  INADA  CoQ10  Others 
 
Past Medical History 
 
 
 
 
Past Psychiatric History 
 
 
 
Systems Inquiry  CVS  Resp  GI  UG  NS
  
 
 
Smoke   Alcohol  Illicit drugs 
 
 
Present Medication      Allergies 
 
 
Social Support       Pets 
 
 
Family History 
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Examination 
 
Pulse  bp  Temperature   
 
Throat  Lymphadenopathy   
 
Joint swelling   Fibromylagia 
 
Heart   Lungs   Abdomen  Neurology 
 
Investigations 
 
FBC Hb WBC Platelets   
ESR      
AANT ANA GPC AMA SMA  
Ig’s IgG IgM IgA IMEP  
CRP TSH U/E LFT   
Anti-EM abs Positive 
Negative 
    
ANA Positive 
Negative 
Pattern Level     
      
 
Assessment 
 
 
Severity of Fatigue: Mild       Moderate        Severe   Very Severe 
 
 
Mild – mobile, self caring, light domestic duties, may be working but to detriment of social, family 
and leisure activities.   
 
Moderate – Reduced mobility, not working, reduced ADL, sleeping in daytime, peaks and troughs of 
activity.    
 
Severe – few ADL, severe cognitive difficulties, wheelchair dependent for mobility, rarely leave 
house, often significant worsening of symptoms with any mental or physical exertion  
  
Very severe – no ADL, bedbound most of time, unable to tolerate any noise & are light sensitive, 
require someone else to wash, toilet and feed them.  
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Recommendations 
 
Treatment Comments Treatment Comments 
GET    
CBT    
SSRI    
Low T4    
    
 
 
REVIEW: As needed 3 months 6 months 1 year          Discharge 
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Supplementary Data 
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Supplementary figure S3.1: Raw abundances of bacterial genera belonging to severe ME 
patients (dataset B, chapter 3). 
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Supplementary figure S3.2: Raw abundance table for bacterial genera belonging to HHCs 
(dataset B, chapter 3) 
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Glycine
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Supplementary figure 4.1: Metabolomic profile of faecal water using 1H-NMR revealed 45 
metabolites in 11 house-bound ME patients and 6 HHCs 
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Supplementary figure 4.2: Metabolomic profile of serum using 1H-NMR revealed 53 
metabolites in 25 ME/CFS patients (14 severe (S); 11 mild/moderate (M)) and 9 HHCs. 
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Supplementary figure 4.3: Metabolomic profile of saline diluted serum using diffusion 
edited spectrum obtained from 1H-NMR revealed 45 metabolites in 14 severe ME, and 11 
mild/moderate ME patients and 9 HHCs. 
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Supplementary figure 4.4: Individual bile acid concentrations in faecal water from 8 ME/CFS patients versus 6 HHCs 
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Supplementary figure 4.4: Individual bile acid concentrations in serum of 14 severe ME, 14 mild/moderate 
ME/CFS, 10 house-hold control & 6 IBD samples 
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Isotype control IgA-APC       
Supplementary figure 5.1 Optimisation of faecal bacterial cell suspension for staining with Sybr green using ME patient faeces. Sybr 
green concentration (1:10,000) stained 1:100 (top row) versus 1:1000 (bottom row) dilution of faecal bacteria in PBS. 
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Isotype control IgA-APC       
Supplementary figure 5.2 Optimisation of faecal bacterial cell suspension for staining with Sybr green using faeces from ME patient’s house-
hold control. Sybr green concentration (1:10,000) stained 1:100 (top row) versus 1:1000 (bottom row) dilution of faecal bacteria in PBS. 
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